{"PMC7489999": [["The international development community has never taken non-communicable diseases (NCDs) seriously.", [["non-communicable diseases", "DISEASE", 56, 81], ["NCDs", "DISEASE", 83, 87]]], ["Seen largely as a challenge for high-income nations, NCDs and their community of advocates have met with, at best, warm words and, more commonly, indifference.", [["NCDs", "DISEASE", 53, 57]]], ["There have been moments for optimism.", [["optimism", "PROBLEM", 28, 36]]], ["The landmark 2005 WHO report, Preventing Chronic Diseases: a Vital Investment;1 the 2011 Political Declaration on NCDs;2 and the inclusion of NCDs in the Sustainable Development Goals (SDG) in 2016 (SDG 3.4: by 2030, reduce premature mortality from NCDs by a third and promote mental health and wellbeing).", [["Chronic Diseases", "DISEASE", 41, 57], ["NCDs", "DISEASE", 114, 118], ["NCDs", "DISEASE", 142, 146], ["NCDs", "DISEASE", 249, 253], ["Chronic Diseases", "PROBLEM", 41, 57], ["NCDs", "TREATMENT", 142, 146], ["Preventing", "UNCERTAINTY", 30, 40], ["Chronic", "OBSERVATION_MODIFIER", 41, 48], ["Diseases", "OBSERVATION", 49, 57]]], ["But, despite an increasingly well organised civil society response, NCDs have not broken through into the mainstream of development and global health.", [["NCDs", "DISEASE", 68, 72]]]], "0a82ca0aba3e11785d01bce1d17a0080f163cbf8": [["IntroductionOver the past 5 years, Brazil has been affected by unprece dented outbreaks of arthropod-borne virus (arbovirus) infections, including Zika and chikungunya viruses, on a background of about 40 years of dengue circulation.", [["arthropod-borne virus (arbovirus) infections", "DISEASE", 91, 135], ["Zika and chikungunya viruses", "DISEASE", 147, 175], ["dengue", "DISEASE", 214, 220], ["arthropod-borne virus", "ORGANISM", 91, 112], ["arbovirus", "ORGANISM", 114, 123], ["chikungunya viruses", "ORGANISM", 156, 175], ["arthropod-borne virus", "SPECIES", 91, 112], ["arthropod-borne virus", "SPECIES", 91, 112], ["dengue", "SPECIES", 214, 220], ["arthropod-borne virus (arbovirus) infections", "PROBLEM", 91, 135], ["Zika", "PROBLEM", 147, 151], ["chikungunya viruses", "PROBLEM", 156, 175], ["dengue circulation", "PROBLEM", 214, 232], ["chikungunya viruses", "OBSERVATION", 156, 175]]], ["[1] [2] [3] [4] All three viruses are transmitted by Aedes aegypti mosquitoes and cause febrile illnesses with arthralgia and rash; dengue virus can also cause haemorrhagic disease and vascular leak, and it is occasionally linked to neurological disease.", [["vascular", "ANATOMY", 185, 193], ["neurological", "ANATOMY", 233, 245], ["Aedes aegypti mosquitoes", "DISEASE", 53, 77], ["febrile illnesses", "DISEASE", 88, 105], ["arthralgia", "DISEASE", 111, 121], ["rash", "DISEASE", 126, 130], ["dengue virus", "DISEASE", 132, 144], ["haemorrhagic disease", "DISEASE", 160, 180], ["vascular leak", "DISEASE", 185, 198], ["neurological disease", "DISEASE", 233, 253], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["Aedes aegypti", "ORGANISM", 53, 66], ["mosquitoes", "ORGANISM", 67, 77], ["dengue virus", "ORGANISM", 132, 144], ["vascular", "MULTI-TISSUE_STRUCTURE", 185, 193], ["Aedes aegypti", "SPECIES", 53, 66], ["Aedes aegypti", "SPECIES", 53, 66], ["dengue virus", "SPECIES", 132, 144], ["All three viruses", "PROBLEM", 16, 33], ["febrile illnesses", "PROBLEM", 88, 105], ["arthralgia", "PROBLEM", 111, 121], ["rash", "PROBLEM", 126, 130], ["dengue virus", "PROBLEM", 132, 144], ["haemorrhagic disease", "PROBLEM", 160, 180], ["vascular leak", "PROBLEM", 185, 198], ["neurological disease", "PROBLEM", 233, 253], ["arthralgia", "OBSERVATION", 111, 121], ["vascular", "ANATOMY", 185, 193], ["leak", "OBSERVATION", 194, 198]]], ["1 The role of chikungunya and Zika viruses in causing neurological disease, which can result in disability and death, is being recognised increasingly by clinicians, particularly in endemic areas.", [["neurological", "ANATOMY", 54, 66], ["chikungunya", "DISEASE", 14, 25], ["Zika viruses", "DISEASE", 30, 42], ["neurological disease", "DISEASE", 54, 74], ["death", "DISEASE", 111, 116], ["chikungunya", "ORGANISM", 14, 25], ["Zika viruses", "ORGANISM", 30, 42], ["chikungunya", "PROBLEM", 14, 25], ["Zika viruses", "PROBLEM", 30, 42], ["neurological disease", "PROBLEM", 54, 74], ["death", "PROBLEM", 111, 116], ["chikungunya", "OBSERVATION", 14, 25]]], ["[5] [6] [7] An association between Zika virus and Guillain-Barr\u00e9 syndrome was first described in French Polynesia in 2013, 8 and subsequently described elsewhere.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 50, 73], ["[5] [6] [7", "SIMPLE_CHEMICAL", 0, 10], ["Zika virus", "ORGANISM", 35, 45], ["Guillain-Barr\u00e9", "ORGANISM", 50, 64], ["Zika virus", "SPECIES", 35, 45], ["Zika virus", "PROBLEM", 35, 45], ["Barr\u00e9 syndrome", "PROBLEM", 59, 73], ["Barr\u00e9 syndrome", "OBSERVATION", 59, 73]]], ["9,10 Large Zika outbreaks affected Brazil from 2015 onwards, when other forms of acute neurological and congenital Zika disease were first reported.", [["neurological", "ANATOMY", 87, 99], ["acute neurological and congenital Zika disease", "DISEASE", 81, 127], ["acute neurological and congenital Zika disease", "PROBLEM", 81, 127], ["Large", "OBSERVATION_MODIFIER", 5, 10], ["Zika", "OBSERVATION", 11, 15], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["congenital", "OBSERVATION_MODIFIER", 104, 114], ["Zika", "OBSERVATION", 115, 119]]], ["11, 12 The role of Zika virus in causing CNS disease after the neonatal period is still not well defined, with the literature comprising mostly case reports and small case series.", [["CNS", "ANATOMY", 41, 44], ["CNS disease", "DISEASE", 41, 52], ["Zika virus", "ORGANISM", 19, 29], ["CNS", "ANATOMICAL_SYSTEM", 41, 44], ["Zika virus", "SPECIES", 19, 29], ["Zika virus", "PROBLEM", 19, 29], ["CNS disease", "PROBLEM", 41, 52], ["small case series", "PROBLEM", 161, 178], ["Zika virus", "OBSERVATION", 19, 29], ["CNS", "ANATOMY", 41, 44], ["disease", "OBSERVATION", 45, 52]]], ["5, [12] [13] [14] Chikungunya virus infection has been linked to both CNS and peripheral nervous system (PNS) disease, though there have been few large studies 6 describing its importance.IntroductionThe diagnosis of infection with these arboviruses is based on detection of virus genome by PCR testing or measurement of specific IgM antibodies by ELISA.", [["CNS", "ANATOMY", 70, 73], ["peripheral nervous system", "ANATOMY", 78, 103], ["PNS", "ANATOMY", 105, 108], ["5, [12] [13] [14]", "CHEMICAL", 0, 17], ["Chikungunya virus infection", "DISEASE", 18, 45], ["CNS and peripheral nervous system (PNS) disease", "DISEASE", 70, 117], ["infection", "DISEASE", 217, 226], ["arboviruses", "DISEASE", 238, 249], ["[12] [13] [14] Chikungunya virus", "ORGANISM", 3, 35], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 78, 103], ["PNS", "ANATOMICAL_SYSTEM", 105, 108], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 330, 344], ["virus genome", "DNA", 275, 287], ["IgM antibodies", "PROTEIN", 330, 344], ["Chikungunya virus", "SPECIES", 18, 35], ["Chikungunya virus", "SPECIES", 18, 35], ["Chikungunya virus infection", "PROBLEM", 18, 45], ["PNS) disease", "PROBLEM", 105, 117], ["few large studies", "PROBLEM", 142, 159], ["infection", "PROBLEM", 217, 226], ["these arboviruses", "PROBLEM", 232, 249], ["virus genome", "PROBLEM", 275, 287], ["PCR testing", "TEST", 291, 302], ["specific IgM antibodies", "TEST", 321, 344], ["both", "ANATOMY_MODIFIER", 65, 69], ["CNS", "ANATOMY", 70, 73], ["peripheral", "ANATOMY_MODIFIER", 78, 88], ["nervous system", "ANATOMY", 89, 103], ["disease", "OBSERVATION", 110, 117], ["few", "OBSERVATION_MODIFIER", 142, 145], ["large", "OBSERVATION_MODIFIER", 146, 151], ["infection", "OBSERVATION", 217, 226]]], ["Because Zika and dengue are both flaviviruses (family Flaviviridae), serological cross-reactivity between them can complicate antibody-based diagnostics; 15 this is not an issue with chikungunya virus because it belongs to a different genus and family (Alphavirus, family Togaviridae).", [["dengue", "DISEASE", 17, 23], ["flaviviruses", "DISEASE", 33, 45], ["chikungunya virus", "DISEASE", 183, 200], ["Zika", "GENE_OR_GENE_PRODUCT", 8, 12], ["chikungunya virus", "ORGANISM", 183, 200], ["chikungunya virus", "SPECIES", 183, 200], ["Zika", "PROBLEM", 8, 12], ["dengue", "PROBLEM", 17, 23], ["serological cross-reactivity", "TEST", 69, 97], ["antibody", "TEST", 126, 134], ["chikungunya virus", "PROBLEM", 183, 200]]], ["After infection with an arbovirus, lifelong immunity typically develops.", [["infection", "DISEASE", 6, 15], ["infection", "PROBLEM", 6, 15], ["an arbovirus", "PROBLEM", 21, 33], ["infection", "OBSERVATION", 6, 15], ["arbovirus", "OBSERVATION", 24, 33]]], ["For dengue, sequential infection by different serotypes can cause more severe disease.", [["dengue", "DISEASE", 4, 10], ["infection", "DISEASE", 23, 32], ["dengue", "SPECIES", 4, 10], ["dengue", "PROBLEM", 4, 10], ["sequential infection", "PROBLEM", 12, 32], ["different serotypes", "PROBLEM", 36, 55], ["more severe disease", "PROBLEM", 66, 85], ["infection", "OBSERVATION", 23, 32], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["disease", "OBSERVATION", 78, 85]]], ["16 Although laboratory studies suggest that Zika virus entry into cells can be enhanced by dengue antibodies, 17, 18 epidemiological data indicate that previous exposure to dengue might protect against symptomatic Zika infec tion.", [["cells", "ANATOMY", 66, 71], ["dengue", "DISEASE", 91, 97], ["dengue", "DISEASE", 173, 179], ["Zika virus", "ORGANISM", 44, 54], ["cells", "CELL", 66, 71], ["dengue antibodies", "PROTEIN", 91, 108], ["Zika virus", "SPECIES", 44, 54], ["dengue", "SPECIES", 91, 97], ["dengue", "SPECIES", 173, 179], ["laboratory studies", "TEST", 12, 30], ["Zika virus entry into cells", "PROBLEM", 44, 71], ["dengue antibodies", "TEST", 91, 108], ["dengue", "PROBLEM", 173, 179], ["symptomatic Zika infec tion", "PROBLEM", 202, 229]]], ["19 Infection with more than one pathogen is thought to contribute to more severe disease in some brain infections.", [["brain", "ANATOMY", 97, 102], ["Infection", "DISEASE", 3, 12], ["brain infections", "DISEASE", 97, 113], ["brain", "ORGAN", 97, 102], ["Infection", "PROBLEM", 3, 12], ["more severe disease", "PROBLEM", 69, 88], ["some brain infections", "PROBLEM", 92, 113], ["Infection", "OBSERVATION", 3, 12], ["thought to contribute to", "UNCERTAINTY", 44, 68], ["more", "OBSERVATION_MODIFIER", 69, 73], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["disease", "OBSERVATION", 81, 88], ["brain", "ANATOMY", 97, 102], ["infections", "OBSERVATION", 103, 113]]], ["20, 21 The effect of previous dengue or chikun gunya infection on the risk of developing neurologi cal Zika disease is not known, although arbovirus co-infection has been reported in some patients with neuro logical disease.", [["dengue", "DISEASE", 30, 36], ["chikun gunya infection", "DISEASE", 40, 62], ["neurologi cal Zika disease", "DISEASE", 89, 115], ["arbovirus co-infection", "DISEASE", 139, 161], ["neuro logical disease", "DISEASE", 202, 223], ["chikun gunya", "ORGANISM", 40, 52], ["patients", "ORGANISM", 188, 196], ["chikun gunya", "SPECIES", 40, 52], ["patients", "SPECIES", 188, 196], ["dengue", "SPECIES", 30, 36], ["chikun gunya", "SPECIES", 40, 52], ["previous dengue", "PROBLEM", 21, 36], ["chikun gunya infection", "PROBLEM", 40, 62], ["developing neurologi cal Zika disease", "PROBLEM", 78, 115], ["arbovirus co-infection", "PROBLEM", 139, 161], ["neuro logical disease", "PROBLEM", 202, 223], ["infection", "OBSERVATION", 53, 62], ["neurologi cal", "OBSERVATION", 89, 102], ["Zika disease", "OBSERVATION", 103, 115]]], ["13, 22 To better understand the spectrum of infectious and post-infectious immune-mediated neurological disease caused by arboviruses, and the effect of dual infection, we studied adults with suspected arboviral neurological disease in Pernambuco, Northeast Brazil, during the 2015-16 Zika and chikungunya outbreaks.", [["neurological", "ANATOMY", 91, 103], ["neurological", "ANATOMY", 212, 224], ["neurological disease", "DISEASE", 91, 111], ["arboviruses", "DISEASE", 122, 133], ["infection", "DISEASE", 158, 167], ["arboviral neurological disease", "DISEASE", 202, 232], ["chikungunya", "DISEASE", 294, 305], ["infectious", "PROBLEM", 44, 54], ["post-infectious immune-mediated neurological disease", "PROBLEM", 59, 111], ["arboviruses", "PROBLEM", 122, 133], ["dual infection", "PROBLEM", 153, 167], ["arboviral neurological disease", "PROBLEM", 202, 232], ["chikungunya outbreaks", "PROBLEM", 294, 315], ["infectious", "OBSERVATION", 44, 54], ["post-infectious", "OBSERVATION_MODIFIER", 59, 74], ["neurological disease", "OBSERVATION", 91, 111], ["arboviruses", "OBSERVATION", 122, 133], ["infection", "OBSERVATION", 158, 167], ["arboviral", "OBSERVATION_MODIFIER", 202, 211], ["neurological disease", "OBSERVATION", 212, 232]]], ["We were especially interested in whether the pattern of disease differed according to the infecting arbovirus, and whether patients with more than one virus infection had a different disease spectrum or severity.Study design and patientsThis prospective observational study was done at Hospital da Restaura\u00e7\u00e3o, Recife, a secondary-level and tertiary-level hospital that sees an estimated 70% of the patientsResearch in contextEvidence before this study We searched PubMed for articles investigating the link between neurological disease in adults and infection with arboviruses, from database inception to Nov 1, 2019, with no language restrictions.", [["neurological", "ANATOMY", 516, 528], ["arbovirus", "DISEASE", 100, 109], ["infection", "DISEASE", 157, 166], ["neurological disease", "DISEASE", 516, 536], ["infection", "DISEASE", 551, 560], ["arbovirus", "ORGANISM", 100, 109], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 399, 407], ["disease", "PROBLEM", 56, 63], ["the infecting arbovirus", "PROBLEM", 86, 109], ["one virus infection", "PROBLEM", 147, 166], ["a different disease spectrum", "PROBLEM", 171, 199], ["severity", "PROBLEM", 203, 211], ["Study design", "TEST", 212, 224], ["This prospective observational study", "TEST", 237, 273], ["this study", "TEST", 442, 452], ["neurological disease", "PROBLEM", 516, 536], ["infection", "PROBLEM", 551, 560], ["arboviruses", "PROBLEM", 566, 577], ["disease", "OBSERVATION", 56, 63], ["infection", "OBSERVATION", 157, 166], ["infection", "OBSERVATION", 551, 560]]], ["Search terms included: \"Zika\", OR \"chikungunya\"; \"meningitis\", \"encephalitis\", \"meningoencephalitis\", \"myelitis\", \"myelopathy\", \"Guillain-Barr\u00e9 syndrome\", \"radiculitis\", \"mononeuropathy\", \"cranial neuropathy\", \"stroke\", \"transient ischaemic attack\", \"central nervous system\", \"peripheral nervous system\", and \"neurological\".", [["cranial", "ANATOMY", 189, 196], ["central nervous system", "ANATOMY", 251, 273], ["peripheral nervous system", "ANATOMY", 277, 302], ["neurological", "ANATOMY", 310, 322], ["chikungunya", "DISEASE", 35, 46], ["meningitis", "DISEASE", 50, 60], ["encephalitis", "DISEASE", 64, 76], ["meningoencephalitis", "DISEASE", 80, 99], ["myelitis", "DISEASE", 103, 111], ["myelopathy", "DISEASE", 115, 125], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 129, 152], ["radiculitis", "DISEASE", 156, 167], ["mononeuropathy", "DISEASE", 171, 185], ["cranial neuropathy", "DISEASE", 189, 207], ["stroke", "DISEASE", 211, 217], ["transient ischaemic attack", "DISEASE", 221, 247], ["central nervous system", "ANATOMICAL_SYSTEM", 251, 273], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 277, 302], ["meningitis", "PROBLEM", 50, 60], ["encephalitis", "PROBLEM", 64, 76], ["meningoencephalitis", "PROBLEM", 80, 99], ["myelitis", "PROBLEM", 103, 111], ["myelopathy", "PROBLEM", 115, 125], ["Barr\u00e9 syndrome\"", "PROBLEM", 138, 153], ["radiculitis", "PROBLEM", 156, 167], ["mononeuropathy\"", "PROBLEM", 171, 186], ["cranial neuropathy\"", "PROBLEM", 189, 208], ["\"stroke\"", "PROBLEM", 210, 218], ["transient ischaemic attack\"", "PROBLEM", 221, 248], ["meningitis", "OBSERVATION", 50, 60], ["encephalitis", "OBSERVATION", 64, 76], ["meningoencephalitis", "OBSERVATION", 80, 99], ["myelitis", "OBSERVATION", 103, 111], ["myelopathy", "OBSERVATION", 115, 125], ["Barr\u00e9 syndrome", "OBSERVATION", 138, 152], ["radiculitis", "OBSERVATION", 156, 167], ["mononeuropathy", "OBSERVATION", 171, 185], ["cranial", "ANATOMY", 189, 196], ["neuropathy", "OBSERVATION", 197, 207], ["ischaemic attack", "OBSERVATION", 231, 247], ["central", "ANATOMY_MODIFIER", 251, 258], ["nervous system", "ANATOMY", 259, 273], ["peripheral", "ANATOMY_MODIFIER", 277, 287], ["nervous system", "ANATOMY", 288, 302]]], ["We found 98 case reports and case series, four cohort studies, and two case-control studies describing neurological complications of chikungunya infection.", [["neurological", "ANATOMY", 103, 115], ["chikungunya infection", "DISEASE", 133, 154], ["chikungunya", "ORGANISM", 133, 144], ["case series", "TEST", 29, 40], ["four cohort studies", "TEST", 42, 61], ["neurological complications", "PROBLEM", 103, 129], ["chikungunya infection", "PROBLEM", 133, 154], ["chikungunya infection", "OBSERVATION", 133, 154]]], ["Encephalopathy was the most common presentation and studies were mainly done in India, Reunion Island, the French West Indies, and Latin America.", [["Encephalopathy", "DISEASE", 0, 14], ["Encephalopathy", "PROBLEM", 0, 14], ["studies", "TEST", 52, 59]]], ["Zika has been linked to Guillain-Barr\u00e9 syndrome in case-control studies in French Polynesia, Brazil, Mexico, and Puerto Rico, and to other forms of neurological disease in case reports and series, mainly from Latin America, but the full range of neurological complications and their relative importance has not been described.", [["neurological", "ANATOMY", 148, 160], ["neurological", "ANATOMY", 246, 258], ["Zika", "DISEASE", 0, 4], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 24, 47], ["neurological disease", "DISEASE", 148, 168], ["neurological complications", "DISEASE", 246, 272], ["Zika", "GENE_OR_GENE_PRODUCT", 0, 4], ["Guillain-Barr\u00e9", "ORGANISM", 24, 38], ["Barr\u00e9 syndrome", "PROBLEM", 33, 47], ["neurological disease", "PROBLEM", 148, 168], ["neurological complications", "PROBLEM", 246, 272], ["Barr\u00e9 syndrome", "OBSERVATION", 33, 47]]], ["For both chikungunya and Zika, most reports are for a single virus infection, although evidence exists that arboviruses increasingly co-circulate.", [["chikungunya", "DISEASE", 9, 20], ["infection", "DISEASE", 67, 76], ["arboviruses", "ORGANISM", 108, 119], ["both chikungunya", "PROBLEM", 4, 20], ["Zika", "PROBLEM", 25, 29], ["a single virus infection", "PROBLEM", 52, 76], ["arboviruses increasingly co-circulate", "PROBLEM", 108, 145], ["chikungunya", "OBSERVATION", 9, 20], ["infection", "OBSERVATION", 67, 76]]], ["More detailed information is needed on the neurological features of patients infected with different arboviruses and on the effect of dual infection.Added value of this studyTo our knowledge, this study is the largest of its kind to describe the neurological features of infection for several arboviruses circulating at the same time, including a thorough investigation of patients with dual infection.", [["neurological", "ANATOMY", 43, 55], ["neurological", "ANATOMY", 246, 258], ["arboviruses", "DISEASE", 101, 112], ["infection", "DISEASE", 139, 148], ["infection", "DISEASE", 271, 280], ["arboviruses", "DISEASE", 293, 304], ["infection", "DISEASE", 392, 401], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 373, 381], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 373, 381], ["different arboviruses", "PROBLEM", 91, 112], ["dual infection", "PROBLEM", 134, 148], ["this study", "TEST", 164, 174], ["this study", "TEST", 192, 202], ["infection", "PROBLEM", 271, 280], ["several arboviruses", "PROBLEM", 285, 304], ["a thorough investigation", "TEST", 345, 369], ["dual infection", "PROBLEM", 387, 401], ["infection", "OBSERVATION", 139, 148], ["largest", "OBSERVATION_MODIFIER", 210, 217], ["infection", "OBSERVATION", 271, 280], ["infection", "OBSERVATION", 392, 401]]], ["This approach differentiates our study from previous ones, which usually describe specific disease syndromes linked to Zika, chikungunya, or dengue virus alone.", [["chikungunya", "DISEASE", 125, 136], ["dengue", "DISEASE", 141, 147], ["dengue virus", "ORGANISM", 141, 153], ["dengue virus", "SPECIES", 141, 153], ["our study", "TEST", 29, 38], ["specific disease syndromes", "PROBLEM", 82, 108], ["Zika", "PROBLEM", 119, 123], ["chikungunya", "PROBLEM", 125, 136], ["dengue virus", "PROBLEM", 141, 153]]], ["Our study shows a high frequency of dual chikungunya and Zika virus infections in patients with neurological disease, underscoring the need for clinicians to investigate for evidence of both pathogens.", [["neurological", "ANATOMY", 96, 108], ["chikungunya", "DISEASE", 41, 52], ["Zika virus infections", "DISEASE", 57, 78], ["neurological disease", "DISEASE", 96, 116], ["Zika virus", "ORGANISM", 57, 67], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Zika virus", "SPECIES", 57, 67], ["Our study", "TEST", 0, 9], ["dual chikungunya", "PROBLEM", 36, 52], ["Zika virus infections", "PROBLEM", 57, 78], ["neurological disease", "PROBLEM", 96, 116], ["both pathogens", "PROBLEM", 186, 200], ["high", "OBSERVATION_MODIFIER", 18, 22], ["dual", "OBSERVATION_MODIFIER", 36, 40], ["chikungunya", "OBSERVATION", 41, 52], ["pathogens", "OBSERVATION", 191, 200]]], ["Although both chikungunya and Zika viruses caused a large range of CNS and peripheral nervous system (PNS) manifestations, chikungunya was more often associated with CNS disease, especially myelitis, whereas Zika was more often linked to PNS disease, especially Guillain-Barr\u00e9 syndrome.Implications of all the available evidenceAn increase in acute neurological disease might be a sentinel for new Zika or chikungunya virus outbreaks, as was seen in 2015 across the Americas.", [["CNS", "ANATOMY", 67, 70], ["peripheral nervous system", "ANATOMY", 75, 100], ["PNS", "ANATOMY", 102, 105], ["CNS", "ANATOMY", 166, 169], ["PNS", "ANATOMY", 238, 241], ["neurological", "ANATOMY", 349, 361], ["chikungunya", "DISEASE", 14, 25], ["Zika viruses", "DISEASE", 30, 42], ["peripheral nervous system (PNS) manifestations", "DISEASE", 75, 121], ["chikungunya", "DISEASE", 123, 134], ["CNS disease", "DISEASE", 166, 177], ["myelitis", "DISEASE", 190, 198], ["Zika", "DISEASE", 208, 212], ["PNS disease", "DISEASE", 238, 249], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 262, 285], ["acute neurological disease", "DISEASE", 343, 369], ["chikungunya virus outbreaks", "DISEASE", 406, 433], ["Zika viruses", "ORGANISM", 30, 42], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 75, 100], ["PNS", "ANATOMICAL_SYSTEM", 102, 105], ["CNS", "ANATOMICAL_SYSTEM", 166, 169], ["Guillain-Barr\u00e9", "ORGANISM", 262, 276], ["chikungunya virus", "ORGANISM", 406, 423], ["Zika viruses", "SPECIES", 30, 42], ["chikungunya virus", "SPECIES", 406, 423], ["both chikungunya", "PROBLEM", 9, 25], ["Zika viruses", "PROBLEM", 30, 42], ["a large range of CNS and peripheral nervous system (PNS) manifestations", "PROBLEM", 50, 121], ["chikungunya", "PROBLEM", 123, 134], ["CNS disease", "PROBLEM", 166, 177], ["myelitis", "PROBLEM", 190, 198], ["Zika", "PROBLEM", 208, 212], ["PNS disease", "PROBLEM", 238, 249], ["Barr\u00e9 syndrome", "PROBLEM", 271, 285], ["acute neurological disease", "PROBLEM", 343, 369], ["new Zika", "PROBLEM", 394, 402], ["chikungunya virus outbreaks", "PROBLEM", 406, 433], ["chikungunya", "OBSERVATION", 14, 25], ["Zika viruses", "OBSERVATION", 30, 42], ["large", "OBSERVATION_MODIFIER", 52, 57], ["range", "OBSERVATION_MODIFIER", 58, 63], ["CNS", "ANATOMY", 67, 70], ["peripheral", "ANATOMY_MODIFIER", 75, 85], ["nervous system", "ANATOMY", 86, 100], ["CNS", "ANATOMY", 166, 169], ["disease", "OBSERVATION", 170, 177], ["Barr\u00e9 syndrome", "OBSERVATION", 271, 285], ["increase", "OBSERVATION_MODIFIER", 331, 339], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["neurological disease", "OBSERVATION", 349, 369]]], ["Epidemiological studies indicate that Zika and chikungunya seroprevelance is not so high as to preclude such outbreaks in the future.", [["chikungunya", "DISEASE", 47, 58], ["Epidemiological studies", "TEST", 0, 23], ["Zika", "PROBLEM", 38, 42], ["chikungunya seroprevelance", "PROBLEM", 47, 73], ["Zika", "OBSERVATION", 38, 42]]], ["Our study will help clinicans to recognise and appropriately investigate patients with arbovirus infections, which will allow them to provide accurate diagnosis and plan management accordingly.", [["arbovirus infections", "DISEASE", 87, 107], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Our study", "TEST", 0, 9], ["arbovirus infections", "PROBLEM", 87, 107]]], ["Policy makers should consider the burden of arbovirus-associated neurological complications when developing public health programmes.", [["neurological", "ANATOMY", 65, 77], ["arbovirus", "DISEASE", 44, 53], ["neurological complications", "DISEASE", 65, 91], ["arbovirus", "PROBLEM", 44, 53], ["associated neurological complications", "PROBLEM", 54, 91]]], ["Future studies should investigate how often arbovirus-associated neurological disease occurs in children, an understudied population, and further characterise the contribution of arbovirus infections to stroke.Implications of all the available evidencewith neurological conditions in the state of Pernambuco, Northeast Brazil.", [["neurological", "ANATOMY", 65, 77], ["arbovirus", "DISEASE", 44, 53], ["neurological disease", "DISEASE", 65, 85], ["arbovirus infections", "DISEASE", 179, 199], ["stroke", "DISEASE", 203, 209], ["children", "ORGANISM", 96, 104], ["arbovirus", "ORGANISM", 179, 188], ["children", "SPECIES", 96, 104], ["Future studies", "TEST", 0, 14], ["arbovirus", "PROBLEM", 44, 53], ["neurological disease", "PROBLEM", 65, 85], ["arbovirus infections", "PROBLEM", 179, 199], ["stroke", "PROBLEM", 203, 209], ["neurological", "OBSERVATION_MODIFIER", 65, 77], ["disease", "OBSERVATION", 78, 85], ["arbovirus infections", "OBSERVATION", 179, 199]]], ["We consecutively recruited patients aged 18 years or older who presented to neurology inpatient services with symp toms of a suspected arboviralassoci ated neurological disease: history of fever, arthralgia, or rash within the preceding 12 months, followed by paralysis, encephalopathy, a seizure, cranial neuropathy, or other focal deficit.", [["neurological", "ANATOMY", 156, 168], ["cranial", "ANATOMY", 298, 305], ["neurological disease", "DISEASE", 156, 176], ["fever", "DISEASE", 189, 194], ["arthralgia", "DISEASE", 196, 206], ["rash", "DISEASE", 211, 215], ["paralysis", "DISEASE", 260, 269], ["encephalopathy", "DISEASE", 271, 285], ["seizure", "DISEASE", 289, 296], ["cranial neuropathy", "DISEASE", 298, 316], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["a suspected arboviralassoci ated neurological disease", "PROBLEM", 123, 176], ["fever", "PROBLEM", 189, 194], ["arthralgia", "PROBLEM", 196, 206], ["rash", "PROBLEM", 211, 215], ["paralysis", "PROBLEM", 260, 269], ["encephalopathy", "PROBLEM", 271, 285], ["a seizure", "PROBLEM", 287, 296], ["cranial neuropathy", "PROBLEM", 298, 316], ["other focal deficit", "PROBLEM", 321, 340], ["fever", "OBSERVATION", 189, 194], ["arthralgia", "OBSERVATION", 196, 206], ["paralysis", "OBSERVATION", 260, 269], ["encephalopathy", "OBSERVATION", 271, 285], ["cranial", "ANATOMY", 298, 305], ["neuropathy", "OBSERVATION", 306, 316], ["focal", "OBSERVATION_MODIFIER", 327, 332], ["deficit", "OBSERVATION", 333, 340]]], ["We chose a 12-month window because we did not want to make presumptions about the latency between infection and neurological disease onset.", [["neurological", "ANATOMY", 112, 124], ["infection", "DISEASE", 98, 107], ["neurological disease", "DISEASE", 112, 132], ["the latency between infection", "PROBLEM", 78, 107], ["neurological disease onset", "PROBLEM", 112, 138], ["infection", "OBSERVATION", 98, 107], ["neurological disease", "OBSERVATION", 112, 132]]], ["However, we also did an analysis for presentations within 3 months, recognising that most infectionrelated neurological dis ease occurs within this time window.", [["neurological", "ANATOMY", 107, 119], ["an analysis", "TEST", 21, 32]]], ["23, 24 Written informed consent was provided by patients, or relatives if they did not have capacity.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["The proto col was approved by the Oswaldo Cruz Foundation, Instituto Aggeu Magalh\u00e3es Ethics Committee (CAAE #511\u00b706115\u00b78 000 5190).ProceduresPatient history, neurological examination findings, and results of investigations-including details of serum and CSF testing, neuroimaging, nerve con duction studies, and electromyography-were noted on case record forms.", [["neurological", "ANATOMY", 158, 170], ["serum", "ANATOMY", 244, 249], ["nerve", "ANATOMY", 281, 286], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["CSF", "GENE_OR_GENE_PRODUCT", 254, 257], ["neurological examination", "TEST", 158, 182], ["investigations", "TEST", 208, 222], ["serum", "TEST", 244, 249], ["CSF testing", "TEST", 254, 265], ["neuroimaging", "TEST", 267, 279], ["nerve con duction studies", "TEST", 281, 306], ["electromyography", "TEST", 312, 328], ["nerve", "ANATOMY", 281, 286]]], ["After a review by a senior neurologist (MLBF), patients were classified by use of standardised case definitions, [25] [26] [27] [28] [29] [30] [31] with levels of diagnostic certainty (appendix 3 pp 1-7), as having CNS disease, if they had well recognised arboviral-associated syndromes (encephalitis, including men ingo encepha litis, rhombo encephalitis, and cerebellitis; mye litis; acute disseminated encephalomyelitis [ADEM]; or seizures); PNS disease (Guillain-Barr\u00e9 syndrome or a variant such as Miller Fisher syndrome, radicu lo pathy, or sensory poly neuropathy); or both.", [["CNS", "ANATOMY", 215, 218], ["PNS", "ANATOMY", 445, 448], ["CNS disease", "DISEASE", 215, 226], ["encephalitis", "DISEASE", 288, 300], ["encepha litis", "DISEASE", 321, 334], ["rhombo encephalitis", "DISEASE", 336, 355], ["cerebellitis", "DISEASE", 361, 373], ["mye litis", "DISEASE", 375, 384], ["acute disseminated encephalomyelitis", "DISEASE", 386, 422], ["ADEM", "DISEASE", 424, 428], ["seizures", "DISEASE", 434, 442], ["PNS disease", "DISEASE", 445, 456], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 458, 481], ["Miller Fisher syndrome", "DISEASE", 503, 525], ["radicu lo pathy", "DISEASE", 527, 542], ["sensory poly neuropathy", "DISEASE", 547, 570], ["patients", "ORGANISM", 47, 55], ["[25] [26] [27] [28] [29] [30", "SIMPLE_CHEMICAL", 113, 141], ["men", "ORGANISM", 312, 315], ["patients", "SPECIES", 47, 55], ["men", "SPECIES", 312, 315], ["diagnostic certainty", "TEST", 163, 183], ["appendix", "TEST", 185, 193], ["CNS disease", "PROBLEM", 215, 226], ["associated syndromes", "PROBLEM", 266, 286], ["encephalitis", "PROBLEM", 288, 300], ["men ingo encepha litis", "PROBLEM", 312, 334], ["rhombo encephalitis", "PROBLEM", 336, 355], ["cerebellitis", "PROBLEM", 361, 373], ["mye litis", "PROBLEM", 375, 384], ["acute disseminated encephalomyelitis", "PROBLEM", 386, 422], ["ADEM", "PROBLEM", 424, 428], ["seizures", "PROBLEM", 434, 442], ["PNS disease", "PROBLEM", 445, 456], ["Barr\u00e9 syndrome", "PROBLEM", 467, 481], ["Miller Fisher syndrome", "PROBLEM", 503, 525], ["radicu lo pathy", "PROBLEM", 527, 542], ["sensory poly neuropathy", "PROBLEM", 547, 570], ["CNS", "ANATOMY", 215, 218], ["disease", "OBSERVATION", 219, 226], ["encephalitis", "OBSERVATION", 343, 355], ["acute", "OBSERVATION_MODIFIER", 386, 391], ["disseminated", "OBSERVATION_MODIFIER", 392, 404], ["encephalomyelitis", "OBSERVATION", 405, 422], ["PNS", "ANATOMY", 445, 448], ["disease", "OBSERVATION", 449, 456], ["Barr\u00e9 syndrome", "OBSERVATION", 467, 481], ["sensory", "OBSERVATION", 547, 554], ["poly neuropathy", "OBSERVATION", 555, 570]]], ["Patients with optic neuritis or other cranial nerve lesions, in the absence of other disease, were classified as having cranial neuro pathies.", [["cranial nerve lesions", "ANATOMY", 38, 59], ["cranial neuro pathies", "ANATOMY", 120, 141], ["optic neuritis", "DISEASE", 14, 28], ["cranial nerve lesions", "DISEASE", 38, 59], ["cranial neuro pathies", "DISEASE", 120, 141], ["Patients", "ORGANISM", 0, 8], ["cranial nerve lesions", "PATHOLOGICAL_FORMATION", 38, 59], ["Patients", "SPECIES", 0, 8], ["optic neuritis", "PROBLEM", 14, 28], ["other cranial nerve lesions", "PROBLEM", 32, 59], ["other disease", "PROBLEM", 79, 92], ["cranial neuro pathies", "PROBLEM", 120, 141], ["optic neuritis", "OBSERVATION", 14, 28], ["cranial nerve", "ANATOMY", 38, 51], ["lesions", "OBSERVATION", 52, 59], ["disease", "OBSERVATION", 85, 92]]], ["The remainder were classified as having other neurological diseases.ProceduresAll serum and CSF samples were blindly tested for Zika, chikungunya, and dengue virus at the Flavivirus Reference Laboratory (Oswaldo Cruz Foundation, Pernambuco, Brazil) by use of well established protocols (appendix 3, p 8).", [["neurological", "ANATOMY", 46, 58], ["serum", "ANATOMY", 82, 87], ["CSF samples", "ANATOMY", 92, 103], ["neurological diseases", "DISEASE", 46, 67], ["chikungunya", "DISEASE", 134, 145], ["dengue", "DISEASE", 151, 157], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["CSF samples", "ORGANISM_SUBSTANCE", 92, 103], ["chikungunya", "ORGANISM", 134, 145], ["dengue virus", "SPECIES", 151, 163], ["other neurological diseases", "PROBLEM", 40, 67], ["Procedures", "TEST", 68, 78], ["All serum", "TEST", 78, 87], ["CSF samples", "TEST", 92, 103], ["Zika", "PROBLEM", 128, 132], ["chikungunya", "PROBLEM", 134, 145], ["dengue virus", "PROBLEM", 151, 163]]], ["Zika, chikungunya, or dengue infection were diagnosed by presence of viral RNA or specific IgM antibodies in serum or CSF, as defined previously.", [["serum", "ANATOMY", 109, 114], ["chikungunya", "DISEASE", 6, 17], ["dengue infection", "DISEASE", 22, 38], ["Zika", "GENE_OR_GENE_PRODUCT", 0, 4], ["chikungunya", "ORGANISM", 6, 17], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 91, 105], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["CSF", "ORGANISM_SUBSTANCE", 118, 121], ["viral RNA", "RNA", 69, 78], ["IgM antibodies", "PROTEIN", 91, 105], ["CSF", "PROTEIN", 118, 121], ["dengue", "SPECIES", 22, 28], ["Zika", "PROBLEM", 0, 4], ["chikungunya", "PROBLEM", 6, 17], ["dengue infection", "PROBLEM", 22, 38], ["viral RNA", "PROBLEM", 69, 78], ["specific IgM antibodies in serum or CSF", "PROBLEM", 82, 121], ["chikungunya", "OBSERVATION", 6, 17], ["viral RNA", "OBSERVATION", 69, 78]]], ["13 Patients with more than one virus detected on PCR or IgM antibody testing were classified as having dual infection, accepting that infec tions might be contemporaneous or sequential.", [["infection", "DISEASE", 108, 117], ["Patients", "ORGANISM", 3, 11], ["IgM antibody", "PROTEIN", 56, 68], ["Patients", "SPECIES", 3, 11], ["one virus", "PROBLEM", 27, 36], ["PCR", "TEST", 49, 52], ["IgM antibody testing", "TEST", 56, 76], ["dual infection", "PROBLEM", 103, 117], ["infection", "OBSERVATION", 108, 117]]], ["If both viruses were detected at the same time by RT-PCR, we classified this as coinfection.", [["coinfection", "DISEASE", 80, 91], ["both viruses", "PROBLEM", 3, 15], ["RT-PCR", "TEST", 50, 56], ["coinfection", "PROBLEM", 80, 91], ["viruses", "OBSERVATION", 8, 15], ["coinfection", "OBSERVATION", 80, 91]]], ["When a patient's samples were positive for IgG but negative for IgM antibodies and virus detection on PCR, this was taken to indicate previous exposure to the virus.ProceduresSamples with IgM antibodies for Zika and dengue virus were also assessed for neutralising antibodies against these viruses by use of plaque reduction neutralisation testing (PRNT) to exclude false positives due to flavivirus 9 We also repeated our analysis excluding these patients.ProceduresWe collected data about admission to intensive care, the need for mechanical ventilation, ongoing disability at discharge, and death.Statistical analysisOur primary aim was to describe and compare demographic and clinical features (including neurological 32 Logistic regression models were used to provide estimates of the odds of having certain outcomes adjusted for demographic and baseline characteristics, including age, sex, history of hypertension, diabetes, and previous dengue infection.", [["samples", "ANATOMY", 17, 24], ["plaque", "ANATOMY", 308, 314], ["dengue", "DISEASE", 216, 222], ["plaque reduction", "DISEASE", 308, 324], ["false positives", "DISEASE", 366, 381], ["disability", "DISEASE", 565, 575], ["death", "DISEASE", 594, 599], ["hypertension", "DISEASE", 908, 920], ["diabetes", "DISEASE", 922, 930], ["dengue infection", "DISEASE", 945, 961], ["patient", "ORGANISM", 7, 14], ["samples", "CANCER", 17, 24], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgM", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 188, 202], ["Zika", "GENE_OR_GENE_PRODUCT", 207, 211], ["dengue virus", "ORGANISM", 216, 228], ["patients", "ORGANISM", 448, 456], ["IgG", "PROTEIN", 43, 46], ["IgM antibodies", "PROTEIN", 64, 78], ["IgM antibodies", "PROTEIN", 188, 202], ["neutralising antibodies", "PROTEIN", 252, 275], ["patient", "SPECIES", 7, 14], ["dengue virus", "SPECIES", 216, 228], ["patients", "SPECIES", 448, 456], ["dengue virus", "SPECIES", 216, 228], ["a patient's samples", "TEST", 5, 24], ["IgG", "TEST", 43, 46], ["IgM antibodies", "PROBLEM", 64, 78], ["virus detection", "TEST", 83, 98], ["PCR", "TEST", 102, 105], ["the virus", "PROBLEM", 155, 164], ["ProceduresSamples", "TEST", 165, 182], ["IgM antibodies", "TEST", 188, 202], ["Zika", "PROBLEM", 207, 211], ["dengue virus", "PROBLEM", 216, 228], ["neutralising antibodies", "TREATMENT", 252, 275], ["these viruses", "PROBLEM", 284, 297], ["plaque reduction", "TREATMENT", 308, 324], ["neutralisation testing", "TEST", 325, 347], ["false positives", "PROBLEM", 366, 381], ["flavivirus", "PROBLEM", 389, 399], ["our analysis", "TEST", 419, 431], ["mechanical ventilation", "TREATMENT", 533, 555], ["death", "PROBLEM", 594, 599], ["hypertension", "PROBLEM", 908, 920], ["diabetes", "PROBLEM", 922, 930], ["previous dengue infection", "PROBLEM", 936, 961], ["hypertension", "OBSERVATION", 908, 920], ["diabetes", "OBSERVATION", 922, 930], ["dengue", "OBSERVATION_MODIFIER", 945, 951], ["infection", "OBSERVATION", 952, 961]]], ["We considered a two-sided p value lower than 0\u00b705 to be significant (appendix 3, p 8).", [["a two-sided p value", "TEST", 14, 33]]], ["Analyses were done using Stata, version 14.1.Role of the funding sourceThe funders of the study had no role in study design, data collection, data analyses, data interpretation, or writing of the Article.", [["Analyses", "TEST", 0, 8], ["Stata, version", "TEST", 25, 39], ["the study", "TEST", 86, 95], ["data collection", "TEST", 125, 140], ["data analyses", "TEST", 142, 155], ["data interpretation", "TEST", 157, 176]]], ["The corresponding authors had full access to all the data, and had final responsibility for the decision to submit for publication.Between13 (32%) 26 (47%) 1 (50%) \u00b7\u00b7 3 (23%) 7 (21%) 1 (25%) \u00b7\u00b7 51 (34%) 12 (23%) \u00b7\u00b7Systemic features of infectionNon-purulent conjunctivitis (table 2; and one (6%) had dysarthria and dysphonia.", [["infection", "DISEASE", 235, 244], ["conjunctivitis", "DISEASE", 257, 271], ["dysarthria", "DISEASE", 299, 309], ["dysphonia", "DISEASE", 314, 323], ["infection", "PROBLEM", 235, 244], ["purulent conjunctivitis", "PROBLEM", 248, 271], ["dysarthria", "PROBLEM", 299, 309], ["dysphonia", "PROBLEM", 314, 323], ["infection", "OBSERVATION", 235, 244], ["purulent", "OBSERVATION_MODIFIER", 248, 256], ["conjunctivitis", "OBSERVATION", 257, 271], ["dysphonia", "OBSERVATION", 314, 323]]], ["Two (13%) patients with Zika infection and three (19%) with chikungunya infection had CSF pleiocytosis.", [["Zika infection", "DISEASE", 24, 38], ["chikungunya infection", "DISEASE", 60, 81], ["CSF pleiocytosis", "DISEASE", 86, 102], ["patients", "ORGANISM", 10, 18], ["chikungunya", "ORGANISM", 60, 71], ["CSF", "ORGANISM_SUBSTANCE", 86, 89], ["patients", "SPECIES", 10, 18], ["Zika infection", "PROBLEM", 24, 38], ["chikungunya infection", "PROBLEM", 60, 81], ["CSF pleiocytosis", "PROBLEM", 86, 102], ["infection", "OBSERVATION", 29, 38], ["chikungunya", "OBSERVATION_MODIFIER", 60, 71], ["infection", "OBSERVATION", 72, 81], ["CSF pleiocytosis", "OBSERVATION", 86, 102]]], ["MRI was done in 13 (81%) patients and showed mostly cortical lesions.", [["cortical lesions", "ANATOMY", 52, 68], ["patients", "ORGANISM", 25, 33], ["cortical lesions", "CANCER", 52, 68], ["patients", "SPECIES", 25, 33], ["MRI", "TEST", 0, 3], ["mostly cortical lesions", "PROBLEM", 45, 68], ["mostly", "OBSERVATION_MODIFIER", 45, 51], ["cortical", "ANATOMY_MODIFIER", 52, 60], ["lesions", "OBSERVATION", 61, 68]]], ["Six (38%) patients were treated with aciclovir for possible herpes simplex virus encephalitis, and ten (63%) were given steroids (table 3).", [["aciclovir", "CHEMICAL", 37, 46], ["herpes simplex virus encephalitis", "DISEASE", 60, 93], ["steroids", "CHEMICAL", 120, 128], ["aciclovir", "CHEMICAL", 37, 46], ["steroids", "CHEMICAL", 120, 128], ["patients", "ORGANISM", 10, 18], ["aciclovir", "SIMPLE_CHEMICAL", 37, 46], ["herpes simplex virus", "ORGANISM", 60, 80], ["patients", "SPECIES", 10, 18], ["herpes simplex virus encephalitis", "SPECIES", 60, 93], ["herpes simplex virus", "SPECIES", 60, 80], ["aciclovir", "TREATMENT", 37, 46], ["herpes simplex virus encephalitis", "PROBLEM", 60, 93], ["steroids", "TREATMENT", 120, 128], ["possible", "UNCERTAINTY", 51, 59], ["herpes simplex virus encephalitis", "OBSERVATION", 60, 93]]], ["The median time of hospitalisation for patients with arboviral encephalitis was 17 days (range 10-24) and ten (63%) of 16 patients had motor or cognitive deficits at discharge, with one (6%) having ongoing seizures; these results did not differ according to viral diagnosis.Systemic features of infectionThe 22 patients with arbovirus-positive myelitis had a preceding fever, rash, or both and a median of 12 days (IQR 7-28) before the onset of neurological symptomsthis did not differ according to viral diagnosis.", [["neurological", "ANATOMY", 445, 457], ["arboviral encephalitis", "DISEASE", 53, 75], ["motor or cognitive deficits", "DISEASE", 135, 162], ["seizures", "DISEASE", 206, 214], ["infection", "DISEASE", 295, 304], ["arbovirus-positive myelitis", "DISEASE", 325, 352], ["fever", "DISEASE", 369, 374], ["rash", "DISEASE", 376, 380], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 311, 319], ["arbovirus", "ORGANISM", 325, 334], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 311, 319], ["arboviral encephalitis", "PROBLEM", 53, 75], ["motor or cognitive deficits", "PROBLEM", 135, 162], ["ongoing seizures", "PROBLEM", 198, 214], ["Systemic features of infection", "PROBLEM", 274, 304], ["arbovirus", "PROBLEM", 325, 334], ["positive myelitis", "PROBLEM", 335, 352], ["a preceding fever", "PROBLEM", 357, 374], ["rash", "PROBLEM", 376, 380], ["IQR", "TEST", 415, 418], ["neurological symptomsthis", "PROBLEM", 445, 470], ["infection", "OBSERVATION", 295, 304], ["myelitis", "OBSERVATION", 344, 352]]], ["These patients typically had paraparesis (14 [64%] patients) or quadriparesis (seven [32%]), which was initially flaccid in four (18%) patients (all with chikungunya infection), often with sensory (21 [95%]) or sphincter involvement (18 [82%] ); this pattern did not differ according to viral infection.", [["sphincter", "ANATOMY", 211, 220], ["paraparesis", "DISEASE", 29, 40], ["quadriparesis", "DISEASE", 64, 77], ["flaccid", "DISEASE", 113, 120], ["chikungunya infection", "DISEASE", 154, 175], ["viral infection", "DISEASE", 287, 302], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 135, 143], ["sphincter", "ORGAN", 211, 220], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 135, 143], ["paraparesis", "PROBLEM", 29, 40], ["quadriparesis", "PROBLEM", 64, 77], ["chikungunya infection", "PROBLEM", 154, 175], ["sphincter involvement", "PROBLEM", 211, 232], ["viral infection", "PROBLEM", 287, 302], ["paraparesis", "OBSERVATION", 29, 40], ["flaccid", "OBSERVATION", 113, 120], ["sphincter", "ANATOMY", 211, 220], ["infection", "OBSERVATION", 293, 302]]], ["Eight (36%) patients with myelitis, all with chikungunya mono-infection or dual infection, also had features of enceph alopathy.", [["myelitis", "DISEASE", 26, 34], ["chikungunya mono-infection", "DISEASE", 45, 71], ["dual infection", "DISEASE", 75, 89], ["enceph alopathy", "DISEASE", 112, 127], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["myelitis", "PROBLEM", 26, 34], ["chikungunya mono-infection", "PROBLEM", 45, 71], ["dual infection", "PROBLEM", 75, 89], ["enceph alopathy", "PROBLEM", 112, 127], ["myelitis", "OBSERVATION", 26, 34], ["chikungunya mono-infection", "OBSERVATION", 45, 71], ["dual", "OBSERVATION_MODIFIER", 75, 79], ["infection", "OBSERVATION", 80, 89], ["enceph alopathy", "OBSERVATION", 112, 127]]], ["13 (59%) patients with myelitis had CSF pleio cytosis, and six (27%) had elevated protein only.", [["myelitis", "DISEASE", 23, 31], ["CSF pleio cytosis", "DISEASE", 36, 53], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["myelitis", "PROBLEM", 23, 31], ["CSF pleio cytosis", "TEST", 36, 53], ["elevated protein", "PROBLEM", 73, 89], ["myelitis", "OBSERVATION", 23, 31]]], ["MRI was done in 16 (73%) of these patients and confirmed the diagnosis of arboviral myelitis in 14 (64%) patients, showing thoracic cord inflammation-sometimes with cervical or brain stem lesions-but not the more diffuse changes seen typically in ADEM.", [["thoracic cord", "ANATOMY", 123, 136], ["cervical", "ANATOMY", 165, 173], ["brain stem lesions", "ANATOMY", 177, 195], ["arboviral myelitis", "DISEASE", 74, 92], ["inflammation", "DISEASE", 137, 149], ["ADEM", "DISEASE", 247, 251], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 105, 113], ["thoracic cord", "ORGAN", 123, 136], ["cervical", "CANCER", 165, 173], ["brain stem lesions", "CANCER", 177, 195], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 105, 113], ["MRI", "TEST", 0, 3], ["arboviral myelitis", "PROBLEM", 74, 92], ["thoracic cord inflammation", "PROBLEM", 123, 149], ["cervical or brain stem lesions", "PROBLEM", 165, 195], ["the more diffuse changes", "PROBLEM", 204, 228], ["ADEM", "PROBLEM", 247, 251], ["arboviral myelitis", "OBSERVATION", 74, 92], ["thoracic cord", "ANATOMY", 123, 136], ["inflammation", "OBSERVATION", 137, 149], ["cervical", "ANATOMY", 165, 173], ["brain", "ANATOMY", 177, 182], ["stem", "ANATOMY_MODIFIER", 183, 187], ["lesions", "OBSERVATION", 188, 195], ["diffuse", "OBSERVATION_MODIFIER", 213, 220], ["ADEM", "OBSERVATION", 247, 251]]], ["Two (9%) patients with myelitis with a normal MRI and six (27%) patients without MRI had clinical features of myelopathy, of whom four (18%) also had CSF pleiocytosis, indicating inflammation.", [["myelitis", "DISEASE", 23, 31], ["myelopathy", "DISEASE", 110, 120], ["CSF pleiocytosis", "DISEASE", 150, 166], ["inflammation", "DISEASE", 179, 191], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 64, 72], ["CSF", "GENE_OR_GENE_PRODUCT", 150, 153], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 64, 72], ["myelitis", "PROBLEM", 23, 31], ["MRI", "TEST", 81, 84], ["myelopathy", "PROBLEM", 110, 120], ["CSF pleiocytosis", "PROBLEM", 150, 166], ["inflammation", "PROBLEM", 179, 191], ["myelitis", "OBSERVATION", 23, 31], ["myelopathy", "OBSERVATION", 110, 120], ["CSF pleiocytosis", "OBSERVATION", 150, 166], ["inflammation", "OBSERVATION", 179, 191]]], ["One (5%) 24-year-old patient with myelitis, unilateral visual loss, and Zika and chikungunya dual infection had an extensive longitudinal cord lesion plus a contrast-enhancing right optic nerve lesion; negative on anti-aquaporin-4 antibody testing, he was diagnosed with neuromyelitis optica spectrum disorder.", [["cord lesion", "ANATOMY", 138, 149], ["right optic nerve lesion", "ANATOMY", 176, 200], ["myelitis", "DISEASE", 34, 42], ["unilateral visual loss", "DISEASE", 44, 66], ["chikungunya", "DISEASE", 81, 92], ["infection", "DISEASE", 98, 107], ["cord lesion", "DISEASE", 138, 149], ["neuromyelitis optica spectrum disorder", "DISEASE", 271, 309], ["patient", "ORGANISM", 21, 28], ["cord", "ORGAN", 138, 142], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 182, 193], ["anti-aquaporin-4", "GENE_OR_GENE_PRODUCT", 214, 230], ["anti-aquaporin-4 antibody", "PROTEIN", 214, 239], ["patient", "SPECIES", 21, 28], ["myelitis", "PROBLEM", 34, 42], ["unilateral visual loss", "PROBLEM", 44, 66], ["Zika", "PROBLEM", 72, 76], ["chikungunya dual infection", "PROBLEM", 81, 107], ["an extensive longitudinal cord lesion", "PROBLEM", 112, 149], ["a contrast-enhancing right optic nerve lesion", "PROBLEM", 155, 200], ["anti-aquaporin", "TEST", 214, 228], ["antibody testing", "TEST", 231, 247], ["neuromyelitis optica spectrum disorder", "PROBLEM", 271, 309], ["myelitis", "OBSERVATION", 34, 42], ["unilateral", "ANATOMY_MODIFIER", 44, 54], ["visual loss", "OBSERVATION", 55, 66], ["extensive", "OBSERVATION_MODIFIER", 115, 124], ["longitudinal", "OBSERVATION_MODIFIER", 125, 137], ["cord", "ANATOMY", 138, 142], ["lesion", "OBSERVATION", 143, 149], ["enhancing", "OBSERVATION_MODIFIER", 166, 175], ["right", "ANATOMY_MODIFIER", 176, 181], ["optic nerve", "ANATOMY", 182, 193], ["lesion", "OBSERVATION", 194, 200], ["neuromyelitis", "OBSERVATION", 271, 284]]], ["16 (73%) patients had corticosteroids and three (14%), with more extensive disease, received immunoglobulin.", [["corticosteroids", "CHEMICAL", 22, 37], ["patients", "ORGANISM", 9, 17], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 93, 107], ["immunoglobulin", "PROTEIN", 93, 107], ["patients", "SPECIES", 9, 17], ["corticosteroids", "TREATMENT", 22, 37], ["more extensive disease", "PROBLEM", 60, 82], ["immunoglobulin", "TREATMENT", 93, 107], ["extensive", "OBSERVATION_MODIFIER", 65, 74], ["disease", "OBSERVATION", 75, 82]]], ["At discharge, after a median 22 days (IQR 17-30) of hospitalisation, all 22 patients had ongoing disability.Systemic features of infectionThe eight patients with arbovirus-positive ADEM presented with various neurological features a median of 9 days (IQR 5-96) after systemic symptoms.", [["neurological", "ANATOMY", 209, 221], ["disability", "DISEASE", 97, 107], ["infection", "DISEASE", 129, 138], ["ADEM", "DISEASE", 181, 185], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 148, 156], ["ongoing disability", "PROBLEM", 89, 107], ["Systemic features of infection", "PROBLEM", 108, 138], ["arbovirus", "PROBLEM", 162, 171], ["positive ADEM", "PROBLEM", 172, 185], ["various neurological features", "PROBLEM", 201, 230], ["systemic symptoms", "PROBLEM", 267, 284], ["infection", "OBSERVATION", 129, 138]]], ["Of these, five (63%) patients had reduced consciousness and confusion, three (38%) had behavioural changes, and one (13%) had a focal seizure.", [["reduced consciousness", "DISEASE", 34, 55], ["confusion", "DISEASE", 60, 69], ["seizure", "DISEASE", 134, 141], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["reduced consciousness", "PROBLEM", 34, 55], ["confusion", "PROBLEM", 60, 69], ["behavioural changes", "PROBLEM", 87, 106], ["a focal seizure", "PROBLEM", 126, 141], ["focal", "OBSERVATION_MODIFIER", 128, 133], ["seizure", "OBSERVATION", 134, 141]]], ["Seven (88%) patients with ADEM had motor deficits, five (63%) also with sensory loss, and two (25%) with cranial nerve involvement (one had ophthalmoplegia, the other facial and bulbar weakness).", [["cranial nerve", "ANATOMY", 105, 118], ["facial", "ANATOMY", 167, 173], ["bulbar", "ANATOMY", 178, 184], ["ADEM", "DISEASE", 26, 30], ["motor deficits", "DISEASE", 35, 49], ["sensory loss", "DISEASE", 72, 84], ["cranial nerve involvement", "DISEASE", 105, 130], ["ophthalmoplegia", "DISEASE", 140, 155], ["bulbar weakness", "DISEASE", 178, 193], ["patients", "ORGANISM", 12, 20], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 105, 118], ["facial", "ORGANISM_SUBDIVISION", 167, 173], ["bulbar", "ORGANISM_SUBDIVISION", 178, 184], ["patients", "SPECIES", 12, 20], ["ADEM", "PROBLEM", 26, 30], ["motor deficits", "PROBLEM", 35, 49], ["sensory loss", "PROBLEM", 72, 84], ["cranial nerve involvement", "PROBLEM", 105, 130], ["ophthalmoplegia", "PROBLEM", 140, 155], ["the other facial and bulbar weakness", "PROBLEM", 157, 193], ["motor deficits", "OBSERVATION", 35, 49], ["sensory loss", "OBSERVATION", 72, 84], ["cranial nerve", "ANATOMY", 105, 118], ["facial", "ANATOMY", 167, 173], ["bulbar", "ANATOMY", 178, 184], ["weakness", "OBSERVATION", 185, 193]]], ["Five (63%) patients with ADEM had CSF pleiocytosis, and in all seven (88%) patients for whom MRI was done, it revealed inflammatory white matter changes in the brain, cervical, and thoracic spinal cord (figure 3A-C).", [["white matter", "ANATOMY", 132, 144], ["brain", "ANATOMY", 160, 165], ["cervical", "ANATOMY", 167, 175], ["thoracic spinal cord", "ANATOMY", 181, 201], ["ADEM", "DISEASE", 25, 29], ["CSF pleiocytosis", "DISEASE", 34, 50], ["patients", "ORGANISM", 11, 19], ["CSF", "ORGANISM_SUBSTANCE", 34, 37], ["patients", "ORGANISM", 75, 83], ["brain", "ORGAN", 160, 165], ["cervical", "ORGAN", 167, 175], ["thoracic spinal cord", "ORGAN", 181, 201], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 75, 83], ["ADEM", "PROBLEM", 25, 29], ["CSF pleiocytosis", "PROBLEM", 34, 50], ["whom MRI", "TEST", 88, 96], ["inflammatory white matter changes in the brain, cervical, and thoracic spinal cord", "PROBLEM", 119, 201], ["CSF pleiocytosis", "OBSERVATION", 34, 50], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131], ["white matter", "OBSERVATION", 132, 144], ["brain", "ANATOMY", 160, 165], ["cervical", "ANATOMY", 167, 175], ["thoracic", "ANATOMY_MODIFIER", 181, 189], ["spinal cord", "ANATOMY", 190, 201]]], ["One (13%) patient with encephalopathy and asymmetrical quadriparesis did not have MRI and was diagnosed clinically as suspected ADEM.", [["encephalopathy", "DISEASE", 23, 37], ["quadriparesis", "DISEASE", 55, 68], ["ADEM", "DISEASE", 128, 132], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["encephalopathy", "PROBLEM", 23, 37], ["asymmetrical quadriparesis", "PROBLEM", 42, 68], ["MRI", "TEST", 82, 85], ["ADEM", "PROBLEM", 128, 132], ["encephalopathy", "OBSERVATION", 23, 37], ["asymmetrical", "OBSERVATION_MODIFIER", 42, 54], ["quadriparesis", "OBSERVATION", 55, 68]]], ["All patients with ADEM received steroids and three (38%) also received intravenous immuno globulin.", [["intravenous", "ANATOMY", 71, 82], ["ADEM", "DISEASE", 18, 22], ["steroids", "CHEMICAL", 32, 40], ["steroids", "CHEMICAL", 32, 40], ["patients", "ORGANISM", 4, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 82], ["immuno globulin", "GENE_OR_GENE_PRODUCT", 83, 98], ["patients", "SPECIES", 4, 12], ["steroids", "TREATMENT", 32, 40], ["intravenous immuno globulin", "TREATMENT", 71, 98]]], ["Patients were discharged after a median 23 days (IQR 11-29), all with ongoing disability.Mono-infection (n=98)Dual infection (n=50) All cases (n=201) ) had a prodrome of fever, rash, or both (one had myalgia and pruritus only).", [["disability", "DISEASE", 78, 88], ["Mono-infection", "DISEASE", 89, 103], ["Dual infection", "DISEASE", 110, 124], ["fever", "DISEASE", 170, 175], ["rash", "DISEASE", 177, 181], ["myalgia", "DISEASE", 200, 207], ["pruritus", "DISEASE", 212, 220], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Mono-infection", "TEST", 89, 103], ["Dual infection", "PROBLEM", 110, 124], ["fever", "PROBLEM", 170, 175], ["rash", "PROBLEM", 177, 181], ["myalgia", "PROBLEM", 200, 207], ["pruritus", "PROBLEM", 212, 220], ["fever", "OBSERVATION", 170, 175]]], ["These symptoms started a median of 7 days (IQR 3-17) before neurological symptom onset for Zika-associated Guillain-Barr\u00e9 syndrome, which was shorter than the median 26 days (15-61) for chikungunyaassociated Guillain-Barr\u00e9 syndrome (p=0\u00b70028), but simi-lar to the median 9 days (5-20) for patients with Zika and chikungunya dual infection.", [["neurological", "ANATOMY", 60, 72], ["Zika", "DISEASE", 91, 95], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 107, 130], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 208, 231], ["chikungunya dual infection", "DISEASE", 312, 338], ["Guillain-Barr\u00e9", "ORGANISM", 208, 222], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["These symptoms", "PROBLEM", 0, 14], ["neurological symptom", "PROBLEM", 60, 80], ["Zika", "PROBLEM", 91, 95], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 107, 130], ["chikungunyaassociated Guillain-Barr\u00e9 syndrome", "PROBLEM", 186, 231], ["Zika", "PROBLEM", 303, 307], ["chikungunya dual infection", "PROBLEM", 312, 338], ["Barr\u00e9 syndrome", "OBSERVATION", 116, 130], ["Barr\u00e9 syndrome", "OBSERVATION", 217, 231], ["infection", "OBSERVATION", 329, 338]]], ["46 (98%) patients with Guillain-Barr\u00e9 syndrome presented with progressive paralysis.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 23, 46], ["paralysis", "DISEASE", 74, 83], ["patients", "ORGANISM", 9, 17], ["Guillain-Barr\u00e9", "ORGANISM", 23, 37], ["patients", "SPECIES", 9, 17], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 23, 46], ["progressive paralysis", "PROBLEM", 62, 83], ["Barr\u00e9 syndrome", "OBSERVATION", 32, 46], ["progressive", "OBSERVATION_MODIFIER", 62, 73], ["paralysis", "OBSERVATION", 74, 83]]], ["Facial paralysis was seen in 26 (55%) patients, more often bilateral (Mixed CNS and PNS diseasePolyneuropathy with meningism and encephalopathy [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] for those with monoinfection; p=0\u00b70028).", [["Facial", "ANATOMY", 0, 6], ["CNS", "ANATOMY", 76, 79], ["PNS", "ANATOMY", 84, 87], ["Facial paralysis", "DISEASE", 0, 16], ["Mixed CNS and PNS diseasePolyneuropathy", "DISEASE", 70, 109], ["meningism", "DISEASE", 115, 124], ["encephalopathy", "DISEASE", 129, 143], ["monoinfection", "DISEASE", 214, 227], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Facial paralysis", "PROBLEM", 0, 16], ["more often bilateral (Mixed CNS and PNS diseasePolyneuropathy", "PROBLEM", 48, 109], ["meningism", "PROBLEM", 115, 124], ["encephalopathy", "PROBLEM", 129, 143], ["monoinfection", "PROBLEM", 214, 227], ["paralysis", "OBSERVATION", 7, 16], ["bilateral", "ANATOMY_MODIFIER", 59, 68], ["CNS", "ANATOMY", 76, 79], ["PNS disease", "OBSERVATION", 84, 95], ["encephalopathy", "OBSERVATION", 129, 143]]], ["These differences remained when we excluded the three patients with more than 3 months from systemic infection to neurological symptom onset (appendix 3, p 13).", [["neurological", "ANATOMY", 114, 126], ["infection", "DISEASE", 101, 110], ["neurological symptom", "DISEASE", 114, 134], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["systemic infection to neurological symptom", "PROBLEM", 92, 134], ["infection", "OBSERVATION", 101, 110]]], ["At discharge, 46 (98%) patients with Guillain-Barr\u00e9 syndrome had disability, but this did not differ according to arboviral diagnosis.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 37, 60], ["disability", "DISEASE", 65, 75], ["patients", "ORGANISM", 23, 31], ["Guillain-Barr\u00e9", "ORGANISM", 37, 51], ["patients", "SPECIES", 23, 31], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 37, 60], ["disability", "PROBLEM", 65, 75]]], ["We identified 13 patients admitted with a stroke (n=11) or transient ischaemic attack (n=2) who had a preceding fever or rash syndrome and were positive for arbovirus on laboratory testing: two (15%) patients with Zika infection, three (23%) with chikungunya infection, and eight (62%) infected with both viruses, including two with co-infection.", [["stroke", "DISEASE", 42, 48], ["transient ischaemic attack", "DISEASE", 59, 85], ["fever", "DISEASE", 112, 117], ["rash syndrome", "DISEASE", 121, 134], ["Zika infection", "DISEASE", 214, 228], ["chikungunya infection", "DISEASE", 247, 268], ["co-infection", "DISEASE", 333, 345], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 200, 208], ["a stroke", "PROBLEM", 40, 48], ["transient ischaemic attack", "PROBLEM", 59, 85], ["a preceding fever", "PROBLEM", 100, 117], ["rash syndrome", "PROBLEM", 121, 134], ["arbovirus", "PROBLEM", 157, 166], ["laboratory testing", "TEST", 170, 188], ["Zika infection", "PROBLEM", 214, 228], ["chikungunya infection", "PROBLEM", 247, 268], ["both viruses", "PROBLEM", 300, 312], ["co-infection", "PROBLEM", 333, 345], ["stroke", "OBSERVATION", 42, 48], ["ischaemic", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 219, 228], ["chikungunya", "OBSERVATION_MODIFIER", 247, 258], ["infection", "OBSERVATION", 259, 268], ["viruses", "OBSERVATION", 305, 312], ["co-infection", "OBSERVATION", 333, 345]]], ["The interval between systemic arbovirus symptoms and neurological symptom onset was a median of 119 days (IQR 103-134) for patients with Zika infection, 51 days (7-124) for those with chikungunya infection, and 88 days (14-102) for those with dual infection.", [["neurological", "ANATOMY", 53, 65], ["systemic arbovirus symptoms", "DISEASE", 21, 48], ["Zika infection", "DISEASE", 137, 151], ["chikungunya infection", "DISEASE", 184, 205], ["infection", "DISEASE", 248, 257], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["systemic arbovirus symptoms", "PROBLEM", 21, 48], ["neurological symptom", "PROBLEM", 53, 73], ["IQR", "TEST", 106, 109], ["Zika infection", "PROBLEM", 137, 151], ["chikungunya infection", "PROBLEM", 184, 205], ["dual infection", "PROBLEM", 243, 257], ["systemic", "OBSERVATION_MODIFIER", 21, 29], ["arbovirus", "OBSERVATION", 30, 39], ["infection", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 196, 205], ["infection", "OBSERVATION", 248, 257]]], ["12 (92%) of these patients presented with hemiparesis, of whom three (23%) had dysarthria, and one (8%) presented with a seizure and reduced consciousness only.", [["hemiparesis", "DISEASE", 42, 53], ["dysarthria", "DISEASE", 79, 89], ["seizure", "DISEASE", 121, 128], ["reduced consciousness", "DISEASE", 133, 154], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["hemiparesis", "PROBLEM", 42, 53], ["dysarthria", "PROBLEM", 79, 89], ["a seizure", "PROBLEM", 119, 128], ["reduced consciousness", "PROBLEM", 133, 154], ["hemiparesis", "OBSERVATION", 42, 53], ["dysarthria", "OBSERVATION", 79, 89]]], ["All patients with stroke or transient ischaemic attack underwent imaging: four (31%) had MRI, eight (62%) had CT, and one (7%) had both.", [["stroke", "DISEASE", 18, 24], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["stroke", "PROBLEM", 18, 24], ["transient ischaemic attack", "PROBLEM", 28, 54], ["imaging", "TEST", 65, 72], ["MRI", "TEST", 89, 92], ["CT", "TEST", 110, 112], ["ischaemic", "OBSERVATION_MODIFIER", 38, 47]]], ["Seven (54%) of these patients had evidence of ischaemic changes only and three (23%) had evidence of ischaemia with haemorrhagic transformation (figure 3D-I; appendix 3, p 14).", [["ischaemia", "DISEASE", 101, 110], ["haemorrhagic transformation", "DISEASE", 116, 143], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["ischaemic changes", "PROBLEM", 46, 63], ["ischaemia", "PROBLEM", 101, 110], ["haemorrhagic transformation", "PROBLEM", 116, 143], ["appendix", "TEST", 158, 166], ["evidence of", "UNCERTAINTY", 34, 45], ["ischaemic", "OBSERVATION", 46, 55], ["evidence of", "UNCERTAINTY", 89, 100], ["ischaemia", "OBSERVATION", 101, 110], ["haemorrhagic", "OBSERVATION_MODIFIER", 116, 128], ["appendix", "ANATOMY", 158, 166]]], ["No distinguishing clinical or radiological features were found between patients with mono-infection or dual infection who had a stroke or transient ischaemic attack.", [["mono-infection", "DISEASE", 85, 99], ["infection", "DISEASE", 108, 117], ["stroke", "DISEASE", 128, 134], ["transient ischaemic attack", "DISEASE", 138, 164], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["distinguishing clinical or radiological features", "PROBLEM", 3, 51], ["mono-infection", "PROBLEM", 85, 99], ["dual infection", "PROBLEM", 103, 117], ["a stroke", "PROBLEM", 126, 134], ["transient ischaemic attack", "PROBLEM", 138, 164], ["infection", "OBSERVATION", 108, 117], ["stroke", "OBSERVATION", 128, 134], ["transient", "OBSERVATION_MODIFIER", 138, 147], ["ischaemic attack", "OBSERVATION", 148, 164]]], ["The increased risk of cerebrovascular disease after dual infection versus mono-infection remained significant, even after excluding patients who presented more than 3 months after their febrile syndrome (six [15%] of 40 patients vs two [2\u00b75%] of 81, p=0\u00b7031).", [["cerebrovascular", "ANATOMY", 22, 37], ["cerebrovascular disease", "DISEASE", 22, 45], ["infection", "DISEASE", 57, 66], ["mono-infection", "DISEASE", 74, 88], ["febrile syndrome", "DISEASE", 186, 202], ["cerebrovascular", "ANATOMICAL_SYSTEM", 22, 37], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 220, 228], ["cerebrovascular disease", "PROBLEM", 22, 45], ["dual infection", "PROBLEM", 52, 66], ["mono-infection", "PROBLEM", 74, 88], ["their febrile syndrome", "PROBLEM", 180, 202], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["cerebrovascular disease", "OBSERVATION", 22, 45], ["infection", "OBSERVATION", 57, 66]]], ["We also adjusted for age and comorbidities, which are known risk factors for stroke.", [["stroke", "DISEASE", 77, 83], ["comorbidities", "PROBLEM", 29, 42], ["stroke", "PROBLEM", 77, 83]]], ["Although age did not differ significantly between stroke patients with mono-infection compared to dual infection, when adjusting for this and other variables, dual infection was no longer a significant risk factor for acute cerebrovascular disease (appendix 3, p 11).", [["cerebrovascular", "ANATOMY", 224, 239], ["stroke", "DISEASE", 50, 56], ["mono-infection", "DISEASE", 71, 85], ["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 164, 173], ["acute cerebrovascular disease", "DISEASE", 218, 247], ["patients", "ORGANISM", 57, 65], ["cerebrovascular", "ORGAN", 224, 239], ["patients", "SPECIES", 57, 65], ["mono-infection", "PROBLEM", 71, 85], ["dual infection", "PROBLEM", 98, 112], ["dual infection", "PROBLEM", 159, 173], ["acute cerebrovascular disease", "PROBLEM", 218, 247], ["infection", "OBSERVATION", 103, 112], ["infection", "OBSERVATION", 164, 173], ["no longer", "UNCERTAINTY", 178, 187], ["acute", "OBSERVATION_MODIFIER", 218, 223], ["cerebrovascular disease", "OBSERVATION", 224, 247]]], ["Median age of patients with arbovirus infection and who presented acutely with cerebrovascular disease was 65 years (IQR 61-78), which was greater than the median age of patients with an acute neurological disease other than stroke or transient ischaemic attack who tested positive for an arbovirus.", [["cerebrovascular", "ANATOMY", 79, 94], ["neurological", "ANATOMY", 193, 205], ["arbovirus infection", "DISEASE", 28, 47], ["cerebrovascular disease", "DISEASE", 79, 102], ["acute neurological disease", "DISEASE", 187, 213], ["stroke", "DISEASE", 225, 231], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 170, 178], ["arbovirus infection", "PROBLEM", 28, 47], ["cerebrovascular disease", "PROBLEM", 79, 102], ["IQR", "TEST", 117, 120], ["an acute neurological disease", "PROBLEM", 184, 213], ["stroke", "PROBLEM", 225, 231], ["transient ischaemic attack", "PROBLEM", 235, 261], ["an arbovirus", "PROBLEM", 286, 298], ["arbovirus infection", "OBSERVATION", 28, 47], ["cerebrovascular", "ANATOMY", 79, 94], ["disease", "OBSERVATION", 95, 102], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["neurological disease", "OBSERVATION", 193, 213], ["transient", "OBSERVATION_MODIFIER", 235, 244], ["ischaemic", "OBSERVATION_MODIFIER", 245, 254], ["arbovirus", "OBSERVATION", 289, 298]]], ["Additionally, almost all these patientsDiscussionTo our knowledge, our study is the largest of its kind to compare Zika-associated and chikungunya-associated neurological disease.", [["neurological", "ANATOMY", 158, 170], ["chikungunya", "DISEASE", 135, 146], ["neurological disease", "DISEASE", 158, 178], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["our study", "TEST", 67, 76], ["Zika", "PROBLEM", 115, 119], ["chikungunya", "PROBLEM", 135, 146], ["neurological disease", "PROBLEM", 158, 178], ["neurological disease", "OBSERVATION", 158, 178]]], ["We have shown that, although the viruses cause a similar broad range of CNS and PNS manifestations, Guillain-Barr\u00e9 syndrome is predominant in patients with Zika infections, whereas CNS disease is more common in patients with chikun gunya infections.", [["CNS", "ANATOMY", 72, 75], ["PNS", "ANATOMY", 80, 83], ["CNS", "ANATOMY", 181, 184], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 100, 123], ["Zika infections", "DISEASE", 156, 171], ["CNS disease", "DISEASE", 181, 192], ["chikun gunya infections", "DISEASE", 225, 248], ["CNS", "ANATOMICAL_SYSTEM", 72, 75], ["PNS", "ANATOMICAL_SYSTEM", 80, 83], ["Guillain-Barr\u00e9", "ORGANISM", 100, 114], ["patients", "ORGANISM", 142, 150], ["CNS", "ANATOMICAL_SYSTEM", 181, 184], ["patients", "ORGANISM", 211, 219], ["chikun gunya", "ORGANISM", 225, 237], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 211, 219], ["chikun gunya", "SPECIES", 225, 237], ["the viruses", "PROBLEM", 29, 40], ["CNS", "PROBLEM", 72, 75], ["PNS manifestations", "PROBLEM", 80, 98], ["Barr\u00e9 syndrome", "PROBLEM", 109, 123], ["Zika infections", "PROBLEM", 156, 171], ["CNS disease", "PROBLEM", 181, 192], ["chikun gunya infections", "PROBLEM", 225, 248], ["viruses", "OBSERVATION", 33, 40], ["CNS", "ANATOMY", 72, 75], ["Barr\u00e9 syndrome", "OBSERVATION", 109, 123], ["predominant", "OBSERVATION_MODIFIER", 127, 138], ["infections", "OBSERVATION", 238, 248]]], ["The past two decades have seen a remarkable spread in the distribution of these emerging arboviruses.", [["arboviruses", "DISEASE", 89, 100], ["arboviruses", "ORGANISM", 89, 100], ["remarkable", "OBSERVATION_MODIFIER", 33, 43], ["spread", "OBSERVATION", 44, 50], ["arboviruses", "OBSERVATION", 89, 100]]], ["Chikungunya virus, first identified in Tanzania in 1953, caused outbreaks in Africa and southeast Asia in the 1960s and 1970s.", [["Chikungunya virus", "DISEASE", 0, 17], ["Chikungunya virus", "ORGANISM", 0, 17], ["Chikungunya virus", "SPECIES", 0, 17], ["Chikungunya virus", "SPECIES", 0, 17], ["Chikungunya virus", "PROBLEM", 0, 17]]], ["From 2004 onwards, chikungunya virus caused large epidemics, spreading to the Pacific Islands in 2011, and the Americas in 2013.", [["chikungunya virus", "DISEASE", 19, 36], ["chikungunya virus", "ORGANISM", 19, 36], ["chikungunya virus", "SPECIES", 19, 36], ["chikungunya virus", "PROBLEM", 19, 36], ["large epidemics", "PROBLEM", 44, 59], ["large", "OBSERVATION_MODIFIER", 44, 49], ["epidemics", "OBSERVATION", 50, 59]]], ["6 Zika virus has spread even more rapidly.", [["Zika virus", "ORGANISM", 2, 12], ["Zika virus", "SPECIES", 2, 12], ["Zika virus", "PROBLEM", 2, 12], ["Zika virus", "OBSERVATION", 2, 12]]], ["Isolated initially in Uganda in 1947, the virus was considered a benign cause of occasional febrile illness.", [["febrile illness", "DISEASE", 92, 107], ["the virus", "PROBLEM", 38, 47], ["occasional febrile illness", "PROBLEM", 81, 107], ["benign", "OBSERVATION_MODIFIER", 65, 71], ["occasional", "OBSERVATION_MODIFIER", 81, 91], ["febrile", "OBSERVATION_MODIFIER", 92, 99], ["illness", "OBSERVATION", 100, 107]]], ["33 However, Zika virus caused large outbreaks in Micronesia in 2007, French Polynesia in 2014 (where the Guillain-Barr\u00e9 syndrome link was first recognised), and Brazil in 2015, where its role in causing microcephaly was established.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 105, 128], ["microcephaly", "DISEASE", 203, 215], ["Zika virus", "ORGANISM", 12, 22], ["Zika virus", "SPECIES", 12, 22], ["Zika virus", "PROBLEM", 12, 22], ["the Guillain-Barr\u00e9 syndrome", "TREATMENT", 101, 128], ["microcephaly", "PROBLEM", 203, 215], ["large", "OBSERVATION_MODIFIER", 30, 35], ["outbreaks", "OBSERVATION_MODIFIER", 36, 45], ["microcephaly", "OBSERVATION", 203, 215]]], ["8, 11, 34 As arboviruses spread, the need to understand their severe manifestations and the effect of dual infection becomes even more crucial, particularly because the areas affected by different viruses overlap increasingly.", [["infection", "DISEASE", 107, 116], ["arboviruses spread", "PROBLEM", 13, 31], ["their severe manifestations", "PROBLEM", 56, 83], ["dual infection", "PROBLEM", 102, 116], ["infection", "OBSERVATION", 107, 116], ["more crucial", "OBSERVATION_MODIFIER", 130, 142], ["different", "OBSERVATION_MODIFIER", 187, 196], ["viruses", "OBSERVATION", 197, 204]]], ["4, 13, 22 We found that, while both Zika and chikungunya viruses can cause Guillain-Barr\u00e9 syndrome, patients with Zika infection presented more rapidly after their prodromal illness than those with chikungunya infection (median 7 vs 26 days).", [["chikungunya viruses", "DISEASE", 45, 64], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 75, 98], ["Zika infection", "DISEASE", 114, 128], ["chikungunya infection", "DISEASE", 198, 219], ["4, 13, 22", "CHEMICAL", 0, 9], ["Zika", "GENE_OR_GENE_PRODUCT", 36, 40], ["chikungunya viruses", "ORGANISM", 45, 64], ["Guillain-Barr\u00e9", "ORGANISM", 75, 89], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["chikungunya viruses", "SPECIES", 45, 64], ["chikungunya viruses", "PROBLEM", 45, 64], ["Barr\u00e9 syndrome", "PROBLEM", 84, 98], ["Zika infection", "PROBLEM", 114, 128], ["their prodromal illness", "PROBLEM", 158, 181], ["chikungunya infection", "PROBLEM", 198, 219], ["Barr\u00e9 syndrome", "OBSERVATION", 84, 98]]], ["The rapid onset of Guillain-Barr\u00e9 syndrome after Zika infection has been suggested as a useful distinguishing feature, 9,10 reflecting para-infectious rather than post-infectious mechanisms, 35 but whether this time interval is significantly shorter than that for other pathogens is unclear.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 19, 42], ["Zika infection", "DISEASE", 49, 63], ["Guillain-Barr\u00e9", "ORGANISM", 19, 33], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 19, 42], ["Zika infection", "PROBLEM", 49, 63], ["post-infectious mechanisms", "PROBLEM", 163, 189], ["other pathogens", "PROBLEM", 264, 279], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["onset", "OBSERVATION_MODIFIER", 10, 15], ["Barr\u00e9 syndrome", "OBSERVATION", 28, 42], ["pathogens", "OBSERVATION", 270, 279]]], ["36 High incidence of facial involvement has also been suggested as a marker of Zika-associated Guillain-Barr\u00e9 syndrome, 5 but we found that facial involvement was equally common (just higher than 50%) in patients with chikungunya-associated Guillain-Barr\u00e9 syndrome.DiscussionApproximately half of our patients with chikungunya infection with CNS presentations had myelitis.", [["facial", "ANATOMY", 21, 27], ["facial", "ANATOMY", 140, 146], ["CNS", "ANATOMY", 342, 345], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 95, 118], ["chikungunya", "DISEASE", 218, 229], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 241, 264], ["chikungunya infection", "DISEASE", 315, 336], ["myelitis", "DISEASE", 364, 372], ["facial", "ORGAN", 21, 27], ["Guillain-Barr\u00e9", "ORGANISM", 95, 109], ["facial", "ORGAN", 140, 146], ["patients", "ORGANISM", 204, 212], ["Guillain-Barr\u00e9", "ORGANISM", 241, 255], ["patients", "ORGANISM", 301, 309], ["CNS", "ANATOMICAL_SYSTEM", 342, 345], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 301, 309], ["facial involvement", "PROBLEM", 21, 39], ["Zika", "PROBLEM", 79, 83], ["Barr\u00e9 syndrome", "PROBLEM", 104, 118], ["facial involvement", "PROBLEM", 140, 158], ["chikungunya", "PROBLEM", 218, 229], ["Barr\u00e9 syndrome", "PROBLEM", 250, 264], ["chikungunya infection", "PROBLEM", 315, 336], ["myelitis", "PROBLEM", 364, 372], ["facial", "ANATOMY", 21, 27], ["involvement", "OBSERVATION", 28, 39], ["facial", "ANATOMY", 140, 146], ["involvement", "OBSERVATION", 147, 158], ["Barr\u00e9 syndrome", "OBSERVATION", 250, 264], ["myelitis", "OBSERVATION", 364, 372]]], ["Although myelitis has been described with chikungunya infection before, 6 its importance compared with encephalitis has not been emphasised previously.", [["myelitis", "DISEASE", 9, 17], ["chikungunya infection", "DISEASE", 42, 63], ["encephalitis", "DISEASE", 103, 115], ["myelitis", "PROBLEM", 9, 17], ["chikungunya infection", "PROBLEM", 42, 63], ["encephalitis", "PROBLEM", 103, 115], ["myelitis", "OBSERVATION", 9, 17], ["chikungunya", "OBSERVATION_MODIFIER", 42, 53], ["infection", "OBSERVATION", 54, 63], ["encephalitis", "OBSERVATION", 103, 115]]], ["In our 2018 systematic review, 322 (37%) of 856 patients with chikungunyaassociated neurological disease had encephalopathy, but just 19 (2%) had myelopathy.", [["neurological", "ANATOMY", 84, 96], ["neurological disease", "DISEASE", 84, 104], ["encephalopathy", "DISEASE", 109, 123], ["myelopathy", "DISEASE", 146, 156], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["chikungunyaassociated neurological disease", "PROBLEM", 62, 104], ["encephalopathy", "PROBLEM", 109, 123], ["myelopathy", "PROBLEM", 146, 156], ["neurological disease", "OBSERVATION", 84, 104], ["encephalopathy", "OBSERVATION", 109, 123], ["myelopathy", "OBSERVATION", 146, 156]]], ["6 We also saw myelitis in patients with Zika mono-infection and dual infection in our study.", [["myelitis", "DISEASE", 14, 22], ["mono-infection", "DISEASE", 45, 59], ["infection", "DISEASE", 69, 78], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["myelitis", "PROBLEM", 14, 22], ["Zika mono-infection", "PROBLEM", 40, 59], ["dual infection", "PROBLEM", 64, 78], ["our study", "TEST", 82, 91], ["myelitis", "OBSERVATION", 14, 22], ["infection", "OBSERVATION", 69, 78]]], ["Considerable attention has been given to acute flaccid myelitis caused by enteroviruses, particularly enterovirus D68; 37 our study is a pertinent reminder that arboviruses should also be considered in such cases in endemic areas or in returning travellers.", [["flaccid myelitis", "DISEASE", 47, 63], ["enteroviruses", "DISEASE", 74, 87], ["enterovirus D68", "DISEASE", 102, 117], ["arboviruses", "DISEASE", 161, 172], ["enterovirus D68", "ORGANISM", 102, 117], ["arboviruses", "ORGANISM", 161, 172], ["acute flaccid myelitis", "PROBLEM", 41, 63], ["enteroviruses", "PROBLEM", 74, 87], ["our study", "TEST", 122, 131], ["arboviruses", "TREATMENT", 161, 172], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["flaccid", "OBSERVATION_MODIFIER", 47, 54], ["myelitis", "OBSERVATION", 55, 63], ["enteroviruses", "OBSERVATION", 74, 87]]], ["ADEM was another important presentation seen in our study, especially after chikungunya infection; this finding sug gests that infection can result in post-infectious immune-mediated CNS disease.DiscussionWe were interested particularly in whether dual arbovirus neurological infections were more severe than mono-infections, as suggested by preliminary reports 13, 22 and seen in other brain infections.", [["CNS", "ANATOMY", 183, 186], ["neurological", "ANATOMY", 263, 275], ["brain", "ANATOMY", 387, 392], ["ADEM", "DISEASE", 0, 4], ["chikungunya infection", "DISEASE", 76, 97], ["infection", "DISEASE", 127, 136], ["arbovirus neurological infections", "DISEASE", 253, 286], ["mono-infections", "DISEASE", 309, 324], ["brain infections", "DISEASE", 387, 403], ["CNS", "ANATOMICAL_SYSTEM", 183, 186], ["arbovirus", "ORGANISM", 253, 262], ["brain", "ORGAN", 387, 392], ["ADEM", "PROBLEM", 0, 4], ["our study", "TEST", 48, 57], ["chikungunya infection", "PROBLEM", 76, 97], ["infection", "PROBLEM", 127, 136], ["post-infectious immune-mediated CNS disease", "PROBLEM", 151, 194], ["dual arbovirus neurological infections", "PROBLEM", 248, 286], ["other brain infections", "PROBLEM", 381, 403], ["infection", "OBSERVATION", 88, 97], ["infection", "OBSERVATION", 127, 136], ["post-infectious", "OBSERVATION_MODIFIER", 151, 166], ["CNS", "ANATOMY", 183, 186], ["disease", "OBSERVATION", 187, 194], ["brain", "ANATOMY", 387, 392], ["infections", "OBSERVATION", 393, 403]]], ["20, 21 We found that dual infections were common, accounting for approximately a third of patients with an arbovirus-positive laboratory test, and probably reflecting an overlap of two epidemics.", [["infections", "DISEASE", 26, 36], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["dual infections", "PROBLEM", 21, 36], ["an arbovirus", "TEST", 104, 116], ["two epidemics", "PROBLEM", 181, 194], ["dual", "OBSERVATION_MODIFIER", 21, 25], ["infections", "OBSERVATION", 26, 36], ["arbovirus", "OBSERVATION", 107, 116], ["probably reflecting", "UNCERTAINTY", 147, 166], ["two", "OBSERVATION_MODIFIER", 181, 184], ["epidemics", "OBSERVATION", 185, 194]]], ["4 This prevalence of dual infections is higher than that in a Brazilian study of non-neurological arboviral disease (with 9% of patients having dual arbovirus infection), 38 but lower than that of a small neurological disease study from Ecuador (where 75% of patients had arbovirus coinfection).", [["neurological", "ANATOMY", 205, 217], ["infections", "DISEASE", 26, 36], ["arboviral disease", "DISEASE", 98, 115], ["arbovirus infection", "DISEASE", 149, 168], ["neurological disease", "DISEASE", 205, 225], ["arbovirus coinfection", "DISEASE", 272, 293], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 259, 267], ["dual infections", "PROBLEM", 21, 36], ["a Brazilian study", "TEST", 60, 77], ["non-neurological arboviral disease", "PROBLEM", 81, 115], ["dual arbovirus infection", "PROBLEM", 144, 168], ["a small neurological disease study", "PROBLEM", 197, 231], ["arbovirus coinfection", "PROBLEM", 272, 293], ["dual", "OBSERVATION_MODIFIER", 21, 25], ["infections", "OBSERVATION", 26, 36], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["arboviral disease", "OBSERVATION", 98, 115], ["small", "OBSERVATION_MODIFIER", 199, 204], ["neurological disease", "OBSERVATION", 205, 225]]], ["22 We found that patients with Guillain-Barr\u00e9 syndrome and dual infection more often required intensive care support and mechanical ventilation, and spent on average nearly 7 days longer in hospital than those with Zika or chikungunya mono-infections, which suggests that patients with dual infection had more severe disease.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 31, 54], ["infection", "DISEASE", 64, 73], ["chikungunya", "DISEASE", 223, 234], ["infection", "DISEASE", 291, 300], ["patients", "ORGANISM", 17, 25], ["Guillain-Barr\u00e9", "ORGANISM", 31, 45], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 272, 280], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 31, 54], ["dual infection", "PROBLEM", 59, 73], ["intensive care support", "TREATMENT", 94, 116], ["mechanical ventilation", "TREATMENT", 121, 143], ["Zika", "PROBLEM", 215, 219], ["chikungunya mono-infections", "PROBLEM", 223, 250], ["dual infection", "PROBLEM", 286, 300], ["more severe disease", "PROBLEM", 305, 324], ["Barr\u00e9 syndrome", "OBSERVATION", 40, 54], ["infection", "OBSERVATION", 64, 73], ["mechanical ventilation", "OBSERVATION", 121, 143], ["infection", "OBSERVATION", 291, 300], ["severe", "OBSERVATION_MODIFIER", 310, 316], ["disease", "OBSERVATION", 317, 324]]], ["We found no evidence that patients with previous dengue infection had more severe disease than those without, although we observed a high rate of previous exposure to dengue across all disease groups.DiscussionIntriguingly, presentations with cerebrovascular disease were nearly 3 times more common in patients with dual infection than in those with mono-infection (17% vs 6%; OR 3\u00b783, 95% CI 1\u00b718-12\u00b747), although significance was lost when accounting for other much stronger risk factors (age, hypertension, and diabetes; appendix 3, p 11).", [["cerebrovascular", "ANATOMY", 243, 258], ["dengue infection", "DISEASE", 49, 65], ["dengue", "DISEASE", 167, 173], ["cerebrovascular disease", "DISEASE", 243, 266], ["infection", "DISEASE", 321, 330], ["mono-infection", "DISEASE", 350, 364], ["hypertension", "DISEASE", 496, 508], ["diabetes", "DISEASE", 514, 522], ["patients", "ORGANISM", 26, 34], ["cerebrovascular", "ORGAN", 243, 258], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 302, 310], ["dengue", "SPECIES", 167, 173], ["previous dengue infection", "PROBLEM", 40, 65], ["more severe disease", "PROBLEM", 70, 89], ["dengue across all disease groups", "PROBLEM", 167, 199], ["cerebrovascular disease", "PROBLEM", 243, 266], ["dual infection", "PROBLEM", 316, 330], ["mono-infection", "TEST", 350, 364], ["CI", "TEST", 390, 392], ["hypertension", "PROBLEM", 496, 508], ["diabetes", "PROBLEM", 514, 522], ["appendix", "TEST", 524, 532], ["no evidence that", "UNCERTAINTY", 9, 25], ["dengue", "OBSERVATION_MODIFIER", 49, 55], ["infection", "OBSERVATION", 56, 65], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["disease", "OBSERVATION", 82, 89], ["cerebrovascular", "ANATOMY", 243, 258], ["disease", "OBSERVATION", 259, 266], ["infection", "OBSERVATION", 321, 330], ["hypertension", "OBSERVATION", 496, 508], ["appendix", "ANATOMY", 524, 532]]], ["Case reports exist of stroke after chikungunya or Zika virus infection.", [["stroke", "DISEASE", 22, 28], ["chikungunya", "DISEASE", 35, 46], ["Zika virus infection", "DISEASE", 50, 70], ["Zika virus", "ORGANISM", 50, 60], ["Zika virus", "SPECIES", 50, 60], ["stroke", "PROBLEM", 22, 28], ["chikungunya", "PROBLEM", 35, 46], ["Zika virus infection", "PROBLEM", 50, 70], ["stroke", "OBSERVATION", 22, 28]]], ["14, 39 The risk of stroke after infection is known to be increased, especially for varicella zoster virus, which causes vasculitis, and HIV, which is thought to disrupt the vascular endothelium.", [["vascular endothelium", "ANATOMY", 173, 193], ["stroke", "DISEASE", 19, 25], ["infection", "DISEASE", 32, 41], ["varicella zoster", "DISEASE", 83, 99], ["vasculitis", "DISEASE", 120, 130], ["varicella zoster virus", "ORGANISM", 83, 105], ["vascular endothelium", "TISSUE", 173, 193], ["varicella zoster virus", "SPECIES", 83, 105], ["HIV", "SPECIES", 136, 139], ["varicella zoster virus", "SPECIES", 83, 105], ["HIV", "SPECIES", 136, 139], ["stroke", "PROBLEM", 19, 25], ["infection", "PROBLEM", 32, 41], ["varicella zoster virus", "PROBLEM", 83, 105], ["vasculitis", "PROBLEM", 120, 130], ["HIV", "PROBLEM", 136, 139], ["stroke", "OBSERVATION", 19, 25], ["infection", "OBSERVATION", 32, 41], ["vasculitis", "OBSERVATION", 120, 130], ["vascular endothelium", "ANATOMY", 173, 193]]], ["24, 40 Stroke is also being reported increasingly in association with COVID-19, caused by severe acute respiratory syndrome coronavirus 2.", [["Stroke", "DISEASE", 7, 13], ["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["COVID", "TEST", 70, 75], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 90, 135], ["Stroke", "OBSERVATION", 7, 13], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome coronavirus", "OBSERVATION", 103, 135]]], ["41 A retrospective, population-based cohort study of 13 787 patients in Taiwan sug gested that stroke risk might also be increased after dengue infection.", [["stroke", "DISEASE", 95, 101], ["dengue infection", "DISEASE", 137, 153], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["dengue", "SPECIES", 137, 143], ["cohort study", "TEST", 37, 49], ["stroke risk", "PROBLEM", 95, 106], ["dengue infection", "PROBLEM", 137, 153], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["infection", "OBSERVATION", 144, 153]]], ["42 Our findings strengthen the evidence for a link between cerebrovascular disease and arboviral infection, although our patients had other risk factors, suggesting that this disease is multifactorial.", [["cerebrovascular", "ANATOMY", 59, 74], ["cerebrovascular disease", "DISEASE", 59, 82], ["arboviral infection", "DISEASE", 87, 106], ["cerebrovascular", "ANATOMICAL_SYSTEM", 59, 74], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["a link between cerebrovascular disease", "PROBLEM", 44, 82], ["arboviral infection", "PROBLEM", 87, 106], ["this disease", "PROBLEM", 170, 182], ["cerebrovascular", "ANATOMY", 59, 74], ["disease", "OBSERVATION", 75, 82], ["arboviral", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["Clearly, a case-control approach is needed to better understand this question.DiscussionOur study was limited by the challenges of doing research during outbreaks; for example, sample availability was limited, and we could not study some patients in extremis (eg, those who died before inclusion in the study).", [["extremis", "DISEASE", 250, 258], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["a case-control approach", "TREATMENT", 9, 32], ["Our study", "TEST", 88, 97], ["the study", "TEST", 299, 308]]], ["We only recruited patients admitted under the neurology service with preceding symptoms of sys temic arbovirus infection, meaning that we would not have captured patients with disease manifestations that were neurological alone.", [["arbovirus infection", "DISEASE", 101, 120], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 162, 170], ["preceding symptoms", "PROBLEM", 69, 87], ["sys temic arbovirus infection", "PROBLEM", 91, 120], ["disease manifestations", "PROBLEM", 176, 198]]], ["Although distinguishing Zika from dengue virus can be challenging, we adopted the most robust approaches available, including the use of con firmatory neutralisation antibody testing in cases when doubt remained.", [["dengue", "DISEASE", 34, 40], ["Zika", "CANCER", 24, 28], ["dengue virus", "ORGANISM", 34, 46], ["dengue virus", "SPECIES", 34, 46], ["Zika", "PROBLEM", 24, 28], ["dengue virus", "PROBLEM", 34, 46], ["con firmatory neutralisation antibody testing", "TEST", 137, 182]]], ["Nevertheless, for five patients, we were unable to distinguish serologically between dengue and Zika viruses and classified them as Zika on the basis of the epidemiology, an approach used previously.", [["dengue", "DISEASE", 85, 91], ["patients", "ORGANISM", 23, 31], ["Zika viruses", "ORGANISM", 96, 108], ["patients", "SPECIES", 23, 31], ["dengue", "SPECIES", 85, 91], ["Zika viruses", "SPECIES", 96, 108], ["dengue and Zika viruses", "PROBLEM", 85, 108]]], ["9 Excluding these five patients did not alter our findings overall.DiscussionIn summary, we have shown that Zika virus infection was associated with various CNS and PNS manifestations beyond Guillain-Barr\u00e9 syndrome, whereas for chikungunya virus infection, encephalitis, and myelitis were the most important presentations.", [["CNS", "ANATOMY", 157, 160], ["PNS", "ANATOMY", 165, 168], ["Zika virus infection", "DISEASE", 108, 128], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 191, 214], ["chikungunya virus infection", "DISEASE", 228, 255], ["encephalitis", "DISEASE", 257, 269], ["myelitis", "DISEASE", 275, 283], ["patients", "ORGANISM", 23, 31], ["Zika virus", "ORGANISM", 108, 118], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["PNS", "ANATOMICAL_SYSTEM", 165, 168], ["Guillain-Barr\u00e9", "ORGANISM", 191, 205], ["chikungunya virus", "ORGANISM", 228, 245], ["patients", "SPECIES", 23, 31], ["chikungunya virus", "SPECIES", 228, 245], ["Zika virus", "SPECIES", 108, 118], ["chikungunya virus", "SPECIES", 228, 245], ["Zika virus infection", "PROBLEM", 108, 128], ["various CNS", "PROBLEM", 149, 160], ["PNS manifestations", "PROBLEM", 165, 183], ["Barr\u00e9 syndrome", "PROBLEM", 200, 214], ["chikungunya virus infection", "PROBLEM", 228, 255], ["encephalitis", "PROBLEM", 257, 269], ["myelitis", "PROBLEM", 275, 283], ["Barr\u00e9 syndrome", "OBSERVATION", 200, 214], ["encephalitis", "OBSERVATION", 257, 269]]], ["The overall effect of arboviral outbreaks on neurology services is large: 148 (10%) of our 1410 neurology department admissions over 2 years were patients with laboratory-confirmed arboviral infection.", [["arboviral infection", "DISEASE", 181, 200], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["arboviral infection", "PROBLEM", 181, 200], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["effect", "OBSERVATION_MODIFIER", 12, 18], ["arboviral", "OBSERVATION_MODIFIER", 22, 31], ["large", "OBSERVATION_MODIFIER", 67, 72], ["arboviral infection", "OBSERVATION", 181, 200]]], ["We see about 70% of all neurological patients in the public health system of Pernambuco (popula tion 9\u00b75 million), so we believe that our findings are fairly representative.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45]]], ["Clinicians and public health officials need to be aware of the wide spectrum of neurological diseases linked to arboviruses and appreciate that dual infection is common and might affect disease pattern and severity.", [["neurological", "ANATOMY", 80, 92], ["neurological diseases", "DISEASE", 80, 101], ["arboviruses", "DISEASE", 112, 123], ["infection", "DISEASE", 149, 158], ["neurological diseases", "PROBLEM", 80, 101], ["arboviruses", "PROBLEM", 112, 123], ["dual infection", "PROBLEM", 144, 158], ["disease pattern and severity", "PROBLEM", 186, 214], ["infection", "OBSERVATION", 149, 158], ["severity", "OBSERVATION_MODIFIER", 206, 214]]]], "6d933440ebabd5b2625d7da6628ec1951cb94e55": [["BackgroundVietnam's HIV epidemic has stabilized after peaking in the early 2000s.", [["HIV epidemic", "DISEASE", 20, 32], ["HIV", "SPECIES", 20, 23], ["BackgroundVietnam's HIV epidemic", "PROBLEM", 0, 32]]], ["However, HIV still remains a public health threat in Vietnam, with an estimated 220,000 to 280,000 people living with HIV (PLHIV) and 11,000 new HIV infections in 2017 [1] .", [["HIV", "DISEASE", 118, 121], ["HIV infections", "DISEASE", 145, 159], ["HIV", "ORGANISM", 9, 12], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 9, 12], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 145, 148], ["HIV", "PROBLEM", 9, 12], ["new HIV infections", "PROBLEM", 141, 159]]], ["The HIV epidemic is concentrated in key populations, including people who inject drugs; 45% of new infections in 2013 occurred among men who shared needles when injecting drugs [2] .BackgroundOver the last two decades, large international cooperation networks have supported antiretroviral therapy (ART) in Vietnam, including, but not limited to, the United States' President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.", [["infections", "DISEASE", 99, 109], ["AIDS", "DISEASE", 397, 401], ["AIDS", "DISEASE", 447, 451], ["Tuberculosis", "DISEASE", 453, 465], ["Malaria", "DISEASE", 470, 477], ["people", "ORGANISM", 63, 69], ["men", "ORGANISM", 133, 136], ["HIV", "SPECIES", 4, 7], ["people", "SPECIES", 63, 69], ["men", "SPECIES", 133, 136], ["HIV", "SPECIES", 4, 7], ["The HIV epidemic", "PROBLEM", 0, 16], ["drugs", "TREATMENT", 81, 86], ["new infections", "PROBLEM", 95, 109], ["antiretroviral therapy", "TREATMENT", 275, 297], ["AIDS Relief", "TREATMENT", 397, 408], ["Fight AIDS", "PROBLEM", 441, 451], ["Tuberculosis", "PROBLEM", 453, 465], ["Malaria", "PROBLEM", 470, 477], ["HIV", "OBSERVATION", 4, 7], ["concentrated", "OBSERVATION_MODIFIER", 20, 32], ["large", "OBSERVATION_MODIFIER", 219, 224], ["antiretroviral therapy", "OBSERVATION", 275, 297], ["Tuberculosis", "OBSERVATION", 453, 465], ["Malaria", "OBSERVATION", 470, 477]]], ["However, as Vietnam's economy has grown, these organizations have been phasing out their activities in Vietnam; the largest source of international aid, the PEPFAR program, will end its direct support for ART by the end of 2019.BackgroundTo sustainably finance the maintenance and expansion of HIV care and treatment, Vietnam is now shifting toward integrating HIV services into the public health system using social health insurance (SHI).", [["HIV", "ORGANISM", 361, 364], ["HIV", "SPECIES", 294, 297], ["HIV", "SPECIES", 361, 364], ["HIV care", "TREATMENT", 294, 302], ["treatment", "TREATMENT", 307, 316]]], ["With the goal of universal coverage, the Vietnamese government issued the first SHI law (Decree No. 63) in 2008, which expanded coverage to people experiencing poverty by fully subsidizing premiums for this group and informal-sector workers.", [["poverty", "DISEASE", 160, 167], ["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["universal coverage", "TREATMENT", 17, 35]]], ["To increase universal health coverage, the SHI law was revised in 2014 and SHI became mandatory for all citizens [3] .", [["universal health coverage", "TREATMENT", 12, 37]]], ["According to a report from the Vietnam Social Security (VSS), Vietnam has achieved a remarkable increase in SHI coverage; the number of health insurance card holders reached 83.5 million (88.5% of the total population) in 2019 [4] .", [["SHI coverage", "TREATMENT", 108, 120]]], ["As part of the transition from donor-based to SHI-based HIV service delivery, a Prime Minister's Decision (No. 2188/QD-TTg) was issued in 2016 that introduced a new goal of 100% SHI coverage (hereafter referred to \"universal SHI coverage\") for PLHIV by 2020.", [["HIV", "ORGANISM", 56, 59], ["HIV", "SPECIES", 56, 59]]], ["As a result, SHI coverage for PLHIV improved dramatically from 40% in 2014 [5] to more than 85% in 2018 [6] .BackgroundThe HIV finance transition includes the move from a centralized to a decentralized HIV service delivery system.", [["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 202, 205], ["PLHIV", "PROBLEM", 30, 35], ["a decentralized HIV service delivery system", "TREATMENT", 186, 229]]], ["As ART has been provided free of charge mainly owing to the support of international donors, many HIV patients are currently served by central urban hospitals and receive better quality of care.", [["donors", "ORGANISM", 85, 91], ["HIV", "ORGANISM", 98, 101], ["patients", "ORGANISM", 102, 110], ["HIV", "SPECIES", 98, 101], ["patients", "SPECIES", 102, 110], ["HIV", "SPECIES", 98, 101], ["international donors", "TREATMENT", 71, 91]]], ["However, to be eligible for SHI coverage for HIV services, PLHIV must obtain a SHI card that can be used only in a SHI-registered health facility near their registered residence or in samelevel facilities of a SHI-registered hospital/clinic in the same province.", [["HIV", "SPECIES", 45, 48], ["HIV services", "TREATMENT", 45, 57]]], ["Although SHI coverage and decentralization improve access to HIV services at lower levels of care, they may pose new challenges for PLHIV who have been receiving ART free of charge at higherlevel hospitals [7] .", [["HIV", "SPECIES", 61, 64], ["SHI coverage", "TREATMENT", 9, 21], ["HIV services", "TREATMENT", 61, 73]]], ["For example, many district-and commune-level HIV clinics have insufficient capacity and experience for HIV care and treatment, so that essential laboratory tests to monitor ART effectiveness, such as the viral load (VL) test, are often not available.", [["HIV", "ORGANISM", 45, 48], ["HIV", "SPECIES", 45, 48], ["HIV", "SPECIES", 103, 106], ["insufficient capacity", "PROBLEM", 62, 83], ["HIV care", "TREATMENT", 103, 111], ["treatment", "TREATMENT", 116, 125], ["essential laboratory tests", "TEST", 135, 161], ["the viral load (VL) test", "TEST", 200, 224]]], ["Furthermore, owing to the lack of privacy of health care, PLHIV may face difficulties keeping their HIV status confidential if they regularly visit local HIV clinics [8, 9] .BackgroundThe above-mentioned transition seems to be progressing rapidly owing to strong political commitments rather than patient-centered approaches [10] .", [["patient", "ORGANISM", 297, 304], ["patient", "SPECIES", 297, 304], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 154, 157], ["privacy of health care", "TREATMENT", 34, 56], ["face difficulties", "PROBLEM", 68, 85]]], ["To achieve universal health coverage and to ensure a decentralized service delivery system that meets the needs of PLHIV, it is important to listen carefully to patients' voices to safeguard the continuation of effective, local HIV treatment, and to prevent patients from worrying about the new health system.", [["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 258, 266], ["HIV", "SPECIES", 228, 231], ["universal health coverage", "TREATMENT", 11, 36], ["a decentralized service delivery system", "TREATMENT", 51, 90], ["PLHIV", "TREATMENT", 115, 120], ["local HIV treatment", "TREATMENT", 222, 241]]], ["Therefore, this study was designed to investigate the current SHI coverage situation and patients' perspectives on the transition in the HIV service delivery system, and to provide possible solutions to reduce the negative impacts of the transition.Study design and study subjectsWe conducted a self-administered questionnaire survey using a hospital-based cohort of PLHIV on ART (aged \u226518 years) in October and November 2018.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["HIV", "SPECIES", 137, 140], ["this study", "TEST", 11, 21], ["solutions", "TREATMENT", 190, 199], ["Study design", "TEST", 249, 261], ["study subjects", "TEST", 266, 280], ["negative", "OBSERVATION", 214, 222]]], ["This cohort, the so-called \"Hanoi cohort,\" was established in 2007 at the HIV outpatient clinic at the National Hospital for Tropical Diseases (NHTD), one of the largest central-level HIV clinics in Hanoi, Vietnam.", [["Tropical Diseases", "DISEASE", 125, 142], ["NHTD", "DISEASE", 144, 148], ["HIV", "SPECIES", 74, 77], ["Tropical Diseases", "PROBLEM", 125, 142], ["Diseases", "OBSERVATION", 134, 142]]], ["At the time of the survey, the Hanoi cohort participants were still regularly receiving ART and other HIV services in NHTD, and they were invited to complete the survey during their regular consultations.", [["participants", "SPECIES", 44, 56], ["HIV", "SPECIES", 102, 105]]], ["Individuals who provided informed consent participated in the survey on the same day as their consultation.Study design and study subjectsTo develop the questionnaire used in this survey, an expert panel was formed by HIV/AIDS specialists, including HIV clinicians, social workers, and a social epidemiologist.", [["HIV/AIDS", "DISEASE", 218, 226], ["HIV", "ORGANISM", 218, 221], ["HIV", "ORGANISM", 250, 253], ["HIV", "SPECIES", 250, 253], ["HIV", "SPECIES", 218, 221], ["HIV", "SPECIES", 250, 253], ["Study design", "TEST", 107, 119], ["study subjects", "TEST", 124, 138], ["an expert panel", "TEST", 188, 203]]], ["The panel developed the questionnaire and response options using information from previous relevant reports [10, 11] and experiences in day-to-day clinical practice.SHI coverageSHI coverage was evaluated by asking whether participants had a valid SHI card.", [["participants", "SPECIES", 222, 234], ["The panel", "TEST", 0, 9], ["SHI coverageSHI coverage", "TREATMENT", 165, 189]]], ["Participants who did not have a SHI card were asked to provide reasons using the question \"Why don't you have a SHI card?\"", [["Participants", "SPECIES", 0, 12]]], ["Participants could select as many responses as were applicable.", [["Participants", "SPECIES", 0, 12]]], ["If they selected \"Other,\" they were able to provide reasons (although this was optional).Concerns about receiving HIV services in SHI-registered hospitals/clinicsThe presence of perceived concerns about receiving HIV services in SHI-registered hospitals/clinics was evaluated with the question \"Do you have any concerns about receiving HIV services in your SHI-registered health facilities?\"; possible responses were \"yes\" or \"no.\"", [["HIV", "SPECIES", 114, 117], ["HIV", "SPECIES", 213, 216], ["HIV", "SPECIES", 336, 339], ["HIV services", "TREATMENT", 213, 225]]], ["Participants with perceived concerns were then asked about the nature of their concerns; possible responses were \"Disclosure of HIV status to neighbors,\" \"Low quality of HIV services,\" \"Fear of not getting along with unfamiliar medical staffs,\" and \"Other.\"", [["Participants", "SPECIES", 0, 12], ["HIV", "SPECIES", 170, 173]]], ["Participants could select as many items as were applicable.", [["Participants", "SPECIES", 0, 12]]], ["If they selected \"Other,\" they were able to provide reasons (although this was optional).Willingness to regularly visit the current hospitalPatients' willingness to regularly visit their current hospital was evaluated with the question \"Are you willing to continue visiting NHTD every 6 months for VL monitoring after being transferred to the SHI-registered local hospital/clinic?\"", [["Patients", "ORGANISM", 140, 148], ["Patients", "SPECIES", 140, 148], ["VL monitoring", "TEST", 298, 311]]], ["Participants who responded \"yes\" were further asked about their reasons, and possible responses were \"I think that VL monitoring is beneficial for me,\" \"I want to keep in contact with NHTD,\" \"I want to meet staffs here,\" and \"Other.\"", [["NHTD", "DISEASE", 184, 188], ["Participants", "SPECIES", 0, 12]]], ["Participants could select as many items as were applicable.", [["Participants", "SPECIES", 0, 12]]], ["If they selected \"Other,\" they were able to provide reasons (although this was optional).Demographics and HIV-related factorsThe following data on demographic and HIV-related factors were collected: sex, age, history of injection drug use (IDU), duration of receiving HIV services at NHTD, marital status, residence, educational attainment, employment, individual income, and disclosure of HIV status.", [["HIV", "SPECIES", 106, 109], ["HIV", "SPECIES", 268, 271], ["HIV", "SPECIES", 390, 393], ["HIV services", "TREATMENT", 268, 280], ["HIV status", "PROBLEM", 390, 400]]], ["History of IDU was divided into two categories: IDU (ever used injection drugs) and non-IDU (never used injection drugs).", [["IDU", "CHEMICAL", 48, 51], ["non-IDU", "CHEMICAL", 84, 91], ["injection drugs", "TREATMENT", 63, 78], ["injection drugs", "TREATMENT", 104, 119]]], ["Duration of receiving HIV services at NHTD was divided into the following categories using 25th and 75th percentile values: < 5 years, 5-9 years, and \u2265 10 years.", [["HIV", "ORGANISM", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV services", "TREATMENT", 22, 34]]], ["Individual income was divided into the following categories according to monthly income per capita in 2012, as reported by the General Statistics Office of Vietnam [12] : low (< 1,500, 000 Vietnamese dong [VND]), middle (1,500,000-4,999, 999 VND), and high (\u22655,000,000 VND) (1 VND = 0.000043 USD).", [["middle", "ANATOMY_MODIFIER", 213, 219]]], ["Disclosure of HIV status was evaluated dichotomously.", [["HIV", "ORGANISM", 14, 17], ["HIV", "SPECIES", 14, 17], ["HIV status", "PROBLEM", 14, 24], ["HIV", "OBSERVATION", 14, 17]]], ["Educational attainment was divided into three groups based on the fact that the primary school enrollment rate reached over 90% and the tertiary education enrollment rate reached 25 to 30% in 2018 [13] : low (never went to school, primary school, or junior high school), middle (high school), and high (vocational school/college or university).Statistical analysisBaseline characteristics were summarized for all participants.", [["participants", "SPECIES", 413, 425], ["enrollment rate", "TEST", 155, 170]]], ["We calculated SHI coverage, the proportion of participants who had concerns about receiving HIV services in SHI-registered hospitals/clinics, and the proportion of participants willing to regularly visit the current hospital, and then summarized the reasons for not having a SHI card, the nature of concerns, and reasons for the willingness to regularly attend the current hospital.", [["participants", "SPECIES", 46, 58], ["participants", "SPECIES", 164, 176], ["HIV", "SPECIES", 92, 95]]], ["Logistic regression analyses were then performed to analyze the factors associated with \"not having a SHI card\" and \"having concerns about receiving HIV services in SHI-registered hospitals/clinics,\" and crude and multivariate-adjusted odds ratios (OR) were calculated.", [["HIV", "SPECIES", 149, 152], ["Logistic regression analyses", "TEST", 0, 28]]], ["In the multivariate analyses, we used variables that had p-values < 0.05 in the univariate analysis for adjustment.", [["p-values", "TEST", 57, 65], ["the univariate analysis", "TEST", 76, 99]]], ["As a sensitivity analysis, we conducted multivariate analyses using a stepwise selection method for all variables (inclusion and exclusion criteria = 0.2 for each).Statistical analysisAll analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).", [["a sensitivity analysis", "TEST", 3, 25], ["multivariate analyses", "TEST", 40, 61], ["a stepwise selection method", "TREATMENT", 68, 95], ["exclusion criteria", "TEST", 129, 147], ["Statistical analysis", "TEST", 164, 184], ["All analyses", "TEST", 184, 196], ["SAS", "TEST", 218, 221]]], ["All tests were twosided, with the significance level set at 5%.", [["All tests", "TEST", 0, 9]]], ["Missing data were excluded from the analyses.Study participantsSince October 2007, 1820 patients had registered for the Hanoi cohort, and 1348 were still enrolled and underwent follow-up in October and November 2018.", [["patients", "ORGANISM", 88, 96], ["participants", "SPECIES", 51, 63], ["patients", "SPECIES", 88, 96], ["Missing data", "TEST", 0, 12], ["the analyses", "TEST", 32, 44]]], ["All patients agreed to participate in the survey (response rate: 100%).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["response rate", "TEST", 50, 63]]], ["In all, 58.3% of participants were males.", [["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29]]], ["Furthermore, 22.9% of participants had a history of IDU, and nearly 90% had been receiving HIV services at NHTD for 5 years or longer.", [["IDU", "DISEASE", 52, 55], ["participants", "ORGANISM", 22, 34], ["participants", "SPECIES", 22, 34], ["HIV", "SPECIES", 91, 94], ["HIV services", "TREATMENT", 91, 103]]], ["Approximately one-third lived in provinces far from Hanoi (there was even one participant who lived in Hue, a city in the middle of Vietnam).SHI coverage and reasons for not having a SHI cardIn total, 1051 (78.0%) participants had a SHI card; of these, 35.3% were registered at district-level hospitals/ clinics and 21.4% at commune-level hospitals/clinics (Fig. 1) .", [["participants", "ORGANISM", 214, 226], ["participant", "SPECIES", 78, 89], ["participants", "SPECIES", 214, 226]]], ["Of the 187 participants who did not have a SHI card, the most frequently reported reason was that obtaining a card \"felt burdensome\" (44.4%), followed by \"don't know how to get it\" (20.9%) and \"cannot afford it\" (17.1%).", [["participants", "SPECIES", 11, 23]]], ["Some other reasons reported were \"fear of revealing HIV status\" and \"don't feel that it's necessary\" (Fig. 2 ).Concerns about receiving HIV services in SHI-registered hospitals/clinicsIn total, 1167 (86.6%) participants had concerns about receiving HIV services in SHI-registered hospitals/ clinics.", [["HIV", "SPECIES", 136, 139], ["participants", "SPECIES", 207, 219], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 136, 139], ["HIV", "SPECIES", 249, 252], ["HIV status", "PROBLEM", 52, 62]]], ["Of these, 84.2% were concerned about disclosure of their HIV status to neighbors and 53.0% were concerned about the low quality of HIV services.", [["HIV", "ORGANISM", 131, 134], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 131, 134], ["HIV services", "TREATMENT", 131, 143]]], ["Some other concerns reported were \"not wishing to change hospital\" and \"influence on work or family\" (Fig. 3) .Willingness to regularly visit the current hospitalThere were 1232 (91.4%) participants who were willing to continue visiting NHTD after being transferred to SHI-registered local hospitals/clinics.", [["participants", "SPECIES", 186, 198]]], ["The most frequently reported reason for their willingness was \"I want to keep in contact with NHTD\" (81.5%) followed by \"I think that VL monitoring is beneficial for me\" (79.9%) and \"I want to meet staffs here\" (58.9%) (Fig. 4 ).Willingness to regularly visit the current hospitalFactors associated with not having a SHI card and having concerns about receiving HIV services in SHI-registered hospitals/clinics Table 2 shows ORs and 95% confidence intervals (95% CI) for the univariate and multivariate logistic regression models with not having a SHI card as the outcome variable.Willingness to regularly visit the current hospitalIn the univariate model, age (< 40 years old) (OR = 1.48, 95% CI: 1.09-2.03 vs. \u226540 years old) and not being married (OR = 1.74, 95% CI: 1.09-2.77 vs. being married) were significantly associated with not having a SHI card.", [["NHTD", "DISEASE", 94, 98], ["HIV", "SPECIES", 362, 365], ["the univariate", "TEST", 471, 485], ["CI", "TEST", 694, 696], ["CI", "TEST", 765, 767]]], ["In the multivariate model, both age (< 40 years old) (OR = 1.46, 95% CI: 1.02-2.08 vs. \u226540 years old) and not being married (OR = 1.64, 95% CI: 1.02-2.62 vs. being married) remained significant, which was consistent with the results of the multivariate model using the stepwise selection method.", [["CI", "TEST", 69, 71], ["CI", "TEST", 140, 142], ["the stepwise selection method", "TREATMENT", 265, 294], ["significant", "OBSERVATION_MODIFIER", 182, 193]]], ["Table 3 shows ORs and 95% CIs for the univariate and multivariate logistic regression models with having concerns about receiving HIV services in SHI-registered hospitals/clinics as the outcome variable.", [["HIV", "SPECIES", 130, 133]]], ["In theDiscussionIn this study, we evaluated patients' perspectives on the current transition of the HIV service delivery system in Vietnam.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["HIV", "SPECIES", 100, 103], ["this study", "TEST", 19, 29], ["the HIV service delivery system", "TREATMENT", 96, 127]]], ["The SHI coverage was 78.0%; over half the participants were SHI-registered at district-or communelevel clinics.", [["participants", "ORGANISM", 42, 54], ["participants", "SPECIES", 42, 54], ["The SHI coverage", "TREATMENT", 0, 16]]], ["Most participants had concerns about receiving HIV services in SHI-registered hospitals/clinics; the most frequently reported concerns were disclosure of HIV status to neighbors and low quality of HIV services.", [["participants", "SPECIES", 5, 17], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 154, 157], ["HIV", "SPECIES", 197, 200], ["HIV status", "PROBLEM", 154, 164], ["HIV services", "TREATMENT", 197, 209]]], ["Over 90% of participants were willing to continue regularly visiting NHTD after being transferred to SHIregistered local clinics.Toward universal SHI coverageThe transition of HIV finance is not an issue only in Vietnam.", [["participants", "ORGANISM", 12, 24], ["HIV", "ORGANISM", 176, 179], ["participants", "SPECIES", 12, 24], ["HIV", "SPECIES", 176, 179], ["universal SHI coverage", "TREATMENT", 136, 158]]], ["As international funding decreases, many lowand middle-income countries are now making efforts to increase domestic resources to fill the gap [14, 15] .", [["decreases", "OBSERVATION_MODIFIER", 25, 34], ["middle", "ANATOMY_MODIFIER", 48, 54]]], ["In 2018, approximately 56% of the total resources for HIV in low-and middle-income countries were from domestic sources [16] .", [["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 54, 57], ["the total resources", "TREATMENT", 30, 49], ["HIV", "PROBLEM", 54, 57], ["middle", "ANATOMY_MODIFIER", 69, 75]]], ["Although challenging for those countries, a shift toward domestic funding has advantages in terms of ownership, accountability, and sustainability of the national HIV response [17] .", [["HIV", "SPECIES", 163, 166], ["domestic funding", "TREATMENT", 57, 73]]], ["At NHTD, one of the largest HIV clinics in Hanoi, the SHI coverage was 78%, indicating that SHI enrollment has been rapidly progressing (40% in 2014 [5] ), 7), \"feeling no necessity\" (4), \"just changed jobs\" (3), \"no time\" (2), \"forgot\" (1), and \"NA\" (18) .", [["HIV", "SPECIES", 28, 31], ["the SHI coverage", "TREATMENT", 50, 66], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["rapidly", "OBSERVATION_MODIFIER", 116, 123], ["progressing", "OBSERVATION_MODIFIER", 124, 135]]], ["SHI: social health insurance but that universal SHI coverage has not been reached.", [["universal SHI coverage", "TREATMENT", 38, 60]]], ["Although previous reports have highlighted financial burden as the main barrier to SHI access [11, 18] , in this study, the most frequently reported reasons for not having a SHI card were that obtaining one was burdensome and there was a lack of information about accessing SHI, rather than financial problems.", [["this study", "TEST", 108, 118]]], ["Various recent policies and schemes introduced by central and local government (e.g., subsidies for premiums for people living in poverty and near-poverty, allocation of local budgets for purchasing SHI cards) might have successfully contributed to the expansion of SHI.", [["people", "ORGANISM", 113, 119], ["SHI", "PROTEIN", 266, 269], ["people", "SPECIES", 113, 119]]], ["This interpretation should be tested in other settings, as our study participants at NHTD may be receiving better financial support from local government and other authorities; such support may vary between provinces depending on their financial resources and commitment to HIV prevention and control.Toward universal SHI coverageFeeling that it was burdensome to obtain a SHI card and lacking information on how to obtain a SHI card were the most frequently reported reasons for not having one, and younger age (< 40 years old) and being unmarried were identified as possible risk factors.", [["participants", "SPECIES", 69, 81], ["HIV", "SPECIES", 274, 277], ["our study", "TEST", 59, 68], ["HIV prevention", "TREATMENT", 274, 288], ["universal SHI coverage", "TREATMENT", 308, 330]]], ["A burdensome feeling could arise for various reasons, including complicated administrative procedures for SHI registration, long waiting times, or feeling that a card is not necessary [11] .", [["A burdensome feeling", "PROBLEM", 0, 20], ["SHI registration", "TREATMENT", 106, 122]]], ["As SHI cards are issued based on residential information, disclosure of HIV status to others at the time of obtaining a card may be an additional reason for not having one.", [["HIV", "ORGANISM", 72, 75], ["HIV", "SPECIES", 72, 75], ["HIV status", "PROBLEM", 72, 82]]], ["Alternatively, the reported lack of information about obtaining SHI cards may reflect patient lack of interest in SHI, as well as problems related to availability and accessibility of information.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93]]], ["In particular, it may be difficult for younger people to understand the benefits of SHI, and unmarried persons might be less motivated to enroll into SHI.", [["people", "ORGANISM", 47, 53], ["persons", "ORGANISM", 103, 110], ["people", "SPECIES", 47, 53], ["persons", "SPECIES", 103, 110]]], ["In a previous study, we found that family is often the only and the strongest supporter of PLHIV [20] .", [["a previous study", "TEST", 3, 19]]], ["Raising awareness of the necessity and benefits of SHI, especially among younger and unmarried individuals, Fig. 3 Concerns about receiving HIV services in SHI-registered hospitals/clinics.", [["HIV", "SPECIES", 140, 143]]], ["Other (n = 41) includes \"not wishing to change hospital\" (16) , \"satisfied with quality of service at NHTD\" (15) , \"convenience\" (5), \"fear of HIV disclosure\" (3) , and other (2) .", [["HIV disclosure", "DISEASE", 143, 157]]], ["NHTD: National Hospital for Tropical Diseases; SHI: social health insurance; VL: viral load and providing support tailored to individual needs (e.g., the most convenient way to register for SHI) for both patients and family could enhance the understanding of SHI enrollment and patients' willingness to join SHI and help to achieve universal SHI coverage.Patients' worries and anxieties during decentralization HIV stigma in the communityParticipants' biggest concern about the decentralization of the HIV service delivery system was disclosure of HIV status to neighbors.", [["NHTD", "DISEASE", 0, 4], ["HIV stigma", "DISEASE", 411, 421], ["patients", "ORGANISM", 204, 212], ["patients", "ORGANISM", 278, 286], ["Patients", "ORGANISM", 355, 363], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 278, 286], ["Patients", "SPECIES", 355, 363], ["Participants", "SPECIES", 438, 450], ["HIV", "SPECIES", 411, 414], ["HIV", "SPECIES", 502, 505], ["HIV", "SPECIES", 548, 551], ["Tropical Diseases", "PROBLEM", 28, 45], ["viral load", "PROBLEM", 81, 91], ["universal SHI coverage", "TREATMENT", 332, 354], ["anxieties", "PROBLEM", 377, 386], ["the HIV service delivery system", "TREATMENT", 498, 529]]], ["In Vietnam, the HIV epidemic is concentrated among high-risk groups (e.g., IDU and sex workers) and many PLHIV live with substantial HIV stigma [21] [22] [23] .", [["HIV stigma", "DISEASE", 133, 143], ["HIV", "SPECIES", 16, 19], ["HIV", "SPECIES", 133, 136], ["the HIV epidemic", "PROBLEM", 12, 28], ["substantial HIV stigma", "PROBLEM", 121, 143]]], ["Over half of the study participants live outside Hanoi, and seeking HIV services far from home is a way of keeping their HIV status confidential and avoiding the negative consequences of disclosure (e.g., effects on work and family).", [["participants", "ORGANISM", 23, 35], ["participants", "SPECIES", 23, 35], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 121, 124]]], ["It is well known that HIVrelated stigma is the main barrier to accessing HIV services [24, 25] .", [["HIV", "ORGANISM", 73, 76], ["HIV", "SPECIES", 73, 76], ["HIVrelated stigma", "PROBLEM", 22, 39]]], ["Therefore, the Vietnamese Ministry of Health issued a stigma reduction guideline in health care settings in 2017 and encouraged HIV clinics to develop an action plan for stigma reduction.", [["stigma reduction", "DISEASE", 170, 186], ["HIV", "SPECIES", 128, 131], ["a stigma reduction guideline", "TREATMENT", 52, 80], ["stigma reduction", "TREATMENT", 170, 186]]], ["Over the past decade, there has been remarkable progress in research on interventions for stigma reduction, and an increase in the number and quality of intervention strategies [26] .", [["interventions", "TREATMENT", 72, 85], ["stigma reduction", "TREATMENT", 90, 106], ["intervention strategies", "TREATMENT", 153, 176], ["remarkable", "OBSERVATION_MODIFIER", 37, 47], ["progress", "OBSERVATION_MODIFIER", 48, 56], ["increase", "OBSERVATION_MODIFIER", 115, 123]]], ["Many research interventions have focused not only on PLHIV and health care workers, but also on local government, non-governmental organizations, community leaders or members, students, family, and women [26, 27] .", [["women", "ORGANISM", 198, 203], ["women", "SPECIES", 198, 203]]], ["Some researchers have suggested that interventions that combine multiple strategies (e.g., information-based approaches, skills building, counseling/support, and contact with affected groups) to address multiple stigma domains (e.g., drivers, facilitators, intersecting stigmas, and manifestations of stigma) may be more effective [26] [27] [28] .", [["interventions", "TREATMENT", 37, 50]]], ["During the HIV service delivery transition, policymakers in Vietnam need to learn lessons from other countries and focus on expanding stigma reduction activities in various fields, to ensure that PLHIV can receive local HIV services without experiencing stigma.Low quality of health services at lower-level health facilitiesNotably, over half of study participants were concerned about the low quality of services in SHI-registered hospitals/clinics.", [["HIV", "SPECIES", 11, 14], ["participants", "SPECIES", 352, 364], ["HIV", "SPECIES", 11, 14], ["HIV", "SPECIES", 220, 223], ["expanding stigma reduction activities", "TREATMENT", 124, 161], ["local HIV services", "TREATMENT", 214, 232], ["stigma", "PROBLEM", 254, 260]]], ["Historically, HIV services in Vietnam have been provided through the preventive medicine system.", [["HIV", "SPECIES", 14, 17]]], ["To decentralize the HIV service delivery system, the Ministry of Health has encouraged prevention-focused facilities to sign contracts with the VSS to allow provision of and reimbursement for HIV/AIDS curative services through the SHI fund [5] .", [["AIDS", "DISEASE", 196, 200], ["HIV", "SPECIES", 20, 23], ["HIV", "SPECIES", 192, 195], ["HIV/AIDS curative services", "TREATMENT", 192, 218]]], ["However, HIV patients do not yet trust the quality of health services at the new local facilities that have signed contracts with the VSS.", [["HIV", "ORGANISM", 9, 12], ["patients", "ORGANISM", 13, 21], ["HIV", "SPECIES", 9, 12], ["patients", "SPECIES", 13, 21], ["HIV", "SPECIES", 9, 12]]], ["Like our study participants, many PLHIV have been receiving ART at urban hospitals for a long time, and their VL has been successfully controlled [29] .", [["PLHIV", "ORGANISM", 34, 39], ["participants", "SPECIES", 15, 27], ["our study", "TEST", 5, 14]]], ["In this context, it is easy to understand that PLHIV worry about being transferred to lower-level facilities just for political reasons, rather than to meet their own needs.Low quality of health services at lower-level health facilitiesIn the present study, many participants showed a willingness to regularly visit NHTD after being transferred to SHI-registered hospitals/clinics.", [["participants", "SPECIES", 263, 275], ["the present study", "TEST", 239, 256]]], ["This suggests that strengthening links between higher-level and lower-level facilities to continuously transfer knowledge and techniques for HIV treatment and care is a possible way to ensure the good quality of HIV services at all levels and to mitigate patients' worries and anxieties.", [["HIV", "ORGANISM", 212, 215], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["HIV", "SPECIES", 141, 144], ["HIV", "SPECIES", 212, 215], ["HIV treatment", "TREATMENT", 141, 154], ["HIV services", "TREATMENT", 212, 224], ["anxieties", "PROBLEM", 277, 286], ["strengthening", "OBSERVATION", 19, 32]]], ["Although NHTD and other large HIV clinics have been organizing HIV training courses for medical doctors who have just started providing HIV treatment, these are mainly classroom lectures based on project-based grants from international organizations.", [["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 63, 66], ["HIV", "SPECIES", 136, 139], ["HIV treatment", "TREATMENT", 136, 149], ["large", "OBSERVATION_MODIFIER", 24, 29], ["HIV", "OBSERVATION", 30, 33]]], ["The Vietnamese Ministry of Health must show stronger leadership to establish an effective hospital network to promote technical assistance in more systematic and practical ways.", [["technical assistance", "TREATMENT", 118, 138]]], ["This would certainly help to achieve 90-90-90 targets in Vietnam.Factors associated with concerns about decentralizationWe found that female and older (\u226540 years old) participants were more likely to report concerns about the decentralization of HIV services.", [["participants", "ORGANISM", 167, 179], ["HIV", "ORGANISM", 246, 249], ["participants", "SPECIES", 167, 179], ["HIV", "SPECIES", 246, 249], ["HIV services", "TREATMENT", 246, 258]]], ["Considering the influence of gender roles on childbearing, women are more likely to be concerned about influences on their children [30] .", [["women", "ORGANISM", 59, 64], ["children", "ORGANISM", 123, 131], ["women", "SPECIES", 59, 64], ["children", "SPECIES", 123, 131]]], ["Indeed, some participants reported that \"It will influence my child's school life\" and \"It will stress my children.\"", [["participants", "SPECIES", 13, 25], ["children", "SPECIES", 106, 114]]], ["Alternatively, the association between older age and having concerns about decentralization might be partly explained by the double stigma of HIV and ageism (i.e., patients are recognized as being too old to have HIV) and higher demands on the quality of health services to address multiple health complications [31] .", [["HIV", "DISEASE", 142, 145], ["ageism", "DISEASE", 150, 156], ["HIV", "ORGANISM", 142, 145], ["patients", "ORGANISM", 164, 172], ["HIV", "SPECIES", 142, 145], ["patients", "SPECIES", 164, 172], ["HIV", "SPECIES", 142, 145], ["HIV", "SPECIES", 213, 216], ["HIV", "PROBLEM", 142, 145], ["HIV", "PROBLEM", 213, 216], ["multiple health complications", "PROBLEM", 282, 311]]], ["Considering that women and older people are more likely to develop psychiatric disorders such as depression [32, 33] and anxiety [34, 35] , which may be triggered by loneliness or social isolation [36, 37] , more attention should be paid to their unique needs to prevent mental illness in these groups.Strengths and limitationsA strength of the present study is the uniqueness of the data, which reflect patients' voices about the current HIV financial and service transition obtained from one of the largest HIV patient cohorts in Vietnam, with a response rate of 100%.", [["psychiatric disorders", "DISEASE", 67, 88], ["depression", "DISEASE", 97, 107], ["anxiety", "DISEASE", 121, 128], ["loneliness", "DISEASE", 166, 176], ["illness", "DISEASE", 278, 285], ["women", "ORGANISM", 17, 22], ["people", "ORGANISM", 33, 39], ["patients", "ORGANISM", 404, 412], ["patient", "ORGANISM", 513, 520], ["women", "SPECIES", 17, 22], ["people", "SPECIES", 33, 39], ["patients", "SPECIES", 404, 412], ["patient", "SPECIES", 513, 520], ["HIV", "SPECIES", 439, 442], ["HIV", "SPECIES", 509, 512], ["psychiatric disorders", "PROBLEM", 67, 88], ["depression", "PROBLEM", 97, 107], ["anxiety", "PROBLEM", 121, 128], ["mental illness in these groups", "PROBLEM", 271, 301], ["the present study", "TEST", 341, 358], ["the data", "TEST", 380, 388], ["a response rate", "TEST", 546, 561]]], ["These findings could contribute to the development of strategies based on patients' perspectives to successfully implement the decentralized HIV service delivery using the SHI fund.", [["patients", "ORGANISM", 74, 82], ["HIV", "ORGANISM", 141, 144], ["patients", "SPECIES", 74, 82], ["HIV", "SPECIES", 141, 144], ["the decentralized HIV service delivery", "TREATMENT", 123, 161]]], ["However, a few limitations should be acknowledged.", [["few", "OBSERVATION_MODIFIER", 11, 14]]], ["First, as this was a single-center study, the participants who were receiving HIV services at a central urban hospital may not be representative of Vietnam's entire HIV population.", [["participants", "ORGANISM", 46, 58], ["participants", "SPECIES", 46, 58], ["HIV", "SPECIES", 78, 81], ["HIV", "SPECIES", 165, 168], ["HIV services", "TREATMENT", 78, 90]]], ["Third, as the purpose of the survey was to urgently assess the needs of HIV patients, the response options that we generated may have been too narrow to fully reflect their opinions.", [["HIV", "ORGANISM", 72, 75], ["patients", "ORGANISM", 76, 84], ["HIV", "SPECIES", 72, 75], ["patients", "SPECIES", 76, 84], ["HIV", "SPECIES", 72, 75], ["HIV patients", "TREATMENT", 72, 84]]], ["However, these responses were selected based on previous reports and experts' opinions about HIV in Vietnam.ConclusionsAlthough SHI coverage has been rapidly progressing, most patients are concerned about disclosure of their HIV status and the quality of services at lower-level facilities, and are willing to maintain contact with their current hospital.", [["HIV", "ORGANISM", 93, 96], ["patients", "ORGANISM", 176, 184], ["HIV", "ORGANISM", 225, 228], ["HIV", "SPECIES", 93, 96], ["patients", "SPECIES", 176, 184], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 225, 228], ["SHI coverage", "TREATMENT", 128, 140]]], ["In response to their voiced concerns, the establishment of a hospital network to strengthen the links between higher-level and lower-level facilities could facilitate good quality HIV services at all levels, mitigate patients' worries and anxieties, and help to achieve the 90-90-90 targets in Vietnam.", [["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["HIV", "SPECIES", 180, 183], ["anxieties", "PROBLEM", 239, 248]]]], "2cab6a693805c161448094a13c6a70a2e7627dcc": [["techniques and implants.", [["techniques and implants", "TREATMENT", 0, 23], ["implants", "OBSERVATION", 15, 23]]], ["3 However, the frequency of talar osteonecrosis in patients with talar fracture dislocation is still higher.", [["talar", "ANATOMY", 28, 33], ["talar", "ANATOMY", 65, 70], ["osteonecrosis", "DISEASE", 34, 47], ["fracture", "DISEASE", 71, 79], ["dislocation", "DISEASE", 80, 91], ["talar", "ORGANISM_SUBDIVISION", 28, 33], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["talar osteonecrosis", "PROBLEM", 28, 47], ["talar fracture dislocation", "PROBLEM", 65, 91], ["talar", "ANATOMY", 28, 33], ["osteonecrosis", "OBSERVATION", 34, 47], ["talar", "ANATOMY", 65, 70], ["fracture dislocation", "OBSERVATION", 71, 91], ["higher", "OBSERVATION_MODIFIER", 101, 107]]], ["Steroid use increases the blood level of fat, which induces microcontusions, leading to osteonecrosis.", [["blood", "ANATOMY", 26, 31], ["fat", "ANATOMY", 41, 44], ["microcontusions", "DISEASE", 60, 75], ["osteonecrosis", "DISEASE", 88, 101], ["Steroid", "CHEMICAL", 0, 7], ["Steroid", "SIMPLE_CHEMICAL", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["fat", "TISSUE", 41, 44], ["Steroid use", "TREATMENT", 0, 11], ["microcontusions", "PROBLEM", 60, 75], ["osteonecrosis", "PROBLEM", 88, 101], ["blood", "ANATOMY", 26, 31], ["fat", "ANATOMY", 41, 44], ["microcontusions", "OBSERVATION", 60, 75], ["osteonecrosis", "OBSERVATION", 88, 101]]], ["5 Delanois and colleagues 12 reported that 20 of 24 subjects with traumatic talar osteonecrosis had a history of steroid therapy.", [["traumatic talar osteonecrosis", "DISEASE", 66, 95], ["steroid", "CHEMICAL", 113, 120], ["steroid", "CHEMICAL", 113, 120], ["talar", "ORGANISM_SUBDIVISION", 76, 81], ["steroid", "SIMPLE_CHEMICAL", 113, 120], ["traumatic talar osteonecrosis", "PROBLEM", 66, 95], ["steroid therapy", "TREATMENT", 113, 128], ["traumatic", "OBSERVATION_MODIFIER", 66, 75], ["talar", "ANATOMY", 76, 81], ["osteonecrosis", "OBSERVATION", 82, 95], ["steroid therapy", "OBSERVATION", 113, 128]]], ["However, no evidence supports the correlation.", [["no evidence supports", "UNCERTAINTY", 9, 29]]]], "ed4cfdbf89d8a58e3d8ad44e7c7abf36e090e933": [["SummaryBackground In countries with declining numbers of confirmed cases of COVID-19, lockdown measures are gradually being lifted.", [["COVID", "TEST", 76, 81], ["lockdown measures", "TREATMENT", 86, 103]]], ["Contact tracing via conventional methods or mobile app technology is central to control strategies during de-escalation of physical distancing.", [["Contact tracing", "TEST", 0, 15], ["mobile app technology", "TREATMENT", 44, 65]]], ["We aimed to identify key factors for a contact tracing strategy to be successful.Methods We evaluated the impact of timeliness and completeness in various steps of a contact tracing strategy using a stochastic mathematical model with explicit time delays between time of infection and symptom onset, and between symptom onset, diagnosis by testing, and isolation (testing delay).", [["infection", "DISEASE", 271, 280], ["a contact tracing strategy", "TREATMENT", 37, 63], ["Methods", "TREATMENT", 81, 88], ["a contact tracing strategy", "TREATMENT", 164, 190], ["a stochastic mathematical model", "TREATMENT", 197, 228], ["infection", "PROBLEM", 271, 280], ["symptom onset", "PROBLEM", 285, 298], ["testing", "TEST", 340, 347], ["isolation (testing delay", "TEST", 353, 377], ["infection", "OBSERVATION", 271, 280]]], ["The model also includes tracing of close contacts (eg, household members) and casual contacts, followed by testing regardless of symptoms and isolation if testing positive, with different tracing delays and coverages.", [["symptoms", "PROBLEM", 129, 137], ["testing positive", "PROBLEM", 155, 171], ["different tracing delays", "PROBLEM", 178, 202]]], ["We computed effective reproduction numbers of a contact tracing strategy (R CTS ) for a population with physical distancing measures and various scenarios for isolation of index cases and tracing and quarantine of their contacts.Findings For the most optimistic scenario (testing and tracing delays of 0 days and tracing coverage of 100%), and assuming that around 40% of transmissions occur before symptom onset, the model predicts that the estimated effective reproduction number of 1\u00b72 (with physical distancing only) will be reduced to 0\u00b78 (95% CI 0\u00b77-0\u00b79) by adding contact tracing.", [["a contact tracing strategy", "TEST", 46, 72], ["R CTS", "TEST", 74, 79], ["physical distancing measures", "TREATMENT", 104, 132], ["isolation of index cases", "TREATMENT", 159, 183], ["tracing", "TEST", 188, 195], ["tracing coverage", "TEST", 313, 329], ["CI", "TEST", 549, 551]]], ["The model also shows that a similar reduction can be achieved when testing and tracing coverage is reduced to 80% (R CTS 0\u00b78, 95% CI 0\u00b77-1\u00b70).", [["a similar reduction", "TREATMENT", 26, 45], ["testing", "TEST", 67, 74], ["tracing coverage", "TEST", 79, 95], ["R CTS", "TEST", 115, 120], ["CI", "TEST", 130, 132]]], ["A testing delay of more than 1 day requires the tracing delay to be at most 1 day or tracing coverage to be at least 80% to keep R CTS below 1.", [["CTS", "DISEASE", 131, 134], ["A testing delay", "TEST", 0, 15], ["the tracing delay", "TEST", 44, 61], ["R CTS", "TEST", 129, 134]]], ["The effect of minimising tracing delay (eg, with appbased technology) declines with decreasing coverage of app use, but app-based tracing alone remains more effective than conventional tracing alone even with 20% coverage, reducing the reproduction number by 17\u00b76% compared with 2\u00b75%.", [["minimising tracing delay", "PROBLEM", 14, 38], ["app", "TEST", 120, 123], ["conventional tracing", "TEST", 172, 192], ["20% coverage", "TREATMENT", 209, 221]]], ["The proportion of onward transmissions per index case that can be prevented depends on testing and tracing delays, and given a 0-day tracing delay, ranges from up to 79\u00b79% with a 0-day testing delay to 41\u00b78% with a 3-day testing delay and 4\u00b79% with a 7-day testing delay.IntroductionMany countries are preparing so-called exit strategies from the COVID-19 lockdown while attempting to successfully control transmission.", [["COVID-19 lockdown", "DNA", 347, 364], ["testing", "TEST", 87, 94], ["tracing delays", "TEST", 99, 113]]], ["Contact tracing, in combination with the quarantine and potential testing of contacts, is considered a key component in a phase when lockdown measures are gradually lifted.", [["Contact tracing", "TEST", 0, 15], ["lockdown measures", "TREATMENT", 133, 150]]], ["[1] [2] [3] [4] [5] [6] [7] [8] Contact tracing is an intervention where an index case with confirmed infection is asked to provide information about contact people who were at risk of acquiring infection from the index case within a given time period before the positive test result.", [["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 195, 204], ["[1] [2] [3] [4] [5] [6] [7] [8", "SIMPLE_CHEMICAL", 0, 30], ["people", "ORGANISM", 158, 164], ["people", "SPECIES", 158, 164], ["Contact tracing", "TEST", 32, 47], ["an intervention", "TREATMENT", 51, 66], ["infection", "PROBLEM", 102, 111], ["acquiring infection", "PROBLEM", 185, 204], ["the positive test result", "PROBLEM", 259, 283], ["infection", "OBSERVATION", 102, 111], ["infection", "OBSERVATION", 195, 204]]], ["These contacts are then traced and informed about their risk, quarantined, and tested if eligible for testing according to national testing guidelines.", [["testing", "TEST", 102, 109]]], ["This requires upscaling of conventional contact tracing capacity.", [["conventional contact tracing capacity", "TEST", 27, 64]]], ["The potential of mobile device apps to support contact tracing is widely discussed and such technology has been used in several countries such as South Korea and Taiwan.", [["mobile device apps", "TREATMENT", 17, 35], ["contact tracing", "TEST", 47, 62], ["mobile device", "OBSERVATION", 17, 30]]], ["Although these countries have successfully reduced case numbers, no causal relationship between use of app technology and epidemic control has yet been shown.", [["app technology", "TREATMENT", 103, 117], ["epidemic control", "TREATMENT", 122, 138]]], ["[9] [10] [11] [12] [13] [14] Many uncertainties remain on the optimal process of contact tracing with conventional methods or mobile apps, on the timing of testing for current or past infection, and on the required coverage of contact tracing needed.IntroductionModelling studies have shown how mobile apps can increase effectiveness of contact tracing compared with conventional approaches, but effectiveness depends on what proportion of the population will use the app consistently for a sufficiently long period of time.", [["[9] [10] [11", "CHEMICAL", 0, 12], ["infection", "DISEASE", 184, 193], ["[9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 0, 28], ["contact tracing", "TEST", 81, 96], ["testing", "TEST", 156, 163], ["past infection", "PROBLEM", 179, 193], ["contact tracing", "TEST", 227, 242], ["IntroductionModelling studies", "TEST", 250, 279], ["contact tracing", "TEST", 337, 352], ["infection", "OBSERVATION", 184, 193]]], ["9 Modelling studies have predicted that contact tracing alone cannot control an outbreak if tracing coverage is too low.", [["Modelling studies", "TEST", 2, 19], ["tracing coverage", "TEST", 92, 108]]], ["2, 15 The tracing coverage needed depends on how much transmission occurs before symptom onset, and on the details of the tracing process.IntroductionIn previous work, we have investigated the impact of timeliness and completeness of case reporting on the effectiveness of surveillance and interventions, 16, 17 and we quantified the timeliness of contact tracing of infected passengers during an airline flight for the 2009 influenza pandemic.", [["influenza pandemic", "DISEASE", 425, 443], ["2, 15", "CHEMICAL", 0, 5], ["The tracing coverage", "TREATMENT", 6, 26], ["surveillance", "TEST", 273, 285], ["interventions", "TEST", 290, 303]]], ["18 In all of these studies, the timing of various steps in the monitoring and intervention chain emerged as a key factor for effectiveness of a public health response.", [["these studies", "TEST", 13, 26], ["the monitoring", "TEST", 59, 73], ["intervention chain", "TREATMENT", 78, 96]]], ["Usually, there are identifiable delays in the response chain that might be crucial to the overall effectiveness of a strategy.IntroductionHere, we analyse in detail the process chain of identifying index cases by symptom reporting, testing of index cases, and subsequent contact tracing, with the aim to inform policy makers on the relative importance of key steps in the process.", [["identifiable delays in the response chain", "PROBLEM", 19, 60], ["a strategy", "TREATMENT", 115, 125], ["testing of index cases", "TEST", 232, 254], ["subsequent contact tracing", "TEST", 260, 286], ["delays", "OBSERVATION_MODIFIER", 32, 38]]], ["We use a mathematical model that reflects the various steps and delays in the contact tracing process to quantify how delays affect the effective repro duction number and the fraction of onward transmission prevented per diagnosed index case.", [["a mathematical model", "TREATMENT", 7, 27]]], ["5, 19Time delays in contact tracingOur starting point is an assumed effective reproduction number (R e ) for COVID-19 of around 1, describing a situation with physical distancing but measures lifted to some extent.", [["contact tracing", "TEST", 20, 35], ["COVID", "TEST", 109, 114], ["some extent", "OBSERVATION_MODIFIER", 202, 213]]], ["We then quantify the relative contribution of the individual components of a contact tracing strategy required to bring and maintain the effective reproduction number with contact tracing (R CTS ) to a value below 1.", [["contact tracing", "TEST", 172, 187]]], ["For simplicity, we do not include transmission in health-care settings, because in settings such as nursing homes, which can be viewed as closed populations, other interventions might be more appropriate.Time delays in contact tracingWe break down the process of contact tracing into two steps (figure 1; appendix p 6).", [["other interventions", "TREATMENT", 158, 177], ["contact tracing", "TEST", 219, 234]]], ["In the first step, an index case acquires the infection (at time T 0 ), then after a short latent period becomes infectious (at time T 1 ) and then possibly symptomatic (at time T 2 ), which here is defined as being eligible for testing.", [["infection", "DISEASE", 46, 55], ["the infection", "PROBLEM", 42, 55], ["infectious", "PROBLEM", 113, 123], ["symptomatic", "PROBLEM", 157, 168], ["testing", "TEST", 229, 236], ["infection", "OBSERVATION", 46, 55], ["infectious", "OBSERVATION", 113, 123], ["possibly", "UNCERTAINTY", 148, 156], ["symptomatic", "OBSERVATION_MODIFIER", 157, 168]]], ["Subsequently, a proportion of these symptomatic individ uals, determined by the testing coverage, gets tested and diagnosed (at time T 3 ).", [["these symptomatic individ uals", "PROBLEM", 30, 60], ["the testing coverage", "TEST", 76, 96], ["symptomatic", "OBSERVATION_MODIFIER", 36, 47]]], ["The time between T 2 and T 3 is called the testing delay (D 1 = T 3 \u2212 T 2 ) and can vary between 0 and 7 days, and in this period individuals might self-quarantine.", [["T 3", "GENE_OR_GENE_PRODUCT", 25, 28], ["the testing delay", "TEST", 39, 56], ["D", "TEST", 58, 59]]], ["We define testing See Online for appendixResearch in contextEvidence before this study We searched PubMed, bioRxiv, and medRxiv for articles published in English from Jan 1 to June 20, 2020, with the following keywords: (\"2019-nCoV\" OR \"novel coronavirus\" OR \"COVID-19\" OR \"SARS-CoV-2\") AND \"contact tracing\" AND \"model*\".", [["coronavirus", "DISEASE", 243, 254], ["SARS", "DISEASE", 274, 278], ["testing", "TEST", 10, 17], ["this study", "TEST", 76, 86], ["bioRxiv", "TREATMENT", 107, 114]]], ["Population-level modelling studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have suggested that isolation and tracing alone might not be sufficient to control outbreaks and additional measures might be required.", [["acute respiratory syndrome coronavirus", "DISEASE", 45, 83], ["SARS-CoV-2", "ORGANISM", 87, 97], ["severe acute respiratory syndrome coronavirus", "SPECIES", 38, 83], ["SARS-CoV-2", "SPECIES", 87, 97], ["level modelling studies", "TEST", 11, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 38, 83], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["tracing", "TEST", 133, 140], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["respiratory syndrome", "OBSERVATION", 51, 71]]], ["However, few studies have focused on the effects of lifting individual measures once the first wave of the epidemic has been controlled.", [["few studies", "TEST", 9, 20], ["lifting individual measures", "TREATMENT", 52, 79], ["the epidemic", "PROBLEM", 103, 115]]], ["A detailed analysis, with special emphasis on the effects of time delays in testing of index patients and tracing of contacts, has not been done.Added value of this studyWe did a systematic analysis of the various steps required in the process of testing and diagnosing an index case as well as tracing and isolating possible secondary cases of the index case.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["A detailed analysis", "TEST", 0, 19], ["this study", "TEST", 160, 170], ["a systematic analysis", "TEST", 177, 198], ["testing", "TEST", 247, 254], ["tracing", "TEST", 295, 302]]], ["We then used a stochastic transmission model that distinguishes between close contacts (eg, household members) and casual contacts to assess which steps and (possible) delays are crucial in determining the effectiveness of a contact tracing strategy.", [["a stochastic transmission model", "TREATMENT", 13, 44], ["a contact tracing strategy", "TREATMENT", 223, 249]]], ["We evaluated how delays and the level of contact tracing coverage influence the effective reproduction number, and how fast contact tracing needs to be to keep the reproduction number below 1.", [["contact tracing coverage", "TREATMENT", 41, 65]]], ["We also analysed what proportion of onward transmission can be prevented with short testing and tracing delays and high contact tracing coverage.", [["short testing", "TEST", 78, 91], ["tracing delays", "TEST", 96, 110]]], ["Assuming that around 40% of transmission occurs before symptom onset, we estimate that keeping the time between symptom onset and testing and isolation of an index case short (<3 days) is imperative for successful contact tracing.", [["symptom onset", "PROBLEM", 112, 125], ["testing", "TEST", 130, 137]]], ["This implies that the process leading from symptom onset to receiving a positive test should be minimised by providing a sufficient number of easily accessible testing facilities.", [["symptom", "PROBLEM", 43, 50], ["a positive test", "TEST", 70, 85]]], ["In addition, reducing contact tracing delays also helps to keep the reproduction number below 1.Implications of all the available evidenceOur analyses highlight that a contact tracing strategy will only contribute to containment of COVID-19 if it can be organised such that delays in the process from symptom onset to isolation of the index case and their contacts are very short.", [["a contact tracing strategy", "TREATMENT", 166, 192]]], ["The process of conventional contact tracing should be reviewed and streamlined, while mobile app technology might offer a tool for speeding up the process.", [["conventional contact tracing", "TEST", 15, 43]]], ["Reducing delay in testing individuals for SARS-CoV-2 should be a key objective of a contact tracing strategy.Implications of all the available evidencecoverage as the proportion of all symptomatic cases that are tested.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV", "SPECIES", 42, 50], ["Reducing delay", "PROBLEM", 0, 14], ["testing individuals", "TEST", 18, 37], ["SARS", "PROBLEM", 42, 46]]], ["After being diagnosed, we assume index cases are isolated with no further transmission.Implications of all the available evidenceThe second step is tracing contacts of the index case, which occurs at time T 4 .", [["index cases", "PROBLEM", 33, 44]]], ["A fraction of those contacts, determined by the tracing coverage, will be found and tested.", [["the tracing coverage", "TEST", 44, 64], ["fraction", "OBSERVATION_MODIFIER", 2, 10]]], ["We assumed that all traced contacts do not transmit any further, either because they are tested and isolated if infected or because they are effectively quarantined.", [["infected", "PROBLEM", 112, 120]]], ["The time between T 3 and T 4 is the tracing delay (D 2 =T 4 -T 3 ), which can range from 0 days (eg, with app technology) to 3 days (with conventional approaches); this range was obtained through personal communications with public health professionals who are working with contact tracing in practice, as well as existing estimates for influenza.", [["influenza", "DISEASE", 337, 346], ["T 3", "CELL", 17, 20], ["the tracing delay", "TEST", 32, 49], ["D", "TEST", 51, 52], ["influenza", "PROBLEM", 337, 346]]], ["18 In this step, tracing coverage is defined as the proportion of contacts detected, which either depends on the capacity of conventional approaches or on the fraction of the population using suitable app technology for screen ing.Strategies consideredWe considered two particular contact tracing strategies: conven tional contact tracing and mobile app technology contact tracing (reproduction number R CTS ).", [["CTS", "DISEASE", 404, 407], ["tracing coverage", "TREATMENT", 17, 33], ["screen", "TEST", 220, 226]]], ["We did not consider hybrid approaches of combined conventional and mobile app-based strategies.", [["hybrid approaches", "TREATMENT", 20, 37], ["mobile app", "TREATMENT", 67, 77]]], ["We compared these strategies with a physical distancing strategy (reproduction number R e ) and an isolation strategy where symptomatic individuals get tested and isolated without subsequent contact tracing (repro duction number R iso ).Strategies consideredAs 100% testing and tracing coverages are difficult to achieve, we defined a best-case scenario with 80% testing and tracing coverage, where people eligible for testing are immediately tested with a very fast test result (testing delay 0 days) and immediate isolation when testing positive.", [["individuals", "ORGANISM", 136, 147], ["people", "ORGANISM", 399, 405], ["people", "SPECIES", 399, 405], ["a physical distancing strategy", "TREATMENT", 34, 64], ["an isolation strategy", "TREATMENT", 96, 117], ["symptomatic individuals", "PROBLEM", 124, 147], ["subsequent contact tracing", "TEST", 180, 206], ["tracing coverages", "TEST", 278, 295], ["tracing coverage", "TEST", 375, 391], ["testing", "TEST", 419, 426], ["testing", "TEST", 531, 538]]], ["In contact tracing strategies, this is followed by immediate tracing of contacts (tracing delay 0 days), who immediately adhere to isolation measures.", [["isolation measures", "TREATMENT", 131, 149]]], ["We consider more realistic scenarios where testing and tracing are suboptimaleg, a con ventional contact tracing strategy-and we vary these parameters separately in a sensitivity analysis (appendix pp 9-12).Effectiveness of contact tracing at the population levelTo analyse the impact of delays in testing and tracing on the effectiveness of contact tracing strategies at the population level, we use a model introduced by Kretzschmar and colleagues, 19 which was adapted for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 483, 521], ["severe acute respiratory syndrome coronavirus", "SPECIES", 476, 521], ["SARS-CoV-2", "SPECIES", 525, 535], ["testing", "TEST", 43, 50], ["tracing", "TEST", 55, 62], ["a con ventional contact tracing strategy", "TEST", 81, 121], ["a sensitivity analysis", "TEST", 165, 187], ["appendix pp", "TEST", 189, 200], ["contact tracing", "TEST", 224, 239], ["delays in testing", "TEST", 288, 305], ["tracing", "TEST", 310, 317], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 476, 521], ["CoV", "TEST", 530, 533], ["acute", "OBSERVATION_MODIFIER", 483, 488], ["respiratory syndrome", "OBSERVATION", 489, 509]]], ["5 The stochastic model describes an epidemic as a branching process with progression through latent infection and an infectious period in time steps of 1 day.", [["infection", "DISEASE", 100, 109], ["a branching process", "PROBLEM", 48, 67], ["latent infection", "PROBLEM", 93, 109], ["stochastic model", "OBSERVATION", 6, 22], ["epidemic", "OBSERVATION_MODIFIER", 36, 44], ["branching", "OBSERVATION_MODIFIER", 50, 59], ["progression", "OBSERVATION_MODIFIER", 73, 84], ["latent", "OBSERVATION_MODIFIER", 93, 99], ["infection", "OBSERVATION", 100, 109], ["infectious", "OBSERVATION_MODIFIER", 117, 127]]], ["Infectivity and probability of symptom onset per day of the infectious period and numbers of contacts per day were fitted to distributions taken from published data.", [["symptom", "PROBLEM", 31, 38], ["infectious", "OBSERVATION", 60, 70]]], ["[20] [21] [22] [23] [24] With these distributions, around 40% of transmissions take place before symp tom onset.", [["[20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 24]]], ["We distinguish between close contacts (eg, household contacts) and casual contacts, which differ in the risk of acquiring infection from the index case.", [["infection", "DISEASE", 122, 131], ["acquiring infection", "PROBLEM", 112, 131], ["infection", "OBSERVATION", 122, 131]]], ["Contact definitions were based on those used in the Polymod study, 23 where a contact is defined as having a two-way con versation of three or more words in physical presence or having physical contact with another person.", [["person", "SPECIES", 215, 221], ["the Polymod study", "TEST", 48, 65]]], ["Additionally, the time required for tracing and isolating infected contacts and the coverage of tracing can differ between these types of contacts and between different types of contact tracing (eg, conventional vs mobile app supported).", [["tracing", "TEST", 36, 43], ["isolating infected contacts", "PROBLEM", 48, 75], ["contact tracing", "TEST", 178, 193], ["infected", "OBSERVATION", 58, 66]]], ["We assume that isolation is perfect-ie, that isolated people do not transmit any longer-and that all traced infected contacts are isolated, regardless of whether they develop symptoms or not.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["symptoms", "PROBLEM", 175, 183]]], ["The model allows for explicit computation of the basic reproduction number R 0 , R e , R iso , and R CTS .", [["CTS", "DISEASE", 101, 104], ["R e , R iso", "TEST", 81, 92], ["R CTS", "TEST", 99, 104]]], ["Reproduction numbers were calculated as expectations, and distributions of individual repro duction numbers were simulated.", [["Reproduction numbers", "TEST", 0, 20], ["individual repro duction numbers", "TEST", 75, 107]]], ["The model was coded in Mathematica 12.1.", [["Mathematica", "TEST", 23, 34]]], ["Further details are presented in the appendix (pp 3-9).Parameter settingsWe assumed that without physical distancing, individuals have on average four close contacts and nine casual contacts per day, with stochastic variability.", [["appendix", "ORGAN", 37, 45], ["pp", "TEST", 47, 49], ["Parameter settings", "TREATMENT", 55, 73], ["appendix", "ANATOMY", 37, 45], ["stochastic variability", "OBSERVATION", 205, 227]]], ["The distributions were fitted to data from the Polymod study for the Netherlands.", [["the Polymod study", "TEST", 43, 60]]], ["We assumed that 80% of all infected people develop symptoms at some time during their infectious period and 20% remain asymptomatic.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["symptoms", "PROBLEM", 51, 59], ["asymptomatic", "PROBLEM", 119, 131], ["infected", "OBSERVATION_MODIFIER", 27, 35]]], ["Symptomatic and asymptomatic cases were assumed to be equally infectious.", [["Symptomatic and asymptomatic cases", "PROBLEM", 0, 34], ["infectious", "OBSERVATION", 62, 72]]], ["The resulting effective Positive test resultParameter settingsPrevented by isolation Prevented by contact tracing reproduction number was R e =1\u00b72.", [["Parameter settings", "TREATMENT", 44, 62]]], ["More details on the parameters are given in the appendix (pp 2-4).Uncertainty of model outcomesWe considered uncertainty due to stochastic variability and uncertainty due to possible variation in parameter estimates.", [["the parameters", "TEST", 16, 30], ["pp", "TEST", 58, 60], ["stochastic variability", "PROBLEM", 128, 150], ["variation in parameter estimates", "PROBLEM", 183, 215], ["appendix", "ANATOMY", 48, 56], ["stochastic variability", "OBSERVATION", 128, 150]]], ["We dealt with stochastic variability by computing individual reproduction numbers for 1000 individuals for all scenarios and plotted their distributions as boxplots.", [["stochastic variability", "OBSERVATION", 14, 36]]], ["Parameter uncertainty was explored by performing simulations using hypercube sampling for transmission probabilities and probabilities of symptom onset per day of the infectious period (appendix pp 9-10).Scenarios modelledFor conventional contact tracing, we assumed baseline values of 80% testing coverage and higher tracing coverage for close contacts than for casual contacts, set at 80% and 50%, respectively.", [["hypercube sampling", "TREATMENT", 67, 85], ["transmission probabilities", "PROBLEM", 90, 116], ["appendix pp", "TEST", 186, 197], ["conventional contact tracing", "TEST", 226, 254], ["testing coverage", "TEST", 290, 306], ["higher tracing coverage", "TREATMENT", 311, 334], ["infectious", "OBSERVATION", 167, 177], ["appendix", "ANATOMY", 186, 194]]], ["We analysed the effect of various testing and tracing delays and tracing coverage on R CTS while keeping the testing coverage at 80%.", [["CTS", "DISEASE", 87, 90], ["various testing", "TEST", 26, 41], ["tracing delays", "TEST", 46, 60], ["tracing coverage", "TEST", 65, 81], ["R CTS", "TEST", 85, 90], ["the testing coverage", "TEST", 105, 125]]], ["For comparison, we also considered the isolation strategy (R iso ), again with testing coverage at 80%.", [["the isolation strategy", "TREATMENT", 35, 57], ["testing coverage", "TREATMENT", 79, 95]]], ["In sensitivity analyses, we varied the testing delay D 1 between 0 and 7 days and the tracing delay D 2 between 0 and 3 days; furthermore, we varied both testing coverage and tracing coverages separately between 20% and 80% in increments of 20 percentage points.", [["tracing coverages", "TEST", 175, 192]]], ["We then compared the effectiveness of conventional contact tracing alone with a scenario in which mobile app technology is used for alerting people to be tested and for tracing contacts; exact parameter values for this comparison are shown in table 1.", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["conventional contact tracing", "TEST", 38, 66], ["exact parameter values", "TEST", 187, 209]]], ["Differences between these strategies were taken as follows.", [["these strategies", "TEST", 20, 36]]], ["The testing delay (D 1 ) is reduced by 4 days with mobile app technology.", [["mobile app technology", "TREATMENT", 51, 72]]], ["We assumed a conventional contact tracing setting in which symptomatic individuals need to decide to seek health care to get tested, and we assumed that with app technology, individuals reporting symptoms to the app are automatically offered a test without having to seek health care.", [["individuals", "ORGANISM", 71, 82], ["symptoms", "PROBLEM", 196, 204], ["a test", "TEST", 242, 248]]], ["For conventional contact tracing, we assumed suboptimal coverage in identifying contacts from the week before diagnosis due to recall bias, especially for casual contacts.", [["conventional contact tracing", "TEST", 4, 32]]], ["For contact tracing with mobile app technology, we assume 80% tracing coverage of the contacts of symptomatic people using mobile app technology as a best-case scenario, but also consider other coverages as detailed below and in table 1.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["mobile app technology", "TREATMENT", 123, 144], ["other coverages", "TREATMENT", 188, 203]]], ["We assume that tracing goes back for 7 days before the positive test result for both strategies.Scenarios modelledNext, we quantified the impact of coverage of testing and mobile app use on the effectiveness of different strategies.", [["tracing", "TEST", 15, 22], ["the positive test result", "PROBLEM", 51, 75], ["coverage of testing", "TREATMENT", 148, 167], ["mobile app", "TREATMENT", 172, 182], ["different strategies", "TREATMENT", 211, 231]]], ["We varied the percentage of app users in the population between 20% and 100% in increments of 20 percentage points.", [["percentage", "OBSERVATION_MODIFIER", 14, 24]]], ["We first considered the situation where testing is provided for 80% of people with symptoms independently of app use, and app use only influences the fraction of contacts that are traced (ie, tracing coverage varies between 20% and 100%).", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["testing", "TEST", 40, 47], ["symptoms", "PROBLEM", 83, 91], ["tracing coverage", "TEST", 192, 208]]], ["Alternatively, we assumed that only app users are tested (ie, testing coverage varies between 20% and 100%), and coverage of tracing also depends on fraction of app use.", [["testing coverage", "TEST", 62, 78]]], ["For isolation-only and conventional contact tracing strategies, we assumed a baseline testing coverage of 80% (see appendix pp 11-12 for sensitivity analyses).", [["a baseline testing coverage", "TEST", 75, 102], ["appendix pp", "TEST", 115, 126], ["sensitivity analyses", "TEST", 137, 157]]], ["For mobile app contact tracing strategies, we varied the testing coverage between 20% and 100%, and assumed 80% as a best-case scenario.", [["the testing coverage", "TREATMENT", 53, 73]]], ["For conventional contact tracing, delays and coverages were chosen to reflect current practice, whereas for mobile app contact tracing, we varied coverages to reflect different levels of app use.", [["conventional contact tracing", "TEST", 4, 32], ["mobile app contact tracing", "TEST", 108, 134]]], ["Finally, we quantified the fraction of transmissions of an index case that can be prevented, and the contribution to the fraction prevented from isolation and from tracing contacts with decreasing delays.", [["the fraction", "PROBLEM", 117, 129], ["decreasing delays", "PROBLEM", 186, 203]]], ["For contacts, this is the fraction of the total infectivity that lies after the time of isolation-ie, the part of infec tiousness that is prevented by contact tracing.", [["the total infectivity", "PROBLEM", 38, 59], ["total", "OBSERVATION_MODIFIER", 42, 47], ["infectivity", "OBSERVATION", 48, 59]]], ["In other words, a contact person who is detected and isolated before the start of their infectious period is counted as a fully prevented transmission, whereas a contact person who is only traced and identified after 70% of their infectivity has passed is counted as 0\u00b73 of a prevented onward transmission.Role of the funding sourceThe funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the manuscript, or the decision to submit for publication.", [["person", "SPECIES", 26, 32], ["person", "SPECIES", 170, 176], ["the study", "TEST", 347, 356], ["data collection", "TEST", 386, 401], ["data analysis", "TEST", 403, 416], ["data interpretation", "TEST", 418, 437], ["infectious", "OBSERVATION", 88, 98]]], ["All authors had full access to all the data in the study and were responsible for the decision to submit the manuscript for publication.ResultsIf 80% of infectious people who develop symptoms are tested and isolated within 1 day after symptom onset, the effective reproduction number R e is expected to decline from 1\u00b72 to an R iso of 1\u00b70 (95% CI 0\u00b79-1\u00b71), using an isolation strategy without contact tracing (figure 2).", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["the study", "TEST", 47, 56], ["symptoms", "PROBLEM", 183, 191], ["symptom onset", "PROBLEM", 235, 248], ["an R iso", "TEST", 323, 331], ["CI", "TEST", 344, 346], ["an isolation strategy", "TREATMENT", 363, 384]]], ["Contact tracing has the potential to further decrease the reproduction number to 0\u00b78 (95% CI 0\u00b77-0\u00b79), as shown by the mobile app contact tracing scenario with 100% testing and tracing (figure 2).", [["Contact tracing", "TEST", 0, 15], ["CI", "TEST", 90, 92], ["tracing", "TEST", 177, 184]]], ["In our predefined best-case scenario, with 80% testing coverage, testing and tracing delays of 0 days, and a tracing coverage of 80%, the model predicts a 30% reduction of R e , down to an R CTS of 0\u00b78 (0\u00b77-1\u00b70).", [["CTS", "DISEASE", 191, 194], ["80% testing coverage", "TREATMENT", 43, 63], ["testing", "TEST", 65, 72], ["a tracing coverage", "TEST", 107, 125], ["an R CTS", "TEST", 186, 194]]], ["However, once the testing delay approaches 2 days, tracing delay needs to be at most 1 day or tracing coverage needs to be at least 80% to keep R CTS below 1 (appendix p 10).", [["CTS", "DISEASE", 146, 149], ["tracing delay", "TEST", 51, 64], ["R CTS", "TEST", 144, 149]]], ["From these scenarios, the reduction of R CTS achieved by implementing the best-case scenario is estimated at 17% (appendix p 10).", [["CTS", "DISEASE", 41, 44], ["R CTS", "TEST", 39, 44]]], ["Once testing delay becomes 3 days or longer, even perfect contact tracing (ie, 100% testing and tracing coverage with no tracing delay) cannot bring R CTS values below 1.ResultsOur assumption that conventional contact tracing has a longer tracing delay and lower tracing coverage than a strategy based on mobile app technology resulted in marked differences in R CTS for the whole range of testing delay (figure 2).", [["CTS", "DISEASE", 151, 154], ["CTS", "DISEASE", 363, 366], ["tracing coverage", "TREATMENT", 96, 112], ["tracing delay", "PROBLEM", 121, 134], ["R CTS values", "TEST", 149, 161], ["conventional contact tracing", "TEST", 197, 225], ["a longer tracing delay", "PROBLEM", 230, 252], ["lower tracing coverage", "TREATMENT", 257, 279], ["mobile app technology", "TREATMENT", 305, 326], ["R CTS", "TEST", 361, 366], ["testing delay", "PROBLEM", 390, 403], ["marked", "OBSERVATION_MODIFIER", 339, 345]]], ["With conventional contact tracing, R CTS would remain above 1 if the testing delay exceeds 0 days, whereas contact tracing based on mobile app technology could still keep R CTS below 1 with a delay of up to 2 days, as long as testing and tracing coverage are at least 80%, or with a testing delay of 1 day if tracing coverage is at least 60%.", [["CTS", "DISEASE", 37, 40], ["CTS", "DISEASE", 173, 176], ["conventional contact tracing", "TEST", 5, 33], ["R CTS", "TEST", 35, 40], ["contact tracing", "TEST", 107, 122], ["R CTS", "TEST", 171, 176], ["tracing coverage", "TEST", 238, 254], ["tracing coverage", "TEST", 309, 325]]], ["If the testing delay reaches 5 days or more, app technology adds little effectiveness to conventional contact tracing or just isolation of symptomatic cases.ResultsThe reductions of R e (based on physical distancing) achieved by isolation of symptomatic cases only, conventional contact tracing, and mobile app-based contact tracing are shown in figure 3A .", [["conventional contact tracing", "TEST", 89, 117], ["symptomatic cases", "PROBLEM", 139, 156], ["The reductions of R e", "TREATMENT", 164, 185], ["conventional contact tracing", "TEST", 266, 294], ["mobile app", "TEST", 300, 310]]], ["For isolation only and for conventional contact tracing, we assumed a delay of 4 days between symptom onset and isolation of the index case.", [["conventional contact tracing", "TEST", 27, 55], ["symptom onset", "PROBLEM", 94, 107]]], ["For the isolation scenario and conventional contact tracing scenario, we assumed a 4-day delay between symptom onset and isolation of the index case.", [["symptom onset", "PROBLEM", 103, 116], ["isolation of the index case", "TREATMENT", 121, 148]]], ["For mobile app contact tracing, testing delay was assumed to be 0 days.", [["mobile app contact tracing", "TEST", 4, 30], ["testing delay", "TEST", 32, 45]]], ["Testing coverage was assumed to be 80% in the isolation and conventional contact tracing scenarios; app use prevalence was assumed to be 60%, 80%, and 100% in the mobile app contact tracing scenario.", [["Testing coverage", "TEST", 0, 16]]], ["The relative reductions are independent of the level of R e , with similar percentage reductions seen when starting from R 0 -ie, in a situation without physical distancing (appendix p 14).", [["reductions", "OBSERVATION_MODIFIER", 13, 23]]], ["At 80% testing coverage, conventional contact tracing, even if applied for all infected individuals with symptoms, is less effective than mobile app-based contact tracing (difference 27\u00b79 percentage points), due to longer tracing delays and lower tracing coverage (figure 3; table 1 ).", [["conventional contact tracing", "TEST", 25, 53], ["all infected individuals", "PROBLEM", 75, 99], ["symptoms", "PROBLEM", 105, 113], ["longer tracing delays", "PROBLEM", 215, 236], ["lower tracing coverage", "TREATMENT", 241, 263]]], ["When considering the distributions of individual reproduction numbers for the assumed testing delaysie, 4 days for isolation and con ventional contact tracing and 0 days for app-based contact tracing-we found that the mean reproduction number was less than 1 only for mobile app-based contact tracing ( figure 3 ).", [["app-based contact tracing", "TEST", 174, 199], ["mobile app", "TEST", 268, 278]]], ["The effectiveness of mobile app-based technology declines with lower fractions of the population using it ( figure 4 ).", [["mobile app", "TREATMENT", 21, 31]]], ["Yet, app-based tracing on its own remains more effective than conventional tracing alone, even with 20% coverage, due to its inherent speed.", [["app", "TEST", 5, 8], ["based tracing", "TEST", 9, 22], ["20% coverage", "TREATMENT", 100, 112]]], ["Even with low coverage, there is a reduction of R e , due to fast tracing of a small part of the population.", [["a reduction of R e", "PROBLEM", 33, 51], ["fast tracing", "TEST", 61, 73], ["low coverage", "OBSERVATION_MODIFIER", 10, 22], ["reduction", "OBSERVATION_MODIFIER", 35, 44], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["Depending on R e , such an approach might be sufficient to reduce R CTS to levels below 1.", [["CTS", "DISEASE", 68, 71], ["R CTS", "TEST", 66, 71]]], ["This can be seen in the distributions of R CTS : when the app is used only for contact tracing (ie, all symptomatic individuals can be tested, regardless of whether they use the app), the means of the R CTS distributions are below 1 when at least 40% of the population are using the app, whereas when the app is used for contact tracing and testing (ie, only app users can be tested), this is the case when at least 60% of the population are using the app ( figure 4) .ResultsWe quantified proportions of transmissions per index case that can be prevented depending on testing delay, stratified by isolation of index cases and tracing delays (table 2).", [["CTS", "DISEASE", 43, 46], ["CTS", "DISEASE", 203, 206], ["contact tracing", "TEST", 79, 94], ["the R CTS distributions", "PROBLEM", 197, 220], ["contact tracing", "TEST", 321, 336], ["testing", "TEST", 341, 348]]], ["In the best-case scenario, with testing and tracing delays of 0 days, 79\u00b79% of transmissions can be prevented if the tracing coverage is 80%.", [["testing", "TEST", 32, 39], ["the tracing coverage", "TEST", 113, 133]]], ["If tracing delay is also increased to 3 days, only 21\u00b70% of onward transmissions can still be prevented.DiscussionUsing a mathematical model that describes the different steps of a contact tracing strategy for COVID-19, we have quantified the relevance of delays and coverage proportions for controlling SARS-CoV-2 transmission.", [["SARS", "DISEASE", 304, 308], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 304, 314], ["SARS-CoV", "SPECIES", 304, 312], ["tracing delay", "PROBLEM", 3, 16], ["COVID", "TEST", 210, 215], ["delays and coverage proportions", "TREATMENT", 256, 287]]], ["We conclude that reducing the testing delay-ie, shortening the time between symptom onset and a positive test result, assuming immediate isolation-is the most import ant factor for improving contact tracing effectiveness.", [["the testing delay", "TEST", 26, 43], ["a positive test result", "PROBLEM", 94, 116]]], ["Reducing the tracing delay-ie, shortening the time to trace contacts, assuming immediate testing and isolation if found positive-might further enhance contact tracing effectiveness.", [["immediate testing", "TEST", 79, 96], ["positive", "PROBLEM", 120, 128]]], ["Yet this additional effect rapidly declines with increasing testing delay.", [["increasing testing delay", "PROBLEM", 49, 73], ["effect", "OBSERVATION_MODIFIER", 20, 26], ["rapidly", "OBSERVATION_MODIFIER", 27, 34], ["declines", "OBSERVATION_MODIFIER", 35, 43], ["increasing", "OBSERVATION_MODIFIER", 49, 59]]], ["The effectiveness of mobile app-based contact tracing declines with lower app use coverage, but it remains more effective than conventional contact tracing even with lower coverage, due to its inherent speed.", [["mobile app", "TEST", 21, 31], ["lower app use coverage", "TREATMENT", 68, 90], ["conventional contact tracing", "TEST", 127, 155], ["lower coverage", "TREATMENT", 166, 180]]], ["If an index case is tested positive and enters this information into the app, other users who have been in contact can be warned immediately, because the app will have recorded these contacts via Bluetooth.Isolation only Isolation plus contact tracingInterventions explored are isolation of only the index case or isolation of the index case with tracing and isolation of 80% of infected contacts, according to tracing delay D 2 , ranging from 0 to 3 days.", [["contact tracingInterventions", "TREATMENT", 236, 264], ["tracing", "TEST", 347, 354], ["isolation", "TREATMENT", 359, 368], ["infected contacts", "PROBLEM", 379, 396]]], ["All interventions are varied by testing delay D 1 , ranging from 0 to 7 days.", [["All interventions", "TREATMENT", 0, 17]]], ["Several factors can reduce the effectiveness of contact tracing, such as large proportions of cases who remain asymptomatic or are otherwise not diagnosed and large proportions of contacts who cannot be traced.", [["contact tracing", "TEST", 48, 63], ["asymptomatic", "PROBLEM", 111, 123]]], ["Low participation does not render contact tracing useless, however, because it could help to locally extinguish clusters before they grow larger.", [["larger", "OBSERVATION_MODIFIER", 138, 144]]], ["In addition, every measure that lowers the effective reproduction number, even if it is already below 1, will lower the cumulative case number and speed up the time until elimination of the virus from the population.Isolation only Isolation plus contact tracingA strength of our approach is that it explicitly takes many details of the contact tracing process into account, such that the key factors can be identified.", [["the virus", "PROBLEM", 186, 195], ["Isolation", "TREATMENT", 216, 225]]], ["A limitation of our approach is that it does not take population age structure into account, which might influence the proportion of asymptomatic cases and mobile app use coverage.", [["asymptomatic cases", "PROBLEM", 133, 151], ["mobile app use coverage", "TREATMENT", 156, 179]]], ["Also, the willingness of a case to self-isolate depends on age and social norms, might be influenced by socioeconomic status, and is affected by perceived benefit of isolation in relation to perceived risk of the infection to others.", [["infection", "DISEASE", 213, 222], ["isolation", "TREATMENT", 166, 175], ["the infection", "PROBLEM", 209, 222], ["infection", "OBSERVATION", 213, 222]]], ["25 We also excluded other hetero geneities while assuming homogeneous mixing, 26, 27 and assumed homogeneously distributed use of app technology for different coverage levels.", [["other hetero geneities", "PROBLEM", 20, 42], ["app technology", "TREATMENT", 130, 144], ["different coverage levels", "TREATMENT", 149, 174], ["hetero geneities", "OBSERVATION", 26, 42], ["homogeneous", "OBSERVATION_MODIFIER", 58, 69]]], ["Clustering of non-users could have consequences for the overall effectiveness of contact tracing, similar to clustering of non-vaccinated people.", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["contact tracing", "TEST", 81, 96]]], ["28 The model also ignores that some contacts of the index case might have self-quarantined with symptoms before they are traced, which lowers the benefits of a contact tracing strategy.Isolation only Isolation plus contact tracingOur study adds to results from other modelling studies, which have shown that contact tracing can be an effective intervention if tracing coverage is high and if the process is fast.", [["symptoms", "PROBLEM", 96, 104], ["a contact tracing strategy", "TREATMENT", 158, 184], ["contact tracing", "TEST", 215, 230], ["Our study", "TEST", 230, 239], ["other modelling studies", "TEST", 261, 284], ["contact tracing", "TEST", 308, 323], ["an effective intervention", "TREATMENT", 331, 356], ["tracing coverage", "TEST", 360, 376]]], ["2, 15 A determining factor is the proportion of transmissions occurring before symptom onset, which determines the urgency of tracing and isolating contacts as fast as possible.", [["2, 15", "CHEMICAL", 0, 5], ["the urgency of tracing", "PROBLEM", 111, 133]]], ["Our study showed in detail what the role is of each step in the contact tracing process in making it successful.", [["Our study", "TEST", 0, 9]]], ["Our model differs from other published models in that it makes a distinction between close and casual contacts and we consider scenarios for conventional contact tracing and mobile app-based contact tracing characterised by specific delays and coverages.Isolation only Isolation plus contact tracingOur finding of the crucial importance of the first step of contact tracing-establishing a diagnosis in cases with symptoms-has important consequences.", [["conventional contact tracing", "TEST", 141, 169], ["contact tracing", "TEST", 191, 206], ["contact tracing", "TEST", 284, 299], ["contact tracing", "TEST", 358, 373], ["symptoms", "PROBLEM", 413, 421]]], ["It requires an infrastructure for testing that allows people with symptoms to be quickly tested and alerted to their results, preferably within 1 day of symptom onset.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["an infrastructure for testing", "TEST", 12, 41], ["symptoms", "PROBLEM", 66, 74], ["symptom onset", "PROBLEM", 153, 166]]], ["Studies have shown that the sensitivity of current PCR tests is low during the first 3 days after infection due to low but steadily increasing viral load in the respiratory tract; 29,30 testing on the fourth day after infection, regardless of symptoms, might therefore be optimal.", [["respiratory tract", "ANATOMY", 161, 178], ["infection", "DISEASE", 98, 107], ["infection", "DISEASE", 218, 227], ["respiratory tract", "ORGANISM_SUBDIVISION", 161, 178], ["current PCR tests", "TEST", 43, 60], ["infection", "PROBLEM", 98, 107], ["steadily increasing viral load in the respiratory tract", "PROBLEM", 123, 178], ["infection", "PROBLEM", 218, 227], ["symptoms", "PROBLEM", 243, 251], ["increasing", "OBSERVATION_MODIFIER", 132, 142], ["viral load", "OBSERVATION", 143, 153], ["respiratory tract", "ANATOMY", 161, 178], ["infection", "OBSERVATION", 218, 227]]], ["However, when more sensitive PCR tests become available, earlier testing might further enhance effectiveness.", [["sensitive PCR tests", "TEST", 19, 38], ["earlier testing", "TEST", 57, 72]]], ["As the clinical symptoms of COVID-19 are mostly mild and heterogeneous, many people should be eligible for testing, resulting in a large proportion of negative test results.", [["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["the clinical symptoms", "PROBLEM", 3, 24], ["COVID", "TEST", 28, 33], ["testing", "TEST", 107, 114], ["mostly", "OBSERVATION_MODIFIER", 41, 47], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70]]], ["Future work should determine the optimal balance between the proportion of negative tests and the effectiveness of contact tracing.Isolation only Isolation plus contact tracingOur findings also provide strong support to optimise contact tracing.", [["contact tracing", "TEST", 115, 130], ["contact tracing", "TEST", 161, 176]]], ["This procedure is labour intensive, time consuming, prone to recall bias, incomplete (anonymous contacts cannot be traced), and usually takes several days.", [["This procedure", "TREATMENT", 0, 14]]], ["Optimising this process by improving testing and tracing capacity, removing testing barriers, and by adding app-based or other digital technologies to minimise tracing delay is needed to establish optimal control of transmission.", [["improving testing", "TEST", 27, 44], ["tracing capacity", "TEST", 49, 65], ["testing barriers", "TREATMENT", 76, 92]]], ["Overall, our findings suggest that an optimised contact tracing strategy, with short delays and high coverage for testing and tracing, could substantially reduce the reproduction number, which would allow alleviation of more stringent control measures.ContributorsMEK and MJMB conceived the study.", [["an optimised contact tracing strategy", "TEST", 35, 72], ["short delays", "PROBLEM", 79, 91], ["testing", "TEST", 114, 121], ["tracing", "TEST", 126, 133], ["more stringent control measures", "TREATMENT", 220, 251], ["the study", "TEST", 287, 296]]], ["MEK designed and programmed the model and produced the output.", [["MEK", "GENE_OR_GENE_PRODUCT", 0, 3], ["MEK", "PROTEIN", 0, 3], ["MEK", "TEST", 0, 3], ["the output", "TEST", 51, 61], ["output", "OBSERVATION_MODIFIER", 55, 61]]], ["MvB, MCJB, and GR helped with the analysis and literature research.", [["GR", "GENE_OR_GENE_PRODUCT", 15, 17], ["MvB", "PROTEIN", 0, 3], ["MCJB", "PROTEIN", 5, 9], ["GR", "PROTEIN", 15, 17], ["MvB", "PROBLEM", 0, 3], ["the analysis", "TEST", 30, 42]]], ["JHHMvdW contributed to data interpretation and writing.", [["JHHMvdW", "PROTEIN", 0, 7]]]], "9e45a7589181a54f58053641b1187908dbfbf18b": [["a b s t r a c tBackground: After the declaration of COVID-19 pandemic on March 11th , 2020, local transmission chains starting in different countries including Canada are forcing governments to take decisions on public health interventions to mitigate the spread of the epidemic.a b s t r a c tMethods: We conduct data-driven and model-free estimations for the growth rates of the COVID-19 epidemics in Italy and Canada, by fitting an exponential curve to the daily reported cases.", [["COVID", "TEST", 52, 57], ["local transmission chains", "TREATMENT", 92, 117], ["public health interventions", "TREATMENT", 212, 239], ["the growth rates", "TEST", 357, 373], ["the COVID", "TEST", 377, 386]]], ["We use these estimates to predict epidemic trends in Canada under different scenarios of public health interventions.a b s t r a c tResults: In Italy, the initial growth rate (0.22) has reduced to 0.1 two weeks after the lockdown of the country on March 8th , 2020.", [["public health interventions", "TREATMENT", 89, 116], ["the initial growth rate", "TEST", 151, 174]]], ["This corresponds to an increase of the doubling time from about 3.15 to almost 7 days.", [["increase", "OBSERVATION_MODIFIER", 23, 31], ["doubling", "OBSERVATION_MODIFIER", 39, 47]]], ["In comparison, the growth rate in Canada has increased from 0.13 between March 1st and 13th, to 0.25 between March 13th to 22nd.", [["the growth rate", "TEST", 15, 30], ["increased", "OBSERVATION_MODIFIER", 45, 54]]], ["However, the case number may be reduced to 4000 if escalated public health interventions could instantly reduce the growth rate to 0.1, the same level achieved in Italy.a b s t r a c tInterpretation: Prompt and farsighted interventions are critical to counteract the very rapid initial growth of the COVID-19 epidemic in Canada.", [["public health interventions", "TREATMENT", 61, 88], ["the growth rate", "TEST", 112, 127], ["Prompt and farsighted interventions", "TREATMENT", 200, 235], ["the COVID", "TEST", 296, 305]]], ["Mitigation plans must take into account the delayed effect of interventions by up to 2-weeks and the short doubling time of 3e4 days.a b s t r a c t\u00a9 2020 The Authors.", [["Mitigation plans", "TREATMENT", 0, 16], ["interventions", "TREATMENT", 62, 75]]], ["This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionSince late December 2019, SARS-CoV-2, a novel coronavirus, has caused a large-scale outbreak that has spread globally, resulting in a pandemic (Wang, Du, Yue, & Chen, 2020) .", [["CC", "CHEMICAL", 41, 43], ["coronavirus", "DISEASE", 171, 182], ["SARS-CoV-2", "ORGANISM", 151, 161], ["coronavirus", "ORGANISM", 171, 182], ["SARS-CoV", "SPECIES", 151, 159], ["SARS", "TEST", 151, 155], ["CoV", "TEST", 156, 159], ["a novel coronavirus", "PROBLEM", 163, 182], ["a large-scale outbreak", "PROBLEM", 195, 217], ["coronavirus", "OBSERVATION", 171, 182], ["large", "OBSERVATION_MODIFIER", 197, 202]]], ["SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus, that is responsible for generally mild respiratory communicable disorders and, occasionally, for severe or even lethal infections (COVID-19) (Adhikari et al., 2020) .", [["SARS", "DISEASE", 0, 4], ["respiratory communicable disorders", "DISEASE", 110, 144], ["infections", "DISEASE", 190, 200], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["single-stranded RNA virus", "PROBLEM", 44, 69], ["generally mild respiratory communicable disorders", "PROBLEM", 95, 144], ["even lethal infections", "PROBLEM", 178, 200], ["positive", "OBSERVATION", 28, 36], ["responsible for", "UNCERTAINTY", 79, 94], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["respiratory", "OBSERVATION", 110, 121], ["communicable disorders", "OBSERVATION", 122, 144]]], ["A series of unprecedented public health interventions enforced in the entire country has contributed to effectively containing the spread of the novel coronavirus in China (Tang et al., 2020a (Tang et al., , 2020b (Tang et al., , 2020c .IntroductionIn Italy, the first case was detected on February 20th , 2020 but the peak time has not passed yet (as of March 22nd), despite a series of gradually enhanced public health interventions (Remuzzi & Remuzzi, 2020; Tuite, Ng, Rees, & Fisman, 2020) .", [["coronavirus", "DISEASE", 151, 162], ["coronavirus", "ORGANISM", 151, 162], ["unprecedented public health interventions", "TREATMENT", 12, 53]]], ["While the stringent package of intervention measures implemented in China may be considered as unsustainable in other countries, the epidemic trajectory in Italy may provide a baseline for Canada to project its infection risk and COVID-19 generated disease burden under feasible scenarios of public health interventions due to substantial similarity of demographic profiles and public health capacity.IntroductionItaly has put in place a series of intervention measures including schools and universities closures (started from February 24th for North Italy, and extended on March 5th to the entire country), lockdown of the country with restriction of movement (enforced from March 8th when the number of cumulative cases reached 7375), closure of all non-essential shops, restaurants and pubs (March 12th when the cumulative cases reached 15,113), and, finally, the closure of all workplaces except for those responsible for essential activities (March 22nd when the cumulative cases reached 59,138).", [["infection", "DISEASE", 211, 220], ["intervention measures", "TREATMENT", 31, 52], ["Canada", "TREATMENT", 189, 195], ["its infection risk", "PROBLEM", 207, 225], ["COVID-19 generated disease burden", "PROBLEM", 230, 263], ["public health interventions", "TREATMENT", 292, 319], ["intervention measures", "TREATMENT", 448, 469], ["closure", "TREATMENT", 738, 745], ["the closure of all workplaces", "TREATMENT", 864, 893], ["infection", "OBSERVATION", 211, 220], ["closure", "OBSERVATION", 868, 875]]], ["Unfortunately, two weeks from the first lockdown, the peak of daily cases and fatalities has not been reached, with more than 5500 daily detected cases and 650 daily deaths as of March 22nd , 2020.IntroductionIn Canada, the first case positive for COVID-19 was identified on January 25th , 2020 (Marchand-Sen ecal et al., 2020).", [["fatalities", "DISEASE", 78, 88], ["deaths", "DISEASE", 166, 172], ["COVID", "TEST", 248, 253]]], ["As of March 22nd , 2020, Canada has reported a total of 1563 cases, with 21 deaths.", [["deaths", "DISEASE", 76, 82]]], ["The different provinces and territories declared state of emergency between March 12th (Quebec) and 22nd (Nova Scotia).", [["different", "OBSERVATION_MODIFIER", 4, 13], ["provinces", "OBSERVATION_MODIFIER", 14, 23]]], ["The Canadian government has issued several intervention measures and has gradually enhanced them.", [["several intervention measures", "TREATMENT", 35, 64]]], ["On March 18th , 2020, the closure of the Canada-US border was announced and became effective as of March 20th , 2020.", [["closure", "OBSERVATION", 26, 33]]], ["From March 12th , 2020, the closure of schools and universities was gradually implemented in various provinces and territories of Canada, as well as the closure of several business practices, unless they were able to transit to a \"to go\"/\"take-away\" modality.IntroductionAs of March 21st , 2020, about 47% of Canadian reported cases are travel-related, and 41% are related to local transmission.", [["closure", "OBSERVATION", 28, 35]]], ["The latter figure is slightly lower than the Chinese and Italian figures, see Table 1 .IntroductionThe present paper aims to predict the trend of the COVID-19 outbreak in Canada by means of comparative modeling, using Italy as comparison.MethodsWe conduct a data-driven and model-free analysis of the ongoing COVID-19 epidemic in Italy and Canada.", [["slightly lower", "PROBLEM", 21, 35], ["the COVID", "TEST", 146, 155], ["a data", "TEST", 256, 262], ["the ongoing COVID", "TEST", 297, 314], ["slightly", "OBSERVATION_MODIFIER", 21, 29], ["lower", "OBSERVATION_MODIFIER", 30, 35]]], ["For Italy, we also collected data about daily hospitalizations, daily ICU, and cumulative deaths (Ministero della Salute, 2020).", [["deaths", "DISEASE", 90, 96]]], ["For Italy, we obtain estimates of the epidemic growth during three time frames: prior the first lockdown (March 8th), between March 8th and March 12th, when all non-essential productive activities were interrupted, and after March 12th.MethodsFor Canada, we split the data fitting in two different periods, to estimate the initial (before March 13th) and more recent (after March 13th) epidemic growth rate.", [["the epidemic growth", "PROBLEM", 34, 53], ["epidemic growth rate", "TEST", 386, 406], ["productive", "OBSERVATION_MODIFIER", 175, 185]]], ["For US we fit one single exponential growth rate after March 1st, since no substantial change in the epidemic growth rate is noticeable.", [["substantial change", "PROBLEM", 75, 93], ["the epidemic growth rate", "TEST", 97, 121], ["no", "UNCERTAINTY", 72, 74], ["substantial", "OBSERVATION_MODIFIER", 75, 86], ["change", "OBSERVATION_MODIFIER", 87, 93]]], ["We then make projections of the early phase of epidemic transmission in Canada by using the growth rate estimated for Canada for the most recent time period and the minimum growth rate estimated for Italy two weeks after lockdown.", [["the growth rate", "TEST", 88, 103], ["the minimum growth rate", "TEST", 161, 184]]], ["By assuming that the case severity in the Canadian population is comparable with the Italian data, i.e., daily hospitalizations are about 40% of the total number of cumulative cases (cf. Fig. 2) , we show projections about the expected numbers of daily hospitalizations up to March 31st.ResultsBy fitting an exponential curve to the Italian daily reported data, we estimated: the initial (before the first lockdown on March 8th) growth rate of 0.22, corresponding to a doubling time of 3.1 days; the reduced growth rate of 0.14 between March 8th and March 12th, when non-essential activities were ordered for closure; and the further reduced growth rate of 0.1 after March 12th, corresponding to a doubling time of about 7 days (see Fig. 1 ).", [["growth rate", "TEST", 429, 440], ["the reduced growth rate", "TEST", 496, 519], ["closure", "TREATMENT", 609, 616], ["the further reduced growth rate", "TEST", 622, 653], ["reduced", "OBSERVATION_MODIFIER", 500, 507], ["growth", "OBSERVATION_MODIFIER", 508, 514], ["reduced", "OBSERVATION_MODIFIER", 634, 641], ["growth", "OBSERVATION_MODIFIER", 642, 648]]], ["This estimated growth rate is consistent using datasets of cumulative cases, cumulative deaths, daily hospitalizations and daily ICU, suggesting that the bias resulted from detection strategy and under-reporting does not have a major effect, see Fig. 2 .ResultsBy fitting Canadian epidemic data, we estimated the initial growth rate of 0.13 between March 1st and March 13th, and the growth rate of 0.25 between March 13th and 21st.", [["deaths", "DISEASE", 88, 94], ["This estimated growth rate", "TEST", 0, 26], ["the initial growth rate", "TEST", 309, 332], ["the growth rate", "TEST", 379, 394]]], ["In US, the growth rate is 0.3 between March 1st and March 21st, see Fig. 1 .ResultsUsing the growth rate of 0.25 (estimated in Canada) and the growth rate of 0.1 (estimated in Italy two weeks after its first lockdown), we project the epidemic trend in Canada for 10 days following March 21st and plot the projections of both daily and cumulative cases in Fig. 3 .", [["the growth rate", "TEST", 7, 22], ["the growth rate", "TEST", 89, 104], ["the growth rate", "TEST", 139, 154], ["growth", "OBSERVATION_MODIFIER", 93, 99]]], ["We predict more than 15,000 total infections on March 31st in the first (and the worst) scenario.", [["infections", "DISEASE", 34, 44]]], ["Total infections are reduced to 4000 in the second scenario, if further public health interventions, similar to closure of non-essential activities, are taken immediately to reduce the growth rate by more than half.", [["infections", "DISEASE", 6, 16], ["Total infections", "PROBLEM", 0, 16], ["further public health interventions", "TREATMENT", 64, 99], ["closure of non-essential activities", "TREATMENT", 112, 147], ["the growth rate", "TEST", 181, 196], ["infections", "OBSERVATION", 6, 16], ["reduced", "OBSERVATION_MODIFIER", 21, 28]]], ["We therefore predict a number between 1500 and 6500 hospitalized by March 31st, see Fig. 3 .ResultsTo validate the predictions obtained with growth rates 0.25 and 0.1, we make exponential projections from the Italian cumulative cases, starting from March 1st, March 8th and March 12th, see Fig. 4 .", [["the predictions", "TEST", 111, 126], ["growth rates", "TEST", 141, 153]]], ["Note that the cumulative detected cases are consistent with the proposed minimum and maximum growth scenarios.", [["the proposed minimum and maximum growth scenarios", "PROBLEM", 60, 109], ["consistent with", "UNCERTAINTY", 44, 59], ["maximum", "OBSERVATION_MODIFIER", 85, 92], ["growth scenarios", "OBSERVATION", 93, 109]]], ["To further illustrate the similarity between the early epidemic phase in the two countries, the bottom panel of Fig. 4 shows the time series of cumulative detected cases, shifted in time to visually align with the 1329 confirmed cases in Canada on March 21st with the 1128 detected cases in Italy on February 29th.", [["the bottom panel", "TEST", 92, 108], ["early", "OBSERVATION_MODIFIER", 49, 54], ["epidemic", "OBSERVATION_MODIFIER", 55, 63]]], ["According to total cases, we could therefore argue that the epidemic in Canada is about three weeks behind that in Italy.InterpretationThe Italian data shows that the intervention measures implemented there have resulted in halving the growth rate, which has decreased from 0.22 down to 0.1 over a period of two weeks.", [["the intervention measures", "TREATMENT", 163, 188], ["the growth rate", "TEST", 232, 247], ["growth", "OBSERVATION_MODIFIER", 236, 242], ["rate", "OBSERVATION_MODIFIER", 243, 247], ["decreased", "OBSERVATION_MODIFIER", 259, 268]]], ["Estimates of the most recent Canadian and US incidence data show that the growth rate is comparable with (or even faster than) the Italian early growth rate.", [["US incidence data", "TEST", 42, 59], ["the growth rate", "TEST", 70, 85]]], ["In particular, the most recent incidence data suggest that the doubling time in Canada may be as short as 2.7 days.InterpretationAssuming that intervention measures may have similar effect to those achieved in Italy, we would expect a reduction by half of the growth rate in two-week time, which would correspond to a doubling time of 6e7 days.", [["intervention measures", "TREATMENT", 143, 164], ["the growth rate", "TEST", 256, 271]]], ["Note that this estimate excludes the importation of cases returning to Canada.InterpretationRegarding the expected proportion of severe cases, it can be observed that the Canadian population age distribution is closer to the Italian one, rather than the Chinese distribution (Index Mundi, 2020), see Table 1 .", [["severe cases", "PROBLEM", 129, 141], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["cases", "OBSERVATION", 136, 141]]], ["Since there is strong evidence that COVID-19 has more impact on the older populations, it is not unreasonable to expect relatively more severe cases and fatalities in the population overall.", [["fatalities", "DISEASE", 153, 163], ["COVID-19", "GENE_OR_GENE_PRODUCT", 36, 44], ["COVID-19", "DNA", 36, 44], ["COVID", "TEST", 36, 41], ["strong", "OBSERVATION_MODIFIER", 15, 21]]], ["This may partially explain the higher fatality rates and severe cases observed in Italy compared to China, see Table 2 .InterpretationIn particular, some studies have reported that 80% of deaths occur among individuals aged 65 years and older (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020; Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19), 2020; Istituto Superiore di Sanit a, 2020; Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica and Istituto Superiore di Sanit a, 2020; Public Health Canada, 2020).", [["deaths", "DISEASE", 188, 194], ["Pneumonia", "DISEASE", 266, 275], ["Coronavirus Disease", "DISEASE", 356, 375], ["Patients", "ORGANISM", 342, 350], ["Patients", "SPECIES", 342, 350], ["the higher fatality rates", "PROBLEM", 27, 52], ["severe cases", "PROBLEM", 57, 69], ["Coronavirus Disease", "PROBLEM", 356, 375], ["may partially explain", "UNCERTAINTY", 5, 26], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["Coronavirus", "OBSERVATION_MODIFIER", 254, 265], ["Pneumonia", "OBSERVATION", 266, 275]]], ["Since such an age group is almost double in proportion in Italy and Canada compared to China, an almost doubled fatality rate could be expected.", [["almost", "OBSERVATION_MODIFIER", 27, 33], ["double", "OBSERVATION_MODIFIER", 34, 40]]], ["In fact, the fatality rate is currently as large as 7.8% in Italy, although this number may include the effect of the saturation of the hospital system in Lombardy, the most affected Italian region.InterpretationSpecifically concerning this aspect, in terms of capacity of the health system, it is worthy of noting that, according to the Organization for Economic Cooperation and Development (OECD) (Woolley & Policy Options, 2020) , Canada also has limited resources, with 1.95 acute care hospital beds per 1000 people, even less than the resources of the Italian system (2.62 beds per 1000 people), whereas other countries affected by the COVID-19, such as Japan and South Korea, have 5-and 6-time more facilities.InterpretationSummarizing, given that Italian and Canadian demographic profiles are similar, especially regarding the senior population portions, it is feasible to utilize Italian data to simulate the projected trend of COVID-19 in Canada.", [["people", "SPECIES", 513, 519], ["people", "SPECIES", 592, 598], ["the fatality rate", "TEST", 9, 26], ["Italian data", "TEST", 888, 900], ["COVID", "TEST", 936, 941], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["Given that the case growth rate in Canada in the last week is comparable to that in Italy before its lockdown, it can be concluded that in absence of an immediate escalation in public health interventions, approximately 15,000 cases could be expected by the end of the month.", [["the case growth rate", "TEST", 11, 31], ["public health interventions", "TREATMENT", 177, 204], ["escalation", "OBSERVATION_MODIFIER", 163, 173]]], ["Canada can capitalize on the \"Italian experience\": the epidemic growth rate in Italy has been significantly reduced after implementing and enforcing the closure of all non-essential activities.", [["the closure", "TREATMENT", 149, 160], ["significantly", "OBSERVATION_MODIFIER", 94, 107], ["reduced", "OBSERVATION_MODIFIER", 108, 115]]], ["It is anyway of fundamental importance to consider the delay, which may be as large as two weeks, before intervention measures have a concrete mitigation effect.InterpretationIn conclusion, Canada will not become the \"next Italy\", but will fail to achieve better results in controlling the outbreak if a comprehensive package of public health interventions is not quickly enforced.", [["intervention measures", "TREATMENT", 105, 126], ["public health interventions", "TREATMENT", 329, 356], ["large", "OBSERVATION_MODIFIER", 78, 83]]], ["Considering the delayed effect of intervention measures and the hospital bed shortage, it is imperative to take prompt actions to reduce the epidemic growth rate and to avoid to overwhelm the capacity of the Canadian health system.", [["intervention measures", "TREATMENT", 34, 55], ["prompt actions", "TREATMENT", 112, 126], ["the epidemic growth rate", "PROBLEM", 137, 161]]], ["However, our study is not without limitations.", [["our study", "TEST", 9, 18], ["not without", "UNCERTAINTY", 22, 33]]], ["In particular, the lack of detailed data on COVID-19 hospitalization in Canada makes it difficult to compare the severity observed in the two countries.", [["COVID", "TEST", 44, 49]]], ["Although not mathematically sophisticated, this preliminary analysis is transparent, data driven and represents a sanity check for more complex models.", [["this preliminary analysis", "TEST", 43, 68], ["a sanity check", "TEST", 112, 126]]]], "4f86b52ea8bff1f51c5c9efdbbe7de7bdf05b3fd": [], "290cc974a8d51baa7196b7c4686f146c5a7d408c": [["IntroductionBeta-ketothiolase (mitochondrial acetoacetyl-CoA thiolase, T2) is a key enzyme needed for ketone metabolism and isoleucine catabolism [1] .", [["mitochondrial", "ANATOMY", 31, 44], ["Beta-ketothiolase", "CHEMICAL", 12, 29], ["acetoacetyl-CoA", "CHEMICAL", 45, 60], ["ketone", "CHEMICAL", 102, 108], ["isoleucine", "CHEMICAL", 124, 134], ["acetoacetyl-CoA", "CHEMICAL", 45, 60], ["ketone", "CHEMICAL", 102, 108], ["isoleucine", "CHEMICAL", 124, 134], ["Beta-ketothiolase", "GENE_OR_GENE_PRODUCT", 12, 29], ["mitochondrial", "CELLULAR_COMPONENT", 31, 44], ["acetoacetyl-CoA thiolase", "GENE_OR_GENE_PRODUCT", 45, 69], ["T2", "SIMPLE_CHEMICAL", 71, 73], ["ketone", "SIMPLE_CHEMICAL", 102, 108], ["isoleucine", "AMINO_ACID", 124, 134], ["Beta-ketothiolase", "PROTEIN", 12, 29], ["mitochondrial acetoacetyl-CoA thiolase", "PROTEIN", 31, 69], ["T2", "PROTEIN", 71, 73], ["IntroductionBeta-ketothiolase (mitochondrial acetoacetyl-CoA thiolase", "TREATMENT", 0, 69], ["ketone metabolism", "PROBLEM", 102, 119], ["isoleucine catabolism", "TREATMENT", 124, 145]]], ["T2 deficiency is a rare autosomal recessive disorder with an incidence of less than one per 1,000,000 newborns (1] .", [["T2 deficiency", "DISEASE", 0, 13], ["autosomal recessive disorder", "DISEASE", 24, 52], ["T2 deficiency", "PROBLEM", 0, 13], ["a rare autosomal recessive disorder", "PROBLEM", 17, 52], ["rare", "OBSERVATION_MODIFIER", 19, 23], ["autosomal", "OBSERVATION_MODIFIER", 24, 33], ["recessive", "OBSERVATION_MODIFIER", 34, 43], ["disorder", "OBSERVATION", 44, 52]]], ["It typically manifests between 6-18 months of age as acute and recurrent ketoacidotic episodes triggered by ketogenic stress [1, 2] .", [["acute and recurrent ketoacidotic episodes", "PROBLEM", 53, 94], ["ketogenic stress", "PROBLEM", 108, 124], ["acute", "OBSERVATION_MODIFIER", 53, 58]]], ["Patients are typically asymptomatic between episodes, and the episode frequency decreases with age [2] .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["episodes", "PROBLEM", 44, 52]]], ["The characteristic laboratory finding is the elevation of urine organic acids; tiglylglycine (TIG) 2-methylacetoacetic acid (2MAA) and 3-OH-2-methyl-butyric acid (2M3HB).", [["urine", "ANATOMY", 58, 63], ["organic acids", "CHEMICAL", 64, 77], ["tiglylglycine", "CHEMICAL", 79, 92], ["TIG) 2-methylacetoacetic acid", "CHEMICAL", 94, 123], ["2MAA", "CHEMICAL", 125, 129], ["3-OH-2-methyl-butyric acid", "CHEMICAL", 135, 161], ["2M3HB", "CHEMICAL", 163, 168], ["tiglylglycine", "CHEMICAL", 79, 92], ["TIG", "CHEMICAL", 94, 97], ["2-methylacetoacetic acid", "CHEMICAL", 99, 123], ["2MAA", "CHEMICAL", 125, 129], ["3-OH-2-methyl-butyric acid", "CHEMICAL", 135, 161], ["2M3HB", "CHEMICAL", 163, 168], ["urine", "ORGANISM_SUBSTANCE", 58, 63], ["organic acids", "SIMPLE_CHEMICAL", 64, 77], ["tiglylglycine", "SIMPLE_CHEMICAL", 79, 92], ["TIG) 2-methylacetoacetic acid", "SIMPLE_CHEMICAL", 94, 123], ["2MAA", "SIMPLE_CHEMICAL", 125, 129], ["3-OH-2-methyl-butyric acid", "SIMPLE_CHEMICAL", 135, 161], ["2M3HB", "SIMPLE_CHEMICAL", 163, 168], ["the elevation of urine organic acids", "PROBLEM", 41, 77], ["tiglylglycine (TIG)", "TREATMENT", 79, 98], ["methylacetoacetic acid", "TREATMENT", 101, 123], ["methyl-butyric acid", "TREATMENT", 142, 161]]], ["More than 70 different mutations of the mitochondrial ACAT1 gene have been identified to date as causative for T2 deficiency [3] .", [["mitochondrial", "ANATOMY", 40, 53], ["mitochondrial", "CELLULAR_COMPONENT", 40, 53], ["ACAT1", "GENE_OR_GENE_PRODUCT", 54, 59], ["mitochondrial ACAT1 gene", "DNA", 40, 64], ["the mitochondrial ACAT1 gene", "TREATMENT", 36, 64], ["T2 deficiency", "PROBLEM", 111, 124]]], ["Only one case of T2 deficiency has been reported from Sri Lanka, detected by gas chromatography/mass spectrometry (GC/MS), but the diagnosis was not confirmed by genetic studies or enzyme analysis [4] .", [["T2 deficiency", "DISEASE", 17, 30], ["T2", "CANCER", 17, 19], ["T2", "DNA", 17, 19], ["T2 deficiency", "PROBLEM", 17, 30], ["gas chromatography", "TEST", 77, 95], ["mass spectrometry", "PROBLEM", 96, 113], ["GC/MS", "TEST", 115, 120], ["genetic studies", "TEST", 162, 177], ["enzyme analysis", "TEST", 181, 196]]], ["In this study, we report on the first Sri Lankan case of T2 deficiency confirmed by molecular analysis and characterize a novel mutation in ACAT1 gene.IntroductionA 4-year-old boy who is the second child of healthy, consanguineous parents, presented with a four days' history of vomiting, loose stools and low-grade fever.", [["vomiting", "DISEASE", 279, 287], ["loose stools", "DISEASE", 289, 301], ["low-grade fever", "DISEASE", 306, 321], ["T2", "CANCER", 57, 59], ["ACAT1", "GENE_OR_GENE_PRODUCT", 140, 145], ["boy", "ORGANISM", 176, 179], ["T2", "DNA", 57, 59], ["ACAT1 gene", "DNA", 140, 150], ["boy", "SPECIES", 176, 179], ["this study", "TEST", 3, 13], ["T2 deficiency", "PROBLEM", 57, 70], ["molecular analysis", "TEST", 84, 102], ["a novel mutation in ACAT1 gene", "PROBLEM", 120, 150], ["vomiting", "PROBLEM", 279, 287], ["loose stools", "PROBLEM", 289, 301], ["low-grade fever", "PROBLEM", 306, 321], ["low-grade", "OBSERVATION_MODIFIER", 306, 315], ["fever", "OBSERVATION", 316, 321]]], ["He has been previously well with uneventful birth and neonatal periods and normal development.", [["normal", "OBSERVATION", 75, 81]]], ["Fever settled with medicine prescribed by a general practitioner, but the child's level of consciousness deteriorated.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["medicine", "TREATMENT", 19, 27]]], ["On admission to the pediatric intensive care unit in a tertiary care hospital, he was afebrile, drowsy, unresponsive to painful stimuli and hypotonic, and had decreased reflexes and sluggish, but equally reactive pupils.", [["afebrile", "PROBLEM", 86, 94], ["drowsy", "PROBLEM", 96, 102], ["unresponsive", "PROBLEM", 104, 116], ["painful stimuli", "TEST", 120, 135], ["hypotonic", "PROBLEM", 140, 149], ["decreased reflexes", "PROBLEM", 159, 177], ["sluggish", "OBSERVATION_MODIFIER", 182, 190], ["reactive", "OBSERVATION_MODIFIER", 204, 212], ["pupils", "OBSERVATION", 213, 219]]], ["Acidotic breathing and circulatory collapse were noted.", [["circulatory", "ANATOMY", 23, 34], ["circulatory collapse", "DISEASE", 23, 43], ["Acidotic breathing", "PROBLEM", 0, 18], ["circulatory collapse", "PROBLEM", 23, 43], ["circulatory", "OBSERVATION_MODIFIER", 23, 34], ["collapse", "OBSERVATION", 35, 43]]], ["Clinical examination was negative for skin rashes and neck stiffness.IntroductionInitial investigations revealed severe high anion gap metabolic acidosis (pH 7.28, pCO 2 9.4 mmHg, HCO 3 Radiographic imaging of the chest and abdomen were unremarkable.", [["skin", "ANATOMY", 38, 42], ["neck", "ANATOMY", 54, 58], ["chest", "ANATOMY", 214, 219], ["abdomen", "ANATOMY", 224, 231], ["skin rashes", "DISEASE", 38, 49], ["neck stiffness", "DISEASE", 54, 68], ["acidosis", "DISEASE", 145, 153], ["skin", "ORGAN", 38, 42], ["neck", "ORGANISM_SUBDIVISION", 54, 58], ["chest", "ORGANISM_SUBDIVISION", 214, 219], ["abdomen", "ORGAN", 224, 231], ["Clinical examination", "TEST", 0, 20], ["skin rashes", "PROBLEM", 38, 49], ["neck stiffness", "PROBLEM", 54, 68], ["IntroductionInitial investigations", "TEST", 69, 103], ["severe high anion gap metabolic acidosis", "PROBLEM", 113, 153], ["pH", "TEST", 155, 157], ["pCO", "TEST", 164, 167], ["mmHg", "TEST", 174, 178], ["HCO", "TEST", 180, 183], ["Radiographic imaging of the chest and abdomen", "TEST", 186, 231], ["negative for", "UNCERTAINTY", 25, 37], ["skin", "ANATOMY", 38, 42], ["rashes", "OBSERVATION", 43, 49], ["neck", "ANATOMY", 54, 58], ["stiffness", "OBSERVATION", 59, 68], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["high", "OBSERVATION_MODIFIER", 120, 124], ["anion gap", "OBSERVATION", 125, 134], ["metabolic acidosis", "OBSERVATION", 135, 153], ["chest", "ANATOMY", 214, 219], ["abdomen", "ANATOMY", 224, 231], ["unremarkable", "OBSERVATION", 237, 249]]], ["Non contrast computed tomography of the brain showed multiple cerebral infarctions.IntroductionThe child required intubation, and was symptomatically managed with intravenous fluids, repeated doses of intravenous bicarbonate therapy, inotropes and broad-spectrum antibiotics because of concerns of sepsis.", [["brain", "ANATOMY", 40, 45], ["cerebral", "ANATOMY", 62, 70], ["intravenous", "ANATOMY", 163, 174], ["intravenous", "ANATOMY", 201, 212], ["cerebral infarctions", "DISEASE", 62, 82], ["bicarbonate", "CHEMICAL", 213, 224], ["sepsis", "DISEASE", 298, 304], ["bicarbonate", "CHEMICAL", 213, 224], ["brain", "ORGAN", 40, 45], ["cerebral", "ORGAN", 62, 70], ["child", "ORGANISM", 99, 104], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 201, 212], ["bicarbonate", "SIMPLE_CHEMICAL", 213, 224], ["Non contrast computed tomography of the brain", "TEST", 0, 45], ["multiple cerebral infarctions", "PROBLEM", 53, 82], ["intubation", "TREATMENT", 114, 124], ["intravenous fluids", "TREATMENT", 163, 181], ["intravenous bicarbonate therapy", "TREATMENT", 201, 232], ["inotropes", "TREATMENT", 234, 243], ["broad-spectrum antibiotics", "TREATMENT", 248, 274], ["sepsis", "PROBLEM", 298, 304], ["brain", "ANATOMY", 40, 45], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["cerebral", "ANATOMY", 62, 70], ["infarctions", "OBSERVATION", 71, 82], ["sepsis", "OBSERVATION", 298, 304]]], ["As the child's condition did not improve with the initial management, a urine sample collected in the acute stage was sent to our laboratory at Lady Ridgeway Hospital for Children for organic acid analysis.", [["urine sample", "ANATOMY", 72, 84], ["child", "ORGANISM", 7, 12], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["child", "SPECIES", 7, 12], ["Children", "SPECIES", 171, 179], ["the initial management", "TREATMENT", 46, 68], ["a urine sample", "TEST", 70, 84], ["the acute stage", "PROBLEM", 98, 113], ["organic acid analysis", "TEST", 184, 205], ["acute", "OBSERVATION_MODIFIER", 102, 107]]], ["GC/MS analysis revealed very high levels of 2M3HB and TIG (see Fig. 1 ) which was suggestive of T2 deficiency.", [["2M3HB", "CHEMICAL", 44, 49], ["2M3HB", "SIMPLE_CHEMICAL", 44, 49], ["TIG", "SIMPLE_CHEMICAL", 54, 57], ["2M3HB", "PROTEIN", 44, 49], ["TIG", "PROTEIN", 54, 57], ["GC/MS analysis", "TEST", 0, 14], ["very high levels of 2M3HB", "PROBLEM", 24, 49], ["T2 deficiency", "PROBLEM", 96, 109], ["suggestive of", "UNCERTAINTY", 82, 95], ["T2 deficiency", "OBSERVATION", 96, 109]]], ["However, in the absence of an increase in 2MAA, a deficiency of 2-methyl-3-OH-butyryl-CoA dehydrogenase (MHBD) caused by mutations in HSD17B10 gene was also a possibility.IntroductionTo confirm the diagnosis, ACAT1 and HSD17B10 genes were analyzed by polymerase chain reaction and by sequencing of both DNA strands of the entire coding region and the highly conserved exon-intron splice junctions.", [["2MAA", "CHEMICAL", 42, 46], ["2-methyl-3-OH-butyryl-CoA", "CHEMICAL", 64, 89], ["2MAA", "CHEMICAL", 42, 46], ["2-methyl-3-OH-butyryl-CoA", "CHEMICAL", 64, 89], ["2MAA", "SIMPLE_CHEMICAL", 42, 46], ["2-methyl-3-OH-butyryl-CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 64, 103], ["MHBD", "GENE_OR_GENE_PRODUCT", 105, 109], ["HSD17B10", "GENE_OR_GENE_PRODUCT", 134, 142], ["ACAT1", "GENE_OR_GENE_PRODUCT", 209, 214], ["HSD17B10", "GENE_OR_GENE_PRODUCT", 219, 227], ["DNA", "CELLULAR_COMPONENT", 303, 306], ["splice junctions", "CELLULAR_COMPONENT", 380, 396], ["butyryl-CoA dehydrogenase", "PROTEIN", 78, 103], ["MHBD", "PROTEIN", 105, 109], ["HSD17B10 gene", "DNA", 134, 147], ["ACAT1 and HSD17B10 genes", "DNA", 209, 233], ["an increase in 2MAA", "PROBLEM", 27, 46], ["a deficiency", "PROBLEM", 48, 60], ["CoA dehydrogenase (MHBD)", "PROBLEM", 86, 110], ["mutations in HSD17B10 gene", "PROBLEM", 121, 147], ["ACAT1", "TEST", 209, 214], ["HSD17B10 genes", "TEST", 219, 233], ["polymerase chain reaction", "PROBLEM", 251, 276], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["CoA", "ANATOMY", 86, 89], ["exon-intron splice", "OBSERVATION", 368, 386], ["junctions", "OBSERVATION", 387, 396]]], ["The test was performed on dried blood spots on a filter paper at Centogene AG, Germany.", [["blood", "ANATOMY", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["The test", "TEST", 0, 8], ["dried blood spots", "PROBLEM", 26, 43], ["a filter paper at Centogene AG", "TREATMENT", 47, 77]]], ["The child was homozygous for the novel variant c.152C [ T p.(Pro51-Leu) of ACAT1 NM_000019.3 gene which confirmed the diagnosis of T2 deficiency.IntroductionThe child was ventilator bound for nearly four months.", [["T2 deficiency", "DISEASE", 131, 144], ["child", "ORGANISM", 4, 9], ["Pro51-Leu", "GENE_OR_GENE_PRODUCT", 61, 70], ["ACAT1 NM_000019.3", "GENE_OR_GENE_PRODUCT", 75, 92], ["child", "ORGANISM", 161, 166], ["child", "SPECIES", 4, 9], ["child", "SPECIES", 161, 166], ["T p.", "TEST", 56, 60], ["ACAT1 NM", "TEST", 75, 83], ["T2 deficiency", "PROBLEM", 131, 144], ["ventilator bound", "TREATMENT", 171, 187], ["T2 deficiency", "OBSERVATION", 131, 144]]], ["Total parenteral nutrition was later converted to feeding via a jejunostomy with mild protein restriction.", [["parenteral", "ANATOMY", 6, 16], ["Total parenteral nutrition", "TREATMENT", 0, 26], ["a jejunostomy", "TREATMENT", 62, 75], ["mild protein restriction", "TREATMENT", 81, 105], ["jejunostomy", "ANATOMY", 64, 75], ["protein restriction", "OBSERVATION", 86, 105]]], ["Though the biochemical parameters normalized with treatment, the child entered a continuous vegetative state and expired after another 4 months.DiscussionT2 deficiency is a rare genetic disorder that results from biallelic pathogenic variants of ACAT1 gene located on the chromosome 11q22.3 [2, 3] .", [["chromosome", "ANATOMY", 272, 282], ["DiscussionT2 deficiency", "DISEASE", 144, 167], ["genetic disorder", "DISEASE", 178, 194], ["DiscussionT2", "GENE_OR_GENE_PRODUCT", 144, 156], ["ACAT1", "GENE_OR_GENE_PRODUCT", 246, 251], ["ACAT1 gene", "DNA", 246, 256], ["chromosome 11q22.3", "DNA", 272, 290], ["the biochemical parameters", "TEST", 7, 33], ["treatment", "TREATMENT", 50, 59], ["a continuous vegetative state", "PROBLEM", 79, 108], ["DiscussionT2 deficiency", "PROBLEM", 144, 167], ["a rare genetic disorder", "PROBLEM", 171, 194], ["biallelic pathogenic variants of ACAT1 gene", "PROBLEM", 213, 256]]], ["T2 enzyme cleaves 2-methylacetoacetyl-CoA in isoleucine metabolism, and is also responsible for the last step in ketogenesis in liver and in ketolysis in extra-hepatic tissues [1] (see Fig. 2 ).", [["liver", "ANATOMY", 128, 133], ["extra-hepatic tissues", "ANATOMY", 154, 175], ["2-methylacetoacetyl-CoA", "CHEMICAL", 18, 41], ["isoleucine", "CHEMICAL", 45, 55], ["2-methylacetoacetyl-CoA", "CHEMICAL", 18, 41], ["isoleucine", "CHEMICAL", 45, 55], ["2-methylacetoacetyl-CoA", "SIMPLE_CHEMICAL", 18, 41], ["isoleucine", "AMINO_ACID", 45, 55], ["liver", "ORGAN", 128, 133], ["extra-hepatic tissues", "TISSUE", 154, 175], ["T2 enzyme", "PROTEIN", 0, 9], ["T2 enzyme cleaves", "TEST", 0, 17], ["methylacetoacetyl-CoA in isoleucine metabolism", "PROBLEM", 20, 66], ["the last step in ketogenesis in liver", "PROBLEM", 96, 133], ["liver", "ANATOMY", 128, 133], ["extra-hepatic tissues", "ANATOMY", 154, 175]]], ["Therefore, T2 deficiency leads to ketosis and accumulation of metabolites of upstream reactions.DiscussionThe typical presentation is in early childhood, with vomiting, hyperpnoea, drowsiness, lethargy and coma triggered by a ketogenic stress such as fasting, infection and physical exertion [3] .", [["ketosis", "DISEASE", 34, 41], ["vomiting", "DISEASE", 159, 167], ["hyperpnoea", "DISEASE", 169, 179], ["lethargy", "DISEASE", 193, 201], ["coma", "DISEASE", 206, 210], ["infection", "DISEASE", 260, 269], ["T2 deficiency", "PROBLEM", 11, 24], ["ketosis", "PROBLEM", 34, 41], ["accumulation of metabolites of upstream reactions", "PROBLEM", 46, 95], ["vomiting", "PROBLEM", 159, 167], ["hyperpnoea", "PROBLEM", 169, 179], ["drowsiness", "PROBLEM", 181, 191], ["lethargy", "PROBLEM", 193, 201], ["coma", "PROBLEM", 206, 210], ["a ketogenic stress", "PROBLEM", 224, 242], ["fasting, infection", "PROBLEM", 251, 269], ["ketosis", "OBSERVATION", 34, 41], ["metabolites", "OBSERVATION_MODIFIER", 62, 73], ["infection", "OBSERVATION", 260, 269]]], ["Some may have atypical presentations like metabolic stroke and metabolic encephalopathy and delayed onset as in our case [1] .", [["metabolic stroke", "DISEASE", 42, 58], ["metabolic encephalopathy", "DISEASE", 63, 87], ["metabolic stroke", "PROBLEM", 42, 58], ["metabolic encephalopathy", "PROBLEM", 63, 87], ["metabolic stroke", "OBSERVATION", 42, 58], ["metabolic encephalopathy", "OBSERVATION", 63, 87]]], ["Though rare, neonates can present with vomiting, poor suckling and lethargy [5] .", [["vomiting", "DISEASE", 39, 47], ["lethargy", "DISEASE", 67, 75], ["neonates", "ORGANISM", 13, 21], ["vomiting", "PROBLEM", 39, 47], ["poor suckling", "PROBLEM", 49, 62], ["lethargy", "PROBLEM", 67, 75]]], ["T2 deficiency may mimic central nervous system infection, diabetic ketoacidosis, if associated with stress hyperglycemia; or even salicylate [3] .", [["central nervous system", "ANATOMY", 24, 46], ["central nervous system infection", "DISEASE", 24, 56], ["diabetic ketoacidosis", "DISEASE", 58, 79], ["hyperglycemia", "DISEASE", 107, 120], ["salicylate", "CHEMICAL", 130, 140], ["salicylate", "CHEMICAL", 130, 140], ["central nervous system", "ANATOMICAL_SYSTEM", 24, 46], ["salicylate", "SIMPLE_CHEMICAL", 130, 140], ["T2 deficiency", "PROBLEM", 0, 13], ["central nervous system infection", "PROBLEM", 24, 56], ["diabetic ketoacidosis", "PROBLEM", 58, 79], ["stress hyperglycemia", "PROBLEM", 100, 120], ["central", "ANATOMY_MODIFIER", 24, 31], ["nervous system", "ANATOMY", 32, 46], ["infection", "OBSERVATION", 47, 56], ["diabetic", "OBSERVATION_MODIFIER", 58, 66], ["ketoacidosis", "OBSERVATION", 67, 79]]], ["Patients are reported to be asymptomatic between episodes [6] .DiscussionPatients tend to have severe ketoacidosis outweighing the associated illness (pH \u00a07.3 or HCO 3 -\u00a015 mmol/L, blood total ketone bodies [ 7 mmol/L) with normal or slightly elevated plasma ammonia [5] .", [["blood", "ANATOMY", 181, 186], ["plasma", "ANATOMY", 252, 258], ["ketoacidosis", "DISEASE", 102, 114], ["illness", "DISEASE", 142, 149], ["ketone", "CHEMICAL", 193, 199], ["ammonia", "CHEMICAL", 259, 266], ["HCO", "CHEMICAL", 162, 165], ["ketone", "CHEMICAL", 193, 199], ["ammonia", "CHEMICAL", 259, 266], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["ketone", "SIMPLE_CHEMICAL", 193, 199], ["plasma", "ORGANISM_SUBSTANCE", 252, 258], ["ammonia", "SIMPLE_CHEMICAL", 259, 266], ["Patients", "SPECIES", 0, 8], ["severe ketoacidosis", "PROBLEM", 95, 114], ["the associated illness", "PROBLEM", 127, 149], ["pH", "TEST", 151, 153], ["HCO", "TEST", 162, 165], ["blood total ketone bodies", "TEST", 181, 206], ["mmol/L)", "TEST", 211, 218], ["slightly elevated plasma ammonia", "PROBLEM", 234, 266], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["ketoacidosis", "OBSERVATION", 102, 114], ["normal", "OBSERVATION", 224, 230], ["slightly", "OBSERVATION_MODIFIER", 234, 242], ["elevated", "OBSERVATION", 243, 251]]], ["When associated with high plasma ammonia, organic acidemias should be suspected.", [["plasma", "ANATOMY", 26, 32], ["ammonia", "CHEMICAL", 33, 40], ["ammonia", "CHEMICAL", 33, 40], ["plasma", "ORGANISM_SUBSTANCE", 26, 32], ["ammonia", "SIMPLE_CHEMICAL", 33, 40], ["organic acidemias", "SIMPLE_CHEMICAL", 42, 59], ["high plasma ammonia", "PROBLEM", 21, 40], ["organic acidemias", "PROBLEM", 42, 59], ["organic acidemias", "OBSERVATION", 42, 59]]], ["Normoglycemia is usual, but hyperglycemia and hypoglycemia have been reported [5] .DiscussionUrine organic acid analysis in the acute stage is necessary to exclude other organic acidemias like methylmalonic, propionic and isovaleric acidemia [3] .", [["Normoglycemia", "DISEASE", 0, 13], ["hyperglycemia", "DISEASE", 28, 41], ["hypoglycemia", "DISEASE", 46, 58], ["organic acid", "CHEMICAL", 99, 111], ["methylmalonic", "DISEASE", 193, 206], ["propionic", "CHEMICAL", 208, 217], ["acidemia", "DISEASE", 233, 241], ["methylmalonic, propionic and isovaleric acidemia", "CHEMICAL", 193, 241], ["Urine", "ORGANISM_SUBSTANCE", 93, 98], ["methylmalonic", "SIMPLE_CHEMICAL", 193, 206], ["propionic", "SIMPLE_CHEMICAL", 208, 217], ["isovaleric acidemia", "SIMPLE_CHEMICAL", 222, 241], ["Normoglycemia", "PROBLEM", 0, 13], ["hyperglycemia", "PROBLEM", 28, 41], ["hypoglycemia", "PROBLEM", 46, 58], ["Urine organic acid analysis", "TEST", 93, 120], ["organic acidemias", "PROBLEM", 170, 187], ["methylmalonic, propionic", "PROBLEM", 193, 217], ["isovaleric acidemia", "PROBLEM", 222, 241], ["methylmalonic", "OBSERVATION", 193, 206], ["isovaleric acidemia", "OBSERVATION", 222, 241]]], ["The characteristic organic acid profile in T2 deficiency is an elevation in 2M3HB, TIG and 2MAA, both during the acute episode and in between [6] .", [["organic acid", "CHEMICAL", 19, 31], ["2M3HB", "CHEMICAL", 76, 81], ["TIG", "CHEMICAL", 83, 86], ["2MAA", "CHEMICAL", 91, 95], ["organic acid", "SIMPLE_CHEMICAL", 19, 31], ["T2", "SIMPLE_CHEMICAL", 43, 45], ["2M3HB", "SIMPLE_CHEMICAL", 76, 81], ["TIG", "SIMPLE_CHEMICAL", 83, 86], ["2MAA", "SIMPLE_CHEMICAL", 91, 95], ["The characteristic organic acid profile", "TEST", 0, 39], ["T2 deficiency", "PROBLEM", 43, 56], ["an elevation in 2M3HB", "PROBLEM", 60, 81], ["TIG", "TEST", 83, 86], ["the acute episode", "PROBLEM", 109, 126], ["organic acid profile", "OBSERVATION", 19, 39], ["elevation", "OBSERVATION_MODIFIER", 63, 72], ["acute", "OBSERVATION_MODIFIER", 113, 118]]], ["As 2MAA is volatile, it may not be detected in some laboratories [4, 7] .", [["2MAA", "CHEMICAL", 3, 7], ["2MAA", "CHEMICAL", 3, 7], ["2MAA", "SIMPLE_CHEMICAL", 3, 7], ["may not be", "UNCERTAINTY", 24, 34]]], ["Batch analysis of the stored urine sample and instability during sample transport might have been the reasons for absent 2MAA in our case.DiscussionIn T2 deficiency, a blood acylcarnitine profile by tandem mass spectrometry may reveal tiglylcarnitine (C5:1) and 2-methyl-3-hydroxybutyryl-carnitine [5] .", [["urine sample", "ANATOMY", 29, 41], ["sample", "ANATOMY", 65, 71], ["blood", "ANATOMY", 168, 173], ["acylcarnitine", "CHEMICAL", 174, 187], ["tiglylcarnitine", "CHEMICAL", 235, 250], ["2-methyl-3-hydroxybutyryl-carnitine", "CHEMICAL", 262, 297], ["acylcarnitine", "CHEMICAL", 174, 187], ["tiglylcarnitine", "CHEMICAL", 235, 250], ["2-methyl-3-hydroxybutyryl-carnitine", "CHEMICAL", 262, 297], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["acylcarnitine", "SIMPLE_CHEMICAL", 174, 187], ["tiglylcarnitine", "SIMPLE_CHEMICAL", 235, 250], ["C5:1)", "SIMPLE_CHEMICAL", 252, 257], ["2-methyl-3-hydroxybutyryl-carnitine", "SIMPLE_CHEMICAL", 262, 297], ["Batch analysis", "TEST", 0, 14], ["the stored urine sample", "TEST", 18, 41], ["instability", "PROBLEM", 46, 57], ["sample transport", "TEST", 65, 81], ["T2 deficiency", "PROBLEM", 151, 164], ["a blood acylcarnitine profile", "TEST", 166, 195], ["tandem mass spectrometry", "TEST", 199, 223], ["tiglylcarnitine", "TEST", 235, 250], ["hydroxybutyryl-carnitine", "TREATMENT", 273, 297]]], ["Of individuals with mild mutations blood acylcarnitine profiles can be normal even in the acute stage [6] .DiscussionIndividuals with succinyl CoA:3-oxoacid CoA transferase (SCOT) deficiency can mimic attacks of T2 deficiency, but owing to its neonatal onset, permanent ketosis and non-specific urinary organic acid profile, SCOT deficiency was effectively excluded [1] .", [["blood", "ANATOMY", 35, 40], ["urinary", "ANATOMY", 295, 302], ["acylcarnitine", "CHEMICAL", 41, 54], ["succinyl CoA:3-oxoacid", "CHEMICAL", 134, 156], ["T2 deficiency", "DISEASE", 212, 225], ["ketosis", "DISEASE", 270, 277], ["SCOT", "CHEMICAL", 325, 329], ["acylcarnitine", "CHEMICAL", 41, 54], ["succinyl CoA:3-oxoacid CoA", "CHEMICAL", 134, 160], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["acylcarnitine", "SIMPLE_CHEMICAL", 41, 54], ["succinyl CoA:3-oxoacid CoA transferase", "GENE_OR_GENE_PRODUCT", 134, 172], ["SCOT", "SIMPLE_CHEMICAL", 174, 178], ["urinary organic acid", "SIMPLE_CHEMICAL", 295, 315], ["SCOT", "SIMPLE_CHEMICAL", 325, 329], ["succinyl CoA:3-oxoacid CoA transferase", "PROTEIN", 134, 172], ["SCOT", "PROTEIN", 174, 178], ["mild mutations blood acylcarnitine profiles", "PROBLEM", 20, 63], ["succinyl CoA", "TEST", 134, 146], ["oxoacid CoA transferase (SCOT) deficiency", "PROBLEM", 149, 190], ["T2 deficiency", "PROBLEM", 212, 225], ["permanent ketosis", "PROBLEM", 260, 277], ["non-specific urinary organic acid profile", "PROBLEM", 282, 323], ["SCOT deficiency", "PROBLEM", 325, 340], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["mutations", "OBSERVATION", 25, 34], ["acute", "OBSERVATION_MODIFIER", 90, 95]]], ["MHBD is an X-linked disorder having a similar clinical picture as in T2 deficiency, and urine will contain increased level of 2M3HB and TIG with no increase in 2MAA [1] .", [["urine", "ANATOMY", 88, 93], ["MHBD", "DISEASE", 0, 4], ["2M3HB", "CHEMICAL", 126, 131], ["TIG", "CHEMICAL", 136, 139], ["2MAA", "CHEMICAL", 160, 164], ["T2", "CANCER", 69, 71], ["urine", "ORGANISM_SUBSTANCE", 88, 93], ["2M3HB", "SIMPLE_CHEMICAL", 126, 131], ["TIG", "SIMPLE_CHEMICAL", 136, 139], ["an X-linked disorder", "PROBLEM", 8, 28], ["T2 deficiency", "PROBLEM", 69, 82], ["urine", "TEST", 88, 93], ["increased level of 2M3HB", "PROBLEM", 107, 131], ["TIG", "TEST", 136, 139]]], ["Therefore, MHBD was a differential diagnosis in this case.DiscussionDefinitive diagnosis of T2 deficiency is by enzyme assay and genetic studies.", [["MHBD", "CANCER", 11, 15], ["T2", "CANCER", 92, 94], ["T2 deficiency", "PROBLEM", 92, 105], ["enzyme assay", "TEST", 112, 124], ["genetic studies", "TEST", 129, 144], ["T2 deficiency", "OBSERVATION", 92, 105]]], ["Enzyme analysis for beta-ketothiolase on skin fibroblasts is recommended than using blood mononuclear cells [5, 8] .", [["skin fibroblasts", "ANATOMY", 41, 57], ["blood mononuclear cells", "ANATOMY", 84, 107], ["beta-ketothiolase", "CHEMICAL", 20, 37], ["beta-ketothiolase", "GENE_OR_GENE_PRODUCT", 20, 37], ["skin fibroblasts", "CELL", 41, 57], ["blood mononuclear cells", "CELL", 84, 107], ["beta-ketothiolase", "PROTEIN", 20, 37], ["skin fibroblasts", "CELL_TYPE", 41, 57], ["blood mononuclear cells", "CELL_TYPE", 84, 107], ["Enzyme analysis", "TEST", 0, 15], ["beta", "TEST", 20, 24], ["skin fibroblasts", "PROBLEM", 41, 57], ["blood mononuclear cells", "TEST", 84, 107], ["skin", "ANATOMY", 41, 45], ["fibroblasts", "OBSERVATION", 46, 57]]], ["An abnormal potassium-dependent acetoacetyl-CoA thiolase assay will exclude MHBD deficiency and confirm T2 deficiency [1] .DiscussionThe proband was homozygous for the c.152C [ T p.(Pro51Leu) of ACAT1 gene, classified as a missense likely pathogenic (class2) variant according to the American College of Medical Genetics and Genomics guidelines.", [["potassium", "CHEMICAL", 12, 21], ["acetoacetyl-Co", "CHEMICAL", 32, 46], ["potassium", "CHEMICAL", 12, 21], ["acetoacetyl-CoA", "CHEMICAL", 32, 47], ["potassium", "SIMPLE_CHEMICAL", 12, 21], ["MHBD", "SIMPLE_CHEMICAL", 76, 80], ["ACAT1", "GENE_OR_GENE_PRODUCT", 195, 200], ["ACAT1 gene", "DNA", 195, 205], ["An abnormal potassium", "TEST", 0, 21], ["dependent acetoacetyl", "TREATMENT", 22, 43], ["A thiolase assay", "TEST", 46, 62], ["MHBD deficiency", "PROBLEM", 76, 91], ["T2 deficiency", "PROBLEM", 104, 117], ["homozygous", "PROBLEM", 149, 159], ["ACAT1 gene", "TREATMENT", 195, 205], ["a missense likely pathogenic (class2) variant", "PROBLEM", 221, 266]]], ["This gene mutation is not previously reported in the Exome Aggregation Consortium population database.", [["This gene mutation", "PROBLEM", 0, 18]]], ["Mutations of the mitochondrial ACAT1 gene are highly diverse [3] .", [["mitochondrial", "ANATOMY", 17, 30], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["ACAT1", "GENE_OR_GENE_PRODUCT", 31, 36], ["mitochondrial ACAT1 gene", "DNA", 17, 41], ["Mutations of the mitochondrial ACAT1 gene", "PROBLEM", 0, 41], ["mitochondrial ACAT1", "OBSERVATION", 17, 36]]], ["The only common ACAT1 mutation pattern identified up to date is p.Arg208 * among the Vietnamese [3] .DiscussionThere has been no obvious concordance between the severity of the disease and the genotype [7, 9] .", [["ACAT1", "GENE_OR_GENE_PRODUCT", 16, 21], ["ACAT1", "DNA", 16, 21], ["the disease", "PROBLEM", 173, 184], ["no obvious", "UNCERTAINTY", 126, 136], ["disease", "OBSERVATION", 177, 184]]], ["A high urine TIG level is considered as the most promising predictor of severe metabolic phenotype and a severe block at the T2 enzyme level [7] .", [["urine", "ANATOMY", 7, 12], ["urine", "ORGANISM_SUBSTANCE", 7, 12], ["TIG", "SIMPLE_CHEMICAL", 13, 16], ["A high urine TIG level", "TEST", 0, 22], ["severe metabolic phenotype", "PROBLEM", 72, 98], ["a severe block at the T2 enzyme level", "PROBLEM", 103, 140], ["urine TIG", "OBSERVATION", 7, 16], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["metabolic phenotype", "OBSERVATION", 79, 98], ["severe", "OBSERVATION_MODIFIER", 105, 111]]], ["A very high level of urine TIG was indeed noted in our case.", [["urine", "ANATOMY", 21, 26], ["TIG", "CHEMICAL", 27, 30], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["TIG", "SIMPLE_CHEMICAL", 27, 30], ["urine TIG", "PROTEIN", 21, 30], ["A very high level of urine TIG", "PROBLEM", 0, 30], ["very", "OBSERVATION_MODIFIER", 2, 6], ["high", "OBSERVATION_MODIFIER", 7, 11], ["urine TIG", "OBSERVATION", 21, 30]]], ["However, low levels of urine TIG does not exclude T2 deficiency, as mutations with retained residual activity (e.g. H144P mutation) can give rise to atypical urine organic acid profiles [6, 7] .", [["urine", "ANATOMY", 23, 28], ["urine", "ANATOMY", 158, 163], ["TIG", "CHEMICAL", 29, 32], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["TIG", "SIMPLE_CHEMICAL", 29, 32], ["urine", "ORGANISM_SUBSTANCE", 158, 163], ["organic acid", "SIMPLE_CHEMICAL", 164, 176], ["urine TIG", "PROTEIN", 23, 32], ["urine TIG", "TEST", 23, 32], ["T2 deficiency", "PROBLEM", 50, 63], ["retained residual activity", "PROBLEM", 83, 109], ["atypical urine organic acid profiles", "TEST", 149, 185], ["residual activity", "OBSERVATION", 92, 109]]], ["However, T2 deficiency tends to be a benign condition in most, provided that it is diagnosed early and managed aggressively to prevent complications [3, 9] .DiscussionThe management of an acute episode includes hydration with normal saline and dextrose, intravenous sodium bicarbonate bolus followed by infusion if plasma pH \u00a07.1, correcting hypoglycemia and peritoneal dialysis in severe acidosis [5] .", [["intravenous", "ANATOMY", 254, 265], ["plasma", "ANATOMY", 315, 321], ["peritoneal", "ANATOMY", 359, 369], ["dextrose", "CHEMICAL", 244, 252], ["sodium bicarbonate", "CHEMICAL", 266, 284], ["hypoglycemia", "DISEASE", 342, 354], ["acidosis", "DISEASE", 389, 397], ["dextrose", "CHEMICAL", 244, 252], ["sodium bicarbonate", "CHEMICAL", 266, 284], ["saline", "SIMPLE_CHEMICAL", 233, 239], ["dextrose", "SIMPLE_CHEMICAL", 244, 252], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 254, 265], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 266, 284], ["plasma", "ORGANISM_SUBSTANCE", 315, 321], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 359, 369], ["T2 deficiency", "PROBLEM", 9, 22], ["a benign condition", "PROBLEM", 35, 53], ["complications", "PROBLEM", 135, 148], ["an acute episode", "PROBLEM", 185, 201], ["hydration", "TREATMENT", 211, 220], ["normal saline", "TREATMENT", 226, 239], ["dextrose", "TREATMENT", 244, 252], ["intravenous sodium bicarbonate bolus", "TREATMENT", 254, 290], ["plasma pH", "TEST", 315, 324], ["correcting hypoglycemia", "PROBLEM", 331, 354], ["peritoneal dialysis", "TREATMENT", 359, 378], ["severe acidosis", "PROBLEM", 382, 397], ["benign", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["peritoneal", "ANATOMY", 359, 369], ["severe", "OBSERVATION_MODIFIER", 382, 388], ["acidosis", "OBSERVATION", 389, 397]]], ["A further ketoacidotic event can be prevented by avoiding fasting, taking meals rich in carbohydrates during an infection, glucose infusion in states of poor feeding, restricting excess fat intake, mild protein restriction and L-carnitine supplementation in individuals with low carnitine levels [5] .", [["fat", "ANATOMY", 186, 189], ["infection", "DISEASE", 112, 121], ["glucose", "CHEMICAL", 123, 130], ["L-carnitine", "CHEMICAL", 227, 238], ["carnitine", "CHEMICAL", 279, 288], ["carbohydrates", "CHEMICAL", 88, 101], ["glucose", "CHEMICAL", 123, 130], ["L-carnitine", "CHEMICAL", 227, 238], ["carnitine", "CHEMICAL", 279, 288], ["glucose", "SIMPLE_CHEMICAL", 123, 130], ["fat", "TISSUE", 186, 189], ["L-carnitine", "SIMPLE_CHEMICAL", 227, 238], ["carnitine", "SIMPLE_CHEMICAL", 279, 288], ["A further ketoacidotic event", "PROBLEM", 0, 28], ["an infection", "PROBLEM", 109, 121], ["glucose infusion", "TREATMENT", 123, 139], ["mild protein restriction", "TREATMENT", 198, 222], ["L-carnitine supplementation", "TREATMENT", 227, 254], ["low carnitine levels", "PROBLEM", 275, 295], ["infection", "OBSERVATION", 112, 121]]], ["Screening the family members is necessary to identify asymptomatic individuals and genetic counseling should be provided [1] .", [["asymptomatic individuals", "PROBLEM", 54, 78]]], ["Newborn screening by tandem mass spectrometry will be a good option to identify T2 deficient cases early, but is currently not available in Sri Lanka [1] .ConclusionT2 deficiency should be suspected in early childhood, presenting with severe metabolic ketoacidosis preceded by an acute infection or fasting.", [["ConclusionT2 deficiency", "DISEASE", 155, 178], ["metabolic ketoacidosis", "DISEASE", 242, 264], ["infection", "DISEASE", 286, 295], ["ConclusionT2", "GENE_OR_GENE_PRODUCT", 155, 167], ["Newborn screening", "TEST", 0, 17], ["T2 deficient cases", "PROBLEM", 80, 98], ["ConclusionT2 deficiency", "PROBLEM", 155, 178], ["severe metabolic ketoacidosis", "PROBLEM", 235, 264], ["an acute infection", "PROBLEM", 277, 295], ["severe", "OBSERVATION_MODIFIER", 235, 241], ["metabolic ketoacidosis", "OBSERVATION", 242, 264], ["acute", "OBSERVATION_MODIFIER", 280, 285], ["infection", "OBSERVATION", 286, 295]]], ["T2 deficient patients can have more favorable outcomes with timely diagnosis and judicious management.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["judicious management", "TREATMENT", 81, 101]]]], "a5ebb4f3ddbb6c2c1446849b895958ae528b647a": [["IntroductionTissue damage with vascular leakage occurs after inflammation [1] and requires a fine-tuned activation and deactivation of proteases and their inhibitors released from recruited leukocytes and tissue-resident endothelial cells or fibroblasts to initiate hemostasis executed by the activation of the coagulation system, followed by the activation of the fibrinolytic system driven by plasmin, and the concomitant complement activation.", [["vascular", "ANATOMY", 31, 39], ["leukocytes", "ANATOMY", 190, 200], ["tissue-resident endothelial cells", "ANATOMY", 205, 238], ["fibroblasts", "ANATOMY", 242, 253], ["IntroductionTissue damage", "DISEASE", 0, 25], ["vascular leakage", "DISEASE", 31, 47], ["inflammation", "DISEASE", 61, 73], ["vascular", "MULTI-TISSUE_STRUCTURE", 31, 39], ["leukocytes", "CELL", 190, 200], ["tissue-resident endothelial cells", "CELL", 205, 238], ["fibroblasts", "CELL", 242, 253], ["plasmin", "GENE_OR_GENE_PRODUCT", 395, 402], ["proteases", "PROTEIN", 135, 144], ["recruited leukocytes", "CELL_TYPE", 180, 200], ["tissue-resident endothelial cells", "CELL_TYPE", 205, 238], ["fibroblasts", "CELL_TYPE", 242, 253], ["plasmin", "PROTEIN", 395, 402], ["IntroductionTissue damage", "PROBLEM", 0, 25], ["vascular leakage", "PROBLEM", 31, 47], ["inflammation", "PROBLEM", 61, 73], ["a fine-tuned activation", "TREATMENT", 91, 114], ["proteases", "TREATMENT", 135, 144], ["their inhibitors", "TREATMENT", 149, 165], ["endothelial cells", "PROBLEM", 221, 238], ["fibroblasts", "PROBLEM", 242, 253], ["hemostasis", "TREATMENT", 266, 276], ["the fibrinolytic system", "TREATMENT", 361, 384], ["vascular", "ANATOMY", 31, 39], ["leakage", "OBSERVATION", 40, 47], ["endothelial cells", "OBSERVATION", 221, 238]]], ["Coagulation factors enhance the formation of blood clots (thrombi) that stop hemorrhage (hemostasis) due to damaged vessels.", [["blood clots", "ANATOMY", 45, 56], ["thrombi", "ANATOMY", 58, 65], ["vessels", "ANATOMY", 116, 123], ["thrombi", "DISEASE", 58, 65], ["hemorrhage", "DISEASE", 77, 87], ["Coagulation factors", "GENE_OR_GENE_PRODUCT", 0, 19], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["clots", "ORGANISM_SUBSTANCE", 51, 56], ["thrombi", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 65], ["vessels", "MULTI-TISSUE_STRUCTURE", 116, 123], ["Coagulation factors", "PROTEIN", 0, 19], ["Coagulation factors", "PROBLEM", 0, 19], ["blood clots", "PROBLEM", 45, 56], ["thrombi", "PROBLEM", 58, 65], ["hemorrhage", "PROBLEM", 77, 87], ["damaged vessels", "PROBLEM", 108, 123], ["blood clots", "OBSERVATION", 45, 56], ["thrombi", "OBSERVATION", 58, 65], ["hemorrhage", "OBSERVATION", 77, 87], ["vessels", "ANATOMY", 116, 123]]], ["As blood flow needs to resume for proper tissue repair, thrombi are dissolved, a task taken on by the serine protease plasmin, the key serine protease of the fibrinolytic pathway.IntroductionEndothelial damage leading to excessive thrombin generation or proinflammatory cytokines, including tumor necrosis factor-alpha (TNFa) or interleukins (ILs), like IL-6 [2] enhance the release of tissue-type plasminogen activator (tPA) from storage granules in endothelial cells. tPA and other plasminogen activators enhance the conversion from the proenzyme/zymogen plasminogen into the active enzyme plasmin.IntroductionAside from clot dissolution, recent studies demonstrate plasmin or tPA can modify the inflammatory response on various levels: They can activate proteases like e.g. matrix metalloproteinases (MMPs) thereby modifying the extracellular matrix composition [3] , promote macrophage and dendritic cell (DC) migration, function as a cytokine, and control nuclear factor kappaB (NFkB) activation due to their ability to engage with cellular receptors conveying either pro-or anti-inflammatory cellular responses including the response to Toll-like receptor (TLRs) activation.IntroductionWhile tPA binding to some of these receptors can enhance Plg activation (proteolytic activity), growing evidence suggests that tPA can directly modulate cytokine signaling pathways through a non-enzymatic mechanism.", [["blood", "ANATOMY", 3, 8], ["tissue", "ANATOMY", 41, 47], ["thrombi", "ANATOMY", 56, 63], ["Endothelial", "ANATOMY", 191, 202], ["granules", "ANATOMY", 439, 447], ["endothelial cells", "ANATOMY", 451, 468], ["clot", "ANATOMY", 623, 627], ["extracellular matrix", "ANATOMY", 832, 852], ["macrophage", "ANATOMY", 879, 889], ["dendritic cell", "ANATOMY", 894, 908], ["DC", "ANATOMY", 910, 912], ["cellular", "ANATOMY", 1037, 1045], ["cellular", "ANATOMY", 1098, 1106], ["thrombi", "DISEASE", 56, 63], ["Endothelial damage", "DISEASE", 191, 209], ["tumor necrosis", "DISEASE", 291, 305], ["serine", "CHEMICAL", 102, 108], ["serine", "CHEMICAL", 135, 141], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["tissue", "TISSUE", 41, 47], ["plasmin", "GENE_OR_GENE_PRODUCT", 118, 125], ["Endothelial", "TISSUE", 191, 202], ["thrombin", "GENE_OR_GENE_PRODUCT", 231, 239], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 291, 318], ["TNFa", "GENE_OR_GENE_PRODUCT", 320, 324], ["interleukins", "GENE_OR_GENE_PRODUCT", 329, 341], ["ILs", "GENE_OR_GENE_PRODUCT", 343, 346], ["IL-6", "GENE_OR_GENE_PRODUCT", 354, 358], ["tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 386, 419], ["PA", "GENE_OR_GENE_PRODUCT", 422, 424], ["granules", "ORGANISM_SUBSTANCE", 439, 447], ["endothelial cells", "CELL", 451, 468], ["tPA", "GENE_OR_GENE_PRODUCT", 470, 473], ["plasminogen", "GENE_OR_GENE_PRODUCT", 484, 495], ["zymogen plasminogen", "GENE_OR_GENE_PRODUCT", 549, 568], ["plasmin", "GENE_OR_GENE_PRODUCT", 592, 599], ["clot", "ORGANISM_SUBSTANCE", 623, 627], ["plasmin", "GENE_OR_GENE_PRODUCT", 668, 675], ["tPA", "GENE_OR_GENE_PRODUCT", 679, 682], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 777, 802], ["MMPs", "GENE_OR_GENE_PRODUCT", 804, 808], ["extracellular matrix", "CELLULAR_COMPONENT", 832, 852], ["macrophage", "CELL", 879, 889], ["dendritic cell", "CELL", 894, 908], ["DC", "CELL", 910, 912], ["nuclear factor kappaB", "GENE_OR_GENE_PRODUCT", 961, 982], ["NFkB", "GENE_OR_GENE_PRODUCT", 984, 988], ["cellular", "CELL", 1037, 1045], ["cellular", "CELL", 1098, 1106], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 1143, 1161], ["TLRs", "GENE_OR_GENE_PRODUCT", 1163, 1167], ["tPA", "GENE_OR_GENE_PRODUCT", 1198, 1201], ["Plg", "GENE_OR_GENE_PRODUCT", 1249, 1252], ["tPA", "GENE_OR_GENE_PRODUCT", 1319, 1322], ["serine protease plasmin", "PROTEIN", 102, 125], ["serine protease", "PROTEIN", 135, 150], ["thrombin", "PROTEIN", 231, 239], ["proinflammatory cytokines", "PROTEIN", 254, 279], ["tumor necrosis factor-alpha", "PROTEIN", 291, 318], ["TNFa", "PROTEIN", 320, 324], ["interleukins", "PROTEIN", 329, 341], ["ILs", "PROTEIN", 343, 346], ["tissue-type plasminogen activator", "PROTEIN", 386, 419], ["endothelial cells", "CELL_TYPE", 451, 468], ["tPA", "PROTEIN", 470, 473], ["proenzyme", "PROTEIN", 539, 548], ["zymogen plasminogen", "PROTEIN", 549, 568], ["active enzyme", "PROTEIN", 578, 591], ["plasmin", "PROTEIN", 592, 599], ["plasmin", "PROTEIN", 668, 675], ["tPA", "PROTEIN", 679, 682], ["proteases", "PROTEIN", 757, 766], ["matrix metalloproteinases", "PROTEIN", 777, 802], ["MMPs", "PROTEIN", 804, 808], ["DC", "CELL_TYPE", 910, 912], ["cytokine", "PROTEIN", 939, 947], ["nuclear factor kappaB", "PROTEIN", 961, 982], ["NFkB", "PROTEIN", 984, 988], ["cellular receptors", "PROTEIN", 1037, 1055], ["Toll-like receptor", "PROTEIN", 1143, 1161], ["TLRs", "PROTEIN", 1163, 1167], ["tPA", "PROTEIN", 1198, 1201], ["Plg", "PROTEIN", 1249, 1252], ["tPA", "PROTEIN", 1319, 1322], ["cytokine", "PROTEIN", 1345, 1353], ["blood flow", "TEST", 3, 13], ["proper tissue repair", "TREATMENT", 34, 54], ["thrombi", "PROBLEM", 56, 63], ["the serine protease plasmin", "TREATMENT", 98, 125], ["the fibrinolytic pathway", "TREATMENT", 154, 178], ["IntroductionEndothelial damage", "PROBLEM", 179, 209], ["excessive thrombin generation", "PROBLEM", 221, 250], ["proinflammatory cytokines", "PROBLEM", 254, 279], ["tumor necrosis factor", "PROBLEM", 291, 312], ["alpha (TNFa", "TEST", 313, 324], ["interleukins (ILs", "TEST", 329, 346], ["tissue-type plasminogen activator", "TREATMENT", 386, 419], ["storage granules in endothelial cells", "PROBLEM", 431, 468], ["tPA", "TREATMENT", 470, 473], ["other plasminogen activators", "TREATMENT", 478, 506], ["the conversion", "TREATMENT", 515, 529], ["the proenzyme/zymogen plasminogen", "TREATMENT", 535, 568], ["clot dissolution", "PROBLEM", 623, 639], ["recent studies", "TEST", 641, 655], ["plasmin", "TREATMENT", 668, 675], ["tPA", "TREATMENT", 679, 682], ["the inflammatory response", "PROBLEM", 694, 719], ["matrix metalloproteinases (MMPs)", "TREATMENT", 777, 809], ["the extracellular matrix composition", "TREATMENT", 828, 864], ["macrophage", "TREATMENT", 879, 889], ["dendritic cell (DC) migration", "TREATMENT", 894, 923], ["a cytokine", "TREATMENT", 937, 947], ["cellular receptors", "TREATMENT", 1037, 1055], ["tPA binding", "TREATMENT", 1198, 1209], ["tPA", "TREATMENT", 1319, 1322], ["a non-enzymatic mechanism", "TREATMENT", 1381, 1406], ["repair", "OBSERVATION", 48, 54], ["thrombi", "OBSERVATION", 56, 63], ["Endothelial damage", "OBSERVATION", 191, 209], ["excessive", "OBSERVATION_MODIFIER", 221, 230], ["thrombin generation", "OBSERVATION", 231, 250], ["proinflammatory cytokines", "OBSERVATION", 254, 279], ["tumor", "OBSERVATION_MODIFIER", 291, 296], ["necrosis", "OBSERVATION_MODIFIER", 297, 305], ["endothelial cells", "OBSERVATION", 451, 468], ["clot", "OBSERVATION", 623, 627], ["inflammatory", "OBSERVATION", 698, 710], ["macrophage", "ANATOMY", 879, 889], ["dendritic cell", "OBSERVATION", 894, 908]]], ["Finally, plasmin(ogen) and J o u r n a l P r e -p r o o f its cellular receptors contribute to the resolution of inflammation.IntroductionDepending on the experimental model, the stage of inflammatory disease, and the receptors involved, plasmin(ogen) and tPA orchestrate processes that protect against or are in favor of exacerbation of inflammatory processes, underscoring the complexity of the network induced by fibrinolytic factors at the molecular level.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemVascular damage activates the coagulation system that generates fibrin and supports the formation of a thrombus.", [["cellular", "ANATOMY", 62, 70], ["systemVascular", "ANATOMY", 555, 569], ["thrombus", "ANATOMY", 664, 672], ["inflammation", "DISEASE", 113, 125], ["inflammatory disease", "DISEASE", 188, 208], ["thrombus", "DISEASE", 664, 672], ["plasmin", "GENE_OR_GENE_PRODUCT", 9, 16], ["cellular", "CELL", 62, 70], ["plasmin", "GENE_OR_GENE_PRODUCT", 238, 245], ["ogen", "GENE_OR_GENE_PRODUCT", 246, 250], ["tPA", "GENE_OR_GENE_PRODUCT", 256, 259], ["fibrinolytic factors", "GENE_OR_GENE_PRODUCT", 416, 436], ["fibrin", "GENE_OR_GENE_PRODUCT", 625, 631], ["thrombus", "PATHOLOGICAL_FORMATION", 664, 672], ["plasmin", "PROTEIN", 9, 16], ["ogen", "PROTEIN", 17, 21], ["cellular receptors", "PROTEIN", 62, 80], ["plasmin", "PROTEIN", 238, 245], ["ogen", "PROTEIN", 246, 250], ["tPA", "PROTEIN", 256, 259], ["fibrinolytic factors", "PROTEIN", 416, 436], ["fibrin", "PROTEIN", 625, 631], ["plasmin", "TEST", 9, 16], ["ogen", "TEST", 17, 21], ["its cellular receptors", "PROBLEM", 58, 80], ["inflammation", "PROBLEM", 113, 125], ["inflammatory disease", "PROBLEM", 188, 208], ["plasmin(ogen)", "TREATMENT", 238, 251], ["tPA orchestrate processes", "TREATMENT", 256, 281], ["inflammatory processes", "PROBLEM", 338, 360], ["fibrinolytic factors", "PROBLEM", 416, 436], ["initial coagulation", "TEST", 485, 504], ["fibrinolysis", "TREATMENT", 506, 518], ["the immune systemVascular damage", "PROBLEM", 544, 576], ["the coagulation system", "TEST", 587, 609], ["fibrin", "PROBLEM", 625, 631], ["a thrombus", "PROBLEM", 662, 672], ["resolution", "OBSERVATION_MODIFIER", 99, 109], ["inflammation", "OBSERVATION", 113, 125], ["inflammatory", "OBSERVATION_MODIFIER", 188, 200], ["disease", "OBSERVATION", 201, 208], ["inflammatory", "OBSERVATION", 338, 350], ["fibrin", "OBSERVATION", 625, 631], ["thrombus", "OBSERVATION", 664, 672]]], ["The thrombus establishes a physical barrier for pathogens or non-self-pathogens (part of the innate immune system) and stopping bleeding (hemostasis).", [["thrombus", "ANATOMY", 4, 12], ["thrombus", "DISEASE", 4, 12], ["bleeding", "DISEASE", 128, 136], ["thrombus", "PATHOLOGICAL_FORMATION", 4, 12], ["The thrombus", "PROBLEM", 0, 12], ["a physical barrier", "TREATMENT", 25, 43], ["pathogens", "PROBLEM", 48, 57], ["non-self-pathogens", "PROBLEM", 61, 79], ["the innate immune system", "TREATMENT", 89, 113], ["bleeding", "PROBLEM", 128, 136], ["thrombus", "OBSERVATION", 4, 12]]], ["Inflammation shifts the hemostatic balance towards a prothrombotic and antifibrinolytic state that causesif not properly shut downcauses the devastating consumptive coagulopathy and disseminated coagulation [4] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemTissue damage can activate the complement cascade during the inflammatory response, another cascade of enzymes of the innate immune system that enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells, induce inflammation to attract more macrophages, and activates the cell-killing membrane attack complex (MAC) to destroy the pathogen`s cell membrane ( Figure 1 ).", [["phagocytic cells", "ANATOMY", 510, 526], ["cells", "ANATOMY", 557, 562], ["macrophages", "ANATOMY", 600, 611], ["cell", "ANATOMY", 631, 635], ["membrane", "ANATOMY", 644, 652], ["cell membrane", "ANATOMY", 700, 713], ["Inflammation", "DISEASE", 0, 12], ["coagulopathy", "DISEASE", 165, 177], ["disseminated coagulation", "DISEASE", 182, 206], ["inflammation", "DISEASE", 571, 583], ["phagocytic cells", "CELL", 510, 526], ["cells", "CELL", 557, 562], ["macrophages", "CELL", 600, 611], ["cell", "CELL", 631, 635], ["membrane", "CELLULAR_COMPONENT", 644, 652], ["cell membrane", "CELLULAR_COMPONENT", 700, 713], ["antibodies", "PROTEIN", 495, 505], ["phagocytic cells", "CELL_TYPE", 510, 526], ["damaged cells", "CELL_TYPE", 549, 562], ["macrophages", "CELL_TYPE", 600, 611], ["Inflammation shifts", "PROBLEM", 0, 19], ["the hemostatic balance", "PROBLEM", 20, 42], ["a prothrombotic and antifibrinolytic state", "PROBLEM", 51, 93], ["the devastating consumptive coagulopathy", "PROBLEM", 137, 177], ["disseminated coagulation", "PROBLEM", 182, 206], ["initial coagulation", "TEST", 237, 256], ["fibrinolysis", "TREATMENT", 258, 270], ["the immune systemTissue damage", "PROBLEM", 296, 326], ["the inflammatory response", "PROBLEM", 370, 395], ["antibodies", "TEST", 495, 505], ["phagocytic cells", "PROBLEM", 510, 526], ["damaged cells", "PROBLEM", 549, 562], ["inflammation", "PROBLEM", 571, 583], ["hemostatic balance", "OBSERVATION", 24, 42], ["devastating", "OBSERVATION_MODIFIER", 141, 152], ["consumptive", "OBSERVATION_MODIFIER", 153, 164], ["coagulopathy", "OBSERVATION", 165, 177], ["phagocytic cells", "OBSERVATION", 510, 526], ["cell membrane", "OBSERVATION", 700, 713]]], ["Coagulation Cascade.", [["Coagulation Cascade", "TREATMENT", 0, 19]]], ["While the intrinsic, contact coagulation pathway is mainly activated through exposed endothelial collagen and XII, the extrinsic pathway is activated through the release of the transmembrane receptor tissue factor (TF) from endothelial cells and its plasma cofactor Factor VII/VIIa (Figure 1 ).", [["endothelial", "ANATOMY", 85, 96], ["transmembrane", "ANATOMY", 177, 190], ["endothelial cells", "ANATOMY", 224, 241], ["plasma", "ANATOMY", 250, 256], ["endothelial collagen", "GENE_OR_GENE_PRODUCT", 85, 105], ["XII", "GENE_OR_GENE_PRODUCT", 110, 113], ["tissue factor", "GENE_OR_GENE_PRODUCT", 200, 213], ["TF", "GENE_OR_GENE_PRODUCT", 215, 217], ["endothelial cells", "CELL", 224, 241], ["plasma", "ORGANISM_SUBSTANCE", 250, 256], ["Factor VII/VIIa", "GENE_OR_GENE_PRODUCT", 266, 281], ["Figure 1", "GENE_OR_GENE_PRODUCT", 283, 291], ["endothelial collagen", "PROTEIN", 85, 105], ["XII", "PROTEIN", 110, 113], ["transmembrane receptor tissue factor", "PROTEIN", 177, 213], ["TF", "PROTEIN", 215, 217], ["endothelial cells", "CELL_TYPE", 224, 241], ["plasma cofactor Factor VII", "PROTEIN", 250, 276], ["VIIa", "PROTEIN", 277, 281], ["Figure 1", "PROTEIN", 283, 291], ["contact coagulation pathway", "TEST", 21, 48], ["the transmembrane receptor tissue factor", "TREATMENT", 173, 213], ["endothelial cells", "TEST", 224, 241], ["endothelial", "ANATOMY", 224, 235]]], ["Extrinsic and intrinsic pathways activate Factor X, which renders the zymogen prothrombin into thrombin.", [["Factor X", "GENE_OR_GENE_PRODUCT", 42, 50], ["prothrombin", "GENE_OR_GENE_PRODUCT", 78, 89], ["thrombin", "GENE_OR_GENE_PRODUCT", 95, 103], ["Factor X", "PROTEIN", 42, 50], ["zymogen prothrombin", "PROTEIN", 70, 89], ["thrombin", "PROTEIN", 95, 103], ["the zymogen prothrombin into thrombin", "TREATMENT", 66, 103], ["thrombin", "OBSERVATION", 95, 103]]], ["Factor XII (FXII, also known as Hageman factor) is converted to its active J o u r n a l P r e -p r o o f enzyme (FXIIa) by plasma kallikrein (PKa) or by its unique ability to auto-activate following binding to artificial or biologic surfaces [5] .", [["plasma", "ANATOMY", 124, 130], ["J o u r n a l P r e -p r o o f", "CHEMICAL", 75, 105], ["Factor XII", "GENE_OR_GENE_PRODUCT", 0, 10], ["FXII", "GENE_OR_GENE_PRODUCT", 12, 16], ["Hageman factor", "GENE_OR_GENE_PRODUCT", 32, 46], ["o f enzyme", "GENE_OR_GENE_PRODUCT", 102, 112], ["FXIIa", "GENE_OR_GENE_PRODUCT", 114, 119], ["plasma", "ORGANISM_SUBSTANCE", 124, 130], ["kallikrein", "GENE_OR_GENE_PRODUCT", 131, 141], ["PKa", "GENE_OR_GENE_PRODUCT", 143, 146], ["Factor XII", "PROTEIN", 0, 10], ["FXII", "PROTEIN", 12, 16], ["Hageman factor", "PROTEIN", 32, 46], ["P r e", "DNA", 89, 94], ["FXIIa", "PROTEIN", 114, 119], ["plasma kallikrein", "PROTEIN", 124, 141], ["PKa", "PROTEIN", 143, 146], ["a l P r e -p r o o f enzyme", "TEST", 85, 112], ["FXIIa", "PROBLEM", 114, 119], ["plasma kallikrein (PKa", "TEST", 124, 146]]], ["In disease states of infection, the surface of bacterial pathogens or polyphosphates released by them promotes the autoactivation of FXII [5] .", [["surface", "ANATOMY", 36, 43], ["infection", "DISEASE", 21, 30], ["polyphosphates", "CHEMICAL", 70, 84], ["polyphosphates", "CHEMICAL", 70, 84], ["surface", "CELLULAR_COMPONENT", 36, 43], ["polyphosphates", "SIMPLE_CHEMICAL", 70, 84], ["FXII", "GENE_OR_GENE_PRODUCT", 133, 137], ["FXII", "PROTEIN", 133, 137], ["infection", "PROBLEM", 21, 30], ["bacterial pathogens", "PROBLEM", 47, 66], ["polyphosphates", "PROBLEM", 70, 84], ["disease", "OBSERVATION", 3, 10], ["infection", "OBSERVATION", 21, 30]]], ["FXIIa activation of PK forms plasma kallikrein that reciprocally activates FXII and liberates bradykinin (BK) from high molecular weight kininogen (HK).", [["plasma", "ANATOMY", 29, 35], ["bradykinin", "CHEMICAL", 94, 104], ["BK", "CHEMICAL", 106, 108], ["bradykinin", "CHEMICAL", 94, 104], ["FXIIa", "GENE_OR_GENE_PRODUCT", 0, 5], ["PK", "GENE_OR_GENE_PRODUCT", 20, 22], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["kallikrein", "GENE_OR_GENE_PRODUCT", 36, 46], ["FXII", "GENE_OR_GENE_PRODUCT", 75, 79], ["bradykinin", "SIMPLE_CHEMICAL", 94, 104], ["BK", "SIMPLE_CHEMICAL", 106, 108], ["high molecular weight kininogen", "GENE_OR_GENE_PRODUCT", 115, 146], ["HK", "GENE_OR_GENE_PRODUCT", 148, 150], ["FXIIa", "PROTEIN", 0, 5], ["PK", "PROTEIN", 20, 22], ["plasma kallikrein", "PROTEIN", 29, 46], ["FXII", "PROTEIN", 75, 79], ["high molecular weight kininogen", "PROTEIN", 115, 146], ["HK", "PROTEIN", 148, 150], ["plasma kallikrein", "PROBLEM", 29, 46], ["FXII", "PROBLEM", 75, 79], ["bradykinin", "PROBLEM", 94, 104], ["high molecular weight kininogen", "PROBLEM", 115, 146]]], ["Bradykinin enhances vasodilation and increases capillary permeability, leading to edema and changes in arterial blood pressure.", [["capillary", "ANATOMY", 47, 56], ["edema", "ANATOMY", 82, 87], ["arterial blood", "ANATOMY", 103, 117], ["Bradykinin", "CHEMICAL", 0, 10], ["edema", "DISEASE", 82, 87], ["Bradykinin", "CHEMICAL", 0, 10], ["Bradykinin", "SIMPLE_CHEMICAL", 0, 10], ["capillary", "TISSUE", 47, 56], ["edema", "PATHOLOGICAL_FORMATION", 82, 87], ["arterial", "MULTI-TISSUE_STRUCTURE", 103, 111], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["Bradykinin enhances vasodilation", "PROBLEM", 0, 32], ["increases capillary permeability", "PROBLEM", 37, 69], ["edema", "PROBLEM", 82, 87], ["arterial blood pressure", "TEST", 103, 126], ["vasodilation", "OBSERVATION", 20, 32], ["increases", "OBSERVATION_MODIFIER", 37, 46], ["capillary permeability", "OBSERVATION", 47, 69], ["edema", "OBSERVATION", 82, 87], ["arterial", "ANATOMY_MODIFIER", 103, 111], ["blood", "ANATOMY", 112, 117], ["pressure", "OBSERVATION_MODIFIER", 118, 126]]], ["FXII deficiency is linked to decreased infiltration of inflammatory cells into skin windows [6] .", [["inflammatory cells", "ANATOMY", 55, 73], ["skin", "ANATOMY", 79, 83], ["FXII", "GENE_OR_GENE_PRODUCT", 0, 4], ["inflammatory cells", "CELL", 55, 73], ["skin", "ORGAN", 79, 83], ["FXII", "PROTEIN", 0, 4], ["inflammatory cells", "CELL_TYPE", 55, 73], ["FXII deficiency", "PROBLEM", 0, 15], ["decreased infiltration of inflammatory cells into skin windows", "PROBLEM", 29, 91], ["decreased", "OBSERVATION_MODIFIER", 29, 38], ["infiltration", "OBSERVATION_MODIFIER", 39, 51], ["inflammatory cells", "OBSERVATION", 55, 73], ["skin", "ANATOMY", 79, 83]]], ["FXII facilitates the recruitment of neutrophils, binds to the surface of pathogens (bacteria, fungi, viruses, and neutrophil extracellular traps (NETs) where it autoactivates [7] .", [["neutrophils", "ANATOMY", 36, 47], ["surface", "ANATOMY", 62, 69], ["neutrophil extracellular", "ANATOMY", 114, 138], ["NETs", "ANATOMY", 146, 150], ["FXII", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophils", "CELL", 36, 47], ["neutrophil extracellular traps", "GENE_OR_GENE_PRODUCT", 114, 144], ["FXII", "PROTEIN", 0, 4], ["neutrophils", "CELL_TYPE", 36, 47], ["FXII", "PROBLEM", 0, 4], ["neutrophils", "PROBLEM", 36, 47], ["pathogens", "PROBLEM", 73, 82], ["bacteria", "PROBLEM", 84, 92], ["fungi", "PROBLEM", 94, 99], ["viruses", "PROBLEM", 101, 108], ["neutrophil extracellular traps", "TREATMENT", 114, 144]]], ["FXII promotes neutrophil degranulation [8] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemFactor XIIa also activates FXI and C1 esterases (C1r, C1s), the first components of the macromolecular complex of C1, and the classic complement cascade ( Figure 1 ) [9] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemThe complement cascade is part of the innate immune system.", [["neutrophil", "ANATOMY", 14, 24], ["immune system", "ANATOMY", 404, 417], ["FXII", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophil", "CELL", 14, 24], ["XIIa", "GENE_OR_GENE_PRODUCT", 152, 156], ["FXI", "GENE_OR_GENE_PRODUCT", 172, 175], ["C1 esterases", "GENE_OR_GENE_PRODUCT", 180, 192], ["C1r", "GENE_OR_GENE_PRODUCT", 194, 197], ["C1s", "GENE_OR_GENE_PRODUCT", 199, 202], ["C1", "GENE_OR_GENE_PRODUCT", 259, 261], ["FXII", "PROTEIN", 0, 4], ["neutrophil", "CELL_TYPE", 14, 24], ["immune systemFactor XIIa", "PROTEIN", 132, 156], ["FXI", "PROTEIN", 172, 175], ["C1 esterases", "PROTEIN", 180, 192], ["C1r", "PROTEIN", 194, 197], ["C1s", "PROTEIN", 199, 202], ["macromolecular complex", "PROTEIN", 233, 255], ["C1", "PROTEIN", 259, 261], ["initial coagulation", "TEST", 69, 88], ["fibrinolysis", "TREATMENT", 90, 102], ["the immune systemFactor XIIa", "TEST", 128, 156], ["FXI and C1 esterases", "TEST", 172, 192], ["initial coagulation", "TEST", 341, 360], ["fibrinolysis", "TREATMENT", 362, 374], ["neutrophil degranulation", "OBSERVATION", 14, 38], ["FXI", "OBSERVATION", 172, 175], ["macromolecular", "ANATOMY_MODIFIER", 233, 247], ["C1", "ANATOMY", 259, 261], ["cascade", "OBSERVATION", 432, 439]]], ["Complement factors (C1-9) are small proteins that enhance (complement) the ability of antibodies and macrophages to clear microbes following proteolytic activation (C1a-C9a) ( Figure 1 ): Complement enhances (complements) the antibody's ability and macrophages to clear microbes.", [["macrophages", "ANATOMY", 101, 112], ["macrophages", "ANATOMY", 249, 260], ["Complement factors", "GENE_OR_GENE_PRODUCT", 0, 18], ["C1-9", "GENE_OR_GENE_PRODUCT", 20, 24], ["macrophages", "CELL", 101, 112], ["Complement", "GENE_OR_GENE_PRODUCT", 188, 198], ["macrophages", "CELL", 249, 260], ["Complement factors", "PROTEIN", 0, 18], ["C1-9", "PROTEIN", 20, 24], ["antibodies", "PROTEIN", 86, 96], ["macrophages", "CELL_TYPE", 101, 112], ["macrophages", "CELL_TYPE", 249, 260], ["Complement factors", "TEST", 0, 18], ["small proteins", "PROBLEM", 30, 44], ["antibodies", "TEST", 86, 96], ["macrophages", "PROBLEM", 101, 112], ["proteolytic activation", "TEST", 141, 163], ["the antibody's ability", "TEST", 222, 244], ["small", "OBSERVATION_MODIFIER", 30, 35], ["proteins", "OBSERVATION", 36, 44], ["clear microbes", "OBSERVATION", 264, 278]]], ["Complement factors enhance macrophage and neutrophil chemoattraction and establish a membrane attack complex (MAC, C5b-C9) necessary for the rupture of the cell wall.", [["macrophage", "ANATOMY", 27, 37], ["neutrophil", "ANATOMY", 42, 52], ["membrane", "ANATOMY", 85, 93], ["cell wall", "ANATOMY", 156, 165], ["Complement factors", "GENE_OR_GENE_PRODUCT", 0, 18], ["macrophage", "CELL", 27, 37], ["neutrophil", "CELL", 42, 52], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["C5b-C9", "GENE_OR_GENE_PRODUCT", 115, 121], ["cell wall", "TISSUE", 156, 165], ["Complement factors", "PROTEIN", 0, 18], ["membrane attack complex", "PROTEIN", 85, 108], ["MAC", "PROTEIN", 110, 113], ["C5b", "PROTEIN", 115, 118], ["C9", "PROTEIN", 119, 121], ["neutrophil chemoattraction", "TEST", 42, 68], ["a membrane attack complex (MAC, C5b-C9)", "TREATMENT", 83, 122], ["the rupture of the cell wall", "PROBLEM", 137, 165], ["macrophage", "OBSERVATION_MODIFIER", 27, 37], ["neutrophil chemoattraction", "OBSERVATION", 42, 68], ["rupture", "OBSERVATION", 141, 148], ["cell", "ANATOMY", 156, 160], ["wall", "ANATOMY_MODIFIER", 161, 165]]], ["Thrombin and plasmin enhance the formation of certain complement proteins (namely C3 and C5).", [["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["plasmin", "GENE_OR_GENE_PRODUCT", 13, 20], ["complement proteins", "GENE_OR_GENE_PRODUCT", 54, 73], ["C3", "GENE_OR_GENE_PRODUCT", 82, 84], ["Thrombin", "PROTEIN", 0, 8], ["plasmin", "PROTEIN", 13, 20], ["complement proteins", "PROTEIN", 54, 73], ["C3", "PROTEIN", 82, 84], ["C5", "PROTEIN", 89, 91], ["Thrombin", "TREATMENT", 0, 8], ["plasmin", "TREATMENT", 13, 20], ["complement proteins", "TEST", 54, 73], ["plasmin", "OBSERVATION", 13, 20], ["C5", "ANATOMY_MODIFIER", 89, 91]]], ["Activated complement fragments C3a/C5a can recruit leukocytes and induced the MAC complex on macrophages [10] .", [["leukocytes", "ANATOMY", 51, 61], ["macrophages", "ANATOMY", 93, 104], ["C3a", "GENE_OR_GENE_PRODUCT", 31, 34], ["C5a", "GENE_OR_GENE_PRODUCT", 35, 38], ["leukocytes", "CELL", 51, 61], ["MAC", "GENE_OR_GENE_PRODUCT", 78, 81], ["macrophages", "CELL", 93, 104], ["Activated complement fragments", "PROTEIN", 0, 30], ["C3a", "PROTEIN", 31, 34], ["C5a", "PROTEIN", 35, 38], ["leukocytes", "CELL_TYPE", 51, 61], ["MAC complex", "PROTEIN", 78, 89], ["macrophages", "CELL_TYPE", 93, 104], ["Activated complement fragments C3a/C5a", "TREATMENT", 0, 38], ["leukocytes", "TEST", 51, 61]]], ["One inhibitor of the classical C1 pathway of the complement is C1 inhibitor.", [["C1", "GENE_OR_GENE_PRODUCT", 63, 65], ["C1 inhibitor", "TREATMENT", 63, 75]]], ["Mutations in the C1 inhibitor gene can cause hereditary angioedema due to a reduced regulation of bradykinin by J o u r n a l P r e -p r o o f C1 inhibitor.", [["hereditary angioedema", "DISEASE", 45, 66], ["bradykinin", "CHEMICAL", 98, 108], ["bradykinin", "CHEMICAL", 98, 108], ["o o f C1", "CHEMICAL", 137, 145], ["C1", "GENE_OR_GENE_PRODUCT", 17, 19], ["bradykinin", "SIMPLE_CHEMICAL", 98, 108], ["o f C1", "GENE_OR_GENE_PRODUCT", 139, 145], ["C1 inhibitor gene", "DNA", 17, 34], ["Mutations in the C1 inhibitor gene", "PROBLEM", 0, 34], ["hereditary angioedema", "PROBLEM", 45, 66], ["a reduced regulation of bradykinin", "PROBLEM", 74, 108], ["a l P r e -p r o o f C1 inhibitor", "TREATMENT", 122, 155]]], ["HIV infection can alter the complement system causing further tissue damage [11] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemThrombin converts fibrinogen into fibrin.", [["tissue", "ANATOMY", 62, 68], ["HIV infection", "DISEASE", 0, 13], ["HIV", "ORGANISM", 0, 3], ["tissue", "TISSUE", 62, 68], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 201, 211], ["fibrin", "GENE_OR_GENE_PRODUCT", 217, 223], ["immune systemThrombin", "PROTEIN", 170, 191], ["fibrinogen", "PROTEIN", 201, 211], ["fibrin", "PROTEIN", 217, 223], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV infection", "PROBLEM", 0, 13], ["further tissue damage", "PROBLEM", 54, 75], ["initial coagulation", "TEST", 107, 126], ["fibrinolysis", "TEST", 128, 140], ["the immune systemThrombin", "TEST", 166, 191], ["fibrinogen into fibrin", "PROBLEM", 201, 223], ["infection", "OBSERVATION", 4, 13], ["fibrin", "OBSERVATION", 217, 223]]], ["Factor XIII, another thrombin-generated enzyme, then crosslinks the fibrin protofibrils leading to an insoluble gel that serves as a scaffold for a blood clot (thrombus).", [["blood clot", "ANATOMY", 148, 158], ["thrombus", "ANATOMY", 160, 168], ["thrombus", "DISEASE", 160, 168], ["Factor XIII", "GENE_OR_GENE_PRODUCT", 0, 11], ["thrombin", "GENE_OR_GENE_PRODUCT", 21, 29], ["fibrin", "GENE_OR_GENE_PRODUCT", 68, 74], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["clot", "ORGANISM_SUBSTANCE", 154, 158], ["thrombus", "PATHOLOGICAL_FORMATION", 160, 168], ["Factor XIII", "PROTEIN", 0, 11], ["thrombin", "PROTEIN", 21, 29], ["fibrin protofibrils", "PROTEIN", 68, 87], ["Factor XIII", "TEST", 0, 11], ["another thrombin", "TEST", 13, 29], ["the fibrin protofibrils", "PROBLEM", 64, 87], ["an insoluble gel", "TREATMENT", 99, 115], ["a blood clot", "PROBLEM", 146, 158], ["thrombus", "PROBLEM", 160, 168], ["fibrin protofibrils", "OBSERVATION", 68, 87], ["blood", "ANATOMY", 148, 153], ["clot", "OBSERVATION", 154, 158], ["thrombus", "OBSERVATION", 160, 168]]], ["Endothelial cells that cover the inner vessel wall modulate the balance between coagulation and fibrinolysis by counteracting coagulation through binding of anti-thrombin III, releasing tissue factor pathway inhibitor, expressing thrombomodulin, activating protein C, and producing and secreting tPA [12, 13] .", [["Endothelial cells", "ANATOMY", 0, 17], ["inner vessel wall", "ANATOMY", 33, 50], ["Endothelial cells", "CELL", 0, 17], ["inner vessel wall", "TISSUE", 33, 50], ["anti-thrombin III", "GENE_OR_GENE_PRODUCT", 157, 174], ["tissue factor", "GENE_OR_GENE_PRODUCT", 186, 199], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 230, 244], ["protein C", "GENE_OR_GENE_PRODUCT", 257, 266], ["tPA", "GENE_OR_GENE_PRODUCT", 296, 299], ["Endothelial cells", "CELL_TYPE", 0, 17], ["anti-thrombin III", "PROTEIN", 157, 174], ["thrombomodulin", "PROTEIN", 230, 244], ["protein C", "PROTEIN", 257, 266], ["tPA", "PROTEIN", 296, 299], ["Endothelial cells", "PROBLEM", 0, 17], ["fibrinolysis", "TREATMENT", 96, 108], ["anti-thrombin III", "TREATMENT", 157, 174], ["releasing tissue factor pathway inhibitor", "TREATMENT", 176, 217], ["activating protein C", "PROBLEM", 246, 266], ["secreting tPA", "TREATMENT", 286, 299], ["cells", "OBSERVATION", 12, 17], ["inner", "ANATOMY_MODIFIER", 33, 38], ["vessel", "ANATOMY", 39, 45], ["wall", "ANATOMY_MODIFIER", 46, 50], ["balance", "OBSERVATION", 64, 71]]], ["Protein C -produced in the liver in a Vitamin K-dependent manner -after binding to the endothelial cell protein C receptor in the presence of thrombomodulin and thrombin leads to the generation of activated protein C (APC) [14] .", [["liver", "ANATOMY", 27, 32], ["endothelial cell", "ANATOMY", 87, 103], ["Vitamin", "CHEMICAL", 38, 45], ["Vitamin K-dependent", "CHEMICAL", 38, 57], ["Protein C", "GENE_OR_GENE_PRODUCT", 0, 9], ["liver", "ORGAN", 27, 32], ["Vitamin", "SIMPLE_CHEMICAL", 38, 45], ["endothelial cell protein C receptor", "GENE_OR_GENE_PRODUCT", 87, 122], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 142, 156], ["thrombin", "GENE_OR_GENE_PRODUCT", 161, 169], ["protein C", "GENE_OR_GENE_PRODUCT", 207, 216], ["APC", "GENE_OR_GENE_PRODUCT", 218, 221], ["Protein C", "PROTEIN", 0, 9], ["endothelial cell protein C receptor", "PROTEIN", 87, 122], ["thrombomodulin", "PROTEIN", 142, 156], ["thrombin", "PROTEIN", 161, 169], ["activated protein C", "PROTEIN", 197, 216], ["APC", "PROTEIN", 218, 221], ["Protein C", "TEST", 0, 9], ["a Vitamin K-dependent manner", "TREATMENT", 36, 64], ["the endothelial cell protein C receptor", "TREATMENT", 83, 122], ["thrombomodulin and thrombin", "TREATMENT", 142, 169], ["activated protein C (APC)", "TREATMENT", 197, 222], ["liver", "ANATOMY", 27, 32], ["endothelial", "ANATOMY", 87, 98], ["thrombomodulin", "OBSERVATION", 142, 156], ["thrombin", "OBSERVATION", 161, 169]]], ["APC irreversibly inactivates Factor Va (Leiden) and VIIIa and thereby counteracts thrombin activity.", [["APC", "CHEMICAL", 0, 3], ["APC", "GENE_OR_GENE_PRODUCT", 0, 3], ["Factor Va (Leiden)", "GENE_OR_GENE_PRODUCT", 29, 47], ["VIIIa", "GENE_OR_GENE_PRODUCT", 52, 57], ["thrombin", "GENE_OR_GENE_PRODUCT", 82, 90], ["APC", "CELL_TYPE", 0, 3], ["Factor Va (Leiden) and VIIIa", "PROTEIN", 29, 57], ["thrombin", "PROTEIN", 82, 90], ["APC", "PROBLEM", 0, 3], ["thrombin activity", "TREATMENT", 82, 99], ["VIIIa", "ANATOMY", 52, 57], ["counteracts", "OBSERVATION_MODIFIER", 70, 81], ["thrombin activity", "OBSERVATION", 82, 99]]], ["The fibrinolytic cascade, with plasmin as its central player, is required for fibrin degradation and blood clot/thrombus dissolution to regain vascular patency after initial hemostasis is achieved [18, 19] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemVascular endothelial cells keep tPA and Plg on their surfaces. tPA (encoded by PLAT), urokinase plasminogen activator (uPA, encoded by PLAU), or other enzymes, e.g., plasma kallikrein (PK) and coagulation factor XIIa convert the inactive zymogen Plg into the active enzyme plasmin [20] .", [["fibrin", "ANATOMY", 78, 84], ["blood clot", "ANATOMY", 101, 111], ["thrombus", "ANATOMY", 112, 120], ["vascular", "ANATOMY", 143, 151], ["immune systemVascular endothelial cells", "ANATOMY", 295, 334], ["plasma", "ANATOMY", 474, 480], ["thrombus", "DISEASE", 112, 120], ["plasmin", "GENE_OR_GENE_PRODUCT", 31, 38], ["fibrin", "GENE_OR_GENE_PRODUCT", 78, 84], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["clot", "ORGANISM_SUBSTANCE", 107, 111], ["thrombus", "PATHOLOGICAL_FORMATION", 112, 120], ["vascular", "MULTI-TISSUE_STRUCTURE", 143, 151], ["immune systemVascular endothelial cells", "CELL", 295, 334], ["tPA", "GENE_OR_GENE_PRODUCT", 340, 343], ["Plg", "GENE_OR_GENE_PRODUCT", 348, 351], ["tPA", "GENE_OR_GENE_PRODUCT", 371, 374], ["PLAT", "GENE_OR_GENE_PRODUCT", 387, 391], ["urokinase plasminogen activator", "GENE_OR_GENE_PRODUCT", 394, 425], ["uPA", "GENE_OR_GENE_PRODUCT", 427, 430], ["PLAU", "GENE_OR_GENE_PRODUCT", 443, 447], ["plasma", "ORGANISM_SUBSTANCE", 474, 480], ["kallikrein", "GENE_OR_GENE_PRODUCT", 481, 491], ["PK", "GENE_OR_GENE_PRODUCT", 493, 495], ["coagulation factor XIIa", "GENE_OR_GENE_PRODUCT", 501, 524], ["zymogen Plg", "GENE_OR_GENE_PRODUCT", 546, 557], ["plasmin", "GENE_OR_GENE_PRODUCT", 581, 588], ["plasmin", "PROTEIN", 31, 38], ["fibrin", "PROTEIN", 78, 84], ["immune systemVascular endothelial cells", "CELL_TYPE", 295, 334], ["tPA", "PROTEIN", 340, 343], ["Plg", "PROTEIN", 348, 351], ["tPA", "PROTEIN", 371, 374], ["PLAT", "PROTEIN", 387, 391], ["urokinase plasminogen activator", "PROTEIN", 394, 425], ["uPA", "PROTEIN", 427, 430], ["PLAU", "PROTEIN", 443, 447], ["enzymes", "PROTEIN", 459, 466], ["plasma kallikrein", "PROTEIN", 474, 491], ["PK", "PROTEIN", 493, 495], ["coagulation factor XIIa", "PROTEIN", 501, 524], ["inactive zymogen Plg", "PROTEIN", 537, 557], ["plasmin", "PROTEIN", 581, 588], ["The fibrinolytic cascade", "TREATMENT", 0, 24], ["plasmin", "TREATMENT", 31, 38], ["fibrin degradation", "PROBLEM", 78, 96], ["blood clot", "PROBLEM", 101, 111], ["thrombus dissolution", "PROBLEM", 112, 132], ["initial hemostasis", "TEST", 166, 184], ["initial coagulation", "TEST", 232, 251], ["fibrinolysis", "TREATMENT", 253, 265], ["the immune systemVascular endothelial cells", "TREATMENT", 291, 334], ["tPA", "TREATMENT", 340, 343], ["tPA", "TREATMENT", 371, 374], ["urokinase plasminogen activator", "TREATMENT", 394, 425], ["other enzymes", "TEST", 453, 466], ["plasma kallikrein (PK)", "TEST", 474, 496], ["coagulation factor XIIa", "TEST", 501, 524], ["fibrinolytic cascade", "OBSERVATION", 4, 24], ["clot", "OBSERVATION", 107, 111], ["thrombus", "OBSERVATION", 112, 120], ["vascular", "ANATOMY", 143, 151], ["patency", "OBSERVATION_MODIFIER", 152, 159]]], ["Plg is produced by the liver and circulates in the blood.", [["liver", "ANATOMY", 23, 28], ["blood", "ANATOMY", 51, 56], ["Plg", "CHEMICAL", 0, 3], ["Plg", "GENE_OR_GENE_PRODUCT", 0, 3], ["liver", "ORGAN", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["Plg", "PROTEIN", 0, 3], ["liver", "ANATOMY", 23, 28], ["circulates", "OBSERVATION_MODIFIER", 33, 43], ["blood", "ANATOMY", 51, 56]]], ["Plg is a seven-domain protein comprising an N-terminus PAN-apple domain, five tandem kringle domains, and a C-terminus catalytic domain [21] .", [["Plg", "CHEMICAL", 0, 3], ["C", "CHEMICAL", 108, 109], ["Plg", "GENE_OR_GENE_PRODUCT", 0, 3], ["Plg", "PROTEIN", 0, 3], ["seven-domain protein", "PROTEIN", 9, 29], ["N-terminus", "PROTEIN", 44, 54], ["PAN", "PROTEIN", 55, 58], ["apple domain", "PROTEIN", 59, 71], ["tandem kringle domains", "PROTEIN", 78, 100], ["C-terminus catalytic domain", "PROTEIN", 108, 135], ["an N-terminus PAN-apple domain", "TREATMENT", 41, 71], ["five tandem kringle domains", "TREATMENT", 73, 100], ["a C-terminus catalytic domain", "TREATMENT", 106, 135]]], ["The PAN/apple domain is proteolytically removed, and the kringle domains are responsible for fibrin binding.", [["PAN", "CHEMICAL", 4, 7], ["PAN", "GENE_OR_GENE_PRODUCT", 4, 7], ["fibrin", "GENE_OR_GENE_PRODUCT", 93, 99], ["PAN/apple domain", "PROTEIN", 4, 20], ["kringle domains", "PROTEIN", 57, 72], ["fibrin", "PROTEIN", 93, 99], ["The PAN/apple domain", "TREATMENT", 0, 20], ["the kringle domains", "TEST", 53, 72], ["fibrin binding", "PROBLEM", 93, 107], ["responsible for", "UNCERTAINTY", 77, 92], ["fibrin binding", "OBSERVATION", 93, 107]]], ["The PAN/apple domain-free plasmin can be further degraded by phosphoglucerate kinase to remove the catalytic domain.", [["PAN", "CHEMICAL", 4, 7], ["phosphoglucerate", "CHEMICAL", 61, 77], ["phosphoglucerate", "CHEMICAL", 61, 77], ["PAN", "GENE_OR_GENE_PRODUCT", 4, 7], ["plasmin", "GENE_OR_GENE_PRODUCT", 26, 33], ["phosphoglucerate", "SIMPLE_CHEMICAL", 61, 77], ["PAN/apple domain", "PROTEIN", 4, 20], ["plasmin", "PROTEIN", 26, 33], ["phosphoglucerate kinase", "PROTEIN", 61, 84], ["catalytic domain", "PROTEIN", 99, 115], ["The PAN/apple domain-free plasmin", "TREATMENT", 0, 33], ["phosphoglucerate kinase", "TREATMENT", 61, 84]]], ["The remaining five kringle domains are referred to as angiostatin, an endogenous angiogenesis inhibitor [22] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemUnder steady-state conditions, plasmin activity is low as there is no need for fibrin removal.", [["angiostatin", "GENE_OR_GENE_PRODUCT", 54, 65], ["plasmin", "GENE_OR_GENE_PRODUCT", 242, 249], ["fibrin", "GENE_OR_GENE_PRODUCT", 290, 296], ["kringle domains", "PROTEIN", 19, 34], ["angiostatin", "PROTEIN", 54, 65], ["plasmin", "PROTEIN", 242, 249], ["fibrin", "PROTEIN", 290, 296], ["angiostatin", "TREATMENT", 54, 65], ["an endogenous angiogenesis inhibitor", "TREATMENT", 67, 103], ["initial coagulation", "TEST", 135, 154], ["fibrinolysis", "TREATMENT", 156, 168], ["plasmin activity", "TEST", 242, 258], ["fibrin removal", "TREATMENT", 290, 304], ["no need for", "UNCERTAINTY", 278, 289], ["fibrin removal", "OBSERVATION", 290, 304]]], ["When fibrin had been generated, Plg and tPA bind to fibrin which the cleavage of Plg (at the Arg561-Val562 peptide bond) into the two-chain enzyme plasmin.", [["Arg561-Val562 peptide", "CHEMICAL", 93, 114], ["Arg561-Val562 peptide", "CHEMICAL", 93, 114], ["fibrin", "GENE_OR_GENE_PRODUCT", 5, 11], ["Plg", "SIMPLE_CHEMICAL", 32, 35], ["tPA", "GENE_OR_GENE_PRODUCT", 40, 43], ["fibrin", "GENE_OR_GENE_PRODUCT", 52, 58], ["Plg", "GENE_OR_GENE_PRODUCT", 81, 84], ["plasmin", "GENE_OR_GENE_PRODUCT", 147, 154], ["fibrin", "PROTEIN", 5, 11], ["Plg", "PROTEIN", 32, 35], ["tPA", "PROTEIN", 40, 43], ["fibrin", "PROTEIN", 52, 58], ["Plg", "PROTEIN", 81, 84], ["two-chain enzyme", "PROTEIN", 130, 146], ["plasmin", "PROTEIN", 147, 154], ["fibrin", "PROBLEM", 5, 11], ["Plg and tPA bind", "TREATMENT", 32, 48], ["fibrin", "TREATMENT", 52, 58], ["fibrin", "OBSERVATION", 52, 58]]], ["Plasmin is composed of an N-terminal heavy chain (12-65 kDa) and a Cterminal light chain (25 kDa) that contains the proteolytic active site [13] .", [["N", "CHEMICAL", 26, 27], ["Plasmin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Cterminal light chain", "GENE_OR_GENE_PRODUCT", 67, 88], ["Plasmin", "PROTEIN", 0, 7], ["N-terminal heavy chain", "PROTEIN", 26, 48], ["Cterminal light chain", "PROTEIN", 67, 88], ["25 kDa", "PROTEIN", 90, 96], ["proteolytic active site", "PROTEIN", 116, 139], ["Plasmin", "TEST", 0, 7], ["an N-terminal heavy chain", "TREATMENT", 23, 48], ["a Cterminal light chain", "TREATMENT", 65, 88], ["terminal", "OBSERVATION_MODIFIER", 28, 36], ["heavy", "OBSERVATION_MODIFIER", 37, 42], ["chain", "OBSERVATION_MODIFIER", 43, 48]]], ["Thrombinactivatable fibrinolysis inhibitor (TAFI) prevents Plg binding to fibrin.", [["Thrombinactivatable fibrinolysis inhibitor", "GENE_OR_GENE_PRODUCT", 0, 42], ["TAFI", "GENE_OR_GENE_PRODUCT", 44, 48], ["Plg", "SIMPLE_CHEMICAL", 59, 62], ["fibrin", "GENE_OR_GENE_PRODUCT", 74, 80], ["Thrombinactivatable fibrinolysis inhibitor", "PROTEIN", 0, 42], ["TAFI", "PROTEIN", 44, 48], ["Plg", "PROTEIN", 59, 62], ["fibrin", "PROTEIN", 74, 80], ["Thrombinactivatable fibrinolysis inhibitor", "TREATMENT", 0, 42], ["TAFI)", "TREATMENT", 44, 49], ["Plg binding", "PROBLEM", 59, 70], ["fibrin", "PROBLEM", 74, 80]]], ["Soluble, but not fibrin-bound plasmin can be inactivated by its main inhibitor alpha2-antiplasmin [23] , and by alpha2-anti-macroblogulin.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemEarly studies demonstrated that Lysine-Plg attaches with higher affinity to macrophages found in chronic inflammatory lesions than the native Glu-Plg [24] .", [["macrophages", "ANATOMY", 315, 326], ["lesions", "ANATOMY", 357, 364], ["Lysine-Plg", "CHEMICAL", 271, 281], ["Glu-Plg", "CHEMICAL", 381, 388], ["Lysine", "CHEMICAL", 271, 277], ["Glu", "CHEMICAL", 381, 384], ["fibrin", "GENE_OR_GENE_PRODUCT", 17, 23], ["plasmin", "GENE_OR_GENE_PRODUCT", 30, 37], ["alpha2-antiplasmin [23]", "SIMPLE_CHEMICAL", 79, 102], ["alpha2-anti-macroblogulin", "SIMPLE_CHEMICAL", 112, 137], ["Lysine-Plg", "SIMPLE_CHEMICAL", 271, 281], ["macrophages", "CELL", 315, 326], ["inflammatory lesions", "PATHOLOGICAL_FORMATION", 344, 364], ["fibrin", "PROTEIN", 17, 23], ["plasmin", "PROTEIN", 30, 37], ["alpha2", "PROTEIN", 112, 118], ["macroblogulin", "PROTEIN", 124, 137], ["macrophages", "CELL_TYPE", 315, 326], ["fibrin-bound plasmin", "TREATMENT", 17, 37], ["antiplasmin", "TEST", 86, 97], ["alpha2", "TEST", 112, 118], ["initial coagulation", "TEST", 163, 182], ["fibrinolysis", "TEST", 184, 196], ["the immune systemEarly studies", "TEST", 222, 252], ["Lysine-Plg attaches", "TREATMENT", 271, 290], ["higher affinity to macrophages", "PROBLEM", 296, 326], ["chronic inflammatory lesions", "PROBLEM", 336, 364], ["chronic", "OBSERVATION_MODIFIER", 336, 343], ["inflammatory", "OBSERVATION_MODIFIER", 344, 356], ["lesions", "OBSERVATION", 357, 364]]], ["Plg Carboxy-terminal lysines from proteins and therefore is used to identify novel Plg binding receptors [25] .", [["Plg", "CHEMICAL", 0, 3], ["Carboxy", "CHEMICAL", 4, 11], ["lysines", "CHEMICAL", 21, 28], ["Plg binding receptors", "GENE_OR_GENE_PRODUCT", 83, 104], ["Plg Carboxy-terminal lysines", "PROTEIN", 0, 28], ["Plg binding receptors", "PROTEIN", 83, 104], ["Plg Carboxy-terminal lysines from proteins", "TREATMENT", 0, 42], ["terminal lysines", "OBSERVATION", 12, 28]]], ["The lysine binding sites within the kringle domains of Plg bind to the carboxy-terminal lysine of Plg receptors (reviewed [26, 27] ).", [["lysine", "CHEMICAL", 4, 10], ["lysine", "CHEMICAL", 4, 10], ["carboxy", "CHEMICAL", 71, 78], ["lysine", "CHEMICAL", 88, 94], ["Plg", "GENE_OR_GENE_PRODUCT", 55, 58], ["Plg receptors", "GENE_OR_GENE_PRODUCT", 98, 111], ["lysine binding sites", "PROTEIN", 4, 24], ["kringle domains", "PROTEIN", 36, 51], ["Plg", "PROTEIN", 55, 58], ["carboxy-terminal lysine of Plg receptors", "PROTEIN", 71, 111], ["The lysine binding sites", "TREATMENT", 0, 24], ["lysine", "OBSERVATION", 4, 10], ["binding sites", "OBSERVATION", 11, 24]]], ["Plg receptors include the heterotetrameric complex Annexin A2-S100A10, alpha-enolase-1, histone H2B, and the plasminogen receptor With A C-Terminal Lysine (Plg-RKT) [28] , TBPinteracting protein 49a [29] or the high mobility group box-1 protein (HMGB-1) [30] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemIn chapter 8, we will later discuss recent studies on the role of Plg-RKT for macrophage migration, efferocytosis, and macrophage subtype determination [31] (see chapter 8).The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemtPA is synthesized as a single-chain molecule with low plasmin binding affinity [32] ensuring that in the absence of fibrin the fibrinolytic activity is low.", [["macrophage", "ANATOMY", 439, 449], ["macrophage", "ANATOMY", 480, 490], ["C", "CHEMICAL", 137, 138], ["Lysine", "CHEMICAL", 148, 154], ["Plg receptors", "GENE_OR_GENE_PRODUCT", 0, 13], ["Annexin A2-S100A10", "GENE_OR_GENE_PRODUCT", 51, 69], ["alpha-enolase-1", "GENE_OR_GENE_PRODUCT", 71, 86], ["histone H2B", "GENE_OR_GENE_PRODUCT", 88, 99], ["plasminogen receptor", "GENE_OR_GENE_PRODUCT", 109, 129], ["Plg-RKT", "GENE_OR_GENE_PRODUCT", 156, 163], ["high mobility group box-1", "GENE_OR_GENE_PRODUCT", 211, 236], ["HMGB-1", "GENE_OR_GENE_PRODUCT", 246, 252], ["Plg-RKT", "GENE_OR_GENE_PRODUCT", 427, 434], ["macrophage", "CELL", 439, 449], ["macrophage", "CELL", 480, 490], ["plasmin", "GENE_OR_GENE_PRODUCT", 690, 697], ["fibrin", "GENE_OR_GENE_PRODUCT", 752, 758], ["Plg receptors", "PROTEIN", 0, 13], ["heterotetrameric complex", "PROTEIN", 26, 50], ["Annexin A2", "PROTEIN", 51, 61], ["S100A10", "PROTEIN", 62, 69], ["alpha-enolase-1", "PROTEIN", 71, 86], ["histone H2B", "PROTEIN", 88, 99], ["plasminogen receptor", "PROTEIN", 109, 129], ["Plg", "PROTEIN", 156, 159], ["RKT", "PROTEIN", 160, 163], ["TBPinteracting protein 49a [29", "PROTEIN", 172, 202], ["high mobility group box-1 protein", "PROTEIN", 211, 244], ["HMGB", "PROTEIN", 246, 250], ["Plg", "PROTEIN", 427, 430], ["RKT", "PROTEIN", 431, 434], ["immune systemtPA", "PROTEIN", 622, 638], ["plasmin", "PROTEIN", 690, 697], ["fibrin", "PROTEIN", 752, 758], ["Plg receptors", "TEST", 0, 13], ["the heterotetrameric complex Annexin A2", "TREATMENT", 22, 61], ["alpha-enolase", "TEST", 71, 84], ["histone H2B", "TREATMENT", 88, 99], ["the plasminogen receptor", "TREATMENT", 105, 129], ["A C-Terminal Lysine (Plg", "TREATMENT", 135, 159], ["TBPinteracting protein", "TEST", 172, 194], ["the high mobility group box", "TEST", 207, 234], ["protein", "TEST", 237, 244], ["HMGB", "TEST", 246, 250], ["initial coagulation", "TEST", 285, 304], ["fibrinolysis", "TREATMENT", 306, 318], ["recent studies", "TEST", 397, 411], ["Plg", "TEST", 427, 430], ["macrophage migration", "PROBLEM", 439, 459], ["efferocytosis", "PROBLEM", 461, 474], ["macrophage subtype determination", "TEST", 480, 512], ["initial coagulation", "TEST", 559, 578], ["fibrinolysis", "TREATMENT", 580, 592], ["the immune systemtPA", "TEST", 618, 638], ["a single-chain molecule", "TREATMENT", 657, 680], ["low plasmin binding affinity", "PROBLEM", 686, 714], ["fibrin the fibrinolytic activity", "TEST", 752, 784], ["fibrin", "OBSERVATION", 752, 758], ["fibrinolytic activity", "OBSERVATION", 763, 784], ["low", "OBSERVATION_MODIFIER", 788, 791]]], ["Plasmin cleaves tPA into its two-chain form, a form that has a 10-fold higher affinity for converting Plg into plasmin than the single-chain molecule [32] .", [["Plasmin", "GENE_OR_GENE_PRODUCT", 0, 7], ["tPA", "GENE_OR_GENE_PRODUCT", 16, 19], ["Plg", "GENE_OR_GENE_PRODUCT", 102, 105], ["plasmin", "GENE_OR_GENE_PRODUCT", 111, 118], ["Plasmin", "PROTEIN", 0, 7], ["tPA", "PROTEIN", 16, 19], ["Plg", "PROTEIN", 102, 105], ["plasmin", "PROTEIN", 111, 118], ["Plasmin cleaves tPA", "TREATMENT", 0, 19], ["converting Plg into plasmin", "TREATMENT", 91, 118]]], ["The two chain tPA has a heavy A-chain and the light B-chain.", [["tPA", "GENE_OR_GENE_PRODUCT", 14, 17], ["tPA", "PROTEIN", 14, 17], ["heavy A-chain", "PROTEIN", 24, 37], ["light B-chain", "PROTEIN", 46, 59], ["The two chain tPA", "TREATMENT", 0, 17], ["a heavy A-chain", "TREATMENT", 22, 37], ["two", "OBSERVATION_MODIFIER", 4, 7], ["chain", "OBSERVATION_MODIFIER", 8, 13], ["tPA", "OBSERVATION_MODIFIER", 14, 17], ["heavy", "OBSERVATION_MODIFIER", 24, 29], ["A-chain", "OBSERVATION", 30, 37]]], ["The heavy A-chain is composed of the fibronectin finger domain, an epidermal growth factor analog domain, and Kringle 1 and 2 domains [13] .", [["heavy A-chain", "GENE_OR_GENE_PRODUCT", 4, 17], ["fibronectin", "GENE_OR_GENE_PRODUCT", 37, 48], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 67, 90], ["heavy A-chain", "PROTEIN", 4, 17], ["fibronectin finger domain", "PROTEIN", 37, 62], ["epidermal growth factor analog domain", "PROTEIN", 67, 104], ["Kringle 1 and 2 domains", "PROTEIN", 110, 133], ["the fibronectin finger domain", "PROBLEM", 33, 62], ["an epidermal growth factor analog domain", "PROBLEM", 64, 104], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["A-chain", "OBSERVATION", 10, 17], ["fibronectin finger", "ANATOMY", 37, 55]]], ["The finger domain of tPA is responsible for the binding of fibrin, Annexin II, and low-density lipoprotein receptor-related protein-1 (LRP1) [33, 34] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemThe kringle 1 domain of tPA is involved in the uptake of tPA in the liver [35] , while the Kringle 2 domain is important for interactions with N-methyl-D-aspartic acid receptor (NMDA-R) and PDGFs [36] . tPA also associates with the annexinA2S100A10 complex, Plg-RKT, and mannose receptors [37] [38] [39] [40] [41] .", [["immune system", "ANATOMY", 239, 252], ["liver", "ANATOMY", 320, 325], ["N-methyl-D-aspartic acid", "CHEMICAL", 395, 419], ["NMDA", "CHEMICAL", 430, 434], ["N-methyl-D-aspartic acid", "CHEMICAL", 395, 419], ["NMDA", "CHEMICAL", 430, 434], ["mannose", "CHEMICAL", 523, 530], ["tPA", "GENE_OR_GENE_PRODUCT", 21, 24], ["fibrin", "GENE_OR_GENE_PRODUCT", 59, 65], ["Annexin II", "GENE_OR_GENE_PRODUCT", 67, 77], ["low-density lipoprotein receptor-related protein-1", "GENE_OR_GENE_PRODUCT", 83, 133], ["LRP1", "GENE_OR_GENE_PRODUCT", 135, 139], ["kringle 1", "GENE_OR_GENE_PRODUCT", 256, 265], ["tPA", "GENE_OR_GENE_PRODUCT", 276, 279], ["tPA", "GENE_OR_GENE_PRODUCT", 309, 312], ["liver", "ORGAN", 320, 325], ["Kringle 2", "GENE_OR_GENE_PRODUCT", 343, 352], ["N-methyl-D-aspartic acid receptor", "GENE_OR_GENE_PRODUCT", 395, 428], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 430, 436], ["PDGFs", "GENE_OR_GENE_PRODUCT", 442, 447], ["tPA", "GENE_OR_GENE_PRODUCT", 455, 458], ["annexinA2S100A10", "GENE_OR_GENE_PRODUCT", 484, 500], ["Plg-RKT", "GENE_OR_GENE_PRODUCT", 510, 517], ["mannose receptors [37] [38] [39] [40] [41]", "SIMPLE_CHEMICAL", 523, 565], ["finger domain", "PROTEIN", 4, 17], ["tPA", "PROTEIN", 21, 24], ["fibrin", "PROTEIN", 59, 65], ["Annexin II", "PROTEIN", 67, 77], ["low-density lipoprotein receptor-related protein-1", "PROTEIN", 83, 133], ["LRP1", "PROTEIN", 135, 139], ["kringle 1 domain", "PROTEIN", 256, 272], ["tPA", "PROTEIN", 276, 279], ["tPA", "PROTEIN", 309, 312], ["Kringle 2 domain", "PROTEIN", 343, 359], ["N-methyl-D-aspartic acid receptor", "PROTEIN", 395, 428], ["PDGFs", "PROTEIN", 442, 447], ["tPA", "PROTEIN", 455, 458], ["annexinA2S100A10 complex", "PROTEIN", 484, 508], ["Plg", "PROTEIN", 510, 513], ["RKT", "PROTEIN", 514, 517], ["mannose receptors", "PROTEIN", 523, 540], ["tPA", "TREATMENT", 21, 24], ["fibrin", "TEST", 59, 65], ["Annexin II", "TEST", 67, 77], ["low-density lipoprotein receptor", "TREATMENT", 83, 115], ["initial coagulation", "TEST", 176, 195], ["fibrinolysis", "TREATMENT", 197, 209], ["The kringle 1 domain of tPA", "TREATMENT", 252, 279], ["tPA in the liver", "TREATMENT", 309, 325], ["the Kringle 2 domain", "TREATMENT", 339, 359], ["D-aspartic acid receptor", "TREATMENT", 404, 428], ["NMDA", "TEST", 430, 434], ["tPA", "TREATMENT", 455, 458], ["the annexinA2S100A10 complex", "TEST", 480, 508], ["Plg", "TEST", 510, 513], ["mannose receptors", "TEST", 523, 540], ["finger", "ANATOMY", 4, 10], ["tPA", "OBSERVATION", 21, 24], ["fibrin", "OBSERVATION", 59, 65], ["liver", "ANATOMY", 320, 325]]], ["Natural inhibitors of tPA's fibrinolytic activity are plasminogen activator inhibitor-1 (PAI-1), a circulating serpin (serine protease inhibitor), and PAI-2 [32, 42] .The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemThe specific binding of Plg and tPA to lytic edges of partly degraded fibrin via newly generated C-terminal lysine residues amplifies fibrin digestion generating diffusible J o u r n a l P r e -p r o o f and soluble fibrin fragments.", [["immune system", "ANATOMY", 255, 268], ["C-terminal lysine", "CHEMICAL", 365, 382], ["serine", "CHEMICAL", 119, 125], ["C", "CHEMICAL", 365, 366], ["lysine", "CHEMICAL", 376, 382], ["tPA", "GENE_OR_GENE_PRODUCT", 22, 25], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 54, 87], ["PAI-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["serpin", "GENE_OR_GENE_PRODUCT", 111, 117], ["serine protease", "GENE_OR_GENE_PRODUCT", 119, 134], ["PAI-2", "GENE_OR_GENE_PRODUCT", 151, 156], ["Plg", "GENE_OR_GENE_PRODUCT", 292, 295], ["tPA", "GENE_OR_GENE_PRODUCT", 300, 303], ["fibrin", "GENE_OR_GENE_PRODUCT", 338, 344], ["fibrin", "GENE_OR_GENE_PRODUCT", 402, 408], ["fibrin", "GENE_OR_GENE_PRODUCT", 484, 490], ["tPA", "PROTEIN", 22, 25], ["plasminogen activator inhibitor-1 (PAI-1", "PROTEIN", 54, 94], ["circulating serpin", "PROTEIN", 99, 117], ["Plg", "PROTEIN", 292, 295], ["tPA", "PROTEIN", 300, 303], ["fibrin", "PROTEIN", 338, 344], ["C-terminal lysine residues", "PROTEIN", 365, 391], ["fibrin", "PROTEIN", 402, 408], ["P r e -p r o o f and soluble fibrin fragments", "DNA", 455, 500], ["Natural inhibitors", "TREATMENT", 0, 18], ["tPA's fibrinolytic activity", "TREATMENT", 22, 49], ["plasminogen activator inhibitor", "TREATMENT", 54, 85], ["PAI", "TEST", 89, 92], ["a circulating serpin (serine protease inhibitor", "TREATMENT", 97, 144], ["PAI", "TEST", 151, 154], ["initial coagulation", "TEST", 192, 211], ["fibrinolysis", "TREATMENT", 213, 225], ["Plg and tPA", "TREATMENT", 292, 303], ["partly degraded fibrin", "PROBLEM", 322, 344], ["C-terminal lysine residues", "TREATMENT", 365, 391], ["fibrin digestion", "PROBLEM", 402, 418], ["soluble fibrin fragments", "PROBLEM", 476, 500], ["fibrin", "OBSERVATION", 338, 344], ["soluble", "OBSERVATION", 476, 483], ["fibrin fragments", "OBSERVATION", 484, 500]]], ["Such fibrin degradation products (FDPs) include fragments D and E and D-dimers.", [["fibrin", "GENE_OR_GENE_PRODUCT", 5, 11], ["FDPs", "SIMPLE_CHEMICAL", 34, 38], ["D", "SIMPLE_CHEMICAL", 58, 59], ["E", "SIMPLE_CHEMICAL", 64, 65], ["D-dimers", "SIMPLE_CHEMICAL", 70, 78], ["fibrin degradation products", "PROTEIN", 5, 32], ["FDPs", "PROTEIN", 34, 38], ["fragments D and E and D-dimers", "PROTEIN", 48, 78], ["Such fibrin degradation products", "PROBLEM", 0, 32], ["fragments D and E and D-dimers", "TEST", 48, 78], ["fibrin degradation", "OBSERVATION", 5, 23]]], ["D-dimers are two D fragments joined by a crosslink [43] often used as a measure for the presence of systemic inflammation in clinical settings.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemGene deficient mice for Plg show fibrin deposition in various tissues leading to high mortality, wasting, spontaneous gastrointestinal ulceration, rectal prolapse, severe thrombosis, and delayed wound healing [44] .", [["tissues", "ANATOMY", 306, 313], ["gastrointestinal", "ANATOMY", 362, 378], ["rectal", "ANATOMY", 391, 397], ["wound", "ANATOMY", 439, 444], ["inflammation", "DISEASE", 109, 121], ["wasting", "DISEASE", 341, 348], ["gastrointestinal ulceration", "DISEASE", 362, 389], ["rectal prolapse", "DISEASE", 391, 406], ["thrombosis", "DISEASE", 415, 425], ["D-dimers", "GENE_OR_GENE_PRODUCT", 0, 8], ["systemGene", "GENE_OR_GENE_PRODUCT", 238, 248], ["mice", "ORGANISM", 259, 263], ["Plg", "GENE_OR_GENE_PRODUCT", 268, 271], ["fibrin", "GENE_OR_GENE_PRODUCT", 277, 283], ["tissues", "TISSUE", 306, 313], ["gastrointestinal ulceration", "PATHOLOGICAL_FORMATION", 362, 389], ["rectal", "ORGANISM_SUBDIVISION", 391, 397], ["wound", "PATHOLOGICAL_FORMATION", 439, 444], ["Plg", "PROTEIN", 268, 271], ["fibrin", "PROTEIN", 277, 283], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["two D fragments", "PROBLEM", 13, 28], ["systemic inflammation", "PROBLEM", 100, 121], ["initial coagulation", "TEST", 168, 187], ["fibrinolysis", "TEST", 189, 201], ["Plg", "PROBLEM", 268, 271], ["fibrin deposition in various tissues", "PROBLEM", 277, 313], ["high mortality", "PROBLEM", 325, 339], ["wasting", "PROBLEM", 341, 348], ["spontaneous gastrointestinal ulceration", "PROBLEM", 350, 389], ["rectal prolapse", "PROBLEM", 391, 406], ["severe thrombosis", "PROBLEM", 408, 425], ["delayed wound healing", "PROBLEM", 431, 452], ["two D", "OBSERVATION_MODIFIER", 13, 18], ["fragments", "OBSERVATION_MODIFIER", 19, 28], ["systemic", "OBSERVATION_MODIFIER", 100, 108], ["inflammation", "OBSERVATION", 109, 121], ["fibrin deposition", "OBSERVATION", 277, 294], ["various tissues", "ANATOMY", 298, 313], ["high", "OBSERVATION_MODIFIER", 325, 329], ["mortality", "OBSERVATION", 330, 339], ["spontaneous", "OBSERVATION_MODIFIER", 350, 361], ["gastrointestinal", "ANATOMY", 362, 378], ["ulceration", "OBSERVATION", 379, 389], ["rectal", "ANATOMY", 391, 397], ["prolapse", "OBSERVATION", 398, 406], ["severe", "OBSERVATION_MODIFIER", 408, 414], ["thrombosis", "OBSERVATION", 415, 425], ["delayed", "OBSERVATION_MODIFIER", 431, 438], ["wound", "OBSERVATION_MODIFIER", 439, 444], ["healing", "OBSERVATION_MODIFIER", 445, 452]]], ["Dependent on the disease model tested, mouse mutants with Plg deficiency can suppress or exacerbate inflammatory diseases.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemPlg deficiency exacerbates collagen-induced arthritis [45] , and peripheral nerve injury [46] .", [["peripheral nerve", "ANATOMY", 288, 304], ["Plg", "CHEMICAL", 58, 61], ["arthritis", "DISEASE", 267, 276], ["peripheral nerve injury", "DISEASE", 288, 311], ["mouse", "ORGANISM", 39, 44], ["Plg", "GENE_OR_GENE_PRODUCT", 58, 61], ["systemPlg", "GENE_OR_GENE_PRODUCT", 217, 226], ["collagen", "GENE_OR_GENE_PRODUCT", 250, 258], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 288, 304], ["Plg", "PROTEIN", 58, 61], ["collagen", "PROTEIN", 250, 258], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["Dependent on the disease model tested", "PROBLEM", 0, 37], ["Plg deficiency", "PROBLEM", 58, 72], ["inflammatory diseases", "PROBLEM", 100, 121], ["initial coagulation", "TEST", 147, 166], ["fibrinolysis", "TREATMENT", 168, 180], ["the immune systemPlg deficiency", "PROBLEM", 206, 237], ["collagen-induced arthritis", "PROBLEM", 250, 276], ["peripheral nerve injury", "PROBLEM", 288, 311], ["inflammatory", "OBSERVATION", 100, 112], ["arthritis", "OBSERVATION", 267, 276], ["peripheral", "ANATOMY_MODIFIER", 288, 298], ["nerve", "ANATOMY", 299, 304], ["injury", "OBSERVATION", 305, 311]]], ["The phenotypic abnormalities of Plg deficiency can be rescued in mice genetically deficient in both Plg and fibrinogen [47] or following pharmacological fibrin depletion in Plg knockout mice [45, 46] .", [["Plg", "CHEMICAL", 32, 35], ["Plg", "GENE_OR_GENE_PRODUCT", 32, 35], ["mice", "ORGANISM", 65, 69], ["Plg", "GENE_OR_GENE_PRODUCT", 100, 103], ["fibrinogen [47]", "GENE_OR_GENE_PRODUCT", 108, 123], ["fibrin", "GENE_OR_GENE_PRODUCT", 153, 159], ["Plg", "GENE_OR_GENE_PRODUCT", 173, 176], ["mice", "ORGANISM", 186, 190], ["Plg", "PROTEIN", 32, 35], ["Plg", "PROTEIN", 100, 103], ["fibrinogen", "PROTEIN", 108, 118], ["fibrin", "PROTEIN", 153, 159], ["Plg", "PROTEIN", 173, 176], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 186, 190], ["The phenotypic abnormalities", "PROBLEM", 0, 28], ["Plg deficiency", "PROBLEM", 32, 46], ["fibrinogen", "TEST", 108, 118], ["pharmacological fibrin depletion", "TREATMENT", 137, 169], ["Plg deficiency", "OBSERVATION", 32, 46], ["fibrin depletion", "OBSERVATION", 153, 169]]], ["On the other hand, that Plg deficiency (pharmacological or genetic) improved the outcome of inflammatory diseases in murine models of inflammatory bowel disease [48] or diseases where immune cells release vast amounts of pro-inflammatory factors resulting in a cytokine storm syndrome, like during Graft versus Host Disease (GvHD) and macrophage activation syndrome (MAS) [49, 50] .", [["bowel", "ANATOMY", 147, 152], ["immune cells", "ANATOMY", 184, 196], ["Graft", "ANATOMY", 298, 303], ["macrophage", "ANATOMY", 335, 345], ["Plg", "CHEMICAL", 24, 27], ["inflammatory diseases", "DISEASE", 92, 113], ["inflammatory bowel disease", "DISEASE", 134, 160], ["Graft versus Host Disease", "DISEASE", 298, 323], ["GvHD", "DISEASE", 325, 329], ["MAS", "DISEASE", 367, 370], ["Plg", "CHEMICAL", 24, 27], ["Plg", "GENE_OR_GENE_PRODUCT", 24, 27], ["murine", "ORGANISM", 117, 123], ["bowel", "ORGAN", 147, 152], ["immune cells", "CELL", 184, 196], ["Graft", "TISSUE", 298, 303], ["macrophage", "CELL", 335, 345], ["immune cells", "CELL_TYPE", 184, 196], ["pro-inflammatory factors", "PROTEIN", 221, 245], ["cytokine", "PROTEIN", 261, 269], ["murine", "SPECIES", 117, 123], ["Plg deficiency", "PROBLEM", 24, 38], ["inflammatory diseases", "PROBLEM", 92, 113], ["inflammatory bowel disease", "PROBLEM", 134, 160], ["diseases", "PROBLEM", 169, 177], ["immune cells", "PROBLEM", 184, 196], ["pro-inflammatory factors", "PROBLEM", 221, 245], ["a cytokine storm syndrome", "PROBLEM", 259, 284], ["Host Disease", "PROBLEM", 311, 323], ["GvHD", "PROBLEM", 325, 329], ["macrophage activation syndrome", "PROBLEM", 335, 365], ["inflammatory", "OBSERVATION_MODIFIER", 92, 104], ["inflammatory", "OBSERVATION_MODIFIER", 134, 146], ["bowel", "ANATOMY", 147, 152], ["pro-inflammatory factors", "OBSERVATION", 221, 245], ["cytokine storm syndrome", "OBSERVATION", 261, 284], ["Graft versus Host Disease", "OBSERVATION", 298, 323], ["macrophage activation syndrome", "OBSERVATION", 335, 365]]], ["The specific role of plasmin during the cytokine storm syndrome will be further discussed in chapter 7.", [["plasmin", "GENE_OR_GENE_PRODUCT", 21, 28], ["plasmin", "PROTEIN", 21, 28], ["cytokine", "PROTEIN", 40, 48], ["plasmin", "TREATMENT", 21, 28], ["the cytokine storm syndrome", "PROBLEM", 36, 63]]], ["These studies suggested that a major function of Plg is fibrinolysis.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemAside from the established role of fibrinolytic factors for the recruitment of macrophages, fibrinolytic factors also can change the cellular, immunomodulatory environment through the expansion of mesenchymal stem cell (MSC) expansion.The intricate network of initial coagulation, fibrinolysis and complement activates the immune systemMSCs orchestrate local and systemic innate and adaptive immune responses through the release of immunosuppressive molecules, growth factors, exosomes, chemokines, and complement components.", [["macrophages", "ANATOMY", 249, 260], ["cellular", "ANATOMY", 303, 311], ["mesenchymal stem cell", "ANATOMY", 367, 388], ["MSC", "ANATOMY", 390, 393], ["immune systemMSCs", "ANATOMY", 493, 510], ["exosomes", "ANATOMY", 647, 655], ["Plg", "CHEMICAL", 49, 52], ["Plg", "GENE_OR_GENE_PRODUCT", 49, 52], ["fibrinolytic factors", "GENE_OR_GENE_PRODUCT", 205, 225], ["macrophages", "CELL", 249, 260], ["fibrinolytic factors", "GENE_OR_GENE_PRODUCT", 262, 282], ["cellular", "CELL", 303, 311], ["mesenchymal stem cell", "CELL", 367, 388], ["MSC", "CELL", 390, 393], ["exosomes", "GENE_OR_GENE_PRODUCT", 647, 655], ["Plg", "PROTEIN", 49, 52], ["fibrinolytic factors", "PROTEIN", 205, 225], ["macrophages", "CELL_TYPE", 249, 260], ["fibrinolytic factors", "PROTEIN", 262, 282], ["mesenchymal stem cell", "CELL_TYPE", 367, 388], ["MSC", "CELL_TYPE", 390, 393], ["immunosuppressive molecules", "PROTEIN", 602, 629], ["growth factors", "PROTEIN", 631, 645], ["exosomes", "PROTEIN", 647, 655], ["chemokines", "PROTEIN", 657, 667], ["complement components", "PROTEIN", 673, 694], ["These studies", "TEST", 0, 13], ["fibrinolysis", "PROBLEM", 56, 68], ["initial coagulation", "TEST", 94, 113], ["fibrinolysis", "TREATMENT", 115, 127], ["fibrinolytic factors", "PROBLEM", 205, 225], ["macrophages", "PROBLEM", 249, 260], ["fibrinolytic factors", "PROBLEM", 262, 282], ["mesenchymal stem cell (MSC) expansion", "PROBLEM", 367, 404], ["initial coagulation", "TEST", 430, 449], ["fibrinolysis", "TREATMENT", 451, 463], ["the immune systemMSCs", "TREATMENT", 489, 510], ["adaptive immune responses", "TREATMENT", 553, 578], ["immunosuppressive molecules", "TREATMENT", 602, 629], ["growth factors", "PROBLEM", 631, 645], ["fibrinolysis", "OBSERVATION", 56, 68], ["macrophages", "OBSERVATION", 249, 260], ["expansion", "OBSERVATION_MODIFIER", 354, 363], ["mesenchymal stem cell", "OBSERVATION", 367, 388]]], ["We showed that MSCs express fibrinolytic factors (reviewed in [51] ) and endothelial cells, and that tPA administration promotes MSC J o u r n a l P r e -p r o o f recruitment and expansion [51, 52] .", [["MSCs", "ANATOMY", 15, 19], ["endothelial cells", "ANATOMY", 73, 90], ["MSC", "ANATOMY", 129, 132], ["MSCs", "CELL", 15, 19], ["fibrinolytic factors", "GENE_OR_GENE_PRODUCT", 28, 48], ["endothelial cells", "CELL", 73, 90], ["tPA", "GENE_OR_GENE_PRODUCT", 101, 104], ["MSCs", "CELL_TYPE", 15, 19], ["fibrinolytic factors", "PROTEIN", 28, 48], ["endothelial cells", "CELL_TYPE", 73, 90], ["tPA", "PROTEIN", 101, 104], ["MSC", "CELL_TYPE", 129, 132], ["MSCs express fibrinolytic factors", "PROBLEM", 15, 48], ["endothelial cells", "PROBLEM", 73, 90], ["tPA administration", "TREATMENT", 101, 119], ["recruitment", "PROBLEM", 164, 175], ["expansion", "TEST", 180, 189], ["endothelial cells", "ANATOMY", 73, 90]]], ["Mechanistically, the tPA-mediated release of kit ligand from endothelial cells resulted in the expansion of MSCs due to the release of basic fibroblast growth factor and platelet-derived growth factor-BB from c-kit+ activated MSCs [53] .", [["endothelial cells", "ANATOMY", 61, 78], ["MSCs", "ANATOMY", 108, 112], ["MSCs", "ANATOMY", 226, 230], ["tPA", "GENE_OR_GENE_PRODUCT", 21, 24], ["kit ligand", "GENE_OR_GENE_PRODUCT", 45, 55], ["endothelial cells", "CELL", 61, 78], ["MSCs", "CELL", 108, 112], ["basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 135, 165], ["platelet-derived growth factor-BB", "GENE_OR_GENE_PRODUCT", 170, 203], ["c-kit", "GENE_OR_GENE_PRODUCT", 209, 214], ["MSCs", "CELL", 226, 230], ["tPA", "PROTEIN", 21, 24], ["kit ligand", "PROTEIN", 45, 55], ["endothelial cells", "CELL_TYPE", 61, 78], ["MSCs", "CELL_TYPE", 108, 112], ["basic fibroblast growth factor", "PROTEIN", 135, 165], ["platelet-derived growth factor-BB", "PROTEIN", 170, 203], ["c-kit+ activated MSCs", "CELL_LINE", 209, 230], ["the tPA-mediated release of kit ligand", "TREATMENT", 17, 55], ["endothelial cells", "PROBLEM", 61, 78], ["the expansion of MSCs", "PROBLEM", 91, 112], ["basic fibroblast growth factor", "PROBLEM", 135, 165], ["platelet", "TEST", 170, 178], ["growth factor", "TEST", 187, 200], ["BB", "TEST", 201, 203], ["activated MSCs", "PROBLEM", 216, 230]]], ["These studies show that soluble or membranetype LRP1 can influence the inflammatory response.tPA receptors modulates TLR-mediated cytokine signalingEarlier studies established a link between clotting/fibrinolysis related-proteases and TLR signaling.", [["LRP1", "GENE_OR_GENE_PRODUCT", 48, 52], ["TLR", "GENE_OR_GENE_PRODUCT", 117, 120], ["TLR", "GENE_OR_GENE_PRODUCT", 235, 238], ["membranetype LRP1", "PROTEIN", 35, 52], ["inflammatory response.tPA receptors", "PROTEIN", 71, 106], ["TLR", "PROTEIN", 117, 120], ["cytokine", "PROTEIN", 130, 138], ["fibrinolysis related-proteases", "PROTEIN", 200, 230], ["TLR", "PROTEIN", 235, 238], ["These studies", "TEST", 0, 13], ["soluble or membranetype LRP1", "TREATMENT", 24, 52], ["the inflammatory response.tPA receptors", "TREATMENT", 67, 106], ["TLR", "TEST", 117, 120], ["Earlier studies", "TEST", 148, 163], ["clotting/fibrinolysis", "TREATMENT", 191, 212], ["proteases", "PROBLEM", 221, 230], ["TLR signaling", "PROBLEM", 235, 248], ["inflammatory", "OBSERVATION_MODIFIER", 71, 83], ["fibrinolysis", "OBSERVATION", 200, 212]]], ["One study reported that antithrombin III inhibited the response to LPS in the monocytic cell line THP-1 [66] .", [["monocytic cell line", "ANATOMY", 78, 97], ["LPS", "CHEMICAL", 67, 70], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 24, 40], ["LPS", "SIMPLE_CHEMICAL", 67, 70], ["monocytic cell line THP-1 [66", "CELL", 78, 107], ["antithrombin III", "PROTEIN", 24, 40], ["monocytic cell line", "CELL_LINE", 78, 97], ["One study", "TEST", 0, 9], ["antithrombin III", "PROBLEM", 24, 40], ["LPS", "TEST", 67, 70], ["THP", "TEST", 98, 101], ["monocytic cell line", "OBSERVATION", 78, 97]]], ["C1 inhibition was shown to prevent LPS shock [67] , and fibrinogen was shown to activate TLR4 [68] .", [["LPS", "CHEMICAL", 35, 38], ["shock", "DISEASE", 39, 44], ["C1", "GENE_OR_GENE_PRODUCT", 0, 2], ["LPS", "SIMPLE_CHEMICAL", 35, 38], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 56, 66], ["TLR4", "GENE_OR_GENE_PRODUCT", 89, 93], ["fibrinogen", "PROTEIN", 56, 66], ["TLR4", "PROTEIN", 89, 93], ["C1 inhibition", "TREATMENT", 0, 13], ["LPS shock", "PROBLEM", 35, 44], ["fibrinogen", "TEST", 56, 66], ["TLR4", "TEST", 89, 93]]], ["Ward et al. reported that plasmin exerted proinflammatory functions in monocytes, and potentiated TLR2 and TLR4 signaling [69] .", [["monocytes", "ANATOMY", 71, 80], ["plasmin", "GENE_OR_GENE_PRODUCT", 26, 33], ["monocytes", "CELL", 71, 80], ["TLR2", "GENE_OR_GENE_PRODUCT", 98, 102], ["TLR4", "GENE_OR_GENE_PRODUCT", 107, 111], ["plasmin", "PROTEIN", 26, 33], ["monocytes", "CELL_TYPE", 71, 80], ["TLR2", "PROTEIN", 98, 102], ["TLR4", "PROTEIN", 107, 111], ["plasmin exerted proinflammatory functions", "PROBLEM", 26, 67], ["monocytes", "TEST", 71, 80], ["TLR2", "TEST", 98, 102], ["TLR4 signaling", "TEST", 107, 121], ["plasmin", "OBSERVATION", 26, 33], ["proinflammatory", "OBSERVATION_MODIFIER", 42, 57], ["TLR2", "ANATOMY", 98, 102]]], ["These studies indicated that coagulation factors modulate the J o u r n a l P r e -p r o o f inflammatory TLR response.tPA receptors modulates TLR-mediated cytokine signalingTLR activation enhances the nuclear translocation of transcription factors, like activator protein-1, NFkB, or interferon regulatory factor 3 (IFR3).", [["nuclear", "ANATOMY", 202, 209], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 29, 48], ["TLR", "GENE_OR_GENE_PRODUCT", 106, 109], [".tPA receptors", "GENE_OR_GENE_PRODUCT", 118, 132], ["TLR", "GENE_OR_GENE_PRODUCT", 143, 146], ["signalingTLR", "GENE_OR_GENE_PRODUCT", 165, 177], ["nuclear", "CELLULAR_COMPONENT", 202, 209], ["activator protein-1", "GENE_OR_GENE_PRODUCT", 255, 274], ["NFkB", "GENE_OR_GENE_PRODUCT", 276, 280], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 285, 315], ["IFR3", "GENE_OR_GENE_PRODUCT", 317, 321], ["coagulation factors", "PROTEIN", 29, 48], ["TLR", "PROTEIN", 106, 109], [".tPA receptors", "PROTEIN", 118, 132], ["TLR", "PROTEIN", 143, 146], ["cytokine", "PROTEIN", 156, 164], ["transcription factors", "PROTEIN", 227, 248], ["activator protein-1", "PROTEIN", 255, 274], ["NFkB", "PROTEIN", 276, 280], ["interferon regulatory factor 3", "PROTEIN", 285, 315], ["IFR3", "PROTEIN", 317, 321], ["These studies", "TEST", 0, 13], ["coagulation factors", "PROBLEM", 29, 48], ["inflammatory TLR response", "TREATMENT", 93, 118], ["TLR", "TEST", 143, 146], ["cytokine signalingTLR activation", "TREATMENT", 156, 188], ["transcription factors", "TEST", 227, 248], ["activator protein", "TEST", 255, 272], ["NFkB", "TREATMENT", 276, 280], ["interferon regulatory factor", "TREATMENT", 285, 313]]], ["Of interest, the LRP1 \u03b2 chain is processed by the presenilin-dependent \u03b3-secretase to generate a small fragment-LRP1 C-terminal intracellular domain, which promotes the nuclear export of inflammatory transcription factor IFR3 blocking the transcription of inflammatory genes [70] .tPA receptors modulates TLR-mediated cytokine signalingTo further understand how fibrinolytic factors can alter TLR signaling, it is important to note that LRP1 is linked to uPA receptor urokinase-type plasminogen activator receptor (uPAR) or N-Methyl-D-Aspartate receptor (NMDA-R) via the adapter protein postsynaptic density protein 95.", [["intracellular", "ANATOMY", 128, 141], ["nuclear", "ANATOMY", 169, 176], ["N-Methyl-D-Aspartate", "CHEMICAL", 524, 544], ["NMDA", "CHEMICAL", 555, 559], ["C", "CHEMICAL", 117, 118], ["N-Methyl-D-Aspartate", "CHEMICAL", 524, 544], ["NMDA", "CHEMICAL", 555, 559], ["LRP1 \u03b2 chain", "GENE_OR_GENE_PRODUCT", 17, 29], ["presenilin", "GENE_OR_GENE_PRODUCT", 50, 60], ["\u03b3-secretase", "GENE_OR_GENE_PRODUCT", 71, 82], ["LRP1", "GENE_OR_GENE_PRODUCT", 112, 116], ["nuclear", "CELLULAR_COMPONENT", 169, 176], ["IFR3", "GENE_OR_GENE_PRODUCT", 221, 225], ["TLR", "GENE_OR_GENE_PRODUCT", 305, 308], ["fibrinolytic factors", "GENE_OR_GENE_PRODUCT", 362, 382], ["TLR", "GENE_OR_GENE_PRODUCT", 393, 396], ["LRP1", "GENE_OR_GENE_PRODUCT", 437, 441], ["uPA", "GENE_OR_GENE_PRODUCT", 455, 458], ["urokinase-type plasminogen activator receptor", "GENE_OR_GENE_PRODUCT", 468, 513], ["uPAR", "GENE_OR_GENE_PRODUCT", 515, 519], ["N-Methyl-D-Aspartate receptor", "GENE_OR_GENE_PRODUCT", 524, 553], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 555, 561], ["postsynaptic density protein 95", "GENE_OR_GENE_PRODUCT", 587, 618], ["LRP1 \u03b2 chain", "PROTEIN", 17, 29], ["presenilin-dependent \u03b3-secretase", "PROTEIN", 50, 82], ["LRP1 C-terminal intracellular domain", "PROTEIN", 112, 148], ["inflammatory transcription factor", "PROTEIN", 187, 220], ["IFR3", "PROTEIN", 221, 225], ["inflammatory genes [70] .tPA receptors", "PROTEIN", 256, 294], ["TLR", "PROTEIN", 305, 308], ["cytokine", "PROTEIN", 318, 326], ["fibrinolytic factors", "PROTEIN", 362, 382], ["TLR", "PROTEIN", 393, 396], ["LRP1", "PROTEIN", 437, 441], ["uPA receptor urokinase-type plasminogen activator receptor", "PROTEIN", 455, 513], ["PAR", "PROTEIN", 516, 519], ["N-Methyl-D-Aspartate receptor", "PROTEIN", 524, 553], ["NMDA-R", "PROTEIN", 555, 561], ["adapter protein postsynaptic density protein 95", "PROTEIN", 571, 618], ["the LRP1 \u03b2 chain", "TREATMENT", 13, 29], ["a small fragment", "PROBLEM", 95, 111], ["terminal intracellular domain", "PROBLEM", 119, 148], ["inflammatory transcription factor", "TREATMENT", 187, 220], ["inflammatory genes", "PROBLEM", 256, 274], ["TLR-mediated cytokine signaling", "TREATMENT", 305, 336], ["uPA receptor urokinase", "TEST", 455, 477], ["PAR", "TEST", 516, 519], ["N-Methyl-D-Aspartate receptor", "TEST", 524, 553], ["NMDA", "TEST", 555, 559], ["the adapter protein postsynaptic density protein", "TEST", 567, 615], ["small", "OBSERVATION_MODIFIER", 97, 102], ["fragment", "OBSERVATION", 103, 111], ["inflammatory", "OBSERVATION_MODIFIER", 187, 199]]], ["Due to this linkage, LRP1 can internalize these receptors after ligand binding [71] , and control the presence and signaling of these cellular receptors [37] .tPA receptors modulates TLR-mediated cytokine signalingEarlier studies demonstrated that a2-macroglobulin decreases calcium responses to the glutamate receptor NMDA-R by the expression of NMDA-R1 in rat hippocampal neurons [72] .", [["cellular", "ANATOMY", 134, 142], ["hippocampal neurons", "ANATOMY", 362, 381], ["calcium", "CHEMICAL", 275, 282], ["glutamate", "CHEMICAL", 300, 309], ["NMDA", "CHEMICAL", 319, 323], ["NMDA", "CHEMICAL", 347, 351], ["calcium", "CHEMICAL", 275, 282], ["glutamate", "CHEMICAL", 300, 309], ["NMDA", "CHEMICAL", 319, 323], ["NMDA", "CHEMICAL", 347, 351], ["LRP1", "GENE_OR_GENE_PRODUCT", 21, 25], ["cellular", "CELL", 134, 142], ["TLR", "GENE_OR_GENE_PRODUCT", 183, 186], ["a2-macroglobulin", "GENE_OR_GENE_PRODUCT", 248, 264], ["calcium", "SIMPLE_CHEMICAL", 275, 282], ["glutamate", "SIMPLE_CHEMICAL", 300, 309], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 319, 325], ["NMDA-R1", "GENE_OR_GENE_PRODUCT", 347, 354], ["rat", "ORGANISM", 358, 361], ["hippocampal neurons [72]", "CELL", 362, 386], ["LRP1", "PROTEIN", 21, 25], ["cellular receptors [37] .tPA receptors", "PROTEIN", 134, 172], ["TLR", "PROTEIN", 183, 186], ["cytokine", "PROTEIN", 196, 204], ["a2-macroglobulin", "PROTEIN", 248, 264], ["glutamate receptor NMDA-R", "PROTEIN", 300, 325], ["NMDA-R1", "PROTEIN", 347, 354], ["rat hippocampal neurons", "CELL_TYPE", 358, 381], ["rat", "SPECIES", 358, 361], ["ligand binding", "TEST", 64, 78], ["these cellular receptors", "TEST", 128, 152], ["TLR", "TEST", 183, 186], ["cytokine signaling", "TEST", 196, 214], ["Earlier studies", "TEST", 214, 229], ["a2", "TEST", 248, 250], ["calcium responses", "TEST", 275, 292], ["the glutamate receptor NMDA", "TEST", 296, 323], ["NMDA", "TEST", 347, 351]]], ["Later, it was shown that enzymatically inactive tPA (El-tPA) and a2macroglobulin treatment caused the formation of a complex between LRP1, PSD-95, and NMDA-Rs that activates tyrosine receptor kinase (Trk) receptors and stimulates ERK1/2 activity in neurons [73] .", [["neurons", "ANATOMY", 249, 256], ["a2macroglobulin", "CHEMICAL", 65, 80], ["NMDA", "CHEMICAL", 151, 155], ["tyrosine", "CHEMICAL", 174, 182], ["a2macroglobulin", "CHEMICAL", 65, 80], ["NMDA", "CHEMICAL", 151, 155], ["tyrosine", "CHEMICAL", 174, 182], ["tPA", "GENE_OR_GENE_PRODUCT", 48, 51], ["El-tPA", "GENE_OR_GENE_PRODUCT", 53, 59], ["a2macroglobulin", "SIMPLE_CHEMICAL", 65, 80], ["LRP1", "GENE_OR_GENE_PRODUCT", 133, 137], ["PSD-95", "GENE_OR_GENE_PRODUCT", 139, 145], ["NMDA-Rs", "GENE_OR_GENE_PRODUCT", 151, 158], ["tyrosine receptor kinase (Trk) receptors", "GENE_OR_GENE_PRODUCT", 174, 214], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 230, 236], ["neurons", "CELL", 249, 256], ["LRP1", "PROTEIN", 133, 137], ["PSD", "PROTEIN", 139, 142], ["NMDA-Rs", "PROTEIN", 151, 158], ["tyrosine receptor kinase (Trk) receptors", "PROTEIN", 174, 214], ["ERK1", "PROTEIN", 230, 234], ["enzymatically inactive tPA (El-tPA", "TREATMENT", 25, 59], ["a2macroglobulin treatment", "TREATMENT", 65, 90], ["PSD", "TEST", 139, 142], ["NMDA", "TEST", 151, 155], ["tyrosine receptor kinase", "TREATMENT", 174, 198], ["Trk) receptors", "TREATMENT", 200, 214], ["ERK1", "TEST", 230, 234], ["inactive", "OBSERVATION_MODIFIER", 39, 47]]], ["ERK1/2 activation can enhance MMP9 expression [52, 56, 58] .", [["ERK1/2", "GENE_OR_GENE_PRODUCT", 0, 6], ["MMP9", "GENE_OR_GENE_PRODUCT", 30, 34], ["ERK1/2", "PROTEIN", 0, 6], ["MMP9", "PROTEIN", 30, 34], ["MMP9 expression", "TEST", 30, 45]]], ["These studies indicated El-tPA modifies cellular signaling via LRP1.tPA receptors modulates TLR-mediated cytokine signalingRecent studies elegantly showed that tPA-mediated LRP1 signaling modulates the inflammatory response after TLR stimulation (Figure 2 Similarly, EI-tPA and activated \u03b12-macroglobulin binding to NMDA-R blocks ligand-induced TLR2 and TLR9 and NFkB signaling, but not that of PPRs like NOD1 or NOD2 [75] .tPA receptors modulates TLR-mediated cytokine signalingEndothelial cells, fibroblasts, osteoblasts, smooth muscle, and macrophages produce the macrophage-colony stimulating factor (M-CSF; also known as CSF1).", [["cellular", "ANATOMY", 40, 48], ["Endothelial cells", "ANATOMY", 479, 496], ["fibroblasts", "ANATOMY", 498, 509], ["osteoblasts", "ANATOMY", 511, 522], ["smooth muscle", "ANATOMY", 524, 537], ["macrophages", "ANATOMY", 543, 554], ["NMDA", "CHEMICAL", 316, 320], ["NMDA", "CHEMICAL", 316, 320], ["El-tPA", "GENE_OR_GENE_PRODUCT", 24, 30], ["cellular", "CELL", 40, 48], ["LRP1.tPA receptors", "GENE_OR_GENE_PRODUCT", 63, 81], ["TLR", "GENE_OR_GENE_PRODUCT", 92, 95], ["tPA", "GENE_OR_GENE_PRODUCT", 160, 163], ["LRP1", "GENE_OR_GENE_PRODUCT", 173, 177], ["TLR", "GENE_OR_GENE_PRODUCT", 230, 233], ["EI-tPA", "GENE_OR_GENE_PRODUCT", 267, 273], ["\u03b12-macroglobulin", "GENE_OR_GENE_PRODUCT", 288, 304], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 316, 322], ["TLR2", "GENE_OR_GENE_PRODUCT", 345, 349], ["TLR9", "GENE_OR_GENE_PRODUCT", 354, 358], ["NFkB", "GENE_OR_GENE_PRODUCT", 363, 367], ["PPRs", "GENE_OR_GENE_PRODUCT", 395, 399], ["NOD1", "GENE_OR_GENE_PRODUCT", 405, 409], ["NOD2 [75] .tPA receptors", "GENE_OR_GENE_PRODUCT", 413, 437], ["TLR", "GENE_OR_GENE_PRODUCT", 448, 451], ["Endothelial cells", "CELL", 479, 496], ["fibroblasts", "CELL", 498, 509], ["osteoblasts", "CELL", 511, 522], ["smooth muscle", "TISSUE", 524, 537], ["macrophages", "CELL", 543, 554], ["macrophage-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 567, 603], ["M-CSF", "GENE_OR_GENE_PRODUCT", 605, 610], ["CSF1", "GENE_OR_GENE_PRODUCT", 626, 630], ["tPA", "PROTEIN", 27, 30], ["LRP1", "PROTEIN", 63, 67], [".tPA receptors", "PROTEIN", 67, 81], ["TLR", "PROTEIN", 92, 95], ["cytokine", "PROTEIN", 105, 113], ["tPA", "PROTEIN", 160, 163], ["LRP1", "PROTEIN", 173, 177], ["TLR", "PROTEIN", 230, 233], ["\u03b12", "PROTEIN", 288, 290], ["TLR2", "PROTEIN", 345, 349], ["TLR9", "PROTEIN", 354, 358], ["NFkB", "PROTEIN", 363, 367], ["PPRs", "PROTEIN", 395, 399], ["NOD1", "PROTEIN", 405, 409], ["NOD2 [75] .tPA receptors", "PROTEIN", 413, 437], ["TLR", "PROTEIN", 448, 451], ["cytokine", "PROTEIN", 461, 469], ["Endothelial cells", "CELL_TYPE", 479, 496], ["fibroblasts", "CELL_TYPE", 498, 509], ["osteoblasts", "CELL_TYPE", 511, 522], ["macrophages", "CELL_TYPE", 543, 554], ["macrophage-colony stimulating factor", "PROTEIN", 567, 603], ["CSF", "PROTEIN", 607, 610], ["CSF1", "PROTEIN", 626, 630], ["These studies", "TEST", 0, 13], ["El-tPA", "TREATMENT", 24, 30], ["LRP1.tPA receptors", "TREATMENT", 63, 81], ["TLR", "TEST", 92, 95], ["Recent studies", "TEST", 123, 137], ["tPA", "TREATMENT", 160, 163], ["the inflammatory response", "PROBLEM", 198, 223], ["TLR stimulation", "TREATMENT", 230, 245], ["EI", "TEST", 267, 269], ["tPA", "TREATMENT", 270, 273], ["activated \u03b12-macroglobulin binding", "TREATMENT", 278, 312], ["NMDA", "TEST", 316, 320], ["R blocks ligand", "TREATMENT", 321, 336], ["TLR2 and TLR9", "TREATMENT", 345, 358], ["NFkB signaling", "PROBLEM", 363, 377], ["NOD2", "TEST", 413, 417], [".tPA receptors", "TEST", 423, 437], ["TLR", "TEST", 448, 451], ["cytokine signalingEndothelial cells", "PROBLEM", 461, 496], ["fibroblasts", "PROBLEM", 498, 509], ["osteoblasts", "PROBLEM", 511, 522], ["the macrophage", "TEST", 563, 577], ["colony stimulating factor", "PROBLEM", 578, 603], ["inflammatory", "OBSERVATION_MODIFIER", 202, 214], ["Endothelial cells", "OBSERVATION", 479, 496], ["osteoblasts", "ANATOMY", 511, 522], ["smooth muscle", "ANATOMY", 524, 537], ["macrophages", "ANATOMY", 543, 554], ["macrophage", "OBSERVATION_MODIFIER", 567, 577]]], ["M-CSF signals through the M-CSF receptor (reviewed by Hamilton [76] ), and is required for macrophage survival, proliferation, monocytic cell differentiation, and myeloid cell mobilization into circulation.", [["macrophage", "ANATOMY", 91, 101], ["monocytic cell", "ANATOMY", 127, 141], ["myeloid cell", "ANATOMY", 163, 175], ["M-CSF", "GENE_OR_GENE_PRODUCT", 0, 5], ["M-CSF receptor", "GENE_OR_GENE_PRODUCT", 26, 40], ["macrophage", "CELL", 91, 101], ["monocytic cell", "CELL", 127, 141], ["myeloid cell", "CELL", 163, 175], ["CSF", "PROTEIN", 2, 5], ["M-CSF receptor", "PROTEIN", 26, 40], ["CSF signals", "TEST", 2, 13], ["the M-CSF receptor", "TEST", 22, 40], ["macrophage survival", "PROBLEM", 91, 110], ["proliferation", "PROBLEM", 112, 125], ["monocytic cell differentiation", "TEST", 127, 157], ["myeloid cell mobilization", "TREATMENT", 163, 188], ["monocytic cell differentiation", "OBSERVATION", 127, 157], ["myeloid cell mobilization", "OBSERVATION", 163, 188]]], ["M-CSF enhances NMDA-R expression in macrophages [75] .", [["macrophages", "ANATOMY", 36, 47], ["NMDA", "CHEMICAL", 15, 19], ["NMDA", "CHEMICAL", 15, 19], ["M-CSF", "GENE_OR_GENE_PRODUCT", 0, 5], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 15, 21], ["macrophages", "CELL", 36, 47], ["CSF", "PROTEIN", 2, 5], ["macrophages", "CELL_TYPE", 36, 47], ["NMDA", "TEST", 15, 19], ["macrophages", "ANATOMY", 36, 47]]], ["This study demonstrated EI-tPA engagement with NMDA-R on macrophages keeps cells in a resting, non-inflammatory stage, and that M-CSF could alter the response to fibrinolytic factors.tPA receptors modulates TLR-mediated cytokine signalingWhile TLR-mediated effects of tPA on NFkB signaling did not require plasmin, active plasmin can mount a pro-inflammatory response in macrophages or astrocytes through protease-activated receptor-1 (PAR1) (Figure 3 ).", [["macrophages", "ANATOMY", 57, 68], ["cells", "ANATOMY", 75, 80], ["macrophages", "ANATOMY", 371, 382], ["astrocytes", "ANATOMY", 386, 396], ["NMDA", "CHEMICAL", 47, 51], ["NMDA", "CHEMICAL", 47, 51], ["EI-tPA", "GENE_OR_GENE_PRODUCT", 24, 30], ["NMDA-R", "GENE_OR_GENE_PRODUCT", 47, 53], ["macrophages", "CELL", 57, 68], ["cells", "CELL", 75, 80], ["M-CSF", "GENE_OR_GENE_PRODUCT", 128, 133], [".tPA receptors", "GENE_OR_GENE_PRODUCT", 182, 196], ["TLR", "GENE_OR_GENE_PRODUCT", 207, 210], ["TLR", "GENE_OR_GENE_PRODUCT", 244, 247], ["tPA", "GENE_OR_GENE_PRODUCT", 268, 271], ["NFkB", "GENE_OR_GENE_PRODUCT", 275, 279], ["plasmin", "GENE_OR_GENE_PRODUCT", 306, 313], ["plasmin", "GENE_OR_GENE_PRODUCT", 322, 329], ["macrophages", "CELL", 371, 382], ["astrocytes", "CELL", 386, 396], ["protease-activated receptor-1", "GENE_OR_GENE_PRODUCT", 405, 434], ["PAR1", "GENE_OR_GENE_PRODUCT", 436, 440], ["tPA", "PROTEIN", 27, 30], ["macrophages", "CELL_TYPE", 57, 68], ["CSF", "PROTEIN", 130, 133], ["fibrinolytic factors", "PROTEIN", 162, 182], [".tPA receptors", "PROTEIN", 182, 196], ["TLR", "PROTEIN", 207, 210], ["cytokine", "PROTEIN", 220, 228], ["TLR", "PROTEIN", 244, 247], ["tPA", "PROTEIN", 268, 271], ["NFkB", "PROTEIN", 275, 279], ["plasmin", "PROTEIN", 306, 313], ["plasmin", "PROTEIN", 322, 329], ["macrophages", "CELL_TYPE", 371, 382], ["astrocytes", "CELL_TYPE", 386, 396], ["protease-activated receptor-1", "PROTEIN", 405, 434], ["PAR1", "PROTEIN", 436, 440], ["This study", "TEST", 0, 10], ["EI", "TEST", 24, 26], ["NMDA", "TEST", 47, 51], ["non-inflammatory stage", "PROBLEM", 95, 117], ["fibrinolytic factors", "TREATMENT", 162, 182], ["TLR", "TEST", 207, 210], ["cytokine signaling", "PROBLEM", 220, 238], ["tPA", "TREATMENT", 268, 271], ["plasmin", "TREATMENT", 306, 313], ["active plasmin", "PROBLEM", 315, 329], ["activated receptor", "TREATMENT", 414, 432], ["non-inflammatory", "OBSERVATION_MODIFIER", 95, 111]]], ["PAR1 is a key thrombin receptor on platelets and mediates thrombin-induced platelet aggregation.", [["platelets", "ANATOMY", 35, 44], ["platelet", "ANATOMY", 75, 83], ["platelet aggregation", "DISEASE", 75, 95], ["PAR1", "GENE_OR_GENE_PRODUCT", 0, 4], ["thrombin receptor", "GENE_OR_GENE_PRODUCT", 14, 31], ["platelets", "CELL", 35, 44], ["thrombin", "GENE_OR_GENE_PRODUCT", 58, 66], ["platelet", "CELL", 75, 83], ["PAR1", "PROTEIN", 0, 4], ["thrombin receptor", "PROTEIN", 14, 31], ["platelets", "CELL_TYPE", 35, 44], ["thrombin", "PROTEIN", 58, 66], ["platelets", "TEST", 35, 44], ["thrombin", "TEST", 58, 66], ["platelet aggregation", "PROBLEM", 75, 95], ["thrombin", "OBSERVATION", 58, 66], ["platelet aggregation", "OBSERVATION", 75, 95]]], ["Plg receptors like uPAR or a-enolase present Plg to extracellular tPA, or uPA or intracellular uPA causing the conversion of Plg into active plasmin.", [["extracellular", "ANATOMY", 52, 65], ["intracellular", "ANATOMY", 81, 94], ["Plg receptors", "GENE_OR_GENE_PRODUCT", 0, 13], ["uPAR", "GENE_OR_GENE_PRODUCT", 19, 23], ["a-enolase", "GENE_OR_GENE_PRODUCT", 27, 36], ["Plg", "GENE_OR_GENE_PRODUCT", 45, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["tPA", "GENE_OR_GENE_PRODUCT", 66, 69], ["uPA", "GENE_OR_GENE_PRODUCT", 74, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["uPA", "GENE_OR_GENE_PRODUCT", 95, 98], ["Plg", "GENE_OR_GENE_PRODUCT", 125, 128], ["plasmin", "GENE_OR_GENE_PRODUCT", 141, 148], ["Plg receptors", "PROTEIN", 0, 13], ["uPAR", "PROTEIN", 19, 23], ["a-enolase", "PROTEIN", 27, 36], ["Plg", "PROTEIN", 45, 48], ["extracellular tPA", "PROTEIN", 52, 69], ["uPA", "PROTEIN", 74, 77], ["intracellular uPA", "PROTEIN", 81, 98], ["Plg", "PROTEIN", 125, 128], ["plasmin", "PROTEIN", 141, 148], ["uPAR", "PROBLEM", 19, 23], ["extracellular tPA", "TREATMENT", 52, 69], ["uPA", "TREATMENT", 74, 77], ["intracellular uPA", "TREATMENT", 81, 98], ["the conversion of Plg into active plasmin", "TREATMENT", 107, 148], ["active", "OBSERVATION_MODIFIER", 134, 140], ["plasmin", "OBSERVATION", 141, 148]]], ["In turn, plasmin similar to thrombin, MMP1 [77] , MMP13 [78] , Cathepsin G, and neutrophil elastase [79] can cleave the N-terminal ectodomain part of PAR-1 and activate intracellular signaling pathways [80] like the NFkB pathway [81] .", [["intracellular", "ANATOMY", 169, 182], ["N-", "CHEMICAL", 120, 122], ["plasmin", "GENE_OR_GENE_PRODUCT", 9, 16], ["thrombin", "GENE_OR_GENE_PRODUCT", 28, 36], ["MMP1 [77]", "GENE_OR_GENE_PRODUCT", 38, 47], ["MMP13 [78]", "GENE_OR_GENE_PRODUCT", 50, 60], ["Cathepsin G", "GENE_OR_GENE_PRODUCT", 63, 74], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 80, 99], ["PAR-1", "GENE_OR_GENE_PRODUCT", 150, 155], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 169, 182], ["NFkB", "GENE_OR_GENE_PRODUCT", 216, 220], ["plasmin", "PROTEIN", 9, 16], ["thrombin", "PROTEIN", 28, 36], ["MMP1", "PROTEIN", 38, 42], ["MMP13", "PROTEIN", 50, 55], ["Cathepsin G", "PROTEIN", 63, 74], ["neutrophil elastase", "PROTEIN", 80, 99], ["N-terminal ectodomain part", "PROTEIN", 120, 146], ["PAR-1", "PROTEIN", 150, 155], ["NFkB", "PROTEIN", 216, 220], ["plasmin", "TEST", 9, 16], ["thrombin", "TEST", 28, 36], ["MMP1", "TEST", 38, 42], ["MMP13", "TEST", 50, 55], ["Cathepsin G", "TEST", 63, 74], ["neutrophil elastase", "TEST", 80, 99], ["PAR", "TEST", 150, 153], ["intracellular signaling pathways", "TEST", 169, 201]]], ["Plasmin-mediated PAR-1 activation induces IL-8 expression in human dental pulp fibroblast-like cells [82] and activates NFkB, ERK1/2, and p38 mitogen-activated protein kinase in bone marrowderived macrophages [61] .J o u r n a l P r e -p r o o fOur group demonstrated that plasmin treatment of TLR4 or TLR9 ligand-stimulated macrophages showed enhanced NFkB activation [49, 50] supporting the notion of plasmin as a proinflammatory mediator.", [["dental pulp fibroblast-like cells", "ANATOMY", 67, 100], ["bone marrowderived macrophages", "ANATOMY", 178, 208], ["macrophages", "ANATOMY", 325, 336], ["Plasmin", "GENE_OR_GENE_PRODUCT", 0, 7], ["PAR-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["IL-8", "GENE_OR_GENE_PRODUCT", 42, 46], ["human", "ORGANISM", 61, 66], ["dental pulp fibroblast-like cells [82", "CELL", 67, 104], ["NFkB", "GENE_OR_GENE_PRODUCT", 120, 124], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 126, 132], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 138, 174], ["bone", "TISSUE", 178, 182], ["o fOur", "SIMPLE_CHEMICAL", 242, 248], ["plasmin", "GENE_OR_GENE_PRODUCT", 273, 280], ["TLR4", "GENE_OR_GENE_PRODUCT", 294, 298], ["TLR9", "GENE_OR_GENE_PRODUCT", 302, 306], ["macrophages", "CELL", 325, 336], ["NFkB", "GENE_OR_GENE_PRODUCT", 353, 357], ["plasmin", "GENE_OR_GENE_PRODUCT", 403, 410], ["Plasmin", "PROTEIN", 0, 7], ["PAR", "PROTEIN", 17, 20], ["IL-8", "PROTEIN", 42, 46], ["human dental pulp fibroblast-like cells", "CELL_TYPE", 61, 100], ["NFkB", "PROTEIN", 120, 124], ["ERK1/2", "PROTEIN", 126, 132], ["p38 mitogen-activated protein kinase", "PROTEIN", 138, 174], ["bone marrowderived macrophages", "CELL_TYPE", 178, 208], ["plasmin", "PROTEIN", 273, 280], ["TLR4", "PROTEIN", 294, 298], ["TLR9 ligand", "PROTEIN", 302, 313], ["stimulated macrophages", "CELL_TYPE", 314, 336], ["NFkB", "PROTEIN", 353, 357], ["plasmin", "PROTEIN", 403, 410], ["proinflammatory mediator", "PROTEIN", 416, 440], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Plasmin", "TEST", 0, 7], ["mediated PAR", "TREATMENT", 8, 20], ["IL", "TEST", 42, 44], ["human dental pulp fibroblast", "TEST", 61, 89], ["activates NFkB", "TEST", 110, 124], ["ERK1", "TEST", 126, 130], ["p38 mitogen", "TEST", 138, 149], ["activated protein kinase", "TEST", 150, 174], ["macrophages", "TEST", 197, 208], ["a l P r e -p r o o fOur group", "TEST", 225, 254], ["plasmin treatment", "TREATMENT", 273, 290], ["TLR4", "TEST", 294, 298], ["TLR9 ligand", "TEST", 302, 313], ["enhanced NFkB activation", "PROBLEM", 344, 368], ["plasmin", "TREATMENT", 403, 410], ["a proinflammatory mediator", "TREATMENT", 414, 440], ["pulp", "ANATOMY", 74, 78], ["bone", "ANATOMY", 178, 182]]], ["We showed that plasmin inhibition prevents the progression of inflammatory bowel disease in murine models in part through MMP9 activation [48] .J o u r n a l P r e -p r o o fGiven the proinflammatory role of plasmin, studies evaluated the effect of plasmin inhibition to prevent immunosuppression after traumatic brain injury, ischemic stroke, and cardiac surgery.", [["bowel", "ANATOMY", 75, 80], ["brain", "ANATOMY", 313, 318], ["cardiac", "ANATOMY", 348, 355], ["inflammatory bowel disease", "DISEASE", 62, 88], ["traumatic brain injury", "DISEASE", 303, 325], ["ischemic stroke", "DISEASE", 327, 342], ["plasmin", "GENE_OR_GENE_PRODUCT", 15, 22], ["bowel", "ORGAN", 75, 80], ["murine", "ORGANISM", 92, 98], ["MMP9", "GENE_OR_GENE_PRODUCT", 122, 126], ["plasmin", "GENE_OR_GENE_PRODUCT", 208, 215], ["plasmin", "GENE_OR_GENE_PRODUCT", 249, 256], ["brain", "ORGAN", 313, 318], ["cardiac", "ORGAN", 348, 355], ["plasmin", "PROTEIN", 15, 22], ["MMP9", "PROTEIN", 122, 126], ["plasmin", "PROTEIN", 208, 215], ["plasmin", "PROTEIN", 249, 256], ["murine", "SPECIES", 92, 98], ["plasmin inhibition", "TREATMENT", 15, 33], ["inflammatory bowel disease", "PROBLEM", 62, 88], ["MMP9 activation", "TEST", 122, 137], ["plasmin", "PROBLEM", 208, 215], ["studies", "TEST", 217, 224], ["plasmin inhibition", "TREATMENT", 249, 267], ["immunosuppression", "TREATMENT", 279, 296], ["traumatic brain injury", "PROBLEM", 303, 325], ["ischemic stroke", "PROBLEM", 327, 342], ["cardiac surgery", "TREATMENT", 348, 363], ["progression", "OBSERVATION_MODIFIER", 47, 58], ["inflammatory", "OBSERVATION_MODIFIER", 62, 74], ["bowel", "ANATOMY", 75, 80], ["disease", "OBSERVATION", 81, 88], ["brain", "ANATOMY", 313, 318], ["injury", "OBSERVATION", 319, 325], ["ischemic", "OBSERVATION_MODIFIER", 327, 335], ["stroke", "OBSERVATION", 336, 342], ["cardiac", "ANATOMY", 348, 355], ["surgery", "OBSERVATION", 356, 363]]], ["In a model of brain injury, treatment with tranexamic acid (TXA), the lysine analog that blocks the binding of Plg and the ultimate generation of plasmin on fibrin, increased migration and proliferation of conventional dendritic cells (cDCs), antigen-presenting cells and T cells in the draining cervical lymph nodes [83] .J o u r n a l P r e -p r o o fAcute ischemic stroke similarly can trigger immunosuppression.", [["brain", "ANATOMY", 14, 19], ["dendritic cells", "ANATOMY", 219, 234], ["cDCs", "ANATOMY", 236, 240], ["antigen-presenting cells", "ANATOMY", 243, 267], ["T cells", "ANATOMY", 272, 279], ["cervical lymph nodes", "ANATOMY", 296, 316], ["brain injury", "DISEASE", 14, 26], ["tranexamic acid", "CHEMICAL", 43, 58], ["TXA", "CHEMICAL", 60, 63], ["lysine", "CHEMICAL", 70, 76], ["ischemic stroke", "DISEASE", 359, 374], ["tranexamic acid", "CHEMICAL", 43, 58], ["TXA", "CHEMICAL", 60, 63], ["lysine", "CHEMICAL", 70, 76], ["brain", "ORGAN", 14, 19], ["tranexamic acid", "SIMPLE_CHEMICAL", 43, 58], ["TXA", "SIMPLE_CHEMICAL", 60, 63], ["Plg", "GENE_OR_GENE_PRODUCT", 111, 114], ["plasmin", "GENE_OR_GENE_PRODUCT", 146, 153], ["fibrin", "GENE_OR_GENE_PRODUCT", 157, 163], ["conventional dendritic cells", "CELL", 206, 234], ["cDCs", "CELL", 236, 240], ["cells", "CELL", 262, 267], ["T cells", "CELL", 272, 279], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 296, 316], ["Plg", "PROTEIN", 111, 114], ["plasmin", "PROTEIN", 146, 153], ["fibrin", "PROTEIN", 157, 163], ["conventional dendritic cells", "CELL_TYPE", 206, 234], ["cDCs", "CELL_TYPE", 236, 240], ["antigen-presenting cells", "CELL_TYPE", 243, 267], ["T cells", "CELL_TYPE", 272, 279], ["brain injury", "PROBLEM", 14, 26], ["tranexamic acid (TXA)", "TREATMENT", 43, 64], ["the lysine analog", "TREATMENT", 66, 83], ["Plg", "TREATMENT", 111, 114], ["plasmin on fibrin", "TREATMENT", 146, 163], ["increased migration", "PROBLEM", 165, 184], ["conventional dendritic cells", "PROBLEM", 206, 234], ["antigen", "TEST", 243, 250], ["T cells", "PROBLEM", 272, 279], ["fAcute ischemic stroke", "PROBLEM", 352, 374], ["immunosuppression", "TREATMENT", 397, 414], ["brain", "ANATOMY", 14, 19], ["injury", "OBSERVATION", 20, 26], ["fibrin", "OBSERVATION", 157, 163], ["increased", "OBSERVATION_MODIFIER", 165, 174], ["migration", "OBSERVATION_MODIFIER", 175, 184], ["proliferation", "OBSERVATION_MODIFIER", 189, 202], ["dendritic cells", "OBSERVATION", 219, 234], ["draining", "ANATOMY_MODIFIER", 287, 295], ["cervical", "ANATOMY", 296, 304], ["lymph nodes", "OBSERVATION", 305, 316], ["ischemic", "OBSERVATION_MODIFIER", 359, 367], ["stroke", "OBSERVATION", 368, 374]]], ["Using a mouse model of middle cerebral artery occlusion tPA administration worsened the already due to inflammation established immunosuppressive state by reducing lymphocyte and monocyte counts in circulation, enhancing plasma IL-10 and TNFa levels and decreasing DC subtypes [84] .J o u r n a l P r e -p r o o fExtensive surgery is fraught with a high risk of infection, depicting a state of immunosuppression.", [["middle cerebral artery", "ANATOMY", 23, 45], ["lymphocyte", "ANATOMY", 164, 174], ["monocyte", "ANATOMY", 179, 187], ["plasma", "ANATOMY", 221, 227], ["DC", "ANATOMY", 265, 267], ["inflammation", "DISEASE", 103, 115], ["infection", "DISEASE", 362, 371], ["mouse", "ORGANISM", 8, 13], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 30, 45], ["tPA", "GENE_OR_GENE_PRODUCT", 56, 59], ["lymphocyte", "CELL", 164, 174], ["monocyte", "CELL", 179, 187], ["plasma", "ORGANISM_SUBSTANCE", 221, 227], ["IL-10", "GENE_OR_GENE_PRODUCT", 228, 233], ["TNFa", "GENE_OR_GENE_PRODUCT", 238, 242], ["TNFa", "PROTEIN", 238, 242], ["DC", "CELL_TYPE", 265, 267], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["a mouse model of middle cerebral artery occlusion tPA administration", "TREATMENT", 6, 74], ["inflammation", "PROBLEM", 103, 115], ["immunosuppressive state", "PROBLEM", 128, 151], ["lymphocyte", "TEST", 164, 174], ["monocyte counts", "TEST", 179, 194], ["enhancing plasma IL", "TEST", 211, 230], ["TNFa levels", "TEST", 238, 249], ["decreasing DC subtypes", "PROBLEM", 254, 276], ["fExtensive surgery", "TREATMENT", 312, 330], ["infection", "PROBLEM", 362, 371], ["immunosuppression", "TREATMENT", 394, 411], ["middle cerebral artery", "ANATOMY", 23, 45], ["inflammation", "OBSERVATION", 103, 115], ["monocyte counts", "OBSERVATION", 179, 194], ["infection", "OBSERVATION", 362, 371]]], ["In patients undergoing cardiac surgery, the administration of TXA prevents reduced surgery-induced infection rates and surgery-associated immunosuppression [85] .", [["cardiac", "ANATOMY", 23, 30], ["TXA", "CHEMICAL", 62, 65], ["infection", "DISEASE", 99, 108], ["TXA", "CHEMICAL", 62, 65], ["patients", "ORGANISM", 3, 11], ["cardiac", "ORGAN", 23, 30], ["TXA", "SIMPLE_CHEMICAL", 62, 65], ["patients", "SPECIES", 3, 11], ["cardiac surgery", "TREATMENT", 23, 38], ["TXA", "TREATMENT", 62, 65], ["reduced surgery", "TREATMENT", 75, 90], ["induced infection rates", "PROBLEM", 91, 114], ["surgery", "TREATMENT", 119, 126], ["immunosuppression", "TREATMENT", 138, 155], ["cardiac", "ANATOMY", 23, 30], ["surgery", "OBSERVATION", 31, 38], ["infection", "OBSERVATION", 99, 108]]], ["TXA treatment in patients after surgery and in healthy volunteers reduced CD4+ and CD8 memory cells, and CCR7+ regulatory T cells, but increased CCR7 expression on NK cells, attenuated TNFa, IL6 and IL-1b upregulation after surgery.", [["CD4+ and CD8 memory cells", "ANATOMY", 74, 99], ["CCR7+ regulatory T cells", "ANATOMY", 105, 129], ["NK cells", "ANATOMY", 164, 172], ["TXA", "CHEMICAL", 0, 3], ["TXA", "CHEMICAL", 0, 3], ["TXA", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 17, 25], ["volunteers", "ORGANISM", 55, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD8", "GENE_OR_GENE_PRODUCT", 83, 86], ["CCR7", "GENE_OR_GENE_PRODUCT", 105, 109], ["CCR7", "GENE_OR_GENE_PRODUCT", 145, 149], ["NK cells", "CELL", 164, 172], ["TNFa", "GENE_OR_GENE_PRODUCT", 185, 189], ["IL6", "GENE_OR_GENE_PRODUCT", 191, 194], ["IL-1b", "GENE_OR_GENE_PRODUCT", 199, 204], ["CD4", "PROTEIN", 74, 77], ["CD8 memory cells", "CELL_TYPE", 83, 99], ["CCR7", "PROTEIN", 105, 109], ["regulatory T cells", "CELL_TYPE", 111, 129], ["CCR7", "PROTEIN", 145, 149], ["NK cells", "CELL_TYPE", 164, 172], ["IL6", "PROTEIN", 191, 194], ["patients", "SPECIES", 17, 25], ["TXA treatment", "TREATMENT", 0, 13], ["surgery", "TREATMENT", 32, 39], ["CD4", "TEST", 74, 77], ["CD8 memory cells", "TEST", 83, 99], ["CCR7", "TEST", 105, 109], ["increased CCR7 expression", "PROBLEM", 135, 160], ["NK cells", "TEST", 164, 172], ["TNFa", "TEST", 185, 189], ["IL6", "TREATMENT", 191, 194], ["IL", "TREATMENT", 199, 201], ["surgery", "TREATMENT", 224, 231], ["CD8 memory cells", "OBSERVATION", 83, 99], ["CCR7", "ANATOMY", 105, 109], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["CCR7 expression", "OBSERVATION", 145, 160], ["NK cells", "OBSERVATION", 164, 172]]], ["Finally, TXA increased the monocyte/dendritic activation marker CD83 but reduced the maturation marker HLA-DR.", [["monocyte", "ANATOMY", 27, 35], ["dendritic", "ANATOMY", 36, 45], ["TXA", "CHEMICAL", 9, 12], ["TXA", "CHEMICAL", 9, 12], ["TXA", "SIMPLE_CHEMICAL", 9, 12], ["monocyte", "CELL", 27, 35], ["dendritic", "CELL", 36, 45], ["CD83", "GENE_OR_GENE_PRODUCT", 64, 68], ["CD83", "PROTEIN", 64, 68], ["TXA", "TREATMENT", 9, 12], ["the monocyte/dendritic activation marker CD83", "TREATMENT", 23, 68], ["monocyte", "ANATOMY", 27, 35]]], ["In summary, plasmin J o u r n a l P r e -p r o o f inhibition can mitigate immunosuppression after certain ischemic events including surgery.Role of plasmin during the cytokine storm or cytokine release syndromeInfections cause tissue damage not only because of the virulence of the germ or toxin but also because of the immunological host response to the infectious stimulant.Role of plasmin during the cytokine storm or cytokine release syndromeActivated macrophages, T cells and endothelial cells can mount such a host response and cytokines are key elements of the derailed immunological host response.", [["tissue", "ANATOMY", 228, 234], ["germ", "ANATOMY", 283, 287], ["macrophages", "ANATOMY", 457, 468], ["T cells", "ANATOMY", 470, 477], ["endothelial cells", "ANATOMY", 482, 499], ["Infections", "DISEASE", 211, 221], ["tissue damage", "DISEASE", 228, 241], ["plasmin", "GENE_OR_GENE_PRODUCT", 12, 19], ["plasmin", "GENE_OR_GENE_PRODUCT", 149, 156], ["tissue", "TISSUE", 228, 234], ["germ", "TISSUE", 283, 287], ["plasmin", "GENE_OR_GENE_PRODUCT", 385, 392], ["macrophages", "CELL", 457, 468], ["T cells", "CELL", 470, 477], ["endothelial cells", "CELL", 482, 499], ["plasmin", "PROTEIN", 12, 19], ["plasmin", "PROTEIN", 149, 156], ["cytokine", "PROTEIN", 168, 176], ["cytokine", "PROTEIN", 186, 194], ["plasmin", "PROTEIN", 385, 392], ["cytokine", "PROTEIN", 404, 412], ["cytokine", "PROTEIN", 422, 430], ["Activated macrophages", "CELL_TYPE", 447, 468], ["T cells", "CELL_TYPE", 470, 477], ["endothelial cells", "CELL_TYPE", 482, 499], ["cytokines", "PROTEIN", 535, 544], ["plasmin", "TEST", 12, 19], ["a l P r e -p r o o f inhibition", "TREATMENT", 30, 61], ["immunosuppression", "TREATMENT", 75, 92], ["certain ischemic events", "PROBLEM", 99, 122], ["surgery", "TREATMENT", 133, 140], ["plasmin", "TREATMENT", 149, 156], ["the cytokine storm", "TREATMENT", 164, 182], ["cytokine release syndrome", "PROBLEM", 186, 211], ["tissue damage", "PROBLEM", 228, 241], ["toxin", "PROBLEM", 291, 296], ["plasmin", "TREATMENT", 385, 392], ["the cytokine storm", "TREATMENT", 400, 418], ["cytokine release syndrome", "PROBLEM", 422, 447], ["Activated macrophages", "PROBLEM", 447, 468], ["endothelial cells", "PROBLEM", 482, 499], ["damage", "OBSERVATION", 235, 241], ["infectious", "OBSERVATION", 356, 366], ["macrophages", "OBSERVATION", 457, 468], ["endothelial cells", "OBSERVATION", 482, 499]]], ["The clinical syndrome is therefore called the cytokine storm or the cytokine release syndrome.", [["cytokine", "PROTEIN", 46, 54], ["cytokine", "PROTEIN", 68, 76], ["The clinical syndrome", "PROBLEM", 0, 21], ["the cytokine storm", "TREATMENT", 42, 60], ["the cytokine release syndrome", "PROBLEM", 64, 93]]], ["Cytokines itself can cause typical clinical symptoms: Fever was attributed to TNFa and IL-6 rises.", [["Fever", "DISEASE", 54, 59], ["TNFa", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["Cytokines", "PROTEIN", 0, 9], ["TNFa", "PROTEIN", 78, 82], ["typical clinical symptoms", "PROBLEM", 27, 52], ["Fever", "PROBLEM", 54, 59], ["TNFa", "TEST", 78, 82], ["IL", "TEST", 87, 89], ["Fever", "OBSERVATION", 54, 59]]], ["IL-2 can induce capillary leakage syndrome with hypotension and kidney failure.", [["capillary", "ANATOMY", 16, 25], ["kidney", "ANATOMY", 64, 70], ["hypotension", "DISEASE", 48, 59], ["kidney failure", "DISEASE", 64, 78], ["IL-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["capillary", "TISSUE", 16, 25], ["kidney", "ORGAN", 64, 70], ["IL-2", "PROTEIN", 0, 4], ["IL", "TREATMENT", 0, 2], ["capillary leakage syndrome", "PROBLEM", 16, 42], ["hypotension", "PROBLEM", 48, 59], ["kidney failure", "PROBLEM", 64, 78], ["capillary", "OBSERVATION", 16, 25], ["leakage syndrome", "OBSERVATION", 26, 42], ["hypotension", "OBSERVATION", 48, 59], ["kidney", "ANATOMY", 64, 70], ["failure", "OBSERVATION", 71, 78]]], ["Forward amplification by these cytokines occurs.", [["cytokines", "PROTEIN", 31, 40], ["Forward amplification", "PROBLEM", 0, 21]]], ["Released proinflammatory cytokines further activate newly recruited or resident macrophages, DCs, or endothelial cells to secrete more pro-inflammatory cytokines like IL-1 [86, 87] .Role of plasmin during the cytokine storm or cytokine release syndromeA common feature of severe cytokine storm is endothelial cell death.", [["macrophages", "ANATOMY", 80, 91], ["DCs", "ANATOMY", 93, 96], ["endothelial cells", "ANATOMY", 101, 118], ["endothelial cell", "ANATOMY", 297, 313], ["death", "DISEASE", 314, 319], ["macrophages", "CELL", 80, 91], ["DCs", "CELL", 93, 96], ["endothelial cells", "CELL", 101, 118], ["IL-1", "GENE_OR_GENE_PRODUCT", 167, 171], ["plasmin", "GENE_OR_GENE_PRODUCT", 190, 197], ["endothelial cell", "CELL", 297, 313], ["proinflammatory cytokines", "PROTEIN", 9, 34], ["resident macrophages", "CELL_TYPE", 71, 91], ["DCs", "CELL_TYPE", 93, 96], ["endothelial cells", "CELL_TYPE", 101, 118], ["pro-inflammatory cytokines", "PROTEIN", 135, 161], ["IL", "PROTEIN", 167, 169], ["plasmin", "PROTEIN", 190, 197], ["cytokine", "PROTEIN", 209, 217], ["cytokine", "PROTEIN", 227, 235], ["cytokine", "PROTEIN", 279, 287], ["pro-inflammatory cytokines", "TEST", 135, 161], ["plasmin", "TREATMENT", 190, 197], ["the cytokine storm", "TREATMENT", 205, 223], ["cytokine release syndrome", "PROBLEM", 227, 252], ["severe cytokine storm", "PROBLEM", 272, 293], ["endothelial cell death", "PROBLEM", 297, 319], ["proinflammatory cytokines", "OBSERVATION", 9, 34], ["endothelial", "ANATOMY", 101, 112], ["severe", "OBSERVATION_MODIFIER", 272, 278], ["cytokine storm", "OBSERVATION", 279, 293], ["endothelial cell death", "OBSERVATION", 297, 319]]], ["Vascular damage requires the coagulation system for tissue repair.", [["Vascular", "ANATOMY", 0, 8], ["tissue", "ANATOMY", 52, 58], ["Vascular damage", "DISEASE", 0, 15], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["tissue", "TISSUE", 52, 58], ["Vascular damage", "PROBLEM", 0, 15], ["the coagulation system", "TREATMENT", 25, 47], ["tissue repair", "TREATMENT", 52, 65], ["damage", "OBSERVATION", 9, 15], ["repair", "OBSERVATION", 59, 65]]], ["But over-activation of the coagulation system with the generation of massive thrombi can establish DIC leading to the depletion of platelets (thrombopenia) and coagulation factors.", [["thrombi", "ANATOMY", 77, 84], ["platelets", "ANATOMY", 131, 140], ["thrombi", "DISEASE", 77, 84], ["DIC", "DISEASE", 99, 102], ["thrombopenia", "DISEASE", 142, 154], ["thrombi", "PATHOLOGICAL_FORMATION", 77, 84], ["platelets", "CELL", 131, 140], ["thrombopenia", "SIMPLE_CHEMICAL", 142, 154], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 160, 179], ["platelets", "CELL_TYPE", 131, 140], ["coagulation factors", "PROTEIN", 160, 179], ["the coagulation system", "TEST", 23, 45], ["massive thrombi", "PROBLEM", 69, 84], ["DIC", "PROBLEM", 99, 102], ["the depletion of platelets", "PROBLEM", 114, 140], ["thrombopenia", "PROBLEM", 142, 154], ["coagulation factors", "PROBLEM", 160, 179], ["massive", "OBSERVATION_MODIFIER", 69, 76], ["thrombi", "OBSERVATION", 77, 84]]], ["Hemostatic imbalance also creates lung and kidney damage due to complement-mediated injury.Role of plasmin during the cytokine storm or cytokine release syndromeIn 1993, Ferrara's group first introduced the term cytokine storm to describe the derailed immunological host response during graft-versus-host disease (GvHD), a condition occurring after an allogeneic transplant [88] .", [["lung", "ANATOMY", 34, 38], ["kidney", "ANATOMY", 43, 49], ["graft", "ANATOMY", 287, 292], ["lung and kidney damage", "DISEASE", 34, 56], ["graft-versus-host disease", "DISEASE", 287, 312], ["GvHD", "DISEASE", 314, 318], ["lung", "ORGAN", 34, 38], ["kidney", "ORGAN", 43, 49], ["plasmin", "GENE_OR_GENE_PRODUCT", 99, 106], ["graft", "TISSUE", 287, 292], ["plasmin", "PROTEIN", 99, 106], ["cytokine", "PROTEIN", 118, 126], ["cytokine", "PROTEIN", 136, 144], ["cytokine", "PROTEIN", 212, 220], ["Hemostatic imbalance", "PROBLEM", 0, 20], ["lung and kidney damage", "PROBLEM", 34, 56], ["complement-mediated injury", "PROBLEM", 64, 90], ["plasmin", "TREATMENT", 99, 106], ["the cytokine storm", "TREATMENT", 114, 132], ["the term cytokine storm", "TREATMENT", 203, 226], ["host disease", "PROBLEM", 300, 312], ["GvHD", "PROBLEM", 314, 318], ["a condition", "PROBLEM", 321, 332], ["an allogeneic transplant", "TREATMENT", 349, 373], ["imbalance", "OBSERVATION", 11, 20], ["lung", "ANATOMY", 34, 38], ["kidney", "ANATOMY", 43, 49], ["damage", "OBSERVATION", 50, 56], ["injury", "OBSERVATION", 84, 90], ["host disease", "OBSERVATION", 300, 312]]], ["In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells attack the recipient's body.", [["bone marrow", "ANATOMY", 21, 32], ["peripheral blood stem cells", "ANATOMY", 36, 63], ["body", "ANATOMY", 85, 89], ["cells", "ANATOMY", 118, 123], ["body", "ANATOMY", 147, 151], ["GvHD", "DISEASE", 3, 7], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 21, 32], ["peripheral blood stem cells", "CELL", 36, 63], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["cells", "CELL", 118, 123], ["body", "ORGANISM_SUBDIVISION", 147, 151], ["peripheral blood stem cells", "CELL_TYPE", 36, 63], ["donated cells", "CELL_TYPE", 110, 123], ["GvHD", "PROBLEM", 3, 7], ["the donated bone marrow", "TEST", 9, 32], ["peripheral blood stem cells", "TEST", 36, 63], ["foreign", "PROBLEM", 93, 100], ["GvHD", "OBSERVATION", 3, 7], ["bone marrow", "ANATOMY", 21, 32], ["peripheral", "ANATOMY_MODIFIER", 36, 46], ["blood", "ANATOMY", 47, 52], ["stem cells", "OBSERVATION", 53, 63], ["foreign", "OBSERVATION", 93, 100]]], ["Our group observed increased circulating plasmin levels in mice and men with acute GvHD [49] .", [["GvHD", "DISEASE", 83, 87], ["plasmin", "GENE_OR_GENE_PRODUCT", 41, 48], ["mice", "ORGANISM", 59, 63], ["men", "ORGANISM", 68, 71], ["plasmin", "PROTEIN", 41, 48], ["mice", "SPECIES", 59, 63], ["men", "SPECIES", 68, 71], ["mice", "SPECIES", 59, 63], ["increased circulating plasmin levels", "PROBLEM", 19, 55], ["acute GvHD", "PROBLEM", 77, 87], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["circulating", "OBSERVATION_MODIFIER", 29, 40], ["plasmin levels", "OBSERVATION", 41, 55], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["GvHD", "OBSERVATION", 83, 87]]], ["Pharmacological plasmin J o u r n a l P r e -p r o o f inhibition protected against acute GVHD-associated lethality in mice by reducing the infiltration of inflammatory cells in part due to enhanced MCP1 signaling and augmented release of membrane-associated pro-inflammatory cytokines including TNFa and Fas-ligand partially due to the activation of MMPs.Role of plasmin during the cytokine storm or cytokine release syndromeOther diseases can cause CRS ranging from rheumatological disorders [89] , immune- Aside from a massive cytokine elevation of typical proinflammatory cytokines like TNFa, IL-1, IL-6, and GM-CSF, these patients show typical derailment of the coagulation system.", [["inflammatory cells", "ANATOMY", 156, 174], ["membrane", "ANATOMY", 239, 247], ["GVHD", "DISEASE", 90, 94], ["syndromeOther diseases", "DISEASE", 418, 440], ["CRS", "DISEASE", 451, 454], ["rheumatological disorders", "DISEASE", 468, 493], ["derailment of the coagulation", "DISEASE", 649, 678], ["plasmin", "GENE_OR_GENE_PRODUCT", 16, 23], ["mice", "ORGANISM", 119, 123], ["inflammatory cells", "CELL", 156, 174], ["MCP1", "GENE_OR_GENE_PRODUCT", 199, 203], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["TNFa", "GENE_OR_GENE_PRODUCT", 296, 300], ["Fas-ligand", "GENE_OR_GENE_PRODUCT", 305, 315], ["MMPs", "GENE_OR_GENE_PRODUCT", 351, 355], ["plasmin", "GENE_OR_GENE_PRODUCT", 364, 371], ["TNFa", "GENE_OR_GENE_PRODUCT", 591, 595], ["IL-1", "GENE_OR_GENE_PRODUCT", 597, 601], ["IL-6", "GENE_OR_GENE_PRODUCT", 603, 607], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 613, 619], ["patients", "ORGANISM", 627, 635], ["inflammatory cells", "CELL_TYPE", 156, 174], ["MCP1", "PROTEIN", 199, 203], ["pro-inflammatory cytokines", "PROTEIN", 259, 285], ["TNFa", "PROTEIN", 296, 300], ["Fas-ligand", "PROTEIN", 305, 315], ["MMPs", "PROTEIN", 351, 355], ["plasmin", "PROTEIN", 364, 371], ["cytokine", "PROTEIN", 383, 391], ["cytokine", "PROTEIN", 401, 409], ["cytokine", "PROTEIN", 530, 538], ["proinflammatory cytokines", "PROTEIN", 560, 585], ["TNFa", "PROTEIN", 591, 595], ["IL", "PROTEIN", 597, 599], ["IL-6", "PROTEIN", 603, 607], ["GM", "PROTEIN", 613, 615], ["mice", "SPECIES", 119, 123], ["patients", "SPECIES", 627, 635], ["mice", "SPECIES", 119, 123], ["Pharmacological plasmin", "TEST", 0, 23], ["inhibition", "TREATMENT", 55, 65], ["acute GVHD", "PROBLEM", 84, 94], ["lethality in mice", "PROBLEM", 106, 123], ["inflammatory cells", "PROBLEM", 156, 174], ["enhanced MCP1 signaling", "PROBLEM", 190, 213], ["pro-inflammatory cytokines", "PROBLEM", 259, 285], ["TNFa", "TEST", 296, 300], ["MMPs", "PROBLEM", 351, 355], ["plasmin", "TREATMENT", 364, 371], ["the cytokine storm", "TREATMENT", 379, 397], ["cytokine release syndromeOther diseases", "PROBLEM", 401, 440], ["CRS", "PROBLEM", 451, 454], ["rheumatological disorders", "PROBLEM", 468, 493], ["immune", "TEST", 501, 507], ["a massive cytokine elevation", "PROBLEM", 520, 548], ["typical proinflammatory cytokines", "TEST", 552, 585], ["TNFa", "TEST", 591, 595], ["IL", "TEST", 597, 599], ["IL", "TEST", 603, 605], ["GM-CSF", "TEST", 613, 619], ["typical derailment of the coagulation system", "PROBLEM", 641, 685], ["GVHD", "OBSERVATION", 90, 94], ["lethality", "OBSERVATION", 106, 115], ["infiltration", "OBSERVATION", 140, 152], ["inflammatory cells", "OBSERVATION", 156, 174], ["pro-inflammatory cytokines", "OBSERVATION", 259, 285], ["massive", "OBSERVATION_MODIFIER", 522, 529], ["cytokine elevation", "OBSERVATION", 530, 548], ["proinflammatory cytokines", "OBSERVATION", 560, 585]]], ["The cytokine storm data found in COVID-19 patients seem to indicate increased levels of thrombi, and damage to the vascular endothelium, the involvement of cytokines and immuno-thrombosis [92, 93] .", [["thrombi", "ANATOMY", 88, 95], ["vascular endothelium", "ANATOMY", 115, 135], ["thrombi", "DISEASE", 88, 95], ["patients", "ORGANISM", 42, 50], ["vascular endothelium", "TISSUE", 115, 135], ["cytokine", "PROTEIN", 4, 12], ["cytokines", "PROTEIN", 156, 165], ["patients", "SPECIES", 42, 50], ["The cytokine storm data", "TEST", 0, 23], ["COVID", "TEST", 33, 38], ["increased levels of thrombi", "PROBLEM", 68, 95], ["damage to the vascular endothelium", "PROBLEM", 101, 135], ["cytokines", "PROBLEM", 156, 165], ["immuno-thrombosis", "TEST", 170, 187], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["thrombi", "OBSERVATION", 88, 95], ["vascular endothelium", "ANATOMY", 115, 135]]], ["Pathology analysis of COVID-19 patients' lungs shows widespread thrombosis with microangiopathy.", [["lungs", "ANATOMY", 41, 46], ["thrombosis", "DISEASE", 64, 74], ["microangiopathy", "DISEASE", 80, 95], ["patients", "ORGANISM", 31, 39], ["lungs", "ORGAN", 41, 46], ["patients", "SPECIES", 31, 39], ["Pathology analysis", "TEST", 0, 18], ["COVID", "TEST", 22, 27], ["patients' lungs", "TEST", 31, 46], ["widespread thrombosis", "PROBLEM", 53, 74], ["microangiopathy", "PROBLEM", 80, 95], ["lungs", "ANATOMY", 41, 46], ["widespread", "OBSERVATION_MODIFIER", 53, 63], ["thrombosis", "OBSERVATION", 64, 74], ["microangiopathy", "OBSERVATION", 80, 95]]], ["It is yet to be determined whether plasmin in COVID-19 is a friend or foe as recently summarized in a review by Medcalf et al. [94] .Role of plasmin during the cytokine storm or cytokine release syndromeCytokine storm syndrome resembles hemophagocytic lymphohistiocytosis or macrophage activation syndrome.", [["macrophage", "ANATOMY", 275, 285], ["hemophagocytic lymphohistiocytosis", "DISEASE", 237, 271], ["plasmin", "GENE_OR_GENE_PRODUCT", 35, 42], ["plasmin", "GENE_OR_GENE_PRODUCT", 141, 148], ["macrophage", "CELL", 275, 285], ["plasmin", "PROTEIN", 35, 42], ["plasmin", "PROTEIN", 141, 148], ["cytokine", "PROTEIN", 160, 168], ["cytokine", "PROTEIN", 178, 186], ["plasmin", "TREATMENT", 141, 148], ["the cytokine storm", "TREATMENT", 156, 174], ["cytokine release syndromeCytokine storm syndrome", "PROBLEM", 178, 226], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 237, 271], ["macrophage activation syndrome", "PROBLEM", 275, 305], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 237, 271], ["macrophage activation syndrome", "OBSERVATION", 275, 305]]], ["Typical clinical symptoms of MAS patients are: fever, organomegaly, multi-organ failure, hyperferritinemia, pancytopenia, increases in triglycerides, fibrinogen, ferritin, serum aspartate aminotransferase, and hemophagocytosis (the uptake of erythrocytes into macrophages) in bone marrow aspirates [91] .", [["multi-organ", "ANATOMY", 68, 79], ["serum", "ANATOMY", 172, 177], ["erythrocytes", "ANATOMY", 242, 254], ["macrophages", "ANATOMY", 260, 271], ["bone marrow aspirates", "ANATOMY", 276, 297], ["MAS", "DISEASE", 29, 32], ["fever", "DISEASE", 47, 52], ["organomegaly", "DISEASE", 54, 66], ["multi-organ failure", "DISEASE", 68, 87], ["hyperferritinemia", "DISEASE", 89, 106], ["pancytopenia", "DISEASE", 108, 120], ["aspartate", "CHEMICAL", 178, 187], ["hemophagocytosis", "DISEASE", 210, 226], ["triglycerides", "CHEMICAL", 135, 148], ["aspartate", "CHEMICAL", 178, 187], ["patients", "ORGANISM", 33, 41], ["triglycerides", "SIMPLE_CHEMICAL", 135, 148], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 150, 160], ["ferritin", "GENE_OR_GENE_PRODUCT", 162, 170], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["aspartate", "AMINO_ACID", 178, 187], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 188, 204], ["erythrocytes", "CELL", 242, 254], ["macrophages", "CELL", 260, 271], ["bone marrow aspirates", "MULTI-TISSUE_STRUCTURE", 276, 297], ["fibrinogen", "PROTEIN", 150, 160], ["ferritin", "PROTEIN", 162, 170], ["serum aspartate aminotransferase", "PROTEIN", 172, 204], ["erythrocytes", "CELL_TYPE", 242, 254], ["macrophages", "CELL_TYPE", 260, 271], ["patients", "SPECIES", 33, 41], ["Typical clinical symptoms", "PROBLEM", 0, 25], ["fever", "PROBLEM", 47, 52], ["organomegaly", "PROBLEM", 54, 66], ["multi-organ failure", "PROBLEM", 68, 87], ["hyperferritinemia", "PROBLEM", 89, 106], ["pancytopenia", "PROBLEM", 108, 120], ["increases in triglycerides", "PROBLEM", 122, 148], ["fibrinogen", "TEST", 150, 160], ["ferritin", "TEST", 162, 170], ["serum aspartate aminotransferase", "TEST", 172, 204], ["hemophagocytosis", "PROBLEM", 210, 226], ["the uptake of erythrocytes into macrophages", "PROBLEM", 228, 271], ["bone marrow aspirates", "TEST", 276, 297], ["fever", "OBSERVATION", 47, 52], ["organomegaly", "OBSERVATION", 54, 66], ["multi-organ", "ANATOMY", 68, 79], ["failure", "OBSERVATION", 80, 87], ["hyperferritinemia", "OBSERVATION", 89, 106], ["pancytopenia", "OBSERVATION", 108, 120], ["increases", "OBSERVATION_MODIFIER", 122, 131], ["hemophagocytosis", "OBSERVATION", 210, 226], ["macrophages", "ANATOMY", 260, 271], ["bone marrow", "ANATOMY", 276, 287]]], ["Respiratory symptoms range from mild cases with cough and tachypnea to acute respiratory distress syndrome with dyspnea, hypoxemia, and bilateral opacities on chest X-ray.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 77, 88], ["chest", "ANATOMY", 159, 164], ["Respiratory symptoms", "DISEASE", 0, 20], ["cough", "DISEASE", 48, 53], ["tachypnea", "DISEASE", 58, 67], ["respiratory distress syndrome", "DISEASE", 77, 106], ["dyspnea", "DISEASE", 112, 119], ["hypoxemia", "DISEASE", 121, 130], ["opacities", "DISEASE", 146, 155], ["Respiratory symptoms", "PROBLEM", 0, 20], ["mild cases", "PROBLEM", 32, 42], ["cough", "PROBLEM", 48, 53], ["tachypnea", "PROBLEM", 58, 67], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["dyspnea", "PROBLEM", 112, 119], ["hypoxemia", "PROBLEM", 121, 130], ["bilateral opacities", "PROBLEM", 136, 155], ["chest X-ray", "TEST", 159, 170], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["cough", "OBSERVATION", 48, 53], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory distress", "OBSERVATION", 77, 97], ["dyspnea", "OBSERVATION", 112, 119], ["hypoxemia", "OBSERVATION", 121, 130], ["bilateral", "ANATOMY_MODIFIER", 136, 145], ["opacities", "OBSERVATION", 146, 155], ["chest", "ANATOMY", 159, 164]]], ["Organ failure includes the kidney or heart, and accompanying hemodynamic instability, capillary leak, and consumptive J o u r n a l P r e -p r o o f coagulopathy are also often reported [95] .", [["Organ", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 27, 33], ["heart", "ANATOMY", 37, 42], ["capillary", "ANATOMY", 86, 95], ["Organ failure", "DISEASE", 0, 13], ["coagulopathy", "DISEASE", 149, 161], ["kidney", "ORGAN", 27, 33], ["heart", "ORGAN", 37, 42], ["capillary", "TISSUE", 86, 95], ["Organ failure", "PROBLEM", 0, 13], ["the kidney or heart", "PROBLEM", 23, 42], ["accompanying hemodynamic instability", "PROBLEM", 48, 84], ["capillary leak", "PROBLEM", 86, 100], ["coagulopathy", "PROBLEM", 149, 161], ["failure", "OBSERVATION", 6, 13], ["kidney", "ANATOMY", 27, 33], ["heart", "ANATOMY", 37, 42], ["hemodynamic instability", "OBSERVATION", 61, 84], ["capillary leak", "OBSERVATION", 86, 100], ["coagulopathy", "OBSERVATION", 149, 161]]], ["MAS can occur following severe viral inflammation.", [["MAS", "DISEASE", 0, 3], ["viral inflammation", "DISEASE", 31, 49], ["MAS", "PROBLEM", 0, 3], ["severe viral inflammation", "PROBLEM", 24, 49], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["inflammation", "OBSERVATION", 37, 49]]], ["Viral RNA/DNA can activate TLR9.", [["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["TLR9", "GENE_OR_GENE_PRODUCT", 27, 31], ["Viral RNA", "RNA", 0, 9], ["TLR9", "PROTEIN", 27, 31], ["Viral RNA/DNA", "PROBLEM", 0, 13]]], ["We established a murine MAS model by repeatedly administering the TLR9 activating dinucleotide CpG combined with D-galactosamine, a substance triggering hepatocyte apoptosis and TNFa activation, to test the potential involvement of plasmin in the pathogenesis of MAS [50] .", [["hepatocyte", "ANATOMY", 153, 163], ["CpG", "CHEMICAL", 95, 98], ["D-galactosamine", "CHEMICAL", 113, 128], ["MAS", "DISEASE", 263, 266], ["CpG", "CHEMICAL", 95, 98], ["D-galactosamine", "CHEMICAL", 113, 128], ["murine", "ORGANISM", 17, 23], ["TLR9", "GENE_OR_GENE_PRODUCT", 66, 70], ["D-galactosamine", "SIMPLE_CHEMICAL", 113, 128], ["hepatocyte", "CELL", 153, 163], ["TNFa", "GENE_OR_GENE_PRODUCT", 178, 182], ["plasmin", "GENE_OR_GENE_PRODUCT", 232, 239], ["TLR9", "PROTEIN", 66, 70], ["TNFa", "PROTEIN", 178, 182], ["plasmin", "PROTEIN", 232, 239], ["murine", "SPECIES", 17, 23], ["a murine MAS model", "TREATMENT", 15, 33], ["the TLR9 activating dinucleotide CpG", "TREATMENT", 62, 98], ["D-galactosamine", "TREATMENT", 113, 128], ["a substance triggering hepatocyte apoptosis", "TREATMENT", 130, 173], ["TNFa activation", "TREATMENT", 178, 193], ["plasmin", "PROBLEM", 232, 239], ["hepatocyte apoptosis", "OBSERVATION", 153, 173], ["plasmin", "OBSERVATION", 232, 239]]], ["Plasmin levels were increased during MAS progression in mice.", [["Plasmin", "GENE_OR_GENE_PRODUCT", 0, 7], ["mice", "ORGANISM", 56, 60], ["Plasmin", "PROTEIN", 0, 7], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["Plasmin levels", "TEST", 0, 14], ["increased", "OBSERVATION_MODIFIER", 20, 29]]], ["We found that plasmin inhibition prevented tissue destruction and lethality in MAS mice while suppressing the cytokine peak [50] .", [["tissue", "ANATOMY", 43, 49], ["plasmin", "GENE_OR_GENE_PRODUCT", 14, 21], ["tissue", "TISSUE", 43, 49], ["mice", "ORGANISM", 83, 87], ["plasmin", "PROTEIN", 14, 21], ["cytokine", "PROTEIN", 110, 118], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["plasmin inhibition", "PROBLEM", 14, 32], ["tissue destruction", "PROBLEM", 43, 61], ["lethality in MAS mice", "PROBLEM", 66, 87], ["the cytokine peak", "TEST", 106, 123], ["plasmin", "OBSERVATION", 14, 21], ["tissue", "OBSERVATION_MODIFIER", 43, 49], ["destruction", "OBSERVATION", 50, 61], ["lethality", "OBSERVATION_MODIFIER", 66, 75]]], ["Plasminogen activator administration aggravated the disease.", [["Plasminogen activator", "GENE_OR_GENE_PRODUCT", 0, 21], ["Plasminogen activator administration", "TREATMENT", 0, 36], ["the disease", "PROBLEM", 48, 59], ["disease", "OBSERVATION", 52, 59]]], ["In vitro, the addition of plasmin and TLR9 ligands activated NFkB signaling in macrophages with enhanced production of transmembrane TNFa, CCL2, IL-1, IL-6, and Fas ligand.", [["macrophages", "ANATOMY", 79, 90], ["transmembrane", "ANATOMY", 119, 132], ["plasmin", "GENE_OR_GENE_PRODUCT", 26, 33], ["TLR9", "GENE_OR_GENE_PRODUCT", 38, 42], ["NFkB", "GENE_OR_GENE_PRODUCT", 61, 65], ["macrophages", "CELL", 79, 90], ["transmembrane", "CELLULAR_COMPONENT", 119, 132], ["TNFa", "GENE_OR_GENE_PRODUCT", 133, 137], ["CCL2", "GENE_OR_GENE_PRODUCT", 139, 143], ["IL-1", "GENE_OR_GENE_PRODUCT", 145, 149], ["IL-6", "GENE_OR_GENE_PRODUCT", 151, 155], ["Fas ligand", "GENE_OR_GENE_PRODUCT", 161, 171], ["plasmin", "PROTEIN", 26, 33], ["TLR9", "PROTEIN", 38, 42], ["NFkB", "PROTEIN", 61, 65], ["macrophages", "CELL_TYPE", 79, 90], ["transmembrane TNFa", "PROTEIN", 119, 137], ["CCL2", "PROTEIN", 139, 143], ["IL-1, IL-6", "PROTEIN", 145, 155], ["Fas ligand", "PROTEIN", 161, 171], ["plasmin and TLR9 ligands", "TREATMENT", 26, 50], ["NFkB signaling in macrophages", "PROBLEM", 61, 90], ["transmembrane TNFa", "TEST", 119, 137], ["CCL2", "TEST", 139, 143], ["IL", "TEST", 145, 147], ["IL", "TEST", 151, 153], ["transmembrane TNFa", "OBSERVATION", 119, 137]]], ["This in turn augmented uPA [96] , and PAI-1 expression [97] .", [["uPA", "GENE_OR_GENE_PRODUCT", 23, 26], ["PAI-1", "GENE_OR_GENE_PRODUCT", 38, 43], ["uPA", "PROTEIN", 23, 26], ["PAI", "PROTEIN", 38, 41], ["PAI", "TEST", 38, 41]]], ["Most importantly, our study indicated that plasmin inhibition blocked the vicious cycle of cytokine storm syndrome and hyperfibrinolysis in tandem with coagulation in the MAS model [50] .Role of Plg/plasmin during inflammation resolutionDuring inflammation resolution, apoptotic cells need to be cleaned up in a process known as efferocytosis.", [["cells", "ANATOMY", 279, 284], ["hyperfibrinolysis", "DISEASE", 119, 136], ["inflammation", "DISEASE", 244, 256], ["efferocytosis", "DISEASE", 329, 342], ["plasmin", "GENE_OR_GENE_PRODUCT", 43, 50], ["Plg", "GENE_OR_GENE_PRODUCT", 195, 198], ["plasmin", "GENE_OR_GENE_PRODUCT", 199, 206], ["cells", "CELL", 279, 284], ["plasmin", "PROTEIN", 43, 50], ["cytokine", "PROTEIN", 91, 99], ["Plg", "PROTEIN", 195, 198], ["plasmin", "PROTEIN", 199, 206], ["apoptotic cells", "CELL_TYPE", 269, 284], ["our study", "TEST", 18, 27], ["plasmin inhibition", "TREATMENT", 43, 61], ["cytokine storm syndrome", "PROBLEM", 91, 114], ["hyperfibrinolysis", "PROBLEM", 119, 136], ["coagulation in the MAS model", "TREATMENT", 152, 180], ["Plg/plasmin", "TREATMENT", 195, 206], ["inflammation", "PROBLEM", 214, 226], ["inflammation resolution", "PROBLEM", 244, 267], ["apoptotic cells", "PROBLEM", 269, 284], ["efferocytosis", "PROBLEM", 329, 342], ["cytokine storm syndrome", "OBSERVATION", 91, 114], ["apoptotic cells", "OBSERVATION", 269, 284], ["efferocytosis", "OBSERVATION", 329, 342]]], ["Apoptotic cells activate serum-derived Plg.", [["cells", "ANATOMY", 10, 15], ["serum", "ANATOMY", 25, 30], ["Apoptotic cells", "CELL", 0, 15], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["Apoptotic cells", "CELL_TYPE", 0, 15], ["Apoptotic cells", "TEST", 0, 15], ["serum", "TEST", 25, 30]]], ["The generated plasmin promotes apoptotic cell clearance [98, 99] .", [["cell", "ANATOMY", 41, 45], ["plasmin", "GENE_OR_GENE_PRODUCT", 14, 21], ["cell", "CELL", 41, 45], ["plasmin", "PROTEIN", 14, 21], ["The generated plasmin promotes apoptotic cell clearance", "TEST", 0, 55], ["apoptotic cell clearance", "OBSERVATION", 31, 55]]], ["Das et al. showed that Plg deficient cells showed impaired phagocytic activity [99] .", [["cells", "ANATOMY", 37, 42], ["Plg", "GENE_OR_GENE_PRODUCT", 23, 26], ["cells", "CELL", 37, 42], ["Plg deficient cells", "CELL_LINE", 23, 42], ["Plg deficient cells", "PROBLEM", 23, 42], ["impaired phagocytic activity", "PROBLEM", 50, 78], ["impaired", "OBSERVATION_MODIFIER", 50, 58], ["phagocytic activity", "OBSERVATION", 59, 78]]], ["Recent studies showed that the transmembrane Plg receptor Plg-RKT [101] induce macrophage polarization from the M1 to the M2 type and efferocytosis in the pleurisy model required Plg-RKT and Plg as shown using gene-deficient mice [102] .Role of Plg/plasmin during inflammation resolutionWhile fibrin depositions are part of the normal acute inflammatory reaction, provisional laid down fibrin needs to be removed by MMPs and plasmin to restore tissue homeostasis.", [["transmembrane", "ANATOMY", 31, 44], ["macrophage", "ANATOMY", 79, 89], ["pleurisy", "ANATOMY", 155, 163], ["tissue", "ANATOMY", 444, 450], ["pleurisy", "DISEASE", 155, 163], ["inflammation", "DISEASE", 264, 276], ["transmembrane", "CELLULAR_COMPONENT", 31, 44], ["Plg-RKT [101]", "GENE_OR_GENE_PRODUCT", 58, 71], ["macrophage", "CELL", 79, 89], ["M1", "CELL", 112, 114], ["Plg-RKT", "GENE_OR_GENE_PRODUCT", 179, 186], ["Plg", "GENE_OR_GENE_PRODUCT", 191, 194], ["mice", "ORGANISM", 225, 229], ["Plg", "GENE_OR_GENE_PRODUCT", 245, 248], ["plasmin", "GENE_OR_GENE_PRODUCT", 249, 256], ["fibrin", "GENE_OR_GENE_PRODUCT", 293, 299], ["fibrin", "GENE_OR_GENE_PRODUCT", 386, 392], ["MMPs", "GENE_OR_GENE_PRODUCT", 416, 420], ["plasmin", "GENE_OR_GENE_PRODUCT", 425, 432], ["tissue", "TISSUE", 444, 450], ["transmembrane Plg receptor", "PROTEIN", 31, 57], ["Plg", "PROTEIN", 58, 61], ["Plg", "PROTEIN", 179, 182], ["RKT", "PROTEIN", 183, 186], ["Plg", "PROTEIN", 191, 194], ["Plg", "PROTEIN", 245, 248], ["plasmin", "PROTEIN", 249, 256], ["fibrin", "PROTEIN", 386, 392], ["MMPs", "PROTEIN", 416, 420], ["plasmin", "PROTEIN", 425, 432], ["mice", "SPECIES", 225, 229], ["Recent studies", "TEST", 0, 14], ["the transmembrane Plg receptor Plg", "TEST", 27, 61], ["macrophage polarization", "TEST", 79, 102], ["efferocytosis", "PROBLEM", 134, 147], ["the pleurisy", "PROBLEM", 151, 163], ["Plg-RKT and Plg", "TREATMENT", 179, 194], ["gene-deficient mice", "TREATMENT", 210, 229], ["Plg/plasmin", "TREATMENT", 245, 256], ["inflammation resolution", "PROBLEM", 264, 287], ["fibrin depositions", "PROBLEM", 293, 311], ["the normal acute inflammatory reaction", "PROBLEM", 324, 362], ["provisional laid down fibrin", "TREATMENT", 364, 392], ["plasmin", "TREATMENT", 425, 432], ["macrophage polarization", "OBSERVATION", 79, 102], ["M1", "ANATOMY", 112, 114], ["M2", "ANATOMY", 122, 124], ["efferocytosis", "OBSERVATION", 134, 147], ["pleurisy", "OBSERVATION", 155, 163], ["fibrin depositions", "OBSERVATION", 293, 311], ["normal", "OBSERVATION_MODIFIER", 328, 334], ["acute", "OBSERVATION_MODIFIER", 335, 340], ["inflammatory reaction", "OBSERVATION", 341, 362]]], ["Fibrin laid down within exudates tends to form adhesions between layers of membranes that cover inflamed organs.", [["exudates", "ANATOMY", 24, 32], ["adhesions", "ANATOMY", 47, 56], ["membranes", "ANATOMY", 75, 84], ["organs", "ANATOMY", 105, 111], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["membranes", "CELLULAR_COMPONENT", 75, 84], ["organs", "ORGAN", 105, 111], ["Fibrin", "TREATMENT", 0, 6], ["exudates", "PROBLEM", 24, 32], ["adhesions between layers of membranes", "PROBLEM", 47, 84], ["exudates", "OBSERVATION_MODIFIER", 24, 32], ["adhesions", "OBSERVATION", 47, 56], ["layers", "OBSERVATION_MODIFIER", 65, 71], ["membranes", "ANATOMY_MODIFIER", 75, 84], ["inflamed", "OBSERVATION", 96, 104]]], ["The balance between fibrin deposition and degradation is a critical factor in adhesion formation after surgery leading to adhesive small bowel obstruction.", [["bowel", "ANATOMY", 137, 142], ["bowel obstruction", "DISEASE", 137, 154], ["fibrin", "GENE_OR_GENE_PRODUCT", 20, 26], ["bowel", "ORGAN", 137, 142], ["fibrin", "PROTEIN", 20, 26], ["fibrin deposition", "TREATMENT", 20, 37], ["a critical factor in adhesion formation", "PROBLEM", 57, 96], ["surgery", "TREATMENT", 103, 110], ["adhesive small bowel obstruction", "PROBLEM", 122, 154], ["balance", "OBSERVATION", 4, 11], ["fibrin deposition", "OBSERVATION", 20, 37], ["adhesive", "OBSERVATION_MODIFIER", 122, 130], ["small", "OBSERVATION_MODIFIER", 131, 136], ["bowel", "ANATOMY", 137, 142], ["obstruction", "OBSERVATION", 143, 154]]], ["Scars can form that lead to adhesive small bowel obstruction, a common problem known by surgeons after intestinal surgery.", [["bowel", "ANATOMY", 43, 48], ["intestinal", "ANATOMY", 103, 113], ["bowel obstruction", "DISEASE", 43, 60], ["bowel", "ORGAN", 43, 48], ["intestinal", "ORGAN", 103, 113], ["Scars", "PROBLEM", 0, 5], ["adhesive small bowel obstruction", "PROBLEM", 28, 60], ["intestinal surgery", "TREATMENT", 103, 121], ["adhesive", "OBSERVATION_MODIFIER", 28, 36], ["small", "OBSERVATION_MODIFIER", 37, 42], ["bowel", "ANATOMY", 43, 48], ["obstruction", "OBSERVATION", 49, 60], ["intestinal", "ANATOMY", 103, 113], ["surgery", "OBSERVATION", 114, 121]]], ["Increases in activated resident macrophages were found at the surgical site [103] .", [["macrophages", "ANATOMY", 32, 43], ["macrophages", "CELL", 32, 43], ["activated resident macrophages", "CELL_TYPE", 13, 43], ["macrophages", "OBSERVATION", 32, 43]]], ["These activated macrophages secrete epidermal growth factor (EGF), which induced the upregulation of its receptor EGF receptor (HER1) on peritoneal mesothelial cells.", [["macrophages", "ANATOMY", 16, 27], ["peritoneal mesothelial cells", "ANATOMY", 137, 165], ["macrophages", "CELL", 16, 27], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 36, 59], ["EGF", "GENE_OR_GENE_PRODUCT", 61, 64], ["EGF receptor", "GENE_OR_GENE_PRODUCT", 114, 126], ["HER1", "GENE_OR_GENE_PRODUCT", 128, 132], ["peritoneal mesothelial cells", "CELL", 137, 165], ["activated macrophages", "CELL_TYPE", 6, 27], ["epidermal growth factor", "PROTEIN", 36, 59], ["EGF", "PROTEIN", 61, 64], ["EGF receptor", "PROTEIN", 114, 126], ["HER1", "PROTEIN", 128, 132], ["peritoneal mesothelial cells", "CELL_TYPE", 137, 165], ["These activated macrophages secrete epidermal growth factor (EGF)", "PROBLEM", 0, 65], ["its receptor EGF receptor", "TREATMENT", 101, 126], ["peritoneal mesothelial cells", "TREATMENT", 137, 165], ["macrophages", "OBSERVATION_MODIFIER", 16, 27], ["secrete", "OBSERVATION_MODIFIER", 28, 35], ["epidermal", "OBSERVATION_MODIFIER", 36, 45], ["growth", "OBSERVATION_MODIFIER", 46, 52], ["peritoneal", "ANATOMY", 137, 147], ["mesothelial cells", "OBSERVATION", 148, 165]]], ["HER1-activated mesothelial cells secreted more PAI-1, which together with tPA recruited more macrophages to the surgical site establishing a vicious cycle of impaired fibrinolysis and macrophage accumulation at the adhesive site that can cumulate in adhesive small bowel obstruction.", [["mesothelial cells", "ANATOMY", 15, 32], ["macrophages", "ANATOMY", 93, 104], ["surgical site", "ANATOMY", 112, 125], ["macrophage", "ANATOMY", 184, 194], ["bowel", "ANATOMY", 265, 270], ["bowel obstruction", "DISEASE", 265, 282], ["HER1", "GENE_OR_GENE_PRODUCT", 0, 4], ["mesothelial cells", "CELL", 15, 32], ["PAI-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["tPA", "GENE_OR_GENE_PRODUCT", 74, 77], ["macrophages", "CELL", 93, 104], ["macrophage", "CELL", 184, 194], ["bowel", "ORGAN", 265, 270], ["HER1", "PROTEIN", 0, 4], ["activated mesothelial cells", "CELL_TYPE", 5, 32], ["PAI-1", "PROTEIN", 47, 52], ["tPA", "PROTEIN", 74, 77], ["macrophages", "CELL_TYPE", 93, 104], ["activated mesothelial cells", "PROBLEM", 5, 32], ["tPA", "TREATMENT", 74, 77], ["impaired fibrinolysis", "PROBLEM", 158, 179], ["macrophage accumulation at the adhesive site", "PROBLEM", 184, 228], ["adhesive small bowel obstruction", "PROBLEM", 250, 282], ["mesothelial cells", "OBSERVATION", 15, 32], ["impaired", "OBSERVATION_MODIFIER", 158, 166], ["fibrinolysis", "OBSERVATION", 167, 179], ["macrophage accumulation", "OBSERVATION", 184, 207], ["adhesive site", "OBSERVATION_MODIFIER", 215, 228], ["adhesive", "OBSERVATION_MODIFIER", 250, 258], ["small", "OBSERVATION_MODIFIER", 259, 264], ["bowel", "ANATOMY", 265, 270], ["obstruction", "OBSERVATION", 271, 282]]], ["These studies demonstrate that plasmin contributes to the resolution phase of inflammation by its proteolytic ability (fibrin degradation), its ability to enhance the M1 into M2 macrophage switch, and accelerate the cleaning up of apoptotic neutrophils (efferocytosis).", [["macrophage", "ANATOMY", 178, 188], ["neutrophils", "ANATOMY", 241, 252], ["inflammation", "DISEASE", 78, 90], ["plasmin", "GENE_OR_GENE_PRODUCT", 31, 38], ["fibrin", "GENE_OR_GENE_PRODUCT", 119, 125], ["M2 macrophage", "CELL", 175, 188], ["neutrophils", "CELL", 241, 252], ["plasmin", "PROTEIN", 31, 38], ["fibrin", "PROTEIN", 119, 125], ["apoptotic neutrophils", "CELL_TYPE", 231, 252], ["These studies", "TEST", 0, 13], ["plasmin", "PROBLEM", 31, 38], ["inflammation", "PROBLEM", 78, 90], ["fibrin degradation", "PROBLEM", 119, 137], ["apoptotic neutrophils", "PROBLEM", 231, 252], ["plasmin", "OBSERVATION", 31, 38], ["resolution", "OBSERVATION_MODIFIER", 58, 68], ["phase", "OBSERVATION_MODIFIER", 69, 74], ["inflammation", "OBSERVATION", 78, 90], ["apoptotic neutrophils", "OBSERVATION", 231, 252]]], ["Factors of the coagulation, complement, and fibrinolytic system interact.", [["the coagulation", "TEST", 11, 26]]], ["The imbalance of these proteins can be the cause or the reason for thrombosis and inflammation.", [["thrombosis", "DISEASE", 67, 77], ["inflammation", "DISEASE", 82, 94], ["these proteins", "TREATMENT", 17, 31], ["thrombosis", "PROBLEM", 67, 77], ["inflammation", "PROBLEM", 82, 94], ["imbalance", "OBSERVATION", 4, 13], ["thrombosis", "OBSERVATION", 67, 77], ["inflammation", "OBSERVATION", 82, 94]]], ["During inflammation, tissue damage inflicted by microbes or nonmicrobial stressors activates the coagulation system.", [["tissue", "ANATOMY", 21, 27], ["inflammation", "DISEASE", 7, 19], ["tissue damage", "DISEASE", 21, 34], ["tissue", "TISSUE", 21, 27], ["inflammation", "PROBLEM", 7, 19], ["tissue damage inflicted", "PROBLEM", 21, 44], ["nonmicrobial stressors", "PROBLEM", 60, 82], ["the coagulation system", "TEST", 93, 115], ["inflammation", "OBSERVATION", 7, 19], ["tissue damage", "OBSERVATION_MODIFIER", 21, 34]]], ["Thrombin generates fibrin and enhances platelet activation and their growth factor release through protease activated receptors (PARs).", [["platelet", "ANATOMY", 39, 47], ["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["fibrin", "GENE_OR_GENE_PRODUCT", 19, 25], ["platelet", "CELL", 39, 47], ["protease activated receptors", "GENE_OR_GENE_PRODUCT", 99, 127], ["PARs", "GENE_OR_GENE_PRODUCT", 129, 133], ["Thrombin", "PROTEIN", 0, 8], ["fibrin", "PROTEIN", 19, 25], ["growth factor", "PROTEIN", 69, 82], ["protease activated receptors", "PROTEIN", 99, 127], ["PARs", "PROTEIN", 129, 133], ["Thrombin", "TREATMENT", 0, 8], ["fibrin", "PROBLEM", 19, 25], ["enhances platelet activation", "TREATMENT", 30, 58], ["protease activated receptors (PARs", "TREATMENT", 99, 133], ["fibrin", "OBSERVATION", 19, 25], ["platelet activation", "OBSERVATION", 39, 58]]], ["Tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) activate the inactive proenzyme/zymogen plasminogen (Plg) into active plasmin (Plm).", [["Tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 0, 33], ["tPA", "GENE_OR_GENE_PRODUCT", 35, 38], ["urokinase plasminogen activator", "GENE_OR_GENE_PRODUCT", 44, 75], ["uPA", "GENE_OR_GENE_PRODUCT", 77, 80], ["zymogen plasminogen", "GENE_OR_GENE_PRODUCT", 114, 133], ["Plg", "GENE_OR_GENE_PRODUCT", 135, 138], ["plasmin", "GENE_OR_GENE_PRODUCT", 152, 159], ["Plm", "GENE_OR_GENE_PRODUCT", 161, 164], ["Tissue-type plasminogen activator", "PROTEIN", 0, 33], ["urokinase plasminogen activator", "PROTEIN", 44, 75], ["uPA", "PROTEIN", 77, 80], ["inactive proenzyme", "PROTEIN", 95, 113], ["zymogen plasminogen", "PROTEIN", 114, 133], ["Plg", "PROTEIN", 135, 138], ["plasmin", "PROTEIN", 152, 159], ["Plm", "PROTEIN", 161, 164], ["Tissue-type plasminogen activator (tPA)", "TREATMENT", 0, 39], ["urokinase plasminogen activator (uPA)", "TREATMENT", 44, 81], ["the inactive proenzyme", "TEST", 91, 113], ["zymogen plasminogen", "TEST", 114, 133]]], ["Plasminogen activators are inhibited by plasminogen activator inhibitor-1, -2 (PAI-1, PAI-2), and protein C inhibitor (PCI).", [["Plasminogen", "GENE_OR_GENE_PRODUCT", 0, 11], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 40, 73], ["-2", "GENE_OR_GENE_PRODUCT", 75, 77], ["PAI-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["PAI-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["protein C", "GENE_OR_GENE_PRODUCT", 98, 107], ["PAI", "PROTEIN", 86, 89], ["protein C", "PROTEIN", 98, 107], ["Plasminogen activators", "TEST", 0, 22], ["plasminogen activator inhibitor", "TEST", 40, 71], ["PAI", "TEST", 79, 82], ["PAI", "TEST", 86, 89], ["protein C inhibitor (PCI", "TREATMENT", 98, 122]]], ["Plm functions include its ability to activate complement C3a and C5a, degrade fibrin into fibrinogen degradation products leading to fibrin fragments like the D-dimers, convert the proenzymes of matrix metalloproteinases (MMPs) to their active forms, regulate extracellular matrix (ECM) turnover (remodeling), and contribute to inflammation resolution (efferocytosis, M1 to M2 switch).", [["fibrin fragments", "ANATOMY", 133, 149], ["extracellular matrix", "ANATOMY", 260, 280], ["ECM", "ANATOMY", 282, 285], ["inflammation", "DISEASE", 328, 340], ["complement C3a", "GENE_OR_GENE_PRODUCT", 46, 60], ["C5a", "GENE_OR_GENE_PRODUCT", 65, 68], ["fibrin", "GENE_OR_GENE_PRODUCT", 78, 84], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 90, 100], ["fibrin", "GENE_OR_GENE_PRODUCT", 133, 139], ["D-dimers", "GENE_OR_GENE_PRODUCT", 159, 167], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 195, 220], ["MMPs", "GENE_OR_GENE_PRODUCT", 222, 226], ["extracellular matrix", "CELLULAR_COMPONENT", 260, 280], ["ECM", "CELLULAR_COMPONENT", 282, 285], ["M2", "GENE_OR_GENE_PRODUCT", 374, 376], ["C3a", "PROTEIN", 57, 60], ["C5a", "PROTEIN", 65, 68], ["fibrin", "PROTEIN", 78, 84], ["fibrinogen degradation products", "PROTEIN", 90, 121], ["fibrin fragments", "PROTEIN", 133, 149], ["D-dimers", "PROTEIN", 159, 167], ["matrix metalloproteinases", "PROTEIN", 195, 220], ["MMPs", "PROTEIN", 222, 226], ["Plm functions", "TEST", 0, 13], ["C3a", "TEST", 57, 60], ["C5a", "TEST", 65, 68], ["fibrin into fibrinogen degradation products", "TREATMENT", 78, 121], ["fibrin fragments", "PROBLEM", 133, 149], ["the D-dimers", "PROBLEM", 155, 167], ["the proenzymes of matrix metalloproteinases (MMPs)", "TREATMENT", 177, 227], ["inflammation resolution", "PROBLEM", 328, 351], ["efferocytosis", "PROBLEM", 353, 366], ["fibrin fragments", "OBSERVATION", 133, 149], ["extracellular matrix", "OBSERVATION", 260, 280], ["inflammation", "OBSERVATION", 328, 340]]]], "PMC7124271": [["Epidemiologic, clinical, and pathologic investigations ::: Patients and methodsThe study subjects included all patients with acute appendicitis from the high school during the period from April 1997 to June 2000.", [["appendicitis", "DISEASE", 131, 143], ["Patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 111, 119], ["Patients", "SPECIES", 59, 67], ["patients", "SPECIES", 111, 119], ["pathologic investigations", "TEST", 29, 54], ["The study", "TEST", 79, 88], ["acute appendicitis", "PROBLEM", 125, 143], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["appendicitis", "OBSERVATION", 131, 143]]], ["Data collected included person and time distributions of cases during the initial cluster between April and June 1997, and new cases after that, up to June 2000.", [["person", "SPECIES", 24, 30]]], ["Case history, physical examination, laboratory tests, pathology examination, and exposure history were also recorded.", [["physical examination", "TEST", 14, 34], ["laboratory tests", "TEST", 36, 52], ["pathology examination", "TEST", 54, 75]]], ["Patients were identified by reviewing hospital records.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Exposure history was obtained by interviewing the patients.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Twenty-nine of the 31 patients operated on were from one hospital, from which clinical and laboratory data were obtained for the study; the other 2 patients, who were operated on but whose clinical and laboratory data were not obtained, were not hospitalized at the collaborating hospital.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 148, 156], ["the study", "TEST", 125, 134], ["laboratory data", "TEST", 202, 217]]], ["Routine blood tests were performed before surgery for all patients.", [["blood", "ANATOMY", 8, 13], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Routine blood tests", "TEST", 0, 19], ["surgery", "TREATMENT", 42, 49]]], ["All histologic slides from the appendectomies were reexamined in the Department of Pathology and World Health Organization Collaborating Center for Tropical Diseases, University of Texas Medical Branch, Galveston, Texas.", [["the appendectomies", "TEST", 27, 45], ["Tropical Diseases", "PROBLEM", 148, 165], ["appendectomies", "OBSERVATION", 31, 45], ["Tropical Diseases", "OBSERVATION", 148, 165]]], ["The pathologic examination in the paper was approved by the patients and by the Scientific Section, Medical school, Wuhan University, which is a designated review board.Epidemiologic, clinical, and pathologic investigations ::: Patients and methodsTwo sets of control cases were selected as follows: to examine if there are unique features among the patients in the high school, we selected 8 patients with sporadic acute appendicitis from a college in Wuhan City in 1997 as controls, who were in same hospital; and to explore the causes of the cluster, we designed a case-control study with individual matches.", [["appendicitis", "DISEASE", 422, 434], ["patients", "ORGANISM", 60, 68], ["Patients", "ORGANISM", 228, 236], ["patients", "ORGANISM", 350, 358], ["patients", "ORGANISM", 393, 401], ["patients", "SPECIES", 60, 68], ["Patients", "SPECIES", 228, 236], ["patients", "SPECIES", 350, 358], ["patients", "SPECIES", 393, 401], ["The pathologic examination", "TEST", 0, 26], ["pathologic investigations", "TEST", 198, 223], ["sporadic acute appendicitis", "PROBLEM", 407, 434], ["pathologic", "OBSERVATION", 4, 14], ["acute", "OBSERVATION_MODIFIER", 416, 421], ["appendicitis", "OBSERVATION", 422, 434]]], ["Two normal controls were selected for each case.", [["normal", "OBSERVATION", 4, 10]]], ["One control was selected from an adjacent seat in the classroom of the patient, and the other was selected randomly from the same dormitory room as the patient.", [["patient", "ORGANISM", 71, 78], ["patient", "ORGANISM", 152, 159], ["patient", "SPECIES", 71, 78], ["patient", "SPECIES", 152, 159]]], ["A questionnaire consisted of two parts: (1) clinical history: presence or absence of a cold before the onset of symptoms, stomach disease, typhus fever, dysentery, ascariasis, and schistosomiasis; and (2) exposure factors: presence or absence of unclean or spoiled food intake before the onset of symptoms, type of food intake, dinner party, washing hands before meals, ingestion of water not boiled.", [["stomach", "ANATOMY", 122, 129], ["stomach disease", "DISEASE", 122, 137], ["typhus fever", "DISEASE", 139, 151], ["dysentery", "DISEASE", 153, 162], ["ascariasis", "DISEASE", 164, 174], ["schistosomiasis", "DISEASE", 180, 195], ["stomach", "ORGAN", 122, 129], ["a cold", "PROBLEM", 85, 91], ["symptoms", "PROBLEM", 112, 120], ["stomach disease", "PROBLEM", 122, 137], ["typhus fever", "PROBLEM", 139, 151], ["dysentery", "PROBLEM", 153, 162], ["ascariasis", "PROBLEM", 164, 174], ["schistosomiasis", "PROBLEM", 180, 195], ["symptoms", "PROBLEM", 297, 305], ["stomach", "ANATOMY", 122, 129], ["disease", "OBSERVATION", 130, 137], ["typhus", "OBSERVATION_MODIFIER", 139, 145], ["dysentery", "OBSERVATION_MODIFIER", 153, 162], ["ascariasis", "OBSERVATION", 164, 174], ["schistosomiasis", "OBSERVATION", 180, 195]]], ["To probe why the incidence rate was higher among female students, we also collected gynecologic and menstrual history of the female patients.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140]]], ["The female patients were divided into three groups according to the phase of menstrual cycle in which they presented with appendicitis: the menstrual group (day 1 to 5 after the onset of the period), the follicular group (day 6 to 14 after the onset), and the luteal group (day 15 to 28 after the onset).", [["follicular", "ANATOMY", 204, 214], ["luteal", "ANATOMY", 260, 266], ["appendicitis", "DISEASE", 122, 134], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["menstrual cycle", "TREATMENT", 77, 92], ["appendicitis", "PROBLEM", 122, 134], ["appendicitis", "OBSERVATION", 122, 134], ["luteal", "ANATOMY", 260, 266]]], ["To correct for the different lengths of each phase, the incidence of disease was calculated by dividing the number of instances in each phase by the length of days.Case definition ::: Patients and methodsThe operative cases were defined as those who had typical clinical manifestations of acute appendicitis and who had surgery (appendectomy).", [["appendicitis", "DISEASE", 295, 307], ["Patients", "ORGANISM", 184, 192], ["Patients", "SPECIES", 184, 192], ["disease", "PROBLEM", 69, 76], ["acute appendicitis", "PROBLEM", 289, 307], ["surgery", "TREATMENT", 320, 327], ["appendectomy", "TREATMENT", 329, 341], ["disease", "OBSERVATION", 69, 76], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["appendicitis", "OBSERVATION", 295, 307], ["appendectomy", "OBSERVATION", 329, 341]]], ["Nonoperative cases were defined as patients who had a typical clinical manifestation but were not operated on.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["New cases were defined as patients who had acute appendicitis after the initial cluster, ie, cases occurring after June 1997.Immunohistochemical screening of antigen of enterovirus and adenovirus ::: Patients and methodsTo screen for potential infectious agents using immunohistochemistry, we used monoclonal mouse antienterovirus clone 5-D8/1 (Dako, Glostrup, Denmark), which reacts with 36 enterovirus serotypes of the Echo, Coxsackie including B2 and B5 and poliovirus groups, and monoclonal antiadenvirus group (Argene, Varilhes, France), which reacts with most adenovirus strains including type 7.", [["appendicitis", "DISEASE", 49, 61], ["patients", "ORGANISM", 26, 34], ["enterovirus", "ORGANISM", 169, 180], ["adenovirus", "ORGANISM", 185, 195], ["Patients", "ORGANISM", 200, 208], ["mouse", "ORGANISM", 309, 314], ["Dako", "GENE_OR_GENE_PRODUCT", 345, 349], ["Glostrup", "GENE_OR_GENE_PRODUCT", 351, 359], ["Coxsackie", "ORGANISM", 427, 436], ["B5", "GENE_OR_GENE_PRODUCT", 454, 456], ["adenovirus", "ORGANISM", 566, 576], ["patients", "SPECIES", 26, 34], ["Patients", "SPECIES", 200, 208], ["mouse", "SPECIES", 309, 314], ["mouse", "SPECIES", 309, 314], ["acute appendicitis", "PROBLEM", 43, 61], ["Immunohistochemical screening", "TEST", 125, 154], ["enterovirus", "PROBLEM", 169, 180], ["potential infectious agents", "TREATMENT", 234, 261], ["immunohistochemistry", "TEST", 268, 288], ["monoclonal mouse antienterovirus clone", "TREATMENT", 298, 336], ["the Echo", "TEST", 417, 425], ["Coxsackie", "PROBLEM", 427, 436], ["B2", "TEST", 447, 449], ["B5", "TREATMENT", 454, 456], ["poliovirus groups", "PROBLEM", 461, 478], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["appendicitis", "OBSERVATION", 49, 61]]], ["Positive controls consisted of formalin-fixed and paraffin-embedded culture cells that had been infected with the Coxsackie A-9, Echo-6, and Polio-1.", [["cells", "ANATOMY", 76, 81], ["formalin", "CHEMICAL", 31, 39], ["paraffin", "CHEMICAL", 50, 58], ["cells", "CELL", 76, 81], ["Coxsackie A-9", "ORGANISM", 114, 127], ["Echo-6", "CELL", 129, 135], ["Polio-1", "ORGANISM", 141, 148], ["formalin-fixed and paraffin-embedded culture cells", "CELL_LINE", 31, 81], ["Polio-1", "SPECIES", 141, 148], ["formalin", "TEST", 31, 39], ["embedded culture cells", "PROBLEM", 59, 81], ["the Coxsackie A", "TEST", 110, 125], ["Echo", "TEST", 129, 133], ["Polio", "TEST", 141, 146]]], ["Positive controls also consisted of enterovirus positive control slides (Dako, Ely, United Kingdom) and adenvirus positive control slides (Dako).", [["enterovirus", "ORGANISM", 36, 47], ["Positive controls", "PROBLEM", 0, 17], ["enterovirus", "PROBLEM", 36, 47], ["controls", "OBSERVATION", 9, 17]]], ["Negative controls were the patient's appendical tissue sections and the above positive controls slides incubated with irrelevant antibodies.Immunohistochemical screening of antigen of enterovirus and adenovirus ::: Patients and methodsSections, 5 \u03bcm thick, were prepared from the formalin-fixed, paraffin-embedded tissue blocks of 11 cases in the initial cluster in the high school and 8 cases in the college in 1997.", [["appendical tissue sections", "ANATOMY", 37, 63], ["tissue", "ANATOMY", 314, 320], ["formalin", "CHEMICAL", 280, 288], ["patient", "ORGANISM", 27, 34], ["appendical tissue sections", "TISSUE", 37, 63], ["enterovirus", "ORGANISM", 184, 195], ["adenovirus", "ORGANISM", 200, 210], ["Patients", "ORGANISM", 215, 223], ["tissue", "TISSUE", 314, 320], ["patient", "SPECIES", 27, 34], ["Patients", "SPECIES", 215, 223], ["the patient's appendical tissue sections", "TEST", 23, 63], ["irrelevant antibodies", "PROBLEM", 118, 139], ["Immunohistochemical screening", "TEST", 140, 169], ["enterovirus", "PROBLEM", 184, 195], ["adenovirus", "PROBLEM", 200, 210], ["paraffin-embedded tissue blocks", "TREATMENT", 296, 327]]], ["After deparaffinization in xylene and rehydration through a concentration series of alcohol, slides were treated with 3% H2O2 for 10 minutes at room temperature to inhibit the endogenous peroxidase activity.", [["xylene", "CHEMICAL", 27, 33], ["alcohol", "CHEMICAL", 84, 91], ["H2O2", "CHEMICAL", 121, 125], ["xylene", "CHEMICAL", 27, 33], ["alcohol", "CHEMICAL", 84, 91], ["H2O2", "CHEMICAL", 121, 125], ["xylene", "SIMPLE_CHEMICAL", 27, 33], ["alcohol", "SIMPLE_CHEMICAL", 84, 91], ["H2O2", "SIMPLE_CHEMICAL", 121, 125], ["peroxidase", "GENE_OR_GENE_PRODUCT", 187, 197], ["endogenous peroxidase", "PROTEIN", 176, 197], ["deparaffinization in xylene", "TREATMENT", 6, 33], ["rehydration", "TREATMENT", 38, 49], ["a concentration series of alcohol", "TREATMENT", 58, 91], ["3% H2O2", "TREATMENT", 118, 125], ["endogenous", "OBSERVATION", 176, 186], ["peroxidase activity", "OBSERVATION", 187, 206]]], ["That was followed by incubating the section with 1.5% normal goat serum at room temperature for 30 minutes to block nonspecific secondary antibody binding.", [["serum", "ANATOMY", 66, 71], ["goat", "ORGANISM", 61, 65], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["goat", "SPECIES", 61, 65], ["goat", "SPECIES", 61, 65], ["block nonspecific secondary antibody binding", "PROBLEM", 110, 154], ["antibody binding", "OBSERVATION", 138, 154]]], ["A heating antigen retrieval step was used by immersing the sections in (10% target retrieval solution; Dako, Carpinteria, California), at 100\u00b0C for 10 minutes.", [["sections", "ANATOMY", 59, 67], ["A heating antigen retrieval step", "TREATMENT", 0, 32]]], ["The monoclonal mouse antienterovirus clone 5-D8/1 and monoclonal antiadenvirus group, described above and diluted 1:100, was incubated at room temperature for 30 minutes for each section respectively.", [["5-D8/1", "CHEMICAL", 43, 49], ["mouse", "ORGANISM", 15, 20], ["5-D8/1", "ORGANISM", 43, 49], ["D8/1", "CELL_LINE", 45, 49], ["mouse", "SPECIES", 15, 20], ["mouse", "SPECIES", 15, 20], ["The monoclonal mouse antienterovirus clone", "TREATMENT", 0, 42], ["monoclonal antiadenvirus group", "TREATMENT", 54, 84], ["monoclonal mouse", "OBSERVATION", 4, 20]]], ["After a washing step, the Dako LSAB2 peroxidase detection kit (Dako, Carpinteria, California) was used following the manufacturer's instruction; 3-amino-9-ethylcarazole (AEC) was used as chromogen.", [["3-amino-9-ethylcarazole", "CHEMICAL", 145, 168], ["AEC", "CHEMICAL", 170, 173], ["3-amino-9-ethylcarazole", "CHEMICAL", 145, 168], ["AEC", "CHEMICAL", 170, 173], ["chromogen", "CHEMICAL", 187, 196], ["Dako", "GENE_OR_GENE_PRODUCT", 26, 30], ["3-amino-9-ethylcarazole", "SIMPLE_CHEMICAL", 145, 168], ["AEC", "SIMPLE_CHEMICAL", 170, 173], ["chromogen", "SIMPLE_CHEMICAL", 187, 196], ["Dako LSAB2 peroxidase", "PROTEIN", 26, 47], ["a washing step", "TEST", 6, 20], ["the Dako", "TEST", 22, 30], ["the manufacturer's instruction", "TREATMENT", 113, 143], ["amino", "TREATMENT", 147, 152], ["ethylcarazole (AEC)", "TREATMENT", 155, 174]]], ["Positive controls and negative controls were stained using the same methods.Statistical analysis ::: Patients and methodsIncidence rates were calculated for the operated on patients only.", [["Patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 173, 181], ["Patients", "SPECIES", 101, 109], ["patients", "SPECIES", 173, 181], ["Statistical analysis", "TEST", 76, 96], ["negative controls", "OBSERVATION", 22, 39]]], ["Statistically significant differences in occurrence and exposure factors between patients and healthy controls, and in incidence rates between the male and female students were assessed using 1:2 matched-pair chi-square tests and chi-square tests, respectively.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["pair chi-square tests", "TEST", 204, 225], ["chi-square tests", "TEST", 230, 246], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Class clustering of patients was assessed by binomial distribution.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["binomial distribution", "OBSERVATION", 45, 66]]], ["Statistically significant differences in clinical manifestations, white blood cell counts (WBC), and differential white blood cell counts, between the cluster group and the college control group, were assessed by Fisher's exact test, t test, and t test after arcsine transformation, respectively.", [["white blood cell", "ANATOMY", 66, 82], ["WBC", "ANATOMY", 91, 94], ["white blood cell", "ANATOMY", 114, 130], ["white blood cell", "CELL", 66, 82], ["blood cell", "CELL", 120, 130], ["significant differences in clinical manifestations", "PROBLEM", 14, 64], ["white blood cell counts", "TEST", 66, 89], ["WBC", "TEST", 91, 94], ["differential white blood cell counts", "TEST", 101, 137], ["t test", "TEST", 234, 240], ["t test", "TEST", 246, 252], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["A P value <0.05 was considered significant for the above statistical methods.", [["A P value", "TEST", 0, 9]]], ["SYSTAT software(version10.0 SPSS, Chicago, Illinois) was used for statistical analysis.Epidemiologic findings ::: ResultsLocation and population: the school is a boarding high school, located in an urban district of Wuhan, Hubei Province, which is in central China, by the Yangtze River.", [["statistical analysis", "TEST", 66, 86], ["central China", "ANATOMY", 251, 264]]], ["The building was partitioned by wall on each floor with one side having four rooms (for female students) and another side having three bedrooms (for male students).", [["wall", "ANATOMY", 32, 36], ["wall", "TISSUE", 32, 36], ["wall", "ANATOMY_MODIFIER", 32, 36]]], ["Thirty-one operative cases of acute appendicitis (29 students operated on) occurred in this high school from the onset for the initial cluster (April 1997) to the end of this study (June 2000), among a total of 42 patients who had clinical manifestations of the disease.", [["appendicitis", "DISEASE", 36, 48], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["acute appendicitis", "PROBLEM", 30, 48], ["this study", "TEST", 170, 180], ["the disease", "PROBLEM", 258, 269], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["appendicitis", "OBSERVATION", 36, 48], ["disease", "OBSERVATION", 262, 269]]], ["Two incidence peaks occurred, one between May 14 and May 21, the other between May 29 and June 11.", [["peaks", "OBSERVATION_MODIFIER", 14, 19]]], ["Among the 11 cases, only 1 staff member (a 21-year old man) had appendicitis during the cluster; he had a high level of contact with student patients.", [["appendicitis", "DISEASE", 64, 76], ["man", "ORGANISM", 55, 58], ["patients", "ORGANISM", 141, 149], ["man", "SPECIES", 55, 58], ["patients", "SPECIES", 141, 149], ["appendicitis", "PROBLEM", 64, 76], ["appendicitis", "OBSERVATION", 64, 76]]], ["Five additional cases (4 female and 1 male) presented with clinical manifestations of acute appendicitis, but were not operated on (data not shown).Epidemiologic findings ::: ResultsDuring the initial cluster, the incidence rate of acute appendicitis among students was 3.8% (10 of 290), with 3 male and 7 female students.", [["appendicitis", "DISEASE", 92, 104], ["appendicitis", "DISEASE", 238, 250], ["acute appendicitis", "PROBLEM", 86, 104], ["acute appendicitis", "PROBLEM", 232, 250], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["appendicitis", "OBSERVATION", 92, 104], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["appendicitis", "OBSERVATION", 238, 250]]], ["Among nonresident students who had meals at home, the incidence rate was 5.0% (2 of 40).", [["the incidence rate", "TEST", 50, 68]]], ["A history of mutual contact was found in these patients.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["In addition, cases 7, 8, 9, and 10 were also classmates.Epidemiologic findings ::: ResultsA case-control analysis did not show correlation between disease occurrence and the exposure factors described before.", [["cases", "TEST", 13, 18], ["ResultsA case-control analysis", "TEST", 83, 113], ["disease occurrence", "PROBLEM", 147, 165], ["the exposure factors", "PROBLEM", 170, 190]]], ["In 1996, there were only 2 sporadic cases with acute appendicitis in the school.Epidemiologic findings ::: ResultsThe characteristics of occurrence of the disease after the initial cluster were as follows.", [["appendicitis", "DISEASE", 53, 65], ["acute appendicitis", "PROBLEM", 47, 65], ["the disease", "PROBLEM", 151, 162], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["appendicitis", "OBSERVATION", 53, 65], ["disease", "OBSERVATION", 155, 162]]], ["From September 29, 1997, to June, 2000, 20 operative cases of acute appendicitis were encountered, as shown in Table 2.", [["appendicitis", "DISEASE", 68, 80], ["acute appendicitis", "PROBLEM", 62, 80], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["appendicitis", "OBSERVATION", 68, 80]]], ["Only 1 staff member (a 40-year-old woman) suffered from acute appendicitis during this period; she had the same clinical and histologic features.", [["appendicitis", "DISEASE", 62, 74], ["woman", "ORGANISM", 35, 40], ["woman", "SPECIES", 35, 40], ["acute appendicitis", "PROBLEM", 56, 74], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["appendicitis", "OBSERVATION", 62, 74]]], ["Six additional cases presented with clinical manifestations of acute appendicitis, but were not operated on (not shown).", [["appendicitis", "DISEASE", 69, 81], ["acute appendicitis", "PROBLEM", 63, 81], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["appendicitis", "OBSERVATION", 69, 81]]], ["Among all the new cases, 15 patients operated on and 5 patients not operated on were students enrolled in the school after the initial cluster.Epidemiologic findings ::: ResultsThe cumulative incidence rate for cases after the initial cluster was 3.1% (19 of 618).", [["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 55, 63]]], ["As with the patients in the initial cluster, many of the patients had a history of close contact.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 57, 65]]], ["During this period, three classes each contributed 2 cases operated on sequentially, eg, cases 8 and 10, cases 14 and 15, and cases 18 and 19.", [["cases", "TEST", 89, 94], ["cases", "TEST", 105, 110], ["cases", "TEST", 126, 131]]], ["In addition, cases 8, 9, and 10 lived on the same floor of the dormitory of building.", [["cases", "TEST", 13, 18]]], ["They had a contact history and suffered from acute appendicitis sequentially.", [["appendicitis", "DISEASE", 51, 63], ["acute appendicitis", "PROBLEM", 45, 63], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["appendicitis", "OBSERVATION", 51, 63]]], ["Case 18 had onset of acute appendicitis after caring for case 17.Epidemiologic findings ::: ResultsFor the cases operated on, the total incidence rate in students was 4.1% (29 of 704), and there was a statistically significant difference (chi-square = 10.6, P <0.01) between incidence rates in male (1.9%, 7 of 364) and female students (6.5%, 22 of 340).", [["appendicitis", "DISEASE", 27, 39], ["acute appendicitis", "PROBLEM", 21, 39], ["the total incidence rate", "TEST", 126, 150], ["chi-square", "TEST", 239, 249], ["P", "TEST", 258, 259], ["incidence rates", "TEST", 275, 290], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["appendicitis", "OBSERVATION", 27, 39], ["significant", "OBSERVATION_MODIFIER", 215, 226], ["difference", "OBSERVATION_MODIFIER", 227, 237]]], ["Appendicitis patients were in 11 of 19 classes; 3 classes contributed 4 patients each, 3 classes contributed 3 patients each, and another 3 classes contributed 2 patients each.", [["Appendicitis", "DISEASE", 0, 12], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 162, 170], ["Appendicitis", "PROBLEM", 0, 12]]], ["The remaining 2 classes had only 1 patient each.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42]]], ["Mean age of the patients was 16.6 years (range 15 to 19).Epidemiologic findings ::: ResultsA follow-up study did not find frequent exposure factors with new patients in the high school (data not shown).Epidemiologic findings ::: ResultsThe control patients were 8 college students who had acute appendicitis (7 male and 1 female student) and had their illness in 1997.", [["appendicitis", "DISEASE", 295, 307], ["illness", "DISEASE", 352, 359], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 248, 256], ["A follow-up study", "TEST", 91, 108], ["acute appendicitis", "PROBLEM", 289, 307], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["appendicitis", "OBSERVATION", 295, 307]]], ["All the patients underwent urgent appendectomy.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["urgent appendectomy", "TREATMENT", 27, 46], ["appendectomy", "OBSERVATION", 34, 46]]], ["A total of 2,499 students (1,812 male and 687 female) were present at the college during that time; the incidence rate for these sporadic cases was thus calculated as 0.32%.Clinical and laboratory data ::: ResultsThe 29 patients who were operated on had right lower quadrant pain or pain migrating to the right lower quadrant, and tenderness at or near McBurney's point.", [["right lower quadrant", "ANATOMY", 254, 274], ["right lower quadrant", "ANATOMY", 305, 325], ["pain", "DISEASE", 275, 279], ["pain", "DISEASE", 283, 287], ["tenderness", "DISEASE", 331, 341], ["patients", "ORGANISM", 220, 228], ["lower", "ORGANISM_SUBDIVISION", 311, 316], ["patients", "SPECIES", 220, 228], ["right lower quadrant pain", "PROBLEM", 254, 279], ["pain", "PROBLEM", 283, 287], ["tenderness", "PROBLEM", 331, 341], ["right", "ANATOMY_MODIFIER", 254, 259], ["lower", "ANATOMY_MODIFIER", 260, 265], ["quadrant", "ANATOMY", 266, 274], ["pain", "OBSERVATION", 275, 279], ["pain", "OBSERVATION", 283, 287], ["right", "ANATOMY_MODIFIER", 305, 310], ["lower", "ANATOMY_MODIFIER", 311, 316], ["quadrant", "ANATOMY", 317, 325], ["tenderness", "OBSERVATION", 331, 341]]], ["Twenty had rebound tenderness, 5 had involuntary muscle spasm, and 3 had diarrhea.", [["muscle", "ANATOMY", 49, 55], ["tenderness", "DISEASE", 19, 29], ["involuntary muscle spasm", "DISEASE", 37, 61], ["diarrhea", "DISEASE", 73, 81], ["muscle", "ORGAN", 49, 55], ["rebound tenderness", "PROBLEM", 11, 29], ["involuntary muscle spasm", "PROBLEM", 37, 61], ["diarrhea", "PROBLEM", 73, 81], ["rebound", "OBSERVATION_MODIFIER", 11, 18], ["tenderness", "OBSERVATION", 19, 29], ["muscle", "ANATOMY", 49, 55], ["spasm", "OBSERVATION", 56, 61]]], ["None of the patients had blood in stool.", [["blood", "ANATOMY", 25, 30], ["stool", "ANATOMY", 34, 39], ["patients", "ORGANISM", 12, 20], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["stool", "ORGANISM_SUBSTANCE", 34, 39], ["patients", "SPECIES", 12, 20], ["blood in stool", "PROBLEM", 25, 39], ["stool", "OBSERVATION", 34, 39]]], ["Microscopic stool examination was performed on 5 patients, and no red blood cells were found.", [["stool", "ANATOMY", 12, 17], ["red blood cells", "ANATOMY", 66, 81], ["patients", "ORGANISM", 49, 57], ["red blood cells", "CELL", 66, 81], ["red blood cells", "CELL_TYPE", 66, 81], ["patients", "SPECIES", 49, 57], ["Microscopic stool examination", "TEST", 0, 29], ["red blood cells", "TEST", 66, 81], ["stool", "OBSERVATION", 12, 17]]], ["Four patients had axilla temperatures more than 37\u00b0C (37.1\u00b0C, 37.3\u00b0C, 37.8\u00b0C, and 37.8\u00b0C).", [["axilla", "ANATOMY", 18, 24], ["patients", "ORGANISM", 5, 13], ["axilla", "ORGAN", 18, 24], ["patients", "SPECIES", 5, 13], ["axilla temperatures", "TEST", 18, 37], ["\u00b0C", "TEST", 58, 60], ["C", "TEST", 67, 68], ["C", "TEST", 75, 76], ["axilla", "ANATOMY", 18, 24]]], ["White blood cell counts (WBC) were found to be mildly elevated in 6 cases (range 11.3 \u00d7 109/L to 12.5 \u00d7 109/L) and neutrophil level in the differential WBC was found to be elevated in 12 cases (range 72% to 85%).", [["White blood cell", "ANATOMY", 0, 16], ["WBC", "ANATOMY", 25, 28], ["neutrophil", "ANATOMY", 115, 125], ["WBC", "ANATOMY", 152, 155], ["White blood cell", "CELL", 0, 16], ["WBC", "CELL", 25, 28], ["neutrophil", "CELL", 115, 125], ["neutrophil", "CELL_TYPE", 115, 125], ["White blood cell counts", "TEST", 0, 23], ["WBC", "TEST", 25, 28], ["mildly elevated", "PROBLEM", 47, 62], ["neutrophil level", "TEST", 115, 131], ["the differential WBC", "TEST", 135, 155], ["mildly", "OBSERVATION_MODIFIER", 47, 53], ["elevated", "OBSERVATION", 54, 62], ["elevated", "OBSERVATION_MODIFIER", 172, 180]]], ["Platelet counts and prothrombin times (PT) were within the normal range in all 29 patients.", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["prothrombin", "GENE_OR_GENE_PRODUCT", 20, 31], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Platelet counts", "TEST", 0, 15], ["prothrombin times", "TEST", 20, 37], ["PT", "TEST", 39, 41], ["normal range", "OBSERVATION_MODIFIER", 59, 71]]], ["Physical examination did not show hemorrhagic symptoms or signs.", [["hemorrhagic", "DISEASE", 34, 45], ["Physical examination", "TEST", 0, 20], ["hemorrhagic symptoms", "PROBLEM", 34, 54], ["signs", "PROBLEM", 58, 63]]], ["The mean length of time between onset of symptoms and operation was about 50 hours.", [["symptoms", "PROBLEM", 41, 49], ["operation", "TREATMENT", 54, 63], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15]]], ["Among 21 female patients with regular menstrual period, 2 cases occurred in the menstrual phase (0.41 person/day); 11 occurred in the follicular phase (1.2 person/day); and 8 occurred in the luteal phase (0.57 person/day).Clinical and laboratory data ::: ResultsAll 8 control patients from the college had right lower quadrant pain or pain moving to the right lower quadrant and tenderness at or near McBurney's point.", [["follicular", "ANATOMY", 134, 144], ["right lower quadrant", "ANATOMY", 306, 326], ["right lower quadrant", "ANATOMY", 354, 374], ["pain", "DISEASE", 327, 331], ["pain", "DISEASE", 335, 339], ["tenderness", "DISEASE", 379, 389], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 276, 284], ["lower quadrant", "ORGANISM_SUBDIVISION", 312, 326], ["lower quadrant", "ORGANISM_SUBDIVISION", 360, 374], ["patients", "SPECIES", 16, 24], ["person", "SPECIES", 102, 108], ["person", "SPECIES", 156, 162], ["person", "SPECIES", 210, 216], ["patients", "SPECIES", 276, 284], ["right lower quadrant pain", "PROBLEM", 306, 331], ["pain", "PROBLEM", 335, 339], ["tenderness", "PROBLEM", 379, 389], ["right", "ANATOMY_MODIFIER", 306, 311], ["lower", "ANATOMY_MODIFIER", 312, 317], ["quadrant", "ANATOMY", 318, 326], ["pain", "OBSERVATION", 327, 331], ["pain", "OBSERVATION", 335, 339], ["right", "ANATOMY_MODIFIER", 354, 359], ["lower", "ANATOMY_MODIFIER", 360, 365], ["quadrant", "ANATOMY", 366, 374], ["tenderness", "OBSERVATION", 379, 389]]], ["Seven patients had rebound tenderness, 4 had involuntary muscle spasm, and 3 had axilla temperature more than 37\u00b0C (37.2\u00b0C, 37.2\u00b0C, and 37.7\u00b0C).", [["muscle", "ANATOMY", 57, 63], ["axilla", "ANATOMY", 81, 87], ["tenderness", "DISEASE", 27, 37], ["involuntary muscle spasm", "DISEASE", 45, 69], ["patients", "ORGANISM", 6, 14], ["muscle", "ORGAN", 57, 63], ["axilla", "ORGAN", 81, 87], ["patients", "SPECIES", 6, 14], ["rebound tenderness", "PROBLEM", 19, 37], ["involuntary muscle spasm", "PROBLEM", 45, 69], ["axilla temperature", "TEST", 81, 99], ["\u00b0C", "TEST", 120, 122], ["rebound", "OBSERVATION_MODIFIER", 19, 26], ["tenderness", "OBSERVATION", 27, 37], ["muscle", "ANATOMY", 57, 63], ["spasm", "OBSERVATION", 64, 69], ["axilla", "ANATOMY", 81, 87]]], ["White blood cell counts were elevated in 5 of 8 cases (range 10.6 \u00d7 109/L to 16.2 \u00d7 109/L) and neutrophil level in the differential WBC was elevated in each case (range 75% to 94%).", [["blood cell", "ANATOMY", 6, 16], ["neutrophil", "ANATOMY", 95, 105], ["WBC", "ANATOMY", 132, 135], ["White blood cell", "CELL", 0, 16], ["neutrophil", "CELL", 95, 105], ["neutrophil", "CELL_TYPE", 95, 105], ["White blood cell counts", "TEST", 0, 23], ["elevated", "PROBLEM", 29, 37], ["neutrophil level", "TEST", 95, 111], ["the differential WBC", "TEST", 115, 135], ["elevated", "PROBLEM", 140, 148], ["elevated", "OBSERVATION_MODIFIER", 29, 37]]], ["The mean length of time between onset of symptoms and operation was about 23 hours.", [["symptoms", "PROBLEM", 41, 49], ["operation", "TREATMENT", 54, 63], ["mean length", "OBSERVATION_MODIFIER", 4, 15]]], ["Comparisons of WBC and differential WBC between the two groups of patients are shown in Table 3.", [["WBC", "ANATOMY", 15, 18], ["WBC", "ANATOMY", 36, 39], ["WBC", "CELL", 15, 18], ["patients", "ORGANISM", 66, 74], ["WBC", "CELL_TYPE", 15, 18], ["WBC", "CELL_TYPE", 36, 39], ["patients", "SPECIES", 66, 74], ["WBC", "TEST", 15, 18], ["differential WBC", "TEST", 23, 39]]]]}